Clinical trial NCT03104413
Conditions: Crohn's Disease
Keywords: ABBV-066 BI 655066
Sponsor: AbbVie
Start date: 2017-12-18; Completion date: 2021-05-19
Enrollment: 618 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.

Detailed description:

Arms: arm 1: Participants randomized to receive risankizumab dose 1 in Induction Period 1. arm 2: Participants randomized to receive risankizumab dose 2 in Induction Period 1. arm 3: Participants randomized to receive placebo for risankizumab in Induction Period 1. arm 4: Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2. arm 5: Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2. arm 6: Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
Interventions: intervention 1: placebo for risankizumab IV intervention 2: risankizumab SC intervention 3: risankizumab IV
Intervention descriptions: intervention 1: placebo for risankizumab administered as intravenous (IV) infusion. intervention 2: risankizumab administered by subcutaneous (SC) injection intervention 3: risankizumab administered as intravenous (IV) infusion.

Protocol documents:
ICF_000.pdf: 
Investigator Guidelines and 
Template 
 VA Health Care System 
Research Consent Form
VERBAL INTRODUCTION   
You are being invited to take part in a research study about an investigational drug called 
Risankizumab. Before you decide to take part, it is important for you to know why the research is being 
done and what it will involve. This includes any potential risks to you, as well as any potential benefits 
you might receive. Taking part in this study is completely voluntary.  
Read the information below carefully and discuss it with family and friends if you wish. Ask one of the 
study staff if there is anything that is not clear or if you would like more details. Take your time to 
decide. If you do decide to take part in this study, your signature on this consent form will show that you 
received all the information below, and that you were able to discuss any questions and concerns you 
had with a member of the study team. If you are participating in any other research study, you must 
inform the study staff now. 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy
NCT03104413


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 1 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
1. BRIEF STUDY INFORMATION  
 
A. What is the study about and why are we doing it? 
You are being invited to take part in a voluntary research study about the study drug called 
Risankizumab. The company AbbVie is funding this study. This study hopes to learn how well the 
medicine Risankizumab works compared to placebo (harmless medicine). If the medicine shows 
good results, then it can be used for treatment of Crohn’s disease. 
 
The drug being tested is experimental, meaning it has not been approved for routine clinical use or  
for the use described in this study by the United States Food and Drug Administration (USFDA). 
The USFDA is allowing the use of this drug for research  
 
B. What does the study involve and how long will it last? 
The research study can be up to 49 weeks. You will be required to come to clinic and undergo 
additional testing to make sure the medicine is right for you to take. You may have to come to 
 VA Medical Center 4 times before the start of the medicine. 
 
The study drug will be given subcutaneous, meaning under the skin or intravenous (IV), meaning 
infused into the vein. The infusion will last about 2 hours. 
 
Some of the additional testing that will be done to ensure your safety include: physical exams, urine 
and blood tests, electrical activity of the heart called an ECG and endoscopies, with or without 
biopsies. You complete several questionnaires. You will complete a daily diary. an electronic diary. 
If you are a woman and are or are planning to become pregnant you are not eligible to take part in 
this study.  
 
C. What are the key reasons I might choose to volunteer for this study? 
You may or may not benefit from being in this study but what we learn from your participation may 
help you or others with Crohn’s disease. 
 
D. What re the key reasons I might choose not to volunteer for this study? 
You do not have to take part in the study to be treated for your Crohn’s disease. Other treatments 
are available for your Crohn’s disease and you may choose not to enroll in the study medicine. You 
will not be able to participate in the study if you are unable to come to the VA 
 hospital for 
your visits and to receive medicine. 
 
E. Do I have to take part in this study? 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 2 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
Taking part in this study is completely voluntary. You can choose to participate or not. If you choose 
not to volunteer in this study, you will not lose any services, benefits, or rights you would normally 
have. 
 
F. What if I have questions, suggestions, or concerns? 
The person in charge of the study is Dr. 
 If you have questions, suggestions, or 
concerns regarding this study or you want to withdraw from the study contact 
 the study team at extension 5590. 
 
 
 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 3 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
RESEARCH DETAILS 
 
2. WHAT IS THE PURPOSE OF THIS STUDY?  
This is a research study. We are asking you to volunteer to take part because you have been 
diagnosed with moderate to severe Crohn’s disease. This study is not to treat you for your Crohn’s 
disease but will compare different doses of the study drug Risankizumab with a placebo. A placebo is a 
substance that looks like study drug but has no study drug or active ingredient in it, This study hopes to 
learn how well different doses of the study drug Risankizumab works and the safety of the dosages of 
study drug compared to placebo to improve the symptoms of moderate to severe Crohn’s disease in 
people who are having symptoms such as diarrhea with or without blood, abdominal pain, and/or 
sudden and constant feeling that you have to move your bowels. Also, you may have been unable to 
tolerate or may had insufficient response to treatment with biologic therapies and want to try other 
options. 
 
This study is being conducted at about 400 research centers worldwide and is expected to enroll a total 
of 579 participants with moderately to severely active Crohn’s disease. The 
 VA Health Care 
System
 will enroll about 10 participants.  
 
3. HOW LONG WILL I BE IN THIS STUDY? 
Your total time in this research study could be up to about 49 weeks. This includes a screening period 
of up to 35 days to determine if you are right to take part, and a 12-week double-blind induction period, 
at which you will receive study drug. If you receive no response from the first induction period, you may 
be eligible to take in a second induction period. The second induction period includes about another 3 
visits and a 140 day follow up period.  
 
4. WHAT WILL HAPPEN IF I TAKE PART IN THE STUDY? 
If you decide to take part in this study, this is what will happen. You will sign this consent form. You will 
undergo a screening period over about 35 days, to determine if you are right for the study. At the first 
screening visit you will be given an electronic diary. The electronic diary must be filled in daily for the 
entire study. This will help the study doctor confirm your eligibility at the beginning of the study and to 
determine how the drug is working throughout the study. It is important the diary be completed daily. 
 
The study has several periods or phases; a screening period, to determine if you are right for the study. 
An induction period and a possible second induction period. The induction period is the time from the 
first time the study drug is given and when a response to the drug is seen. The study phases or periods 
are described below and in detail in the Study Activities Table that follows. 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 4 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
If you are enrolled in the study, you will be randomly assigned (by chance, like the flip of a coin) to 
receive either Risankizumab or placebo (inactive substance that looks like Risankizumab). The placebo 
is not a drug and it is not expected to have any chemical effects on your body, and it is not designed to 
treat any disease or illness. This allows the study scientists to make the best judgment on whether the 
study drug is having effects that are greater than are expected by chance alone. 
This is a Double-blind study. Double blind means that neither you nor your study doctor will be able to 
pick which study drug or dose you receive. However, in case of an emergency, your study doctor can 
find out this information.  
 
The study drug (Risankizumab) is the active ingredient and is given as a subcutaneous medication 
(given under the skin) or an intravenous (IV) medication (infused in the vein). The infusion will last 
about 2 hours.  
 
If you have improved enough during the first 12-week double-blind induction period, you may be eligible 
to go into the maintenance study for Risankizumab.  
 
If you have not improved enough with the first induction treatment, another 12-week double blind 
induction period 2, may be started. This period will include about 3-visits to the 
 VA and a 140-
day follow-up period, from the time of your last dose of study drug medication.  
 
If you do not continue into the maintenance study with Risankizumab, or you end your participation 
from the study early, you may be asked to come in for additional unscheduled visits, as necessary. 
 
This study was designed to enroll participants for scientific, regulatory and ethical reasons. If the target 
number of participants has been enrolled, and you are in the screening period, there may be a 
possibility that you will not be enrolled to complete the study if the targeted number of participants has 
already been reached. 
 
There are three study groups: 
 
• 
Group 1 receives 1200 mg of Risankizumab intravenously (through a vein) on study visits 
Weeks 0, 4 and 8.  
• 
Group 2 receives 600 mg of Risankizumab intravenously on study visits Weeks 0, 4 and 8.  
• 
Group 3 receives placebo intravenously on study visits Weeks 0, 4 and 8. 
 
You will have a 2/3rds chance of receiving Risankizumab for 8 weeks and a 1/3rd chance of receiving 
placebo for 8 weeks. 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 5 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
 
If after receiving the study induction treatment your Crohn’s disease has not improved enough, as 
determined by your doctor assessment, you will be eligible to receive Risankizumab treatment in an 
added induction period 2. For this second induction, there are also 3 groups. You will be randomly 
assigned (by chance, like the flip of a coin) to either groups 1, 2, or 3, if you previously received 
Risankizumab during the first induction period. For induction period 2, you will receive either 
Risankizumab infused (intravenous, in the vein) or subcutaneously (injected under the skin); Each 
group will receive both a placebo and an active treatment. Neither you nor your doctor will know which 
treatment you are receiving. The induction period 2 is as follows: 
 
• 
Group 1 in Period 2 receives 1200 mg of Risankizumab intravenously (through a vein) on study 
visits Weeks 12, 16 and 20. This group receives placebo subcutaneously (under the skin) at 
Weeks 12 and 20. 
• 
Group 2 in Period 2 receives 360 mg of Risankizumab subcutaneously on study visits Weeks 12 
and 20. This group receives placebo intravenously at Weeks 12, 16 and 20. 
• 
Group 3 in Period 2 receives 180 mg of Risankizumab subcutaneously on study visits Weeks 12 
and 20. This group receives placebo intravenously at Weeks 12, 16 and 20. 
 
If you received IV placebo during the initial induction treatment you will be assigned, in a double blinded 
manner, meaning that neither you nor your doctor will know of your assignment, to group 4: 
• 
Group 4 receives 1200 mg of Risankizumab intravenously (through a vein) on study visits 
Weeks 12, 16 and 20. This group receives placebo subcutaneously (under the skin) at Weeks 
12 and 20. 
If you have improved enough during the initial 12-week double-blind induction period, you may be 
eligible to go into the maintenance study for Risankizumab.  
 
If you have not improved enough with the initial induction treatment, an additional 12-week double 
blind induction period 2, may be started. This period will include about 3-visits to the 
 VA 
Medical Center and a 140-day follow-up period, from the time of your last dose of study drug 
medication.  
 
Screening Procedures: 
During the screening period this is what will happen: 
• 
Informed consent: You will sign and date a study specific IRB approved Informed Consent Form 
• 
Inclusion/Exclusion criteria 
• 
Medical/Surgical History – including questions regarding tobacco, alcohol, and drug use 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 6 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
• 
Physical Exam 
• 
Vital Signs (blood pressure, heart rate, respiratory rate, and temperature) height and weight  
• 
ECG (a test which records the electrical activity of your heart) 
• 
Endoscopy: During an endoscopy, you will be mildly sedated and a thin, flexible, lighted tube 
will be inserted inside the bowel. This will allow the doctor to look for abnormal areas. A biopsy 
might be taken during this test. 
• 
Endoscopic biopsy: An endoscope is a long thin tube with lights that can be passed into the 
bowel. To perform a biopsy, a small clamp takes a small piece of superficial tissue from an 
abnormal area seen through the tube. 
• 
Blood and Urine Testing:  Blood and urine will be taken to do laboratory tests. For the blood test 
about 29 ml (6 Teaspoons) will be drawn. 
o Blood and urine tests to monitor your health 
o Blood test for hepatitis B and C - Positive hepatitis test results may be reportable to local 
public health department according to local laws, if applicable. You may have to sign a 
separate consent form before hepatitis testing can start. 
o Blood test for HIV: You will not be eligible to take part in this study for study if test 
results show HIV infection. The study doctor or staff will tell you if the test results are 
positive. The test is confidential, and the study doctor or staff will not share your results 
outside of this study unless local law requires it. The results of the test must be negative 
for you to take part in the study. AbbVie Inc. will not receive results from the testing and 
will not be made aware of any results, positive or negative). 
o FSH blood test, if you are female and younger than age 55, to determine if you have 
completed menopause. 
• 
Pregnancy Testing: Test your blood and/or urine to see if you are pregnant. You will only have 
pregnancy testing if you are a woman and able to become pregnant. 
o The study doctor or study staff will tell you if the pregnancy test results are positive. 
o The results of the pregnancy testing must be negative for you to be in the study. 
• 
Review of any medications you are taking 
• 
PPD Skin Test or QuantiFERON-TB Gold Test (or IGRA equivalent such as T-SPOT) to check 
for tuberculosis (TB). 
• 
X-ray: There is the possibility that your doctor will request an X-ray, for example, if you have a 
positive TB test or required by local law. 
• 
Stool samples: you will be required to provide a stool sample for laboratory test. 
• 
Electronic diary: The study site personnel will give you the study electronic diaries and tell you 
how to use them. You must bring the completed electronic diary back to the study center at 
each visit. 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 7 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
 
Study Visit Procedures: 
You will undergo one or more of the study procedures at each study visit: 
• 
Blood Testing:  Blood will be taken to do laboratory tests. For the blood about 8.5ml to 11.5ml 
(1.7 to 2.3 teaspoons) will be drawn at each visit 
o At every visit about 5.5ml (just over 1 teaspoon) of your blood will be taken to test blood 
cells, chemistry (such as glucose, kidney function and lipids), and to test the degree of 
inflammation in your body. 
o At certain visits about 3 ml (less than 1 teaspoon) of your blood will be taken to test the 
amount of Risankizumab in your blood. 
o At certain visits about 3 ml (less than 1 teaspoon) of your blood will be taken to measure 
the number of certain antibodies in the blood. These are antibodies to the study drug 
(ADA) and neutralizing antibody (nAb) (antibodies that can block the effects of the study 
drug) amounts in your blood. 
• 
Vital Signs (blood pressure, heart rate, respiratory rate, and temperature), and weight  
• 
Physical Exam 
• 
Review of any medications you are taking 
• 
Endoscopy at visit Week 12 and also at visit Week 24, if you are in induction period 2. Biopsies 
may be done when performing the endoscopies. 
• 
Pregnancy Testing: Test your blood and/or urine to see if you are pregnant. You will only have 
pregnancy testing if you are a woman and can become pregnant 
o The study doctor or study staff will tell you if the pregnancy test results are positive. 
o The results of the pregnancy testing must be negative in order for you to continue in the 
study. 
• 
Stool samples: you will provide a stool sample for laboratory test  
• 
Urine samples: you will provide a urine samples for laboratory tests.  
• 
Electronic Questionnaires: Instead of using paper and pencil to understand your disease and 
your response to study drugs, an electronic diary device will be used to collect your answers to 
questions about your health. This device meets all regulations for use in clinical studies, 
including those related to your privacy. Your answers to these questions will be transferred to a 
storage facility via a secure internet connection and will be viewed by site and AbbVie Inc. 
• 
Review Electronic Diary: You should bring the completed electronic diary back to the study 
center at each visit. 
• 
Study drug administration 
 
Your Responsibilities: 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 8 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
For this study to provide useful information about how Risankizumab works, you will be expected to do 
the following:  
● Attend all study visits 
● Tell the study doctor if you are feeling bad or worse than before 
● Do not change your basic treatment for Crohn’s disease before discussing it with they study 
doctor. 
● Tell the study doctor if you have any changes in any medications during the study 
● Follow the directions of the study doctor and research team 
● Fill out the electronic questionnaires and electronic diary completely and honestly and bring the 
electronic diary to the study doctor's office at each visit 
● Carry your subject card with you as long as you are in the study and show it to any medical staff 
that may be involved in your healthcare. 
● While taking part in this research study, do not take part in any other research project without 
approval from the study doctor. This is to protect you from possible injury from things such as 
extra blood drawing, extra X-rays, or possible drug interactions. Taking part in other research 
studies without first discussing it with the investigators of this study may invalidate the results of 
this study, as well as that of the other studies.  
 
“A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by 
U.S. Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time.” 
 
Study Activities Table 
 
Screening 
Period 
(35 Days) 
12-Week Double-Blind 
Induction  
Induction Period 2  
 
Study Activity 
Screening 
Baseline  
(Week 
0) 
Week 
4 
Week 
8 
Week 
12 
Week 16 
Week 
20 
Week 
24 
Premature 
D/C from 
Treatment 
Visit 
Unscheduled 
Visit 
140 
Day 
Follow-
upd 
Informed Consent 
X 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
criteria 
X 
X 
 
 
 
 
 
 
 
 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 9 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
Medical and 
Surgical History - 
including questions 
regarding tobacco, 
alcohol, and drug 
use 
X 
X 
 
 
 
 
 
 
 
 
 
Vital Signs blood 
pressure, heart 
rate, respiratory 
rate and 
temperature, 
Weight and Heighta 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Physical Exam 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
ECG (a test which 
records the 
electrical activity of 
your heart) 
X 
 
 
 
 
 
 
 
 
 
 
Endoscopy/Biopsyb 
X 
 
 
 
X 
 
 
X 
 
 
 
TB Screening 
X 
 
 
 
 
 
 
 
 
 
 
Bloodc tests to 
monitor your 
health 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Urine Tests to 
monitor your 
health 
X 
X 
 
 
X 
 
 
X 
X 
 
 
Hepatitis B and 
Hepatitis C 
Screening 
X 
 
 
 
 
 
 
 
 
 
 
HIV testing 
X 
 
 
 
 
 
 
 
 
 
 
C. difficile toxin 
X 
 
 
 
 
 
 
 
 
 
 
Blood Test for the 
assessment of 
risankizumab (PK) 
levels in your blood 
 
 
X 
X 
X 
 
 
X 
X 
X 
 
 Blood Test for the 
assessment of anti-
drug antibody 
 
X 
X 
X 
X 
 
 
X 
X 
X 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 10 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
(ADA) and 
Neutralizing 
Anti-Drug 
Antibodies (nAb) 
levels in your blood 
Stool samples  
 
X 
X 
 
X 
 
 
X 
X 
 
 
Pregnancy Teste 
serum and/or urine 
(only for females 
who are able to get 
pregnant) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Prior and 
Concomitant 
Medication 
Assessment 
(review of any 
other medication 
you are taking) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Adverse Event 
Assessment 
(review of any side 
effects you are 
experiencing, which 
may or may not be 
related to the study 
drug) 
SAEs only 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense Subject 
Diary 
X 
 
 
 
 
 
 
 
 
 
 
Patient 
Questionnaires: 
CSS  
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Patient 
Questionnaires: 
PGIC 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Subject 
Questionnaires: 
EQ-5D-5L 
FACIT-F 
IBDQ 
 
X 
X 
 
X 
 
 
X 
X 
 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 11 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
D/C = Discontinuation 
Please note that you may be asked to repeat a procedure or test if your study doctor feels it is 
needed to evaluate your condition.  
a. 
Height will be measured at Screening only. 
b. 
You will undergo a full colonoscopy with biopsy during Screening and Week 12 visit. If you enter induction period 2, you will 
undergo an additional endoscopy at Week 24. 
c. 
For some of the blood samples it is preferable to be collected while patients are in fasting condition. 
d. You will be contacted 105 days following study drug discontinuation for an assessment of any new or ongoing 
adverse events, except those subjects who will roll over into risankizumab maintenance study M16-000. During 
this follow-up call the results of the follow-up at home pregnancy test should be communicated to the site by you.  
e. A serum pregnancy test will be performed on all women of childbearing potential at Screening. Urine pregnancy 
test will be performed at the site at Baseline all subsequent visits for all women of child bearing potential. If any 
urine pregnancy test is positive, a serum pregnancy test will be performed at the site and sent to the central 
laboratory. If a pregnancy is identified, the pregnancy must be reported to AbbVie 
f. 
Study drug will be administered intravenously (through a vein) during your site visits at Baseline, Week 4, and 
Week 8, after all assessments and examinations scheduled for that day have been completed. Study drug will only 
be administered at week 12 if you enter induction period 2. Study drug administration at week 12 will be 
intravenous and subcutaneous (under the skin)  
 
5. WHAT POSSIBLE RISKS OR DISCOMFORTS MIGHT I HAVE IF I TAKE PART IN THIS STUDY? 
There is always a chance that any procedure can harm you. The procedures in this study are no 
different. In addition to the risks described above, you may experience a previously unknown risk or 
side effect. Risks of the usual care you receive are not risks of this study. Those risks are not included 
in this consent form. You should talk with your health care providers if you have any questions about 
the risks of usual care. 
 
Possible risks of the Study: 
• 
Questionnaires: Some people become uncomfortable at being asked questions about their 
medical condition; if, for any reason, you wish not to answer specific questions, or you wish to 
terminate the session, you will be able to do so. 
SF-36 
WPAI-CD 
Study Drugs 
Dispensing/ 
Administrationf 
 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
Daily diary review 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 12 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
• 
Photographs: There will be no photographs, audio tapes, or video tapes made of you as part of 
this study. The only video taken for this study is the video capture by the endoscopic camera, if 
needed during the endoscopic procedure to document the condition of the bowel. You will not 
be identified personally. 
• 
Confidentiality: Even though the risk is small, it is possible that your data could be seen by 
someone who does not have permission to see it. 
• 
Blood Draw: There may be some discomfort, bruising, or bleeding at the site where the blood is 
drawn. Sometimes people faint from a blood draw. 
• 
Electrocardiogram (ECG): There is no pain or discomfort during an ECG; however, removing 
the pads may cause some irritation to your skin. 
• 
Physical Exam: There are no special risks with an exam, similar to examinations you have had 
in your doctor's office in the past. 
• 
Intravenous (IV) infusion of study drug: a thin needle is placed inside the vein and could cause 
similar risks to the ones described in the blood draw. 
• 
Subcutaneous Injection of study drug: a needle is used to inject the study drug or placebo under 
the skin. This can cause skin irritation and/or itching. 
• 
Placebo: a placebo is not designed to have any chemical effects on your body. No risks are 
expected from a placebo. 
• 
PPD test (to test for TB infection): there may be slight discomfort where injection is 
administered. Rarely people can have a larger skin reaction at the site. This may require 
treatment for a couple of days. 
• 
Serum Pregnancy Testing: The risks are similar with any blood test. 
• 
QuantiFERON test or T-SPOT TB (to test for TB infection): The risks are similar to any blood 
tests. 
• 
X-ray. You may have an X-Ray to check your lungs for TB infection: There can be risks of 
radiation from the X-ray. The total amount of radiation exposure that you will receive is about 
0.02 mSv or 2 mrem. It is about the same amount of radiation exposure of 2 days of exposure to 
natural background radiation. The radiation involved is minimal risk. You may ask the study 
doctor or study staff if you have questions about the risks of the study procedures. 
• 
Endoscopy/ Biopsy: endoscopies may be either a full colonoscopy or a flexible sigmoidoscopy. 
A colonoscopy, sigmoidoscopy and biopsy of the colon are standard and commonly performed 
medical procedures to examine the large bowel. This procedure may involve some pain and 
discomfort. Rare complications include tearing of the colon and/or bleeding that may require 
surgical repair. When a biopsy (removal of a small piece of tissue) is performed during the 
colonoscopy, bleeding from the biopsy site may occur. Other complications that may occur 
include infection at the biopsy site and bacteria in the blood. If sedation is to be given for the 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 13 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
procedure, your study doctor will discuss with you the risks of sedation. You will not be 
permitted to drive immediately after the procedure and, therefore, will need someone to drive 
you home. You will be asked to sign a separate consent for the colonoscopy. Additional risks for 
the procedure include the rare occurrence of bowel perforation (creation of a hole in the bowel) 
and/or bleeding which might require surgery and/or the use of antibiotics. Following the removal 
of tissue for biopsy, you may see a small amount of blood in your stools. 
• 
Fasting for up to 8 hours could cause dizziness, headache, stomach discomfort, or fainting. 
 
Study Drug Risks; Risankizumab Risks 
No adverse effects were seen in animals given Risankizumab up to 26 weeks. 
 
Risankizumab has been given to healthy volunteers and patients with psoriasis, psoriatic arthritis, 
inflammatory bowel disease, ankylosing spondylitis, and asthma. Risankizumab has been given either 
by intravenous infusion (IV, slowly injected into a vein in the arm) or by subcutaneous injection 
(injection into the deepest skin layer). 
 
Taking the study drug in this study may cause you to have one or more of the side effects (or adverse 
events) as listed below. 
 
In a Phase II psoriasis study, 126 patients received Risankizumab by subcutaneous injection (injected 
into the deepest skin layer).  The most commonly reported side effects were nasopharyngitis 
(inflammation of the nasal passage, 32%), headache (9%), back pain (6%) and arthralgia (joint pain, 
5%). In general, there was no difference in rates of the side effects between patients who received 
Risankizumab and those who received an approved drug for psoriasis or psoriatic arthritis 
(ustekinumab) and no evidence that the events were related to the dose of Risankizumab. There were 
eleven (9%) Risankizumab patients with serious side effects as compared to three (8%) patients with 
serious side effects in 40 patients receiving Ustekinumab. All serious side effects were considered not 
related to Risankizumab by the study doctor, except one case of basal cell carcinoma (a type of skin 
cancer). 
 
Eighty-two patients received Risankizumab in a Crohn’s disease (inflammatory bowel disease) ongoing 
blinded Phase II study. The most commonly reported side effects in the Risankizumab treatment 
groups were: nausea (13% of subjects), arthralgia (joint pain, 15%), headache (12%), abdominal pain 
(11%), vomiting (6%), asthenia (lack of energy, 6%), diarrhea (5%) and pyrexia (fever, 5%). The rates 
were similar to the placebo group except the rates of arthralgia (8%) and asthenia (5%) were lower in 
the placebo group. The rates of serious side effects were lower in the Risankizumab treatment group 
compared to the placebo treatment group (15% vs 31%). 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 14 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
 
Other Potential Risks 
Other monoclonal antibodies that affect the immune response have been associated with side effects 
such as increased risk of infection, serious allergic reactions, injection site reactions (if given 
subcutaneously), and possible increased risk of malignancy (cancer). These side effects have not been 
found associated with Risankizumab. 
 
Infections:  Drugs that affect the body’s immune system may increase the risk of infections, including 
tuberculosis. There is insufficient information now to know if treatment with Risankizumab will lead to an 
increased risk of infections. You will be screened for signs of active infection before you start on 
Risankizumab. 
 
Allergic Reactions:  All drugs have a potential risk of an allergic reaction. Allergic reactions may vary 
from mild (rash, hives, itching) to severe reactions such as anaphylaxis (which may include difficulty 
breathing, swelling of the face or throat, low blood pressure, or loss of consciousness). A severe 
allergic reaction requires immediate medical treatment and could result in permanent disability or death. 
It is important to tell your study doctor about any past allergic reactions that you may have had to other 
drugs including antibody drugs (which are usually given by IV or injection under the skin). 
 
Injection Site Reactions:  Injection of study drug under the skin could result in redness, pain, swelling or 
hardness at the site of the injection. Also bleeding or bruising at the injection site may occur. Most 
injection site reactions are not severe and resolve without any treatment but can be uncomfortable for a 
few hours to a few days. 
 
Infusion Site Reaction: Giving study drug by IV may result in an infusion-related reaction with symptoms 
such as fever, flushing of skin, itching, rash or a decrease in blood pressure. If you are receiving study 
drug IV your doctor will monitor for signs of adverse reaction during the infusion. 
 
Malignancy (cancer):  When an immune system pathway is blocked, there is a possibility of a 
decreased immune defense against malignancies. In the completed studies to date, Risankizumab has 
not been associated with an increased risk of malignancies but the risk with long term therapy is not 
known. 
 
Cardiovascular Events:  In addition, an increased risk of major cardiovascular events (such as heart 
attacks, strokes or cardiovascular death) have been reported in patients with moderate to severe 
psoriasis and psoriatic arthritis. Whether receiving Risankizumab further increases the risk of major 
cardiovascular events is unknown. Any new or worsening signs or symptoms such as chest, neck or 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 15 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
arm pain, shortness of breath, sensation of rapid heart rate, new visual symptoms or muscle weakness 
should be immediately reported to your study site and/or primary health care provider. 
 
An antidote against Risankizumab is currently not available. Any side effects occurring because of 
Risankizumab will be treated symptomatically. 
 
Pregnancy risks, risk to nursing infant and contraceptive precautions 
The safe use of Risankizumab in pregnant women and nursing mothers has not been established. 
Consequently, there may be risks to you (or to your embryo or fetus) if you are or may become 
pregnant that are unknown. Women of childbearing potential enrolling in this study must have a 
negative pregnancy test and must agree to continue to use a birth control measures for the duration of 
the study. If, while participating in the study, you suspect you have become pregnant, please contact 
the study physician immediately. Nursing mothers may not take part in this study. 
 
If you are a woman who can have children, the study doctor or study staff will talk to you about birth 
control you must use during study participation and 16 weeks after your last dose of study drug. If you 
are able to become pregnant, you must agree to use at least one accepted method of contraception 
during the study including up to 16 weeks after last dose of study drug. 
 
Acceptable methods of contraception in this study are: 
• 
Combined (estrogen and progestogen containing) hormonal birth control (oral, intravaginal, 
transdermal) associated with inhibition of ovulation  
• 
Progestogen-only hormonal birth control (oral, injectable, transdermal) associated with inhibition 
of ovulation 
• 
Bilateral tubal occlusion/ligation  
• 
Intrauterine device (IUD)  
• 
Intrauterine hormone-releasing system (IUS) 
• 
Male or female condom with or without spermicide 
• 
Cap, diaphragm, or sponge with spermicide   
• 
Vasectomized sexual partner(s) (the vasectomized partner should have received medical 
assessment of the surgical success and is the sole sexual partner of the trial participant) 
• 
True abstinence:  Refraining from heterosexual intercourse when this is in line with the preferred 
and usual lifestyle of the subject (periodic abstinence [e.g., calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable).  
 
Some methods of birth control will not work when you are taking certain drugs. If you decide to take 
part in this study and you are able to become pregnant, a pregnancy test will be done before your 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 16 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
participation in the study and at other visits if necessary.  
 
You also may take part in this study if you are surgically sterilized (both ovaries or fallopian tubes 
removed or uterus removed) or you are post-menopausal (no menses for at least 1 year without other 
cause identified). 
 
Once you’re enrolled in the study, if you become pregnant or think you could be pregnant, it is 
important for you to tell the study doctor or staff immediately. If you become pregnant during the study, 
you will no longer receive study drug. Even if you are no longer in the study or not receiving study drug, 
your study doctor will contact you about the outcome of the pregnancy including following the birth of an 
infant to find out about the baby´s health. Outcomes collected will include the fetal number and fetal 
outcome, date of delivery, birth weight and length, sex, any medically significant complications with the 
mother and/or baby and the presence of any birth defects. 
 
Unknown Risks 
You may experience side effects that are not listed in this informed consent.  As with any investigational 
drug, administration of Risankizumab may involve risks that are currently unknown, including life 
threatening reactions or the remote possibility of death. 
 
You should notify the study doctor of any changes in your health or new symptoms you are 
experiencing, even if you think these changes are not related to study drug. 
 
You will be told of important new information about this study or the study drug that becomes available 
and that may affect your willingness to take part in this study. 
 
Safety Monitoring: 
Blood test, vital signs, ECG, and physical exams will be done through-out the study. 
 
Tell your doctor if you develop any signs of infection including fever, sweats, chills, flu-like symptoms, 
cough shortness of breath, feeling tired, diarrhea, skin rashes or sores, burning when you urinate or 
urinating more often than normal. 
 
6. WHAT ARE THE POSSIBLE BENEFITS OF THIS STUDY? 
You may or may not benefit from being in this study, but knowledge gained from your participation in 
this research study may benefit future patients with Crohn’s disease. 
 
7. WHAT OTHER CHOICES DO I HAVE IF I DO NOT WANT TO JOIN THIS STUDY?  
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 17 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
You do not have to take part in this study to be treated for your Crohn’s disease. Other treatment 
options for your Crohn’s disease are available. Other treatment choices may include getting standard of 
care for Crohn’s disease without being in the study or taking part in another study. You may discuss 
these options with your doctor 
 
8. HOW WILL MY PRIVATE INFORMATION BE PROTECTED? 
The VHA complies with the requirements of the Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 and its privacy regulations and all other applicable laws that protect your privacy as a 
VA patient. Individually identifiable data collected from you will be stored at 
 VA under lock and 
key in the study team office; on password-protected VA computer systems accessible only to the study 
team. Your records will have a unique code in place of information that can be used to identify you 
(such as your name or address). The sponsor and companies working with the sponsor will have 
access to coded records and accompanying data to conduct the research. However, they will not be 
able to see the key that links the code to you. We will include information about your study participation 
in your medical record. 
 
There are times when we might have to show your records to other people for monitoring and auditing 
purposes. For example, someone from the Office of Human Research Protections, the Government 
Accountability Office, the Office of the Inspector General, the VA Office of Research Oversight, the 
Institutional Review Board, our local Research and Development Committee, the FDA and other study 
monitors may look at or copy portions of records that identify you. 
 
Data that can be individually identified as yours will be shared outside of 
VA with only the 
study sponsor and its safety oversight committee (AbbVie, 1 North Waukegan Road, North Chicago, IL 
60064); the laboratory that performs the tests on your samples (
 
); the imaging center 
; 
contractor for the proper collection of data 
 and 
diary entries 
  
 
Despite these protections, once your information is shared outside of 
 VA, there is a possibility 
that your information may no longer be protected by Federal laws or regulations and may be subject to 
re-disclosure by the recipient. 
 
All other data shared outside of the study team will be released in a way that you cannot be individually 
identified. Information about you will be combined with information from other people taking part in the 
study. We will write about the combined data we have gathered. Any talks or papers about this study 
will not identify you. 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 18 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
 
A more detailed description of how we will use and protect your private information will be provided to 
you in a separate document, known as a HIPAA Authorization. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required by U.S. 
Law. This website will not include information that can identify you. At most, the website will include a 
summary of the results. You can search this website at any time. 
 
9. WHAT WILL HAPPEN IF I AM INJURED BECAUSE OF MY BEING IN THE STUDY? 
Every reasonable safety measure will be used to protect your well-being. If you are injured because of 
taking part in this study, the VA will provide necessary medical treatment at no cost to you unless the 
injury was due to your not following the study procedures. You do not give up any of your legal rights 
and you do not release the VA from any liability by signing this form. 
 
If you should have a medical concern or get hurt or sick as a result of taking part in this study, call the 
study investigator Dr. 
 during the day at 
. If 
after hours, contact 
VA Health Care System operator at
 by pressing 0 or by 
staying on the line until they answer. You should inform the operator that you are in a research study 
and give the name of the Principal Investigator of this study. 
 
For emergency care, you should call 911 or VA Emergency Department 
 If 
any medical problems occur in connection with this study, the VA will provide emergency care. You can 
also contact your Primary Care Provider in case you have any additional medical problems or 
questions. Emergency and ongoing medical treatment will be provided as needed. 
 
The next statement is the policy of the outside sponsor of this study and does not waive any of your 
rights as a Veteran or as a research subject, or your rights to legal recourse:  
Treatment for injuries that results from the study drug or study procedures is available. Your 
study doctor will discuss with you the available medical treatment options. You may arrange to 
have treatment performed by the study doctor or a licensed doctor selected by you. 
AbbVie Inc. makes no commitment to provide compensation except as described above.  
 
10. PERSONS TO CONTACT ABOUT THIS STUDY 
If you have questions or concerns about the study, please contact the study investigator Dr. 
 
 or the study team 
. 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 19 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
If you have any questions about the conduct of this study or about your rights as a participant in this study, 
you should contact the Research Service Champion, 
 The 
Champion will follow-up and may further connect you, as appropriate, with the Chairperson of the 
Institutional Review Board (IRB), the Chairperson of the Research and Development Committee, the 
Research Administrative Officer, or the Research Compliance Officer. 
 
11. PARTICIPATION IS VOLUNTARY 
It is up to you to decide whether to take part in this study or not. If you decide to take part, you may still 
withdraw at any time. To withdraw your consent to participate, you need to inform the investigator or 
study team. Once you have withdrawn your consent, no further study visits are required 
 
However, if you decide to end your participation early, you may be asked to return for a last visit as 
soon as possible to check on your health. You may also have a follow-up call 140 days from the last 
dose of the study drug to find out how you are doing. If you withdraw in writing your participation in the 
study ends. 
 
If you do not wish to be in this study or leave the study early, you will not lose any benefits to which you 
are entitled. If you do not take part, you can still receive all usual care that is available to you. Your 
decision not to take part will not affect the relationship you have with your doctor or other staff, and it 
will not affect the usual care that you receive as a patient. 
 
Data already collected for the study prior to your withdrawal, may continue to be reviewed by the study 
investigator but no further information will be collected, except from public records, such as survival 
data. Any specimens already used cannot be withdrawn. 
 
The HIPAA Authorization which permits VA to use and release your medical record is a separate form 
that, unlike this consent form, must be revoked in writing. To ensure that VA cannot be forced to access 
your health records for this study after you withdraw your consent, you should also revoke your HIPAA 
Authorization. The study team can provide a HIPAA revocation form for you to use, or you can send a 
written statement that you revoke your HIPAA authorization to the revocation address on the study’s 
HIPAA Authorization form. 
 
12. RIGHT OF INVESTIGATOR TO TERMINATE MY PARTICIPATION  
At any time, your study doctor may stop your participation for any reason regardless if you signed 
consent. The study doctor may decide to stop your participation without your permission if they think 
that being in the study may cause you harm or for any reason. The study sponsor AbbVie may stop the 
study prematurely for any reason, either in its entirely or at any site  
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 20 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
 
13.  WHAT IS THE COST TO ME AND PAYMENT FOR ME IF I TAKE PART IN THIS STUDY? 
A. Costs to Participants:   
You will not be charged for any treatments or procedures that are part of this study. If you usually 
pay co-payments for VA care and medications, you will still pay these co-payments for VA care and 
medications that are not part of this study.  
 
B. Payment Offered for Participation:   
You will not be compensated for your time and effort taking part in this study.  
However, you will receive $50.00 per visit. The total amount possible for study participation is $400.00. 
The stipend will be on a ClinCard, which works like a gift/credit card. When visits are completed, funds 
will be loaded onto your card.  You will be able to use the funds in approximately one business day. If 
you have issues when using this ClinCard, please contact the study team. The provider of the ClinCard 
(Greenphire) will not have access to your name or contact information.  Instead, they will have your 
study ID number that will be provided to you by the study coordinator.  You will be able to use this study 
ID number to check the balance on your ClinCard. If your ClinCard is lost or stolen, Greenphire cannot 
cancel your card if is lost or stolen, and the entire current balance on the card may be lost. However, 
you will be issued a new card for future payments. If you get more than $600 in one year from ClinCard, 
this will generate Internal Revenue Service (IRS) form 1099. Your SSN will be used for this purpose. 
 
14.  WILL I BE TOLD NEW INFORMATION ABOUT THIS STUDY?  
During the course of a research study, if new information becomes available about Risankizumab that 
might change a person’s decision to stay in the study, your research doctor will tell you about it and 
discuss with you whether you want to continue in the study. If you decide to withdraw from the study, 
your research doctor will arrange for your medical care to continue. If you decide to continue in the 
study, you might be asked to sign an updated informed consent form. Your research doctor could also 
decide to withdraw you from the study in your best interests. If so, he or she will explain the reasons 
and arrange for your usual medical care to continue. 
 
Tests done for research purposes are not meant to provide information for clinical treatment. Your 
individual results for this study will not be provided to you. There is a slight possibility that during this 
study, an investigator could discover something that could affect the health of you or your family. If this 
occurs, the finding will be reviewed by the study team to determine if it is in your best interest to contact 
you. If so the investigator will contact you using the information you provided. With the help of an 
appropriate medical specialist, they will present possible risks or benefits of receiving the information. 
At that time, you can choose to receive or refuse to receive the result or finding. 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 21 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
 
15.  WHO COULD PROFIT FROM THE STUDY RESULTS? 
The use of your donated sample may be used for research that may result in scientific discoveries that 
may lead to new products, tests, or treatments. These discoveries may have potential commercial 
value. If this occurs, there are no plans to provide financial payment or benefits to you or your relatives. 
 
 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy


 
 
 
 VA Health Care System 
Research Consent Form 
 
Version Date:  10/30/2019 
Principal Investigator / Researcher:  
 MD 
Title of Study: Clinical Study Protocol M15-991 A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (eRD 1191) 
 
Participant’s Name: 
_____________  ____________ ___________ 
Last                              First                          Middle                                 
  
Last 4: ____________ 
 
Date of Birth: _____________ 
 
 
Page 22 of 22 
 
 IRB USE ONLY 
 
 
IRB Approval Date:  11/13/2019  ajv 
 
Form valid only if the above completed. 
 
Document # 14 – 28March2019 - pap      
 
AGREEMENT TO PARTICIPATE IN THE RESEARCH STUDY 
The Principal Investigator 
 or his/her study team has explained the study to me. I have 
been told of the risks or discomforts and possible benefits of the study. I have been told of other 
alternatives available to me. I have been given the chance to ask questions and obtain answers. I will 
receive a copy of this consent. 
 
By signing this document below, I voluntarily consent to participate in this study. I also confirm that I 
have read this consent, or it has been read to me. A copy of this signed consent will also be put in your 
medical record. 
 
 
I agree to participate in this research study as has been explained in this document. 
 
 
 
_________________________ 
Participant’s Name 
____________________________ 
Participant’s Signature 
___________ 
Date 
___________________________ 
Name of person obtaining consent 
______________________________ 
Signature of person obtaining consent 
____________ 
Date 
 
VV-TMF-3887061 M15-991 US - 162261 Informed Consent - 30 Oct 2019 - Final Copy

SAP_002.pdf: 
Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
1
Statistical Analysis Plan for Study M15-991
A Multicenter, Randomized, Double-Blind, 
Placebo-Controlled Induction Study to Assess the 
Efficacy and Safety of Risankizumab in Subjects 
with Moderately to Severely Active Crohn's Disease 
Who Failed Prior Biologic Treatment
Date:  23 November 2020
Version 5.0
NCT03104413


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
2
Table of Contents
1.0
Introduction .............................................................................5
2.0
Study Design and Objectives..................................................5
2.1
Objectives, Hypotheses and Estimands .....................................................5
2.2
Study Design Overview .............................................................................9
2.3
Treatment Assignment and Blinding .......................................................12
2.4
Sample Size Determination......................................................................12
3.0
Endpoints................................................................................13
3.1
Primary Endpoint(s).................................................................................14
3.2
Secondary Endpoint(s).............................................................................14
3.3
Other Efficacy Endpoint(s)......................................................................16
3.4
Safety Endpoint(s) ...................................................................................20
3.5
Additional Endpoint(s).............................................................................20
4.0
Analysis Populations .............................................................20
5.0
Subject Disposition................................................................22
6.0
Study Drug Duration and Compliance................................23
6.1
Study Drug Duration................................................................................23
6.2
Study Drug Compliance...........................................................................26
6.2.1
Intravenous Therapy ................................................................................26
6.2.2
Subcutaneous Therapy.............................................................................27
7.0
Demographics, Baseline Characteristics, Medical 
History, and Prior/Concomitant Medications ....................27
7.1
Demographics and Baseline Characteristics............................................27
7.2
Medical History .......................................................................................29
7.3
Prior and Concomitant Medications ........................................................30
8.0
Efficacy Analyses...................................................................30
8.1
General Considerations............................................................................30
8.2
Handling of Potential Intercurrent Events ...............................................32
8.2.1
Premature Discontinuation of Study Drug...............................................32
8.2.2
CD-Related Corticosteroid Therapy ........................................................33
8.3
Handling of Missing Data........................................................................33
8.3.1
Categorical Endpoints..............................................................................34


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
3
8.3.2
Continuous Endpoints..............................................................................35
8.4
Primary Efficacy Endpoint(s) and Analyses............................................37
8.4.1
Primary Efficacy Endpoint(s) ..................................................................37
8.4.2
Handling of Missing Data for the Primary Efficacy Endpoint(s)............38
8.4.3
Primary Efficacy Analysis .......................................................................38
8.4.4
Additional Analyses of the Primary Efficacy Endpoint(s) ......................39
8.5
Secondary Efficacy Analyses...................................................................39
8.5.1
Key Secondary Efficacy Analyses...........................................................39
8.5.2
Supportive Secondary Efficacy Analyses ................................................40
8.6
Additional Efficacy Analyses ..................................................................40
8.7
Efficacy Subgroup Analyses....................................................................42
9.0
Safety Analyses ......................................................................43
9.1
General Considerations............................................................................43
9.2
Adverse Events ........................................................................................44
9.2.1
Treatment-Emergent Adverse Events ......................................................45
9.2.2
Adverse Event Overview .........................................................................46
9.2.3
Treatment-Emergent Adverse Events by SOC and/or PT .......................47
9.2.4
Treatment-Emergent Adverse Events per Patient-Years of 
Exposure ..................................................................................................47
9.2.5
SAEs (Including Deaths) and Adverse Events Leading to Study 
Drug Discontinuation...............................................................................48
9.2.6
Areas of Safety Interest............................................................................48
9.3
Analysis of Laboratory Data....................................................................48
9.4
Analysis of Vital Signs ............................................................................50
10.0
Interim Analyses....................................................................51
10.1
Data Monitoring Committee....................................................................51
11.0
Overall Type-I Error Control ..............................................51
12.0
Version History......................................................................55
13.0
References...............................................................................57
List of Tables
Table 1.
Subgroups for Efficacy Analysis .............................................................43


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
4
Table 2.
SAP Version History Summary...............................................................55
List of Figures
Figure 1.
Study Schematic.........................................................................................9
Figure 2.
Graphical Multiple Testing Procedure for US Specific Protocol ............53
Figure 3.
Graphical Multiple Testing Procedure for Global Protocol Outside 
US ............................................................................................................54
List of Appendices
Appendix A.
Protocol Deviations..................................................................................58
Appendix B.
Areas of Safety Interest (ASI)..................................................................59
Appendix C.
Potentially Clinically Significant Criteria for Safety Endpoints..............63
Appendix D.
Crohn's Disease Activity Index (CDAI) ..................................................65
Appendix E.
Simple Endoscopic Score – CD (SES-CD)..............................................67
Appendix F.
Inflammatory Bowel Disease Questionnaire (IBDQ)..............................69
Appendix G.
FACIT-Fatigue.........................................................................................71
Appendix H.
Random Seeds..........................................................................................73
Appendix I.
Geographic Region ..................................................................................74
Appendix J.
Definition of Estimand for Primary and Ranked Secondary 
Endpoints .................................................................................................75


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
5
1.0
Introduction
This Statistical Analysis Plan (SAP) describes the statistical analyses for risankizumab 
Study M15-991 " A Multicenter, Randomized, Double-Blind, Placebo Controlled 
Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with 
Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment."
Pharmacokinetics/pharmacodynamics, pharmacogenetics, and selected biomarkers will be 
analyzed separately and are not included in this SAP.
The SAP will not be updated in case of administrative changes or amendments to the 
protocol unless the changes impact the analysis.
Unless noted otherwise, all analyses will be performed using SAS Version 9.4 (SAS 
Institute Inc., Cary, NC  27513) or later under the UNIX operating system.
This SAP includes changes to analyses described in the protocol.  Details are outlined in 
Section 12.0.
2.0
Study Design and Objectives
2.1
Objectives, Hypotheses and Estimands
The objective of this study is to evaluate the efficacy and safety of risankizumab versus 
placebo during induction therapy in subjects with moderately to severely active Crohn's 
Disease (CD) who failed prior biologic treatment.
Primary Efficacy Objective
●
For US-specific protocol:
The primary efficacy objective of the study for US-specific protocol is to demonstrate a 
higher rate of a) CDAI clinical remission (defined as Crohn's disease activity index
[CDAI] < 150), and b) endoscopic response (defined as decreasing in Simple Endoscopic 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
6
Score – CD [SES-CD] > 50% from baseline [or for subjects with isolated ileal disease and 
a baseline SES-CD of 4, at least a 2 point reduction from baseline], as scored by central 
reviewer) after 12 weeks of treatment with risankizumab when compared to placebo based 
on Intent-to-Treat (ITT) population ITT1A (see Section 4.0).
Hypotheses corresponding to the primary efficacy objective and endpoints for US-
specific protocol are:
●
The proportion of subjects achieving CDAI clinical remission treated with 
risakizumab is greater than that treated with placebo at Week 12
●
The proportion of subjects achieving endoscopic response treated with 
risakizumab is greater than that treated with placebo at Week 12
The estimands corresponding to the primary efficacy objective for US-specific protocol
are defined as follows:
●
Difference in the percentage of subjects achieving CDAI clinical remission at 
Week 12 regardless of premature discontinuation of study drug and without 
initiation or dose escalation of CD-related corticosteroids (See Section 8.2.2) in 
each of the risankizumab 1200 mg intravenous (IV) and risankizumab 600 mg 
IV groups in comparison with the placebo group in the ITT1A population
●
Difference in the percentage of subjects achieving endoscopic response at 
Week 12 regardless of premature discontinuation of study drug and without 
initiation or dose escalation of CD-related corticosteroids (See Section 8.2.2) in 
each of the risankizumab 1200 mg IV and risankizumab 600 mg IV groups in 
comparison with the placebo group in the ITT1A population. 
●
For global protocol outside US:
The primary efficacy objective of the study for global protocol outside US is to 
demonstrate a higher rate of a) clinical remission (defined as average daily stool 
frequency [SF] ≤ 2.8 and not worse than baseline AND average daily abdominal pain 
[AP] score ≤ 1 and not worse than baseline), and b) endoscopic response after 12 weeks of 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
7
treatment with risankizumab when compared to placebo based on Intent-to-Treat (ITT) 
population ITT1A.
Hypotheses corresponding to the primary efficacy objective and endpoints for global 
protocol outside US is:
●
The proportion of subjects achieving clinical remission treated with 
risakizumab is greater than that treated with placebo at Week 12
●
The proportion of subjects achieving endoscopic response treated with 
risakizumab is greater than that treated with placebo at Week 12
The estimands corresponding to the primary efficacy objective for global protocol outside 
US are defined as follows:
●
Difference in the percentage of subjects achieving clinical remission at Week 
12 regardless of premature discontinuation of study drug and without initiation 
or dose escalation of CD-related corticosteroids (See Section 8.2.2) in each of 
the risankizumab 1200 mg IV and risankizumab 600 mg IV groups in 
comparison with the placebo group in the ITT1A population
●
Difference in the percentage of subjects achieving endoscopic response at 
Week 12 regardless of premature discontinuation of study drug and without 
initiation or dose escalation of CD-related corticosteroids (See Section 8.2.2) in 
each of the risankizumab 1200 mg IV and risankizumab 600 mg IV groups in 
comparison with the placebo group in the ITT1A population. 
Secondary Efficacy Objectives
For both US-specific protocol and global protocol outside US:
The secondary efficacy objectives of this study are to demonstrate higher efficacy of 
treatment with risankizumab when compared to placebo with respect to the ranked
secondary endpoints specified in Section 3.2 under each protocol. The ranked secondary 
efficacy objectives will be assessed based on ITT1A population.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
8
Hypotheses corresponding to the secondary efficacy objectives and endpoints are: 
1.
For each of the ranked binary secondary endpoints (Section 3.2), greater proportion 
of subjects with improvement for the endpoint is achieved with risankizumab when 
compared to that of placebo; 
2.
For each of the ranked continuous endpoints (Section 3.2), greater mean change 
from baseline for the endpoint is achieved with risankizumab when compared to 
that of placebo.
For each of the binary ranked secondary endpoints except for CD-related hospitalization 
endpoint, the estimands corresponding to the secondary efficacy objectives are defined as 
follows: Difference in the percentage of subjects achieving the endpoint regardless of 
premature discontinuation of study drug and without initiation or dose escalation of CD-
related corticosteroids (See Section 8.2.2) in each of the risankizumab 1200 mg IV and 
risankizumab 600 mg IV groups in comparison with the placebo group in the ITT1A
population.
For the secondary endpoint of "Occurrence of CD-related hospitalization through Week 
12," the estimand is defined as follows: Difference in the percentage of subjects having 
CD-related hospitalization through Week 12 regardless of premature discontinuation of 
study drug and regardless of initiation or dose escalation of CD-related corticosteroids
(See Section 8.2.2) in each of the risankizumab 1200 mg IV and risankizumab 600 mg IV 
groups in comparison with the placebo group in the ITT1A population.
For each of the continuous ranked secondary endpoints, the estimands corresponding to 
the secondary efficacy objectives are defined as follows: Difference in the mean change 
from baseline for the endpoint regardless of premature discontinuation of study drug and 
if subjects would not initiate or escalate dose of CD-related corticosteroids (See Section 
8.2.2) in each of the risankizumab 1200 mg IV and risankizumab 600 mg IV groups in 
comparison with the placebo groups in the ITT1A population.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
9
2.2
Study Design Overview
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study 
designed to evaluate the efficacy and safety of risankizumab as an induction therapy in 
subjects with moderately to severely active CD.
The study consists of the following periods:
1.
Screening period of up to a maximum of 35 days
2.
12-week randomized, double-blinded IV therapy induction period (12-Week 
Induction Period) 
3.
12-week randomized, double-blinded, double-dummy Induction Period 2 
(Induction Period 2) for subjects who do not achieve clinical response at Week 12  
4.
20-week follow up period from the last dose of study drug.
The schematic of the study is shown in Figure 1.
Figure 1.
Study Schematic
a.
12-Week Induction Period


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
10
Figure 1.
Study Schematic (Continued)
b. Induction Period 2
DC = discontinued; IR = subjects with inadequate clinical response to induction; IV = intravenous; R = subjects with 
clinical response; RR = re-randomize 
Approximately 579 patients with moderate to severe CD who had baseline eligible SES-
CD (eligible SES-CD is defined as total SES-CD score excluding presence of narrowing 
subscore) of ≥ 6 (≥ 4 for isolated ileal disease) are to be randomized in a ratio of 1:1:1 to 
one of the three following treatment groups in the 12-Week Induction Period. 
●
Placebo IV (n = 193)
●
Risankizumab 600 mg IV (n = 193)
●
Risankizumab 1200 mg IV (n = 193)
In addition to the 579 subjects, up to 58 subjects with a lower SES-CD, defined as an 
eligible SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or SES-CD of 3 for 
isolated ileal disease will be enrolled in order to inform treatment effect in this patient 
population, but these subjects will not be included in the primary ITT population for 
efficacy analysis.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
11
Each treatment group receives the corresponding dose of risankizumab or placebo IV 
infusion at Week 0, Week 4, and Week 8.  At Week 12, patients are evaluated for clinical 
response, defined as ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in 
average daily AP score and both not worse than baseline.  
Visits for clinical evaluation will occur at baseline/Week 0, Weeks 4, 8, and 12 or 
Premature Discontinuation (PD).  
Subjects, who do not achieve clinical response at Week 12 will be randomized by 
Interactive Response Technologies (IRT) to the Induction Period 2, a double-blind, double 
dummy 12-week treatment period. Subjects who received risankizumab induction 
treatment during the 12-Week Induction Period will be randomized 1:1:1 to:
●
Risankizumab 1200 mg IV 
●
Risankizumab 360 mg subcutaneous (SC) 
●
Risankizumab 180 mg subcutaneous (SC) 
Subjects who received placebo induction treatment during the 12-Week Induction Period 
will receive:
●
Risankizumab 1200 mg IV
The IV risankizumab dose or matching IV placebo will be given at Weeks 12, 16, and 20; 
The SC risankizumab dose or matching SC placebo will be given at Weeks 12, and 20.
At Week 24, subjects who participated in the blinded Induction Period 2 will be 
reassessed and undergo a third endoscopy for evaluation of mucosal inflammation.  
Subjects who achieve clinical response at Week 24 may be eligible to enter the Study 
M16-000.  Subjects without clinical response at Week 24, as well as all subjects who are 
terminated the study early (including subjects who are eligible for but do not participate in 
the blinded Induction Period 2), will be discontinued and have a follow-up call 140 days 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
12
from the last dose of study drug to obtain information on any new and/or ongoing adverse 
events (AEs).
2.3
Treatment Assignment and Blinding
At baseline, eligible patients will be randomized to three parallel groups with 1200 mg IV 
and 600 mg IV dose of risankizumab treatments or placebo in a 1:1:1 ratio.  The 12-Week 
Induction Period randomization will be stratified by number of prior biologics failed (1, > 
1), baseline steroid use (Yes, No), and baseline eligible SES-CD (original, alternative), 
where the stratum of "original" includes the patients with baseline eligible SES-CD of ≥ 6 
(or ≥ 4 for subjects with isolated ileal disease), and the stratum of "alternative" includes 
the patients with baseline eligible SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease 
or SES-CD of 3 for isolated ileal disease.  
Subjects with clinical non-response to risankizumab at Week 12 will be re-randomized in 
a 1:1:1 ratio to risankizumab 1200 mg IV dose group, risankizumab 360 mg SC dose 
group, or risankizumab 180 mg SC dose group in the Induction Period 2.  Subjects with 
clinical non-response to placebo at Week 12 will blindly receive risankizumab 1200 mg 
IV dose.  No stratification will be made for the Induction Period 2 randomization.
2.4
Sample Size Determination
For US-specific protocol, the co-primary endpoints are the achievement of CDAI clinical 
remission at Week 12 and the achievement of endoscopic response at Week 12.  For 
global protocol outside US, the co-primary endpoints are the achievement of clinical 
remission at Week 12 and the achievement of endoscopic response at Week 12.
Sample size calculation is based on the larger sample size needed to detect treatment 
difference between the risankizumab treatment group and the placebo group for each of 
the co-primary endpoints.  Since historical data show slightly lower event rate and similar 
treatment difference for the endoscopic response rate compared to the clinical remission 
rate at Week 12, as well as the larger treatment difference for the CDAI clinical remission 
rate compared to the clinical remission rate at Week 12, clinical remission rates at Week 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
13
12 are used for power calculation.  A total of 579 subjects will be randomized into the two 
risankizumab treatment groups and the placebo group in a 1:1:1 ratio (with 193 subjects 
per treatment group).  Assuming the clinical remission rate at Week 12 will be 23.5% for  
one of the risankizumab treatment groups and 10% for the placebo group, this sample size 
of 193 subjects per treatment group will have approximately 89% power to detect the 
treatment difference between risankizumab and placebo using a Fisher's exact test at a 
0.025 significant level (two-sided).  Assuming the Week 12 CDAI clinical remission rate 
will be 34% for one of the risankizumab treatment groups and 15% for the placebo group, 
this sample size will have 97% power to detect the treatment difference between 
risankizumab and placebo using a Fisher's exact test at a 0.025 significant level (two-
sided).  Assuming the Week 12 endoscopic response rate will be 17% for one of the 
risankizumab treatment groups and 5% for the placebo group, this sample size will have 
93% power to detect the endoscopic response treatment difference between risankizumab 
and placebo using a Fisher's exact test at a 0.025 significant level (two-sided).  The rates 
are based on the results from the risankizumab Phase 2 Study 1311.6, where the study 
population comprised approximately 95% bio-IR subjects, and account for lower rates for 
ustekinumab failure patients.
3.0
Endpoints
Below are the definitions of the endpoints used in the efficacy analysis:
●
Clinical remission:  average daily SF ≤ 2.8 and not worse than baseline AND 
average daily AP score ≤ 1 and not worse than baseline
●
Enhanced clinical response:  ≥ 60% decrease in average daily SF and/or 
≥35% decrease in average daily AP score and both not worse than baseline, 
and/or clinical remission
●
Clinical response:  ≥ 30% decrease in average daily SF and/or ≥ 30% decrease 
in average daily AP score and both not worse than baseline
●
Endoscopic response:  decrease in SES-CD > 50% from baseline (or for 
subjects with isolated ileal disease and a baseline SES-CD of 4, at least a 
2 point reduction from baseline), as scored by central reviewer


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
14
●
Ulcer-free endoscopy:  SES-CD ulcerated surface subscore of 0 in subjects 
with SES-CD ulcerated surface subscore ≥ 1 at baseline, as scored by a central 
reviewer
●
Endoscopic remission:  SES-CD ≤ 4 and at least a 2 point reduction versus 
baseline and no subscore greater than 1 in any individual variable, as scored by 
a central reviewer
●
CDAI clinical response:  reduction of CDAI ≥ 100 points from baseline
●
CDAI clinical remission:  CDAI < 150
●
SF remission: average daily SF ≤ 2.8 and not worse than baseline
●
AP remission: average daily AP score ≤ 1 and not worse than baseline
3.1
Primary Endpoint(s)
For US-specific protocol, the co-primary efficacy endpoints are
●
The achievement of CDAI clinical remission at Week 12 
●
The achievement of endoscopic response at Week 12
For global protocol outside US, the co-primary efficacy endpoints are
●
The achievement of clinical remission at Week 12 
●
The achievement of endoscopic response at Week 12
3.2
Secondary Endpoint(s)
For US-specific protocol, the secondary endpoints under overall type I error control 
are: 
1.
The achievement of clinical remission at Week 12
2.
The achievement of CDAI clinical response at Week 4 
3.
The achievement of CDAI clinical response at Week 12 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
15
4.
Change from baseline in Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-Fatigue) at Week 12 
5.
The achievement of CDAI clinical remission at Week 4 
6.
The achievement of CDAI clinical response and endoscopic response at Week 12 
7.
The achievement of SF remission at Week 12 
8.
The achievement of AP remission at Week 12
9.
The achievement of endoscopic remission at Week 12
10.
The achievement of enhanced clinical response at Week 4
11.
The achievement of ulcer-free endoscopy at Week 12
12.
The achievement of enhanced clinical response at Week 12
13.
The achievement of resolution of extra-intestinal manifestations (EIMs) at Week 
12, in subjects with any EIMs at baseline
14.
Occurrence of CD-related hospitalization through Week 12
15.
The achievement of no draining fistulas at Week 12 in subjects with draining 
fistulas at baseline
For global protocol outside US, the secondary endpoints under overall type I error 
control are:
1.
The achievement of CDAI clinical remission at Week 12
2.
The achievement of CDAI clinical response at Week 4 
3.
The achievement of clinical remission at Week 4 
4.
The achievement of CDAI clinical response at Week 12 
5.
Change from baseline in FACIT-Fatigue at Week 12 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
16
6.
Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total 
score at Week 12 
7.
The achievement of enhanced clinical response and endoscopic response at Week 
12 
8.
The achievement of endoscopic remission at Week 12
9.
The achievement of enhanced clinical response at Week 4
10.
The achievement of ulcer-free endoscopy at Week 12
11.
The achievement of enhanced clinical response at Week 12
12.
The achievement of resolution of EIMs at Week 12, in subjects with any EIMs at 
baseline
13.
Occurrence of CD-related hospitalization through Week 12
14.
The achievement of no draining fistulas at Week 12 in subjects with draining 
fistulas at baseline
15.
Change from baseline in Work Productivity and Impairment Questionnaire –
Crohn's disease (WPAI-CD) Overall Work Impairment at Week 12
16.
Change from baseline in Short Form-36 (SF-36) Physical Component Summary 
(PCS) score at Week 12
3.3
Other Efficacy Endpoint(s)
The primary and secondary efficacy endpoints are listed in Section 3.1 and Section 3.2, 
respectively.  The additional efficacy endpoints for each induction period are:  
12-Week Induction Period:
●
Change from baseline in IBDQ at Week 4, Week 12 respectively
●
Change from baseline in individual IBDQ domain scores (bowel, emotional, 
social, systemic) at Week 4, Week 12 respectively


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
17
●
The achievement of IBDQ remission (IBDQ > 170 points) at Week 4, Week 12 
respectively
●
The achievement of IBDQ response (increase in IBDQ > 16 points from 
baseline) at Week 4, Week 12 respectively
●
Change from baseline in WPAI-CD at Week 4, Week 12 respectively
●
Change from baseline in European Quality of Life 5 Dimensions (EQ-5D-5L)
at Week 4, Week 12 respectively
●
Change from baseline in FACIT-Fatigue total score and individual items at 
Week 4, Week 12 respectively
●
The achievement of increase in FACIT-Fatigue total score from baseline ≥7 at 
Week 12
●
The achievement of increase in FACIT-Fatigue total score from baseline ≥9 at 
Week 12
●
The achievement of increase in FACIT-Fatigue total score from baseline ≥11 at 
Week 12
●
Change from baseline in Short Form-36 (PCS and Mental Component 
Summary score [MCS] and all 8 domain scores) at Week 4, Week 12 
respectively
●
Change from baseline in Fecal calprotectin (FCP) at Week 4, Week 12 
respectively
●
Change from baseline in high-sensitivity C-reactive protein (hs-CRP) at Week 
4, Week 8, Week 12 respectively
●
Change from baseline in average daily AP score at Week 4, Week 8, Week 12 
respectively
●
Change from baseline in average daily SF at Week 4, Week 8, Week 12 
respectively
●
The achievement of clinical remission at Week 4, Week 8, Week 12 
respectively
●
The achievement of enhanced clinical response at Week 4, Week 8, Week 12 
respectively
●
The achievement of clinical response at Week 4, Week 8, Week 12 respectively


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
18
●
Change from baseline in SES-CD at Week 12
●
The achievement of a SES-CD ulcerated surface subscore ≤ 1 at Week 12 in 
subjects with a SES-CD ulcerated surface subscore ≥ 2 at baseline
●
Patient Global Impression of Severity (PGIS) response at Week 4, Week 8, 
Week 12 respectively
●
The achievement of subjects who report symptoms to be "Minimal" or 
"Absent" on the PGIS at Week 4, Week 8, Week 12 respectively, for subjects 
who did not report symptoms to be "Minimal" or "Absent" at baseline
●
Patient Global Impression of Change (PGIC) response at Week 4, Week 8, 
Week 12 respectively
●
The achievement of subjects who are "Very much improved" or "Much 
improved" on the Patient Global Impression of Change (PGIC) at Week 4, 
Week 8, Week 12 respectively
●
Change from baseline in PGIS at Week 4, Week 8, Week 12 respectively
●
Occurrence of CD-related surgeries through Week 12
●
The achievement of any reduction in SES-CD at Week 12
●
The achievement of CDAI clinical remission at Week 4, Week 8, Week 12 
respectively
●
The achievement of CDAI clinical response at Week 4, Week 8, Week 12 
respectively
●
The achievement of SF remission at Week 4, Week 8, Week 12 respectively
●
The achievement of AP remission at Week 4, Week 8, Week 12 respectively
●
Change from baseline in CDAI at Week 4, Week 8, Week 12 respectively
●
Change from baseline in Crohn's Symptom Severity (CSS) at Week 4, Week 8, 
Week 12 respectively
●
The achievement of resolution of extra-intestinal manifestations (EIMs) at 
Week 4, Week 8, Week 12 respectively, in subjects with any EIMs at baseline
●
The achievement of no draining fistulas at Week 4, Week 8, Week 12 
respectively, in subjects with draining fistulas at baseline
●
The achievement of no non-draining fistulas at Week 4, Week 8, Week 12 
respectively, in subjects with non-draining fistulas at baseline


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
19
●
The achievement of no anal fissure at Week 4, Week 8, Week 12 respectively, 
in subjects with anal fissure at baseline
Induction Period 2:
●
The achievement of clinical remission at Week 16, 20, 24 respectively
●
The achievement of endoscopic response at Week 24
●
The achievement of CDAI clinical remission at Week 16, 20, 24 respectively
●
The achievement of CDAI clinical response at Week 16, 20, 24 respectively
●
The achievement of SF remission at Week 16, 20, 24 respectively
●
The achievement of AP remission at Week 16, 20, 24 respectively
●
Change from baseline in FACIT-Fatigue at Week 24
●
Change from baseline in IBDQ total score at Week 24
●
The achievement of enhanced clinical response and endoscopic response at 
Week 24 
●
The achievement of CDAI clinical response and endoscopic response at Week 
24 
●
The achievement of endoscopic remission at Week 24
●
The achievement of enhanced clinical response at Week 16, 20, 24 respectively
●
The achievement of ulcer-free endoscopy at Week 24
●
The achievement of resolution of extra-intestinal manifestations (EIMs) at 
Week 16, 20, 24 respectively, in subjects with any EIMs at baseline
●
Occurrence of CD-related hospitalization from Week 12 through Week 24
●
The achievement of no draining fistulas at Week 16, 20, 24 respectively, in 
subjects with draining fistulas at baseline
●
Change from baseline in WPAI-CD at Week 24
●
Change from baseline in SF-36 (PCS, MCS and all 8 domain scores) at 
Week 24


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
20
3.4
Safety Endpoint(s)
●
Treatment-emergent adverse event
●
Laboratory data
●
Vital signs
3.5
Additional Endpoint(s)
Pharmacokinetics/pharmacodynamics, pharmacogenetics, and selected biomarkers will be 
analyzed separately and are not included in this SAP.
4.0
Analysis Populations
The following population sets are defined and will be used for the statistical analyses.
Significant non-compliance was identified at an investigational site (Investigator ID 
). As a result of this finding, efficacy data for the subjects enrolled at this 
investigational site will be excluded from the statistical analyses. Safety data for those 
subjects will be included in the statistical analyses. There were 13 subjects enrolled at the 
site with Investigator ID
in this study.
Intent-to-Treat Population
The Intent-to-Treat (ITT) population includes subjects who received at least one dose of 
study drug.
12-Week Induction Period:
The Intent-to-Treat population for the 12-Week Induction Period (denoted as ITT1) 
includes randomized subjects who received at least one dose of study drug during the 
12-Week Induction Period.
●
ITT1A: This Intent-to-Treat population for the 12-Week Induction Period 
includes the subjects in ITT1 who had baseline eligible SES-CD of ≥ 6 (≥ 4 for 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
21
isolated ileal disease).  This population will be the primary population for 
efficacy analysis of the 12-Week Induction Period. 
●
ITT1B: This Intent-to-Treat population for the 12-Week Induction Period 
includes the subjects who are in ITT1 set but did not have baseline eligible
SES-CD of ≥ 6 (≥ 4 for isolated ileal disease).  This population will be used for 
exploratory efficacy analysis purpose.
Induction Period 2:
The Intent-to-Treat population for the Induction Period 2 (denoted as ITT2) includes 
subjects who are randomized and received at least one dose of risankizumab during the 
Induction Period 2, and the subjects who received placebo induction treatment during 
12-Week Induction Period and entered the Induction Period 2 (denoted as 
placebo/risankizumab).  The placebo/risankizumab subjects will be analyzed as a separate 
treatment group in the Induction Period 2.
●
ITT2A: This Intent-to-Treat population for Induction Period 2 includes 
subjects in ITT2 who had baseline eligible SES-CD of ≥ 6 (≥ 4 for isolated ileal 
disease).  This population will be used for exploratory efficacy analysis 
purpose.
●
ITT2B: This Intent-to-Treat population for Induction Period 2 includes the 
subjects who are in ITT2 set but did not have baseline eligible SES-CD of ≥ 6 
(≥ 4 for isolated ileal disease).  This population will be used for exploratory 
efficacy analysis purpose.
For the corresponding ITT populations, subjects were assigned to a treatment group based 
on the randomization or re-randomization schedule, regardless of the treatment actually 
received.  The demographics/baseline and efficacy analysis will be based on the 
corresponding ITT population. 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
22
Safety Population
For the safety populations, subjects were assigned to a treatment group based on the 
treatment actually received.  The safety population (SA) consists of all subjects who 
received at least one dose of study medication.  The safety analysis in each induction 
period will be based on the following safety population. 
12-Week Induction Period:
●
SA1: This safety population for the 12-Week Induction Period consists of all 
subjects who received at least one dose of study medication from the 12-Week 
Induction Period.  
●
SA1A: This safety population for the 12-Week Induction Period includes the 
subjects in SA1 set who had baseline eligible SES-CD of ≥6 (≥4 for isolated 
ileal disease).
Induction Period 2:
●
SA2: This safety population for the Induction Period 2 consists of subjects who 
received at least one dose of risankizumab during the Induction Period 2. 
●
SA2A: This safety population for the Induction Period 2 includes the subjects 
in SA2 set who had baseline eligible SES-CD of ≥6 (≥4 for isolated ileal 
disease).
All Risankizumab:
●
SA-ALL: This safety population includes all subjects who received at least one 
dose of risankizumab any time during the study.
5.0
Subject Disposition
The total number of subjects who were enrolled, randomized and treated will be 
summarized.  


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
23
A summary of subject accountability will be provided where the number of subjects in 
each of the following categories will be summarized for each treatment group:
●
Subjects enrolled/randomized in the study 
●
Subjects who took at least one dose of study drug (ITT1A for the 12-Week 
Induction Period, ITT2 for the Induction Period 2 and ITT1 for the entire study)
●
Subjects who completed study drug (SA1A for the 12-Week Induction Period, 
SA2 for the Induction Period 2 and SA1 for the entire study)
●
Subjects who prematurely discontinued study drug (SA1A for the 12-Week 
Induction Period, SA2 for the Induction Period 2 and SA1 for the entire study)
●
Subjects who prematurely discontinued from study (ITT1A for the 12-Week 
Induction Period, ITT2 for the Induction Period 2 and ITT1 for the entire study)
●
Subjects who completed study (ITT1A for the 12-Week Induction Period, ITT2 
for the Induction Period 2 and ITT1 for the entire study)
For end of study participation, the number and percentage of subjects who completed the 
protocol defined follow-up period (or did not with associated reasons) will be summarized 
overall and by treatment group.
6.0
Study Drug Duration and Compliance
6.1
Study Drug Duration
12-Week Induction Period:
For the safety population SA1A, the duration of exposure to study drug will be 
summarized for each treatment group in the 12-Week Induction Period.  The study drug 
dose date refers to recorded dates of infusion/injections of study drug.
●
Duration of exposure in the 12-Week Induction Period:
○
If the subject enrolled into M16-000 after the 12-Week Induction Period: 
●
Duration of exposure = min(the first study drug dose date in M16-
000 – the first study drug dose date in the 12-Week Induction Period, 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
24
the last study drug dose date in the 12-Week Induction Period – the 
first study drug dose date in the 12-Week Induction Period +28 days),
○
If the subject enrolled into the Induction Period 2 after the 12-Week 
Induction Period:
●
Duration of exposure = min(the first study drug dose date in the 
Induction Period 2 – the first study drug dose date in the 12-Week 
Induction Period, the last study drug dose date in the 12-Week 
Induction Period – the first study drug dose date in the 12-Week 
Induction Period +28 days),
○
Otherwise:
●
Duration of exposure = the last study drug dose date in the 12-Week 
Induction Period – the first study drug dose date in the 12-Week 
Induction Period +28 days.
For each treatment group and total in this induction period, the duration of exposure will 
be summarized by the number of subjects treated, as well as the mean, standard deviation, 
median, minimum and maximum values.  In addition, the number and percentage of 
subjects exposed to study drug will be summarized for the following exclusive duration 
intervals:
●
1 – 28 days
●
29 – 56 days
●
57 – 84 days 
●
85 – 112 days
●
>112 days
Induction Period 2:
For the safety population SA2A, the duration of exposure to study drug will be 
summarized for each treatment group in the Induction Period 2. The study drug dose date 
refers to recorded dates of infusion/injections of study drug.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
25
●
Duration of exposure in the Induction Period 2:
○
If the subject enrolled into M16-000 after the Induction Period 2: 
●
Duration of exposure = min(the first study drug dose date in M16-000 
– the first study drug dose date in the Induction Period 2, the last study 
drug dose date in the Induction Period 2 – the first study drug dose date 
in the Induction Period 2 +28 days [for IV dose] or 56 days [for SC 
dose]),
○
Otherwise:
●
Duration of exposure = the last study drug dose date in the Induction 
Period 2 – the first study drug dose date in the Induction Period 2 +28 
days (for IV dose) or 56 days (for SC dose).
For each treatment group and total in the Induction Period 2, the duration of exposure will 
be summarized by the number of subjects treated, as well as the mean, standard deviation, 
median, minimum and maximum values.  In addition, the number and percentage of 
subjects exposed to study drug will be summarized for the following exclusive duration 
intervals:
●
1 – 28 days
●
29 – 56 days
●
57 – 84 days 
●
85 – 112 days
●
>112 days
ALL Risankizumab: 
For all risankizumab population SA-ALL, the duration of exposure to study drug will be 
summarized for all risankizumab treatment group over the whole course of the study.  The 
study drug dose date refers to recorded dates of infusion/injections of study drug.
●
Duration of exposure for all risankizumab:
○
If the subject enrolled into M16-000: 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
26
●
Duration of exposure = min(the first study drug dose date in M16-
000 – the first risankizumab dose date in M15-991, the last 
risankizumab dose date in M15-991 – the first risankizumab dose date 
in M15-991 +28 days [if the last dose is IV dose] or 56 days [if the last 
dose is SC dose]),
○
Otherwise:
●
Duration of exposure = the last risankizumab dose date in M15-991 
– the first risankizumab dose date in M15-991 +28 days [if the last 
dose is IV dose] or 56 days [if the last dose is SC dose].
The duration of exposure will be summarized by the number of subjects treated, as well as 
the mean, standard deviation, median, minimum and maximum values.  In addition, the 
number and percentage of subjects exposed to risankizumab will be summarized for the 
following exclusive duration intervals:
●
1 – 28 days
●
29 – 56 days
●
57 – 84 days 
●
85 – 112 days
●
113 – 140 days
●
141 – 196 days
●
>196 days
6.2
Study Drug Compliance
The treatment compliance (%) of study drug information will be summarized for safety 
populations SA1 and SA2:
6.2.1
Intravenous Therapy
●
Percent of subjects who received full volume
●
Average infusion duration (hours)
●
Treatment compliance (%)


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
27
6.2.2
Subcutaneous Therapy
●
Total number of injections received
●
Treatment compliance (%)
7.0
Demographics, Baseline Characteristics, Medical 
History, and Prior/Concomitant Medications
Demographics and baseline or disease characteristics will be summarized for the ITT1A, 
ITT1B, ITT2A, ITT2B, SA1A population overall and by treatment group. Medical 
history and prior medications will be summarized for the ITT1A population overall and 
by treatment group.  Concomitant medications will be summarized for the ITT1A and 
ITT2 population overall and by treatment group.  Categorical variables will be 
summarized with the number and percentage of subjects; percentages will be calculated 
based on the number of non-missing observations. Continuous variables will be 
summarized with descriptive statistics (number of non-missing observations, mean and 
standard deviation, median, minimum and maximum).
7.1
Demographics and Baseline Characteristics
The following demographic and baseline or disease characteristics will be summarized at 
the baseline of the study, where the baseline refers to the last non-missing observation 
before the first administration of any study drug.
Demographics
●
Age (years)
●
Age category [< 18, [18, 40), [40, 65), ≥ 65] 
●
Sex [male/female]
●
Race [American Indian/Alaska Native, Asian, Black or African American, 
Native Hawaiian or Other Pacific Islander, White, Multiple]
●
Ethnicity [Hispanic/Latino, Non-Hispanic/Latino]
●
Geographic region (as defined in Appendix I)


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
28
Tobacco/Nicotine and Alcohol Use
●
Tobacco/Nicotine Use [currently smokes, ex-smoker, never smoked, unknown]
●
Alcohol Use [current drinker, former drinker, non-drinker, unknown]
Vital Signs
●
Systolic and diastolic blood pressure (mmHg)
●
Pulse (bpm)
●
Body temperature (°C)
●
Body weight (kg) – overall and by sex
●
Body weight category (< 60 kg, ≥ 60 kg)
●
Height (cm)
●
Body Mass Index (kg/m2)
●
BMI Category 
○
Underweight [< 18.5 kg/m2]
○
Normal [≥ 18.5 and < 25 kg/m2]
○
Overweight [≥ 25 and < 30 kg/m2]
○
Obese [≥ 30 kg/m2]
Patient Reported Outcomes at Baseline
●
IBDQ – total score and domain scores
●
WPAI-CD – 4 sub-scores
●
CSS – total score
●
FACIT-Fatigue – total score and 13 item scores 
●
EQ-5D-5L – Index score and Vas Pain
●
SF-36 – 8 domain scores, PCS and MCS
●
Average Daily Stool Frequency
●
Average Daily Abdominal Pain


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
29
Other Assessments at Baseline
●
CDAI 
●
SES-CD 
●
Crohn's Disease Duration (years)
●
Fecal calprotectin
●
Baseline corticosteroid use (yes, no) 
●
Baseline immunomodulator use (yes, no)
●
Biologics failure history (<=1, >1)
●
TNF failure history (0, 1, >1)
●
Vedolizumab failure history (yes, no) 
●
Ustekinumab failure history (yes, no)
●
hs-CRP
●
Draining fistulas (yes, no) 
●
Non-draining fistulas (yes, no)
●
Anal fissures (yes, no)
●
Crohn's Disease Location Per SES-CD (colonic only, ileal only, ileal-colonic)
●
Extra Intestinal Manifestation (yes, no)
In addition, some clinical tests at baseline such as TB test, pregnancy test and 
electrocardiogram assessment will be summarized. Crohn's Disease history (Montreal 
classification) and Crohn's Disease surgical history will be summarized separately as well.
7.2
Medical History
Medical history data will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The actual version of the MedDRA coding dictionary will be noted in the 
statistical tables and clinical study report. The number and percentage of subjects in each 
medical history category (by MedDRA system organ class and preferred term) will be 
summarized overall and by treatment group. The system organ class (SOC) will be 
presented in alphabetical order, and the preferred terms will be presented in alphabetical 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
30
order within each SOC. Subjects reporting more than one condition/diagnosis will be 
counted only once in each row (SOC or preferred term).
7.3
Prior and Concomitant Medications
Prior and concomitant medications will be summarized by generic name.  A prior 
medication is defined as any medication taken prior to the date of the first dose of any 
study drug.  A concomitant medication for 12-Week Induction Period is defined as any 
medication other than study drug that (1) was started prior to the first dose of study drug 
and continued to be taken after the first dose of study drug in the 12-Week Induction 
Period or (2) was started after the first dose of study drug during the 12-Week Induction 
Period, but prior to the first dose of Induction Period 2 if the subject enters Induction 
Period 2 or prior to the first dose of M16-000 if the subject enters M16-000, or prior to the 
last dose + 140 days if the subject does not enter Induction Period 2 nor M16-000.
A concomitant medication for Induction Period 2 is defined as any medication other than 
study drug that (1) was started prior to the first dose of study drug in Induction Period 2 
and continued to be taken after the first dose of study drug in Induction Period 2 or (2) 
was started after the first dose of study drug in Induction Period 2, but prior to first dose 
of M16-000 if the subject enters M16-000, or last dose + 140 days if the subject does not 
enter M16-000.  Information about concomitant medications can be collected up to 
140 days after last dose, as per protocol.
The number and percentage of subjects taking medications will be summarized by generic 
drug name based on the World Health Organization (WHO) Drug Dictionary for both 
prior and concomitant medications.
8.0
Efficacy Analyses
8.1
General Considerations
The primary and secondary efficacy endpoints as specified in Section 3.1 and Section 3.2
will be analyzed based on ITT1A for 12-Week Induction Period.  The difference between 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
31
treatment groups for the primary and ranked secondary efficacy endpoints will be tested 
with graphical multiplicity adjustment1 to ensure a strong control of family-wise type I 
error rate at significance level α = 0.05 (two-sided) (see Section 11.0).  Analyses of other 
efficacy endpoints for 12-Week Induction Period as specified in Section 3.3 will be 
performed using ITT1A at the nominal significance level α = 0.05 (two-sided) without 
multiplicity adjustment. 
Analyses for other efficacy endpoints as specified in Section 3.3 for Induction Period 2 
will be performed using ITT2A.  Since the Induction Period 2 is for exploratory purpose, 
no multiplicity adjustment will be performed.
For all efficacy endpoints, the descriptive statistics will be provided by period and by 
treatment group in which the subjects were randomized to at the beginning of each period.  
The statistics include number of observations, mean, standard deviation, minimum, 
median, and maximum for continuous variables, and number and percent for discrete 
variables.
Unless otherwise specified, any subject who is randomized based on a wrong stratum will 
be analyzed according to the actual stratum the subject belongs to.
When all subjects complete their Week 12/PD visit, the database will be locked and un-
blinded for the 12-Week Induction Period.  The planned analysis for the 12-Week 
Induction Period will be performed.  This is the only and final efficacy analysis for the 12-
Week Induction Period.  When all the subjects who enter the Induction Period 2 finish 
Week 24/PD visit, the database will be locked for the whole study and all the planned 
analysis for the Induction Period 2 will be performed.
Analysis of Binary Variables:
For binary variables, frequencies and percentages will be reported for each treatment 
group.  Pairwise comparison of each risankizumab group and placebo will be performed 
using the Cochran Mantel-Haenszel (CMH) test adjusting for stratification factors.  If 
there is a stratum for a treatment group that has no subject in it, a value of 0.1 will be 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
32
added to all cells in the corresponding table in order to prevent dividing by 0, as suggested 
in Greenland and Robins (1985)3.  Point estimates and 95% confidence interval (CI)s for 
the difference in proportions between each of risankizumab treatment groups and placebo 
will be provided.  Construction of CI for the common risk difference will be based on the 
Mantel-Haenszel estimate adjusting for stratification factors. For binary endpoints with 
small number of sample size (such as achievement of no draining fistulas at Week 12 in 
subjects with draining fistulas at baseline), or small number of responders (such as 
occurrence of CD-related hospitalization through Week 12), Chi-square test (or Fisher's 
exact test if ≥ 20% of the cells have expected cell count < 5) will be performed.
Analysis of Continuous Variables:
For continuous variables, the model based mean and standard error will be provided.  The 
baseline and visit means will also be presented for each treatment group.  Continuous
variables collected longitudinally will be using a Mixed-Effect Model Repeated 
Measurement (MMRM) model.  Continuous efficacy variables which are collected at only 
one post-baseline visit (such as SES-CD) will be analyzed using an Analysis of 
Covariance (ANCOVA) model.  Point estimates and 95% CIs of mean change from 
baseline within treatment groups, and between each risankizumab treatment group and 
placebo will be provided.  The baseline refers to the last non-missing observation before 
the first administration of any study drug or randomization if no study drug is given.
8.2
Handling of Potential Intercurrent Events
Potential intercurrent events considered in this study include 1) premature discontinuation 
of study drug and 2) initiation or dose escalation of CD-related corticosteroids defined in 
Section 8.2.2. Intercurrent events will be handled using the following methods for the 
efficacy analysis:
8.2.1
Premature Discontinuation of Study Drug
Data collected will be used regardless of premature discontinuation of study drug.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
33
8.2.2
CD-Related Corticosteroid Therapy
The CD-related corticosteroids intercurrent event is defined as follows.
●
Subjects not on CD-related corticosteroids (systemic or locally acting 
corticosteroids for CD) at baseline who initiated CD-related corticosteroids 
during the study;
●
Subjects on CD-related systemic corticosteroids at baseline who have dosages 
increased to greater than the prednisone equivalent dose of corticosteroid taken 
at baseline, or initiation of any rectal corticosteroids during the study regardless 
of rectal corticosteroid dose;
●
Subjects on CD-related rectal corticosteroids at baseline who have dosages 
increased to greater than the dose taken at baseline, or initiation of any new 
type of rectal or any systemic corticosteroids during the study.
The time point of the CD-related corticosteroids intercurrent event is defined as the earlier 
date when one or more of the scenarios above occurs for a subject.  As such, all 
measurements at or after the occurrence of the CD-related corticosteroids intercurrent 
event through the end of the study will not be used in the analysis and will be handled as 
specified in Appendix J. 
8.3
Handling of Missing Data
Missing data could occur due to various reasons, including missing visits/assessments, 
early withdrawal from the clinical trials, or missing due to Coronavirus disease 2019
(COVID-19) infection or logistic restriction.
The COVID-19 pandemic is interfering with the conduct of many ongoing trials, with 
potential impacts on treatment duration and the collection, analysis, and the interpretation 
of clinical trial data.  Some protocol-specified visits in the clinical trials may be impacted 
due to COVID-19 infection or logistical restrictions during the pandemic.  For example, 
some scheduled visits may be missed due to self-quarantine or local government 
restrictions on travel; some visits may also be delayed or canceled due to healthcare 
resource constraints during the pandemic.  Impacted visits due to COVID-19 will be 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
34
recorded in the database.  The probability of having missed visits and missing data due to 
COVID-19 infection or logistical restrictions related to the COVID-19 pandemic can be 
reasonably assumed to be unrelated to the unobserved values.  Therefore, for the purpose 
of statistical analysis, it is reasonable to assume that these missing data are missing at 
random (MAR) and the statistical models that require MAR assumption are appropriate.  
The intent is to provide reliable estimates of the treatment effects under the scenario 
without the impact of COVID-19 pandemic.
Missing data for the efficacy analyses will be handled using the methods described below.
Handling of missing data in IBDQ and FACIT-Fatigue is shown in Appendix F and 
Appendix G. 
8.3.1
Categorical Endpoints
For binary efficacy endpoints, missing data will be handled using the following 
approaches:
●
The primary approach for handling missing data in the analysis of binary
endpoints will use Non-Responder Imputation (NRI) while incorporating 
Multiple Imputation (MI) to handle missing data due to COVID-19 (NRI-C).
○
The NRI-C will categorize any subject who does not have an evaluation 
during a pre-specified visit window (either due to missing assessment or 
due to early withdrawal from the study) as a non-responder for the visit. 
The only exception is that missing data due to COVID-19 infection or 
logistical restriction will be handled by MI.  At each visit, subjects will be 
characterized as responders or non-responders based on MI imputed values 
if missing due to Covid-19, otherwise subjects will be considered as non-
responder for missing due to other reasons in the NRI-C approach. Of 
note, subjects will be counted as non-responders thereafter and will not be 
imputed by MI after the CD-related corticosteroids censoring time point as 
specified in Section 8.2.2 and Appendix J.
●
A sensitivity analysis for binary endpoints will use NRI with No special data 
handling for missing due to COVID-19 (NRI-NC).


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
35
○
NRI-NC will be performed in the same way as NRI-C without the 
exception above.  Missing due to COVID-19 infection or logistical 
restriction will also be counted as non-responders. This is the same 
method as "NRI" as defined in the protocol.
●
Details on MI method are described below:  
○
Markov Chain Monte Carlo (MCMC) will be first applied to augment data 
into monotonic missing pattern, where applicable, and PROC MI will be 
used to generate 30 datasets using the regression method.  If the binary 
endpoints are derived from the continuous variables, PROC MI will be 
applied to the continuous variables.  The variables to be included in the 
imputation model are: treatment group, randomization stratification factors 
(Number of prior biologics failed (0, 1, > 1), baseline steroid use (Yes, 
No)), age, gender, weight and if applicable, baseline measurement and 
post-baseline measurements at each visit up to the end of the analysis 
period.  The random seed for MCMC and the random seed for PROC MI 
are specified in Appendix H.  The imputed post-baseline measurements 
will be rounded to the same precision as the observed data before the 
determination of responder status.  Prior to applying CMH model, subjects 
will be characterized as responders or non-responders based on MI 
imputed values if missing due to Covid-19, otherwise subjects will be 
considered as non-responder for missing due to other reasons in the NRI-C 
approach.  Using the CMH model adjusted by randomization stratification 
factors, the endpoints will be analyzed using each of the 30 imputed 
datasets.  SAS PROC MIANALYZE will be used to generate the final 
inferences of the risk difference between the risankizumab treatment group 
and placebo group, using Rubin's rule.  The CD-related corticosteroid 
censoring rule, as specified in Section 8.2.2 and Appendix J, will be 
applied before and after applying MI for efficacy assessments. 
8.3.2
Continuous Endpoints
For continuous efficacy endpoints where Mixed-Effect Model Repeat Measurement 
(MMRM) analysis or Analysis of Covariance (ANCOVA) is performed, missing data will 
be handled using the following approaches.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
36
●
Mixed-Effect Model Repeat Measurement (MMRM):  The repeat measurement 
analysis will be conducted using a mixed model including observed 
measurements at all post-baseline visits, after the CD-related corticosteroids 
censoring rule is applied (see Section 8.2.2 and Appendix J).  The mixed model 
includes the categorical fixed effects of treatment, visit and treatment-by-visit 
interaction, stratification factors at randomization, and the continuous fixed 
covariates of baseline measurement.  An unstructured variance covariance 
matrix will be used.  Parameter estimation is based on the method of restrictive 
maximum likelihood (REML).  MMRM will be the primary approach in the 
analysis of continuous variables. 
●
ANCOVA-C: For continuous efficacy variables that are collected at only one 
post-baseline visit (such as SES-CD), the missing data due to COVID-19 will 
be imputed using MI first before applying the ANCOVA model.
In addition, As Observed (AO) and Pattern Mixture Model (PMM) will be performed as 
sensitivity analysis, if appropriate, for categorical or continuous endpoints.
●
As Observed (AO): The AO analysis will not impute values for missing 
evaluations, and thus a subject who does not have an evaluation on a scheduled 
visit will be excluded from the AO analysis for that visit.  AO will include all 
values collected in the study regardless of censoring for steroids or not.
●
Pattern Mixture Model (PMM): Subjects will be classified into pre-specified 
missing data patterns and the pattern variables will be defined based on these 
patterns.  The random effect PMM5 approach will be performed, which 
includes the pattern variables in the model to examine the effect of missing-
data patterns on the outcomes of interest.  PROC GLIMMIX will be used in 
PMM approach for handling categorical endpoints, and PROC MIXED will be 
used for handling continuous endpoints.  The model includes categorical effects 
of treatment, visit, treatment-by-visit interaction, missing-data pattern and 
treatment-by-pattern interaction, and the main stratification factors at 
randomization, and the continuous fixed covariates of baseline measurement, if 
applicable.  The overall treatment effect can be estimated by averaging over the 
estimates from the different missing-data patterns.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
37
8.4
Primary Efficacy Endpoint(s) and Analyses
8.4.1
Primary Efficacy Endpoint(s)
The co-primary endpoints for the primary analysis of efficacy are:
●
For US specific protocol:
○
The achievement of CDAI clinical remission at Week 12 
○
The achievement of endoscopic response at Week 12
●
For global protocol outside US:
○
The achievement of clinical remission at Week 12 
○
The achievement of endoscopic response at Week 12
The primary estimand for US specific protocol is the following:
●
Difference in the percentage of subjects achieving CDAI clinical remission at 
Week 12 regardless of premature discontinuation of study drug and without 
initiation or dose escalation of CD-related corticosteroids (See Section 8.2.2) in 
each of the risankizumab 1200mg IV and risankizumab 600mg IV groups in 
comparison with the placebo group in the ITT1A population
●
Difference in the percentage of subjects achieving endoscopic response at 
Week 12 regardless of premature discontinuation of study drug and without 
initiation or dose escalation of CD-related corticosteroids (See Section 8.2.2) in 
each of the risankizumab 1200mg IV and risankizumab 600mg IV groups in 
comparison with the placebo group in the ITT1A population.
The primary estimand for global protocol outside US is the following:
●
Difference in the percentage of subjects achieving clinical remission at Week 
12 regardless of premature discontinuation of study drug and without initiation 
or dose escalation of CD-related corticosteroids (See Section 8.2.2) in each of 
the risankizumab 1200mg IV and risankizumab 600mg IV groups in 
comparison with the placebo group in the ITT1A population


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
38
●
Difference in the percentage of subjects achieving endoscopic response at 
Week 12 regardless of premature discontinuation of study drug and without 
initiation or dose escalation of CD-related corticosteroids (See Section 8.2.2) in 
each of the risankizumab 1200mg IV and risankizumab 600mg IV groups in 
comparison with the placebo group in the ITT1A population.
Details in estimand definition are outlined in Appendix J.
8.4.2
Handling of Missing Data for the Primary Efficacy 
Endpoint(s)
The NRI-C approach for handling missing data will be used for primary analysis for the 
co-primary endpoints for the 12-Week Induction Period.
The NRI-NC and PMM approaches for handling missing data will be conducted as 
sensitivity analyses for the co-primary endpoints for the 12-Week Induction Period if 
applicable.  For PMM approach, the pre-specified missing-data patterns are given as 
below.  Other missing data patterns could be explored if deemed necessary.
Missing-data Patterns
Non-completers (missing at Week 4 or at Week 8 or at Week 12)
Completers
8.4.3
Primary Efficacy Analysis
The co-primary endpoints will be analyzed between placebo and each of risankizumab 
600 mg IV and 1200 mg IV groups using the CMH test, stratified by the randomization 
factors of number of prior biologics failed (≤1, > 1) and baseline steroid use (Yes, No) 
based on ITT1A.  A CMH based two-sided 95% CI for the difference between treatment 
groups will be constructed.  


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
39
8.4.4
Additional Analyses of the Primary Efficacy Endpoint(s)
For the co-primary efficacy endpoints, an additional analysis using the same CMH test
will be performed using As Observed (AO) data handling without any imputation. The 
analysis will be conducted using the ITT1A population.
8.5
Secondary Efficacy Analyses
8.5.1
Key Secondary Efficacy Analyses
The estimands corresponding to the secondary efficacy endpoints are defined in 
Section 2.1.  Details in estimand definition for the key secondary endpoints are outlined in 
Appendix J.
In general, continuous secondary efficacy endpoints with repeat measurements will be 
analyzed using a MMRM model including factors for treatment group, visit, visit by 
treatment interaction, stratification variables and the continuous fixed covariates of 
baseline measurement.  The MMRM analysis is considered primary for inferential 
purposes.  Continuous secondary efficacy variables which are collected at only one post-
baseline visit (such as SES-CD) will be analyzed using ANCOVA-C approach. 
Categorical secondary efficacy variables will be analyzed using the CMH test controlling 
for stratification variables (prior biologics failed [≤1, > 1] and baseline steroid use [Yes, 
No]), except for the endpoints related to draining fistulas and CD-related hospitalization.  
A CMH based two-sided 95% CI for the difference between each risankizumab treatment 
group and placebo group will be constructed.  The endpoints of "The achievement of no 
draining fistulas at Week 12 in subjects with draining fistulas at baseline" and 
"Occurrence of CD-related hospitalization through Week 12" will be analyzed using Chi-
square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count < 5). 
The NRI-C method will be the primary approach for missing data handling for categorical 
secondary endpoints except for CD-related hospitalization and draining fistulas.  The 
endpoint of "The achievement of no draining fistulas at Week 12 in subjects with draining 
fistulas at baseline" will be analyzed using NRI-NC as the primary approach due to the 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
40
small sample size.  The endpoint of "Occurrence of CD-related hospitalization through 
Week 12" will be analyzed based on the observed data using AO approach only. 
In addition, NRI-NC for missing data handling will be applied as sensitivity analyses for 
the binary secondary endpoints except for CD-related hospitalization and draining fistulas
endpoints. 
Analysis of PMM will also be performed as sensitivity analyses for ranked secondary 
endpoints as appropriate.  Analysis of PMM will not be performed for the endpoint of 
"The achievement of no draining fistulas at Week 12 in subjects with draining fistulas at 
baseline" due to the small sample size.
8.5.2
Supportive Secondary Efficacy Analyses
For the categorical secondary efficacy endpoints, the same CMH analysis will be repeated 
using As Observed (AO) data handling without any imputation as an additional analysis.
The analysis will be conducted using the ITT1A population.
8.6
Additional Efficacy Analyses
Other continuous and categorical efficacy endpoints for the 12-Week Induction Period 
will be analyzed using ITT1A similarly as the secondary efficacy endpoints as described 
in Section 8.5.  No multiplicity adjustment will be performed.  The chi-square test (or 
Fisher's exact test if ≥ 20% of the cells have expected cell count < 5 for analyses of binary 
outcomes) will be used for the following endpoints:
●
Patient Global Impression of Severity (PGIS) response at Week 4, Week 8, 
Week 12 respectively
●
Patient Global Impression of Change (PGIC) response at Week 4, Week 8, 
Week 12 respectively
●
The achievement of no draining fistulas at Week 4, Week 8, Week 12 
respectively, in subjects with draining fistulas at baseline
●
The achievement of no non-draining fistulas at Week 4, Week 8, Week 12 
respectively, in subjects with non-draining fistulas at baseline


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
41
●
The achievement of no anal fissure at Week 4, Week 8, Week 12 respectively, 
in subjects with anal fissure at baseline
PGIC response and PGIS response endpoints will be analyzed based on the observed data 
using AO approach.  The draining fistulas endpoint, non-draining fistulas endpoint and 
anal fissure endpoint will be analyzed using NRI-NC approach due to the small sample 
size.
Analyses for other efficacy endpoints as specified in Section 3.3 for Induction Period 2 
will be performed using ITT2A for exploratory purpose.  Point estimate and 95% CI for 
each treatment group as well as point estimate and 95% CI for pairwise treatment 
differences (i.e., risankizumab 1200mg IV – risankizumab 360mg SC, risankizumab 
1200mg IV – risankizumab 180mg SC, risankizumab 360mg SC - risankizumab 180mg 
SC) will be presented based on the observed data for randomized subjects using AO 
approach.  The subjects in the non-randomized risankizumab 1200mg IV group, who took 
the placebo in the 12-Week Induction Period, will be displayed separately using 
descriptive statistics.  No p-value will be provided.
In addition, the following selected endpoints will be analyzed using ITT1B for 
exploratory purpose.  Point estimate and 95% CI for each treatment group as well as point 
estimate and 95% CI for treatment differences between each risankizumab group and the 
placebo group will be presented based on the observed data using AO approach.  No p-
value will be provided.  
●
The achievement of CDAI clinical remission at Week 12 
●
The achievement of clinical remission at Week 12 
●
The achievement of endoscopic response at Week 12
●
The achievement of SES-CD ≤ 2 or 2 points reduction from the baseline at 
Week 12 among the subjects with baseline eligible SES-CD of >=3 to 6 for 
ileocolonic or colonic disease or 3 for isolated ileal disease
●
The achievement of any reduction in SES-CD at Week 12


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
42
Similarly, the following selected endpoints will be analyzed using ITT2B for exploratory 
purpose.  Point estimate and 95% CI for each treatment group as well as point estimate 
and 95% CI for pairwise treatment differences will be presented based on the observed 
data for randomized subjects using AO approach.  The subjects in the non-randomized 
risankizumab 1200mg IV group, who took the placebo in the 12-Week Induction Period, 
will be displayed separately using descriptive statistics.  No p-value will be provided.  
●
The achievement of CDAI clinical remission at Week 24 
●
The achievement of clinical remission at Week 24 
●
The achievement of endoscopic response at Week 24
●
The achievement of SES-CD ≤ 2 or 2 points reduction from the baseline at 
Week 24 among the subjects with baseline eligible SES-CD of >=3 to <6 for 
ileocolonic or colonic disease or 3 for isolated ileal disease
●
The achievement of any reduction in SES-CD at Week 24
8.7
Efficacy Subgroup Analyses
To evaluate the consistency of the efficacy over demographic and other baseline 
characteristics, subgroup analysis will be performed for the co-primary endpoints for the 
subgroups listed in Table 1 below using ITT1A. 
For efficacy subgroup analysis, point estimate and 95% CI for each treatment group as 
well as point estimate and 95% CI for treatment differences between each risankizumab 
group and the placebo group will be presented.  No p-value will be provided.  If any of the 
resulting subgroups except for age, sex and race has fewer than 10% of the planned study 
size, the subgroup analyses for that category will not be presented.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
43
Table 1.
Subgroups for Efficacy Analysis
Subgroup Factor
Categories
Age
< 18, [18, 40), [40, 65), ≥ 65
Sex
Male or Female
Weight
< 60 kg or ≥ 60 kg
Race
White or non-White
Geographic Region
North America, South/Central America, 
Western Europe, Eastern Europe, Asia, 
Other
Number of Prior Biologics Failed
≤ 1 or > 1  
Prior Ustekinumab Failure
Prior TNF Failure (within subjects with Prior TNF Failure)
Prior Vedolizumab Failure
Baseline Steroids Use 
Yes or No
1, >1
Yes or No
Yes or No
Baseline Immunodulator Use
Yes or No
Baseline CDAI
≤ median or > median
Baseline CDAI
≤ 300 or > 300
Baseline SF
≤ median or > median
Baseline AP Score
≤ median or > median
Baseline SES-CD
≤ median or > median
Baseline SES-CD
≤ 15 or > 15
Disease Duration at Baseline
≤ median or > median
Disease Duration at Baseline
≤ 5 years or > 5 years
Baseline hs-CRP 
≤ median or > median
Baseline hs-CRP 
≤ 5 mg/L or > 5 mg/L
Baseline Calprotectin
≤ median or > median
Baseline Calprotectin
≤ 250 mg/kg or > 250 mg/kg 
Crohn's Disease Location at Baseline
Colonic only, Ileal only, Ileal-colonic
9.0
Safety Analyses
9.1
General Considerations
Safety analyses will include reporting of adverse events, laboratory, and vital signs 
measurements by treatment group, including a total group for all subjects on 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
44
risankizumab.  All safety analyses will be performed for the 12-Week Induction Period at 
the time of database lock.  The separate safety analysis for subjects who received at least 
one dose of risankizumab during the Induction Period 2 will be performed.
The following summary statistics will be presented for subjects who have both baseline 
and post-baseline values for laboratory parameters and vital signs:  the mean value at 
baseline and at each respective protocol specified visit, and the mean, standard deviation 
and median for changes from baseline.  Categorical data will be summarized using 
frequencies and percentages.  The risk difference and 95% CI between each risankizumab 
group and placebo group will be presented for safety analysis.
For the safety analysis, subjects are assigned to a treatment group based on the treatment 
actually received, regardless of the treatment randomized.
For the 12-Week Induction Period analysis, the baseline for safety analysis is defined as 
the last available measurement before study drug administration for all subjects.  For the 
Induction Period 2 analysis, the baseline for safety analysis will be the last available 
measurement before the first dose of risankizumab administration in Induction Period 2.
Missing safety data will not be imputed.
9.2
Adverse Events
Adverse events (AEs) will be summarized and presented using primary MedDRA System 
Organ Classes (SOCs) and preferred terms (PTs) according to the version of the MedDRA 
coding dictionary used for the study at the time of database lock. The actual version of 
the MedDRA coding dictionary used will be noted in the AE tables and in the clinical 
study report. Specific adverse events will be counted once for each subject for calculating 
percentages, unless stated otherwise. In addition, if the same adverse event occurs 
multiple times within a subject, the highest severity and level of relationship to 
investigational product will be reported.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
45
9.2.1
Treatment-Emergent Adverse Events
12-Week Induction Period:  Treatment emergent AEs (TEAEs) for the 12-Week 
Induction Period are defined as events that begin either on or after the first dose of the 
study drug in the 12-Week Induction Period and until the first dose of study drug in the 
Study M16-000 if the subject is enrolled into the Study M16-000 or until first dose of 
study drug in Induction Period 2 if the subject is enrolled into Induction Period 2, or 
within 140 days after the last dose administration of the study drug in 12-Week Induction 
Period if the subject does not participate in the Study M16-000 or the Induction Period 2.
Induction Period 2:  Treatment-emergent AEs (TEAEs) for the Induction Period 2 are 
defined as events that begin either on or after the first dose of the study medication in the 
Induction Period 2 and until first dose of study drug in the Study M16-000 if the subject is 
enrolled into the Study M16-000 or within 140 days after the last dose of the study drug in 
the Induction Period 2 if the subject does not participate in the Study M16-000.  
All Risankizumab:  Treatment-emergent AEs (TEAEs) for "All Risankizumab" are 
defined as events that begin either on or after the first dose of risankizumab and until first 
dose of study drug in the Study M16-000 if the subject is enrolled into the Study M16-000 
or within 140 days after the last dose of risankizumab in the study if the subject does not 
participate in the Study M16-000.
Events where the onset date is the same as the study drug start date are assumed to be 
treatment-emergent, unless the study drug start time and the adverse event start time are 
collected and the adverse event start time is prior to the study drug start time.  If an 
incomplete onset date was collected for an adverse event, the event will be assumed to be 
treatment-emergent unless there is other evidence that confirms that the event was not 
treatment-emergent (e.g., the event end date was prior to the study drug start date).
All treatment-emergent AEs will be summarized overall, as well as by primary MedDRA 
SOC and Preferred Term. The SOCs will be presented in alphabetical order, and the PTs 
will be presented in alphabetical order within each SOC.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
46
The number and percentage of subjects experiencing treatment-emergent AEs will be 
summarized.  The risk difference and 95% CI between each risankizumab group and 
placebo group will be presented.
9.2.2
Adverse Event Overview
An overview of AEs will be presented consisting of the number and percentage of 
subjects experiencing at least one event for each of the following AE categories:
●
Any treatment-emergent AE
●
Any treatment-emergent AE related to COVID-19
●
Any treatment-emergent AE related to study drug according to the investigator
●
Any severe treatment-emergent AE
●
Any serious treatment-emergent AE
●
Any treatment-emergent AE leading to discontinuation of study drug
●
Any treatment-emergent AE leading to death
●
Treatment-emergent AEs of Safety Interest including
○
Adjudicated MACE events
○
Serious infections
○
Active Tuberculosis
○
Opportunistic infections excluding tuberculosis and herpes zoster
○
Malignant tumors
○
Malignancies excluding NMSC
○
Hypersensitivity – serious events only
○
Adjudicated anaphylactic reaction
○
Serious anaphylactic reaction
●
All deaths
○
Deaths occurring ≤ 140 days after last dose of study drug
○
Deaths occurring > 140 days after last dose of study drug
○
Deaths related to COVID-19


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
47
The exposure adjusted rate for AE overview will be presented as well.
9.2.3
Treatment-Emergent Adverse Events by SOC and/or PT
Treatment-emergent adverse events will be summarized by SOC and PT; by maximum 
relationship to study drug as assessed by the investigator (e.g., reasonable possibility or no 
reasonable possibility) and SOC and PT; by maximum severity and SOC and PT; and by 
subject number and SOC and PT. Specific adverse events will be counted once for each 
subject for calculating percentages, unless stated otherwise. In addition, if the same 
adverse event occurs multiple times within a subject, the highest severity and level of 
relationship to investigational product will be reported.
In addition, treatment-emergent adverse events and SAEs will be summarized by PT and 
sorted by decreasing frequency for the total risankizumab group. 
9.2.4
Treatment-Emergent Adverse Events per Patient-Years of 
Exposure
Exposure-adjusted AEs per 100 patient-years will be provided for all TEAEs, where AEs 
per 100 patient-years of exposure are defined as the number of AEs divided by the total 
exposure in 100 patient-years, where the total exposure is calculated as the time from the 
first study drug dose date in the relevant period/study to the last study drug dose date 
+140 days in the relevant period/study or the first dose date of the next period/study, 
whichever occurs earlier.
The exposure adjusted incidence rate (censored at the time of first event) may be 
conducted for deaths and selected Areas of Safety Interest categories including 
adjudicated cardiovascular events, malignant tumors, non-melanoma skin cancer 
(NMSC), and malignant tumors excluding NMSC, as appropriate. 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
48
9.2.5
SAEs (Including Deaths) and Adverse Events Leading to 
Study Drug Discontinuation
SAEs (including deaths) and AEs leading to study drug discontinuation will be 
summarized by SOC and PT and in listing format.  Exposure-adjusted SAEs per 100 
patient-years by SOC and PT will be provided as well.
9.2.6
Areas of Safety Interest
The Areas of Safety Interest (ASI) categories are listed in Appendix B, which include 
serious infections, tuberculosis, opportunistic infections, herpes zoster, malignancies, 
hypersensitivity reaction, anaphylactic reactions, hepatic events, injection site reactions, 
adjudicated cardiovascular events.  These will be summarized by PT and will be based on 
standardized or company MedDRA queries (SMQs or CMQs), or based on adjudication 
results.  The risk difference and 95% CI between each risankizumab group and placebo 
group will be presented.  Exposure-adjusted ASI per 100 patient-years by PT or 
adjudication terms will be provided as well.
Additional ASI may be considered for tabulation/summary based on recommendations 
from Clinical and Safety teams, as deemed appropriate.
9.3
Analysis of Laboratory Data
Data collected from central and local laboratories, including additional laboratory testing 
due to an SAE, will be used in all analyses, except for baseline where SAE-related 
laboratory assessments on or before the first dose of study drug will be excluded. The 
clinical laboratory tests defined in the protocol (e.g., hematology and clinical chemistry) 
will be summarized.
Each laboratory variable will be summarized for all time points (starting with baseline) 
with the number of non-missing observations, mean and standard deviation, median, 
minimum and maximum. Mean change from baseline to each applicable post-baseline 
visit will be summarized for selected laboratory variables, with the number of 
observations, baseline mean, and visit mean. The change from baseline mean, standard 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
49
error, and 95% CI will be presented for the mean change from baseline within each 
treatment group and difference between each risankizumab group and placebo group.
Changes in laboratory parameters will be tabulated using shift tables either based on NCI 
CTC criteria or categorized as low, normal, or high based on the normal ranges of the 
laboratory used for each sample. A shift table from baseline either to the worse value 
(based on NCI CTC criteria) during treatment or to minimum and maximum value (based 
on normal range), will be created. A similar shift table will be provided to summarize 
shifts from baseline to the final post-baseline value.
Laboratory abnormalities will be evaluated based on Potentially Clinically Significant
(PCS) criteria (Appendix C). For each laboratory PCS criterion, the number and 
percentage of subjects who have a laboratory value meeting the criteria will be 
summarized by treatment group. Listings will be provided to summarize subject-level 
laboratory data for subjects meeting PCS criteria.
The liver-specific laboratory tests include the serum glutamic pyruvic transaminase 
(SGPT/ALT), serum glutamic-oxaloacetic transaminase (SGOT/AST), alkaline 
phosphatase (ALP), and total bilirubin (TBL).  The frequencies and percentages of 
subjects with post baseline liver specific function test values that meet the following 
criteria of potential clinical interest will be summarized by treatment group:
●
ALT ≥ 3 × ULN
●
ALT ≥ 5 × ULN
●
ALT ≥ 10 × ULN
●
ALT ≥ 20 × ULN
●
AST ≥ 3 × ULN
●
AST ≥ 5 × ULN
●
AST ≥ 10 × ULN
●
AST ≥ 20 × ULN
●
TBL ≥ 2 × ULN


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
50
●
Alkaline phosphatase ≥ 1.5 × ULN
●
(ALT and/or AST ≥ 3 × ULN) and (TBL ≥ 1.5 × ULN)
●
(ALT and/or AST ≥ 3 × ULN) and (TBL ≥ 2 × ULN)
where ULN is the upper limit of normal.
A listing of potentially clinically significant liver function laboratory values will be 
provided.  The listing will include all subjects who met any of the following 4 criteria at 
any post-baseline visit:
●
ALT ≥ 3 × ULN, or
●
AST ≥ 3 × ULN, or
●
Alkaline phosphatase ≥ 1.5 × ULN, or
●
Total bilirubin ≥ 1.5 × ULN.
A listing of possible Hy's Law cases, defined as those who meet all of the following 
conditions at any post-baseline visit will be provided:
●
ALT of > 3 × ULN or AST of > 3 × ULN, 
●
Total bilirubin ≥ 2 × ULN.
9.4
Analysis of Vital Signs
Vital sign measurements of systolic and diastolic blood pressure, pulse rate and body 
weight will be summarized.
Each vital sign variable will be summarized for all time points (starting with baseline) 
with the number of non-missing observations, mean and standard deviation, median, 
minimum and maximum. Mean change from baseline to each applicable post-baseline 
visit will be summarized for each vital sign variable, with the number of observations, 
baseline mean, and visit mean. The change from baseline mean, standard error, and 95% 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
51
CI will be presented for the mean change from baseline within each treatment group and 
difference between each risankizumab group and placebo group.
Key vital sign variables will be evaluated based on potentially clinically significant (PCS) 
criteria (Appendix C). For each vital sign PCS criterion, the number and percentage of 
subjects who have a vital sign value meeting the criteria will be summarized. Listings 
will be provided to summarize subject-level vital sign data for subjects meeting PCS
criteria.
10.0
Interim Analyses
There will be no efficacy interim analysis planned for this study.
10.1
Data Monitoring Committee
An external independent data monitoring committee (DMC) composed of persons 
independent of AbbVie and with relevant expertise in their field will review unblinded 
safety data from the ongoing study.  The primary responsibility of the DMC will be to 
protect the safety of the subjects participating in this study.
A separate DMC charter describes the roles and responsibilities of the DMC members, 
frequency of data reviews, relevant data to be assessed, and general operations.
Since there are no efficacy analyses for early stopping, no alpha adjustment is needed.
11.0
Overall Type-I Error Control
Both of the co-primary efficacy endpoints will be tested at two-sided significance level of 
0.025 to control the overall type I error rate at alpha = 0.05 (2-sided) for the multiple 
comparisons between each risankizumab dose versus placebo using a multiple testing 
procedure.1  In addition, the overall type I error rate of efficacy evaluation based on the 
co-primary and ranked secondary endpoints for the two doses will be strongly controlled 
at 0.05 (2-sided) level.  Specifically, the testing will utilize the sequence of hypothesis 
testing for the co-primary endpoints followed by the ranked secondary endpoints in the 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
52
order as specified in Section 3.2, and will begin with testing each of the co-primary 
endpoints using α of 0.025 (2-sided) for each dose compared to placebo.  If both co-
primary endpoints achieve statistical significance within a dose level, continued testing 
will follow a pre-specified weight of α allocation between the single hypothesis within the 
family, as well as between the families of hypotheses across the doses (denoted as node).  
The iterative graphical testing procedures are provided in Figure 1 for US specific 
protocol and Figure 2 for global protocol outside US.
In the graphs, the arrows specify the weight of α allocation between nodes.  Once a 
hypothesis is rejected (i.e., deemed the endpoint is significant) at its assigned significance 
level, its significance level will be allocated to the subsequent node.  If more than 
one arrow originates from a node, the significance level will be split between multiple 
subsequent nodes following the pre-specified weight.  The numbers on the arrows denote 
the weights.  For example, the weight 1 denotes 100% transfer of significance level to the 
next node, and the weight 1/2 denotes 50% and 50% splitting of significance level 
between the 2 nodes connected to it.
The two co-primary endpoints will be tested at the same α level in order to allocate the 
significance level to the next sequence of ranked secondary endpoints in the graph.  The 
last group of ranked secondary endpoints in the graph will be tested using the Holm 
procedure.2




Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
54
Figure 3.
Graphical Multiple Testing Procedure for Global Protocol Outside 
US


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
55
12.0
Version History
Table 2.
SAP Version History Summary
SAP Version
Date
1.0
06 OCT 2017
2.0
13 NOV 2018
3.0
25 FEB 2019
4.0
07 FEB 2020
Summary of Changes Between the Previous Version and the Current Version
1.
This version of SAP (Version 5) incorporated estimand language according to the 
guidance provided in ICH E9 R1 Addendum.
2.
The co-primary endpoints and ranked secondary endpoints have been updated for 
US/FDA regulatory purpose in Section 3.0 based on FDA's comments.
3.
Two endpoints (WPAI-CD and SF-36) have been moved from exploratory 
endpoints to ranked secondary endpoints for outside US/FDA regulatory purpose in 
Section 3.0 based on EMA's comments.   
4.
The endpoints related to non-draining fistula and anal fissure, and the endpoints 
related to FACIT-Fatigue have been added as other efficacy endpoints in 
Section 3.0 for clinical importance.
5.
The sample size justification has been updated in Section 2.4 to clarify the sample 
size calculation for different regulatory purpose. 
6.
The exclusion of the data from non-compliance sites has been added in Section 4.0.
7.
The graphic multiple testing procedures have been updated in Section 11.0 for 
US/FDA regulatory purpose and outside US/FDA regulatory purpose respectively. 
8.
Missing imputation methods have been updated in Section 8.3 to include more 
details for multiple imputation method, as well as introducing NRI-C method for 
handling missing data due to Covid-19 pandemic.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
56
9.
CD-related corticosteroid therapy censoring convention has been added in 
Section 8.2.2 to clarify the rules for efficacy censoring.
10.
The primary, secondary and other efficacy analyses have been updated in 
Section 8.0 to use NRI-C method as the primary approach for handling missing 
data.
11.
The language of "The risk difference and 95% CI between risankizumab group and 
placebo group will be presented for safety analysis" has been added in Section 9.0
based on agency's feedback.
12.
The language of "The exposure adjusted incidence rate (censored at the time of first 
event) may be conducted for selected ASI categories as appropriate."  has been 
added in Section 9.2.4 based on agency's feedback.
13.
Details about FACIT-Fatigue has been added in Appendix G.
14.
Areas of Safety Interest (ASI) have been updated in Appendix B to revise the ASI 
categories following new standard.
15.
Random seeds have been added in Appendix H.
Summary of Changes Between the Current Version of SAP and Protocol
1. Missing imputation methods have been updated to include more details for multiple 
imputation method, as well as introducing NRI-C method for handling missing data 
due to Covid-19 pandemic.
2. Two endpoints (WPAI-CD and SF-36) have been moved from exploratory endpoints 
to ranked secondary endpoints for outside US/FDA regulatory purpose based on 
EMA's comments.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
57
13.0
References
1.
Bretz F, Maurer W, Brannath W, et al.  A graphical approach to sequentially 
rejective multiple test procedures.  Stat Med.  2009;28(4):586-604.
2.
Holm, S.  A simple sequentially rejective multiple test procedure.  Scand J Stat.  
1979;6:65-70.
3.
Greenland S, Robins JM.  Estimation of a common effect parameter from sparse 
follow-up data.  Biometrics.  1985;41(1):55-68.
4.
Berglund PA.  An introduction to multiple imputation of complex sample data 
using SAS® v9.2.  2010.  Report No:  21-2010.
5.
Hedeker D, Gibbons RD.  "Application of random-effects pattern-mixture models 
for missing data in longitudinal studies." Psychological methods.  
1997;2(1):64-78.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
58
Appendix A.
Protocol Deviations
The number and percentage of subjects who reported at least one of the following 
protocol deviation categories will be provided.
●
Subject entered into the study even though s/he did not satisfy entry criteria.
●
Subject developed withdrawal criteria during the study and was not withdrawn.
●
Subject received wrong treatment or incorrect dose of study.
●
Subject took prohibited concomitant medication.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
59
Appendix B.
Areas of Safety Interest (ASI)
ASI Grouping
Categories 
(ASI)
Search Criteria
Terms to Display
Include 
in AE 
Overview 
(Y/N)
Adjudicated CV Events
MACE
Adjudicated terms 
will be identified 
using CECAT 
and CETERM 
from the CE 
SDTM dataset.
Display underlined terms 
defined by the following 
adjudicated terms:
!
CV Death which 
includes all CETERM 
values with 
CEDECOD = 
"Cardiovascular 
death" or 
CETERM="Death due 
to stroke"
!
Non-fatal Myocardial 
infarction
!
Non-fatal Stroke
Y
Extended 
MACE
Adjudicated terms 
will be identified 
(for MACE +) 
using CECAT 
and CETERM 
from the CE 
SDTM dataset.
Display underlined terms from 
MACE and underlined terms 
below:
!
Hospitalization for 
Unstable Angina
!
Coronary Revascularization 
Procedures
N


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
60
ASI Grouping
Categories 
(ASI)
Search Criteria
Terms to Display
Include 
in AE 
Overview 
(Y/N)
Serious infections, 
Tuberculosis, 
opportunistic infections 
and herpes zoster
Serious 
infections
Serious AEs 
within the 
Infections and 
Infestations SOC
PTs
Y
Active 
Tuberculosis
Active 
Tuberculosis
CMQ (code 
80000188)
PTs
Y
Opportunistic 
infections 
excluding 
tuberculosis and 
herpes zoster
Opportunistic 
infections 
excluding 
tuberculosis and 
herpes zoster
CMQ 
(code 80000189)
PTs
Y
Herpes Zoster
Herpes zoster 
CMQ (code 
80000175)
PTs
N
Malignancies
Malignant 
Tumours
Narrow
Malignant 
tumours 
(SMQ 20000194)
PTs
Y
Non-melanoma 
skin cancer 
(NMSC)
Broad
Skin malignant 
tumours 
(SMQ 20000204) 
excluding terms 
identified by the 
Melanoma CMQ 
(code 80000119)
PTs
N
Malignancies 
excluding 
NMSC
'Malignancies 
excluding NMSC'
is identified by 
the 'Malignant 
Tumours' search 
excluding terms 
identified by the 
'Non-melanoma 
skin cancer'
(NMSC) search.
PTs
Y


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
61
ASI Grouping
Categories 
(ASI)
Search Criteria
Terms to Display
Include 
in AE 
Overview 
(Y/N)
Hypersensitivity Reaction 
Hypersensitivity
Narrow
Hypersensitivity 
(SMQ 20000214)
PTs
N
Serious 
hypersensitivity
Serious AE 
within narrow
Hypersensitivity 
(SMQ 20000214)
PTs
Y
Anaphylactic Reaction
Adjudicated 
Anaphylactic
Reaction
Adjudicated terms 
will be identified 
using SDTM data 
(e.g., CE and PR 
domains).
Adjudicated term defined in the 
charter
Y
Serious 
anaphylactic 
reactions
Serious AE 
within narrow
Anaphylactic 
reaction 
(SMQ 20000021); 
PTs
Y


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
62
ASI Grouping
Categories 
(ASI)
Search Criteria
Terms to Display
Include 
in AE 
Overview 
(Y/N)
Hepatic events
Hepatic events
Broad 
Hepatic failure, 
fibrosis and 
cirrhosis and 
other liver 
damage-related 
conditions 
(SMQ 20000013)
Broad
Hepatitis, 
non-infectious 
(SMQ 20000010)
Broad
Cholestasis and 
jaundice of 
hepatic origin 
(SMQ 20000009)
Broad
Liver related 
investigations, 
signs and 
symptoms 
(SMQ 20000008)
Narrow
Liver-related 
coagulation and 
bleeding 
disturbances 
(SMQ 20000015)
PTs
N
Injection site reactions
Injection site 
reaction CMQ
(code 80000019)
PTs
N
Injection site 
reaction 
assessment and 
infusion site 
reaction 
assessment CRFs
Terms on the CRF


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
63
Appendix C.
Potentially Clinically Significant Criteria for Safety Endpoints
The criteria for Potentially Clinically Significant (PCS) laboratory findings are described 
in Table C-1 and Table C-2, and the PCS criteria for vital sign findings are described in 
Table C-3.
Table C-1.
Criteria for Potentially Clinically Significant Hematology Values
Hematology Variables
Units
Definition of Grade 3 or Greater
Very Low
Hemoglobin
g/dL
< 8.0
Platelets count
109/L
< 50.0
WBC count
109/L
< 2.0
Neutrophils
109/L
< 1.0
Lymphocytes
109/L
< 0.5
Note:
A post-baseline value must be a higher grade than the baseline CTC grade to be considered a potentially 
clinically significant finding.
Table C-2.
Criteria for Potentially Clinically Significant Chemistry Values
Chemistry Variables
Units
Definition of Grade 3 or Greater
Very Low
Very High
TBL
mcmol/L
> 3.0 × ULN
SGOT/AST
U/L
> 5.0 × ULN
SGPT/ALT
U/L
> 5.0 × ULN
Albumin
g/L
< 20
Glucose
mmol/L
< 2.2
> 13.9
Triglycerides
mmol/L
> 5.7
Creatinine
mcmol/L
> 3.0 × ULN (> 3.0 × BL)
Sodium
mmol/L
< 130
> 155
Potassium
mmol/L
< 3.0
> 6.0
Calcium (corrected for
albumin)
mmol/L
< 1.75
> 3.1
Total Cholesterol
mmol/L
> 10.34
GGT
> 5.0 × ULN
ALP
> 5.0 × ULN


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
64
Table C-2.
Criteria for Potentially Clinically Significant Chemistry Values
(Continued)
Note:
A post-baseline value must be a higher grade than the baseline CTC grade to be considered a potentially 
clinically significant finding.
Table C-3.
Criteria for Potentially Clinically Significant Vital Sign Values
Vital Sign
Category
Criteria for Potential Clinically Significant Vital Signs
Systolic blood pressure 
(mmHg)
Low
Value ≤ 90 mmHg and decrease ≥ 20 mmHg from baseline
High
Value ≥ 160 mmHg and increase ≥ 20 mmHg from baseline
Diastolic blood pressure 
(mmHg)
Low
Value ≤ 50 mmHg and decrease ≥ 10 mmHg from baseline
High
Value ≥ 100 mmHg and increase ≥ 10 mmHg from baseline


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
65
Appendix D.
Crohn's Disease Activity Index (CDAI)
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes 
patient symptoms evaluated over 7 days (abdominal pain, stool frequency and general 
well-being), as well as physical and laboratory findings.  These items are scored 
individually, weighted, and do not contribute equally to the overall score.  The CDAI is 
derived from summing up the weighted individual scores of eight items as outlined below: 
Factor
Subtotal
1.
Number of liquid or very soft stools 
(Record the frequency per day)
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
2
2.
Abdominal pain rating:
0 = none, 1 = mild, 2 = moderate,
3 = severe
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
5
3.
General well-being:
0 = generally well, 1 = slightly 
underpar, 2 = poor, 3 = very poor, 
4 = terrible
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
7
4.
Number of 6 listed categories the 
subject now has
Check all items that apply:
☐
Arthritis/arthralgia
☐
Iritis/uveitis
☐
Erythema nodosum/pyoderma 
gangrenosum/aphthous 
stomatitis
☐
Fissure, abscess and/or anal 
fistula (draining/non-draining)
☐
Other cutaneous fistula 
(draining/non-draining) Fistula
☐
Fever over 100°F (37.8°C) 
during past week
_________________________________ 
_________________________________
Record "0" if no categories checked
×
20
5.
Taking Lomotil/Imodium/
Loperamide/opiates for diarrhea
0 = no, 1 = yes
________
×
30
6.
Abdominal mass
0 = none, 2 = questionable,
5 = defined
________
×
10
7.
Hematocrit:  ___.__
Male:  (47 – hematocrit) =
Female:  (42 – hematocrit) =
Subtotal
If hematocrit > normal, enter "0"
×
6


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
66
Factor
Subtotal
8.
Body weight:  ___.__(kg)
Standard weight:  ___.__(kg)
100 × [1 – (Body wt/Standard wt)] =
Percent below standard weight:  ______
If body wt > std. wt, enter "0"
×
1
Total
CDAI with higher score indicates more severe disease.  For the calculation of CDAI and 
components at each visit, the following rules will be applied:
●
The 7 most recent useable days out of the 14 days preceding the visit will be 
used.
●
If 7 useable days are not available, an average will be calculated based on the 
number of days with available data as follows:
○
Data for days with missing diary entries will be imputed using the average 
of the non-missing days, in order to calculate a CDAI and components 
based on 7 days.
○
An average for the most recent 6 days will be calculated if data for only 
6 days are available
○
An average for the most recent 5 days will be calculated if data for only 
5 days are available
○
An average for the most recent 4 days will be calculated if data for only 
4 days are available
●
If the minimum number of days of diary data (i.e., 4 days for CDAI and 
components) are not available, then the subject's score for that visit will be 
considered missing.
The CDAI score is set to missing under the following conditions:
1.
If there are less than 4 days of any diary data.
2.
If any component other than the diary data is missing.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
67
Appendix E.
Simple Endoscopic Score – CD (SES-CD)
SES-CD is calculated based the sum of individual segment values for four endoscopic 
variables (presence and size of ulcers, ulcerated surface, affected surface and presence of 
narrowing).  Each variable in each segment be scored 0 to 3 resulting in SES-CD values 
ranging from 0 to 56 with higher scores indicating more severe disease.
SES-CD Scoring:
Rectum
Sigmoid and 
Left Colon
Transverse 
Colon
Right 
Colon
Ileum
Total
Size of Ulcers 
Enter:
0 if none
1 if aphthous ulcers (Ø 0.1 to 0.5 cm)
2 if large ulcers (Ø 0.5 to 2 cm)
3 if very large ulcers (Ø > 2 cm)
Ulcerated Surface
Enter:
0 if none
1 if < 10%
2 if 10% – 30%
3 if > 30%
Affected Surface
Enter:
0 if unaffected segments
1 if < 50%
2 if 50% – 75%
3 if > 75%


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
68
Rectum
Sigmoid and 
Left Colon
Transverse 
Colon
Right 
Colon
Ileum
Total
Presence of Narrowing
Enter:
0 if none
1 if single, can be passed
2 if multiple, can be passed
3 if cannot be passed
TOTAL = 


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
69
Appendix F.
Inflammatory Bowel Disease Questionnaire (IBDQ)
The IBDQ is a 32-item (ranges 1 – 7) self-report questionnaire for patients with IBD to 
evaluate the patient reported outcomes across 4 dimensions:  bowel symptoms (loose 
stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social 
function (work attendance, need to cancel social events), and emotional function (anger, 
depression, irritability).  The IBDQ total Score ranges from 32 to 224 with a higher score 
indicating better outcome.
The derivation of the IBDQ total score and the four IBDQ domain scores are as follows:
Domain Scores:
●
S1. BOWEL SYMPTOM:           Q1 + Q5 + Q9 + Q13 + Q17 + Q20 + Q22 + 
Q24 + Q26 + Q29
[score ranges from 10 - 70],
●
S2. SOCIAL FUNCTION:          Q4 + Q8 + Q12 + Q16 + Q28
[score ranges from 5 - 35],


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
70
●
S3. SYSTEMIC SYMPTOM:     Q2 + Q6 + Q10 + Q14 + Q18
[score ranges from 5 - 35],
●
S4. EMOTIONAL FUNCTION: Q3 + Q7 + Q11 + Q15 + Q19 + Q21 + Q23 + 
Q25 + Q27 + Q30 + Q31 + Q32
[score ranges from 12 - 84].
Total Score:
IBDQ Total Score = SUM of (bowel symptom domain score, social function domain 
score, systemic symptom domain score, emotional function domain score).
The following convention applies to Inflammatory Bowel Disease Questionnaire 
(IBDQ):
When not more than 20% of items in a domain of IBDQ were missing, it was substituted 
with the mean values from the items completed in the particular domain; otherwise, they 
were treated as missing.  The 20% threshold in each domain is:  bowel symptom domain:  
2 items, systemic symptom domain:  1 item, social function domain:  1 item, emotional 
function domain:  2 items.  If any of the 4 domain scores is missing, the total IBDQ score 
will be set to missing.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
71
Appendix G.
FACIT-Fatigue
The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system is a 
comprehensive compilation of questions that measure health related quality of life in 
patients with cancer and other chronic diseases (www.facit.org).  The FACIT-Fatigue 
scale is a symptom-specific subscale of FACIT and is composed of 13 fatigue-related 
questions as follows.  The response to each question is as follows: 0=Not at all, 1=A little 
bit, 2=Somewhat, 3=Quite a bit, 4=Very much.
1.
I feel fatigued
2.
I feel weak all over
3.
I feel listless ("washed out")
4.
I feel tired
5.
I have trouble starting things because I am tired
6.
I have trouble finishing things because I am tired
7.
I have energy
8.
I am able to do my usual activities
9.
I need to sleep during the day
10.
I am too tired to eat
11.
I need help doing my usual activities
12.
I am frustrated by being too tired to do the things I want to do
13.
I have to limit my social activity because I am tired
In order to have higher values representing lower level of fatigue, all of the items, except 
for item 7 "I have energy" and item 8 "I am able to do my usual activities," are assigned 
reversed scores: reversed score = 4 – raw score.  The total FACIT-Fatigue score will then 
be calculated as follows:


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
72
●
FACIT-Fatigue score = 13∀[Sum of answered-item scores / Number of items 
answered]
The score ranges from 0 to 52, 52 being the lowest level of fatigue. 
When there are missing data, provided that more than 50% of the items (i.e., at least 7 of 
13 items) were answered in FACIT-Fatigue questionnaire, the total score will not be 
deemed as missing but be calculated as the mean response for all the non-missing-value 
items.  If less than 50% of the items were answered, the total score will have a missing 
value.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
73
Appendix H.
Random Seeds
In case of non-convergence, the random seed will be updated by adding 100000 at each 
attempt until convergence of model happens.
Table H-1.  Random Seeds for NRI-C
Variables
Random Seed
MCMC Procedure
PROC MI
CDAI
21171*
22207#
SES-CD (for 20 individual variables)
21172
22208
SF score
21173
22209
AP score
21174
22210
EIM
21175
22211
FACIT-Fatigue
21176
22212
IBDQ total score
21179
22215
PGIS
21180
22216
PGIC
21181
22217
*
This is SAS numerical form of Dec 18, 2017, which is the date when the first subject randomized in this study.
#
This is SAS numerical form of Oct 19, 2020, which is the projected date when the last subject will be randomized 
in this study.


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
74
Appendix I.
Geographic Region
Below table lists the countries/regions considered for each geographic region.
Geographic Region
Countries/Regions
Asia
Japan (JPN), China (CHN), Hong Kong (HKG), Malaysia (MYS), Singapore 
(SGP), South Korea (KOR), Taiwan (TWN)
Eastern Europe
Belarus (BLR), Bosnia and Herzegovina (BIH), Bulgaria (BGR), Croatia 
(HRV), Czech Republic (CZE), Estonia (EST), Hungary (HUN), Kazakhstan 
(KAZ), Latvia (LVA), Lithuania (LTU), Poland (POL), Romania (ROU), 
Russia (RUS), Serbia (SRB), Slovakia (SVK), Slovenia (SVN), Turkey 
(TUR), Ukraine (UKR)
North America
Canada (CAN), United States (USA), Puerto Rico (PRI)
Other
Australia (AUS), Egypt (EGY), Israel (ISR), New Zealand (NZL), South 
Africa (ZAF), Tunisia (TUN)
South/Central America
Argentina (ARG), Brazil (BRA), Chile (CHL), Colombia (COL), Mexico 
(MEX), Guatemala (GTM)
Western Europe
Austria (AUT), Belgium (BEL), Denmark (DNK), Finland (FIN), France 
(FRA), Germany (DEU), Greece (GRC), Ireland (IRL), Italy (ITA), 
Netherlands (NLD), Norway (NOR), Portugal (PRT), Spain (ESP), 
Switzerland (CHE), Sweden (SWE), United Kingdom (GBR)


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
75
Appendix J.
Definition of Estimand for Primary and Ranked Secondary 
Endpoints
Estimand
Attributes of the Estimand
Population
Endpoint(s)
Treatment
Intercurrent Events
Statistical 
Summary
Primary
ITT1A
population 
For US 
specific 
protocol:
Achievement 
of CDAI 
clinical 
remission at 
Week 12.
Achievement 
of endoscopic 
response at 
Week 12.
For global 
protocol 
outside US:
Achievement 
of clinical 
remission at 
Week 12.
Achievement 
of endoscopic 
response at 
Week 12.
Risankizumab 
1200 mg IV 
vs. placebo
Risankizumab 
600 mg IV vs. 
placebo
IE1: premature 
discontinuation of 
study drug
IE2: Initiation or dose 
escalation of CD-
related corticosteroids
All data after IE1 will 
be used.
All subjects will be 
considered as non-
responders at or after 
IE2
Proportion of 
subjects 
achieving 
CDAI 
clinical 
remission.
Proportion of 
subjects 
achieving 
clinical 
remission.
Proportion of 
subjects 
achieving 
endoscopic 
response.
Binary Key 
Secondary
ITT1A
population
Binary 
secondary 
endpoints as 
defined in 
Section 3.2
except for 
CD-related 
hospitalizatio
n endpoint
Risankizumab
1200 mg IV 
vs. placebo
Risankizumab
600 mg IV vs. 
placebo
IE1: premature 
discontinuation of 
study drug
IE2: Initiation or dose 
escalation of CD-
related corticosteroids
All data after IE1 will 
be used.
All subjects will be 
considered as non-
responders at or after 
IE2
Proportion of 
subjects 
achieving 
each binary 
secondary 
endpoint


Risankizumab (ABBV-066)
M15-991 – Statistical Analysis Plan
Version 5.0 – 23 November 2020
76
Estimand
Attributes of the Estimand
Population
Endpoint(s)
Treatment
Intercurrent Events
Statistical 
Summary
Continuous 
Key 
Secondary
ITT1A
population 
Change from 
Baseline in 
IBDQ total 
score/FACIT-
F score at 
Week 12
Risankizumab
1200 mg IV 
vs. placebo
Risankizumab
600 mg IV vs. 
placebo
IE1: premature 
discontinuation of 
study drug
IE2: Initiation or dose 
escalation of CD-
related corticosteroids
All data after IE1 will 
be used.
All data after IE2 will 
not be used.  MMRM 
will be the primary 
approach for the 
analysis. 
Mean change 
from 
Baseline in 
IBDQ total 
score and 
FACIT-F 
score
CD-related 
hospitalizati
on
ITT1A
population
Occurrence of 
CD-related 
hospitalizatio
n through 
Week 12
Risankizumab
1200 mg IV 
vs. placebo
Risankizumab
600 mg IV vs. 
placebo
IE1: premature 
discontinuation of 
study drug
IE2: Initiation or dose 
escalation of CD-
related corticosteroids
All data after IE1 will 
be used.
All data after IE2 will 
be used
Proportion of 
subjects 
having at 
least one
CD-related 
hospitalizati
on through 
Week 12
In addition, a supplementary analysis corresponding to the AO analysis specified in 
Section 8.3.2 will be conducted for the primary and key binary secondary endpoints in 
which all data after IE1 and IE2 will be included in the analysis.

Prot_001.pdf: 
Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
1
1.0
Title Page
Clinical Study Protocol M15-991
A Multicenter, Randomized, Double-Blind, 
Placebo-Controlled Induction Study to Assess the 
Efficacy and Safety of Risankizumab in Subjects 
with Moderately to Severely Active Crohn's Disease 
Who Failed Prior Biologic Treatment
Incorporating Administrative Change 1, 2, and 3 and 
Amendments 1, 2, 3, 4, 5, 6, 7, and 7.01 (United 
States Only)
AbbVie Investigational
  Product:
Risankizumab
Date:
27 August 2020
Development Phase:
3
Study Design:
Randomized, Double-Blind, Placebo-Controlled Parallel Group Design
EudraCT Number:
2016-003190-17
Investigator(s):
Multicenter Study (Investigator information is on file at AbbVie)
*Sponsor:
Non-European Countries:
AbbVie
1 North Waukegan Road
North Chicago, IL 60064 USA
European Countries:
AbbVie Deutschland GmbH & Co KG
Knollstrasse 50
Ludwigshafen 67061
Germany
Sponsor/Emergency 
  Contact:
Pharmaceutical Development
1 North Waukegan Road
North Chicago, IL 60064 USA
Phone:
Mobile:
Fax:
Email:
* The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country are provided 
within the clinical trial agreement with the Investigator/Institution and in the Clinical Trial Application with the 
Competent Authority.
This study will be conducted in compliance with the protocol, Good Clinical Practice and all other applicable regulatory 
requirements, including the archiving of essential documents.
Confidential Information
No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.
NCT03104413


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
2
1.1
Protocol Amendment:  Summary of Changes
Previous Protocol Versions
Protocol 
Date
Original
17 February 2017
Amendment 1
29 March 2017
Amendment 2
05 July 2017
Amendment 3
29 September 2017
Amendment 4
09 July 2018
Amendment 5
22 February 2019
Amendment 6
19 December 2019
Amendment 7
28 July 2020
The purpose of this amendment is to:
●
Modification of language in Section 3.2 on the re-evaluation of the benefit and 
risk in light of the COVID-19 pandemic, to subjects participating in the study
Rationale: To clarify the effect of immunomodulatory therapies on the course 
of COVID-19 is currently unknown
●
Addition of endpoint definitions in Section 5.3.3
Rationale: to include endpoint definitions for newly added secondary 
endpoints in Section 5.3.3.2 and Section 5.3.3.3
●
Revision of Co-Primary Endpoints in Section 5.3.3.1
Rationale: Co-Primary endpoints were revised based on regulatory input
●
Section 5.3.3.2 updated to reflect new secondary endpoint ranking, addition of 
new secondary endpoints, and update terms
Rationale: Reassessment based on evidence from the Risankizumab CD 
Phase 2 study (Study M15-992), regulatory feedback, clinical relevance of 
endpoints to patients and physicians, alignment with study changes and 
updated terms
●
Revision to Determination of Sample Size in Section 8.2
Rationale:  To update power calculation for revised co-primary endpoint


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
3
An itemized list of all changes made to this protocol under this amendment can be found 
in Appendix J.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
4
1.2
Synopsis
AbbVie Inc.
Protocol Number:  M15-991
Name of Study Drug:  Risankizumab (ABBV-066)
Phase of Development:  3
Name of Active Ingredient:  Risankizumab
Date of Protocol Synopsis:  27 August 2020
Protocol Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to 
Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's 
Disease Who Failed Prior Biologic Treatment
Objectives:  The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab 
versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease 
(CD).
Investigators:  Multicenter
Study Sites:  Approximately 400 sites 
Study Population:  Males and females aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent 
according to local regulations at the Baseline visit, or aged 16 to < 18 years of age where locally 
permitted and who meet the definition of Tanner stage 5 development (refer to Appendix J), at the 
Baseline visit, with a diagnosis of moderately to severely active CD, defined as:
1.
average daily stool frequency (SF) ≥ 4 (when calculating SF, only the number of liquid or very soft 
stools should be recorded) and/or average daily abdominal pain (AP) score ≥ 2; plus 
2.
endoscopic evidence of mucosal inflammation measured by the Simple Endoscopic Score for CD 
(SES-CD).  All eligible scores exclude the presence of narrowing component and are confirmed by 
a central reader.  Endoscopic activity is defined as a SES-CD of ≥ 3.
The number of subjects enrolled with a SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or 
SES-CD of 3 for isolated ileal disease will be no more than 58 subjects.  Once cap of no more than 
58 subjects is reached, enrollment criterion will be an eligibility SES-CD of ≥ 6 for ileocolonic or 
colonic disease, or eligibility SES-CD of ≥ 4 for isolated ileal disease.
The study will enroll 100% of subjects who have had an inadequate response or intolerance to prior 
biologic therapy (bio-IR).  The bio-IR population is defined as subjects with documented intolerance or 
inadequate response to one or more of the approved biologic agents for CD (infliximab, adalimumab, 
certolizumab, natalizumab, ustekinumab and/or vedolizumab).  The percent of subjects with exposure, 
including intolerance or inadequate response to ustekinumab will be no more than 20%. 
Number of Subjects to be Enrolled:  Approximately 579 for the primary ITT population used for 
efficacy analysis; additionally, up to 58 subjects with lower SES-CD will be enrolled


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
5
Methodology:  
Study M15-991 is a randomized, double blind, placebo-controlled 12-week induction study.
Subjects (n = 579) will be randomized 1:1:1 to 1200 mg risankizumab or 600 mg risankizumab or 
placebo intravenous (IV) given at Baseline, Weeks 4, 8.  The randomization will be stratified by both the 
number of prior biologics failed (1, > 1), Baseline steroid use (yes, no), and Baseline SES-CD (original, 
alternative), where the stratum of "original" includes the patients with baseline SES-CD of ≥ 6 (or ≥ 4 
for subjects with isolated ileal disease), and the stratum of "alternative" includes the patients with
baseline SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or SES-CD of 3 for isolated ileal 
disease.
Visits during the study will occur at Baseline and Weeks 4, 8, and 12/Premature Discontinuation (PD) to 
collect clinical and laboratory assessments of disease activity.  Subjects who do not achieve clinical 
response at Week 12 may be eligible for treatment with blinded risankizumab in Induction Period 2 with 
evaluation for clinical response at Week 24.
All subjects will be provided with a subject diary where they will record CD related symptoms 
throughout the study.  Subjects will also be dispensed a patient information card during Screening.  
Additionally, subjects will complete symptom, quality of life (QoL) and work productivity 
questionnaires throughout the study.  Clinical labs including, but not limited to, urinalysis, chemistry and 
hematology, high-sensitivity C-reactive protein (hs-CRP), serum risankizumab concentrations, and 
serum anti-drug antibody (ADA) levels will be collected throughout the study.  In addition, stool 
samples for calprotectin analysis will be collected and should be taken before starting bowel preparations 
for endoscopy.  All endoscopies will be evaluated using SES-CD and will be confirmed by a central 
reader.  Biopsy to confirm diagnosis (during Screening) or to rule out dysplasia/malignancy may be 
performed during the same time points as the endoscopy.  Optional exploratory research samples may be 
taken during the study.
At the Week 12/PD visit, all subjects will undergo an endoscopy for evaluation of mucosal 
inflammation.  It is expected that all subjects who remain in the study through at least Week 8 will have 
a Week 12/PD endoscopy.  All subjects achieving clinical response, defined as ≥ 30% decrease in 
average daily SF and/or ≥ 30% decrease in average daily AP score (both not worse than Baseline) at 
Week 12 may be eligible to enter Study M16-000.  Subjects are not eligible to enter Study M16-000 
until endoscopy has been completed (local reader results will be used for stratification for 
Study M16-000).  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive blinded 
treatment with risankizumab in Induction Period 2 as described below.  Subjects are not eligible to enter 
Induction Period 2 until Week 12 endoscopy has been completed.  


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
6
Methodology (Continued):
Induction Period 2
At Week 12, subjects who do not achieve clinical response will be randomized by Interactive Response 
Technologies (IRT) to Induction Period 2, a double-blind, double-dummy 12-week treatment period.
Subjects who received IV risankizumab induction treatment will be randomized 1:1:1 to:
!
Group 1:  1200 mg IV risankizumab
!
Group 2:  360 mg SC risankizumab
!
Group 3:  180 mg SC risankizumab
Subjects who received placebo induction treatment will receive:
!
Group 4:  1200 mg IV risankizumab
The IV risankizumab dose or matching IV placebo will be given at Weeks 12, 16, and 20; The SC 
risankizumab dose or matching SC placebo will be given at Weeks 12, and 20.
At Week 24, subjects who received treatment in Induction Period 2 will be reassessed and undergo a 
third endoscopy for evaluation of mucosal inflammation.  Subjects who achieve clinical response at 
Week 24 may be eligible to enter Study M16-000.  Subjects without clinical response at Week 24, as 
well as all subjects who terminate the study early (including subjects who are eligible for, but do not 
receive treatment during Induction Period 2) will be discontinued and have a follow-up call 140 days 
from the last dose of study drug to obtain information on any new or ongoing AEs.
Concomitant Aminosalicylates, Immunomodulators (Azathioprine [AZA], 6-Mercaptopurine 
[6-MP], Methotrexate [MTX]), and/or CD-Related Antibiotics
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at Baseline must 
continue these treatments for the duration of the study.  Initiating and/or increasing doses of 
aminosalicylates, immunomodulators, and/or CD-related antibiotics during the study is prohibited.  
Decreasing doses of aminosalicylates, immunomodulators, and/or CD-related antibiotics is prohibited 
during the study, except in the event of moderate-to-severe treatment related toxicities and after 
discussion with the AbbVie Therapeutic Area Medical Director (TA MD).  CD-related antibiotics may 
be discontinued in Induction Period 2 at the discretion of the Investigator.
Note:  the duration of the study includes Induction Period 2.
Concomitant Corticosteroids
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at the Baseline 
dose for the duration of the 12-week induction period.  Initiation and/or increasing doses of systemic 
and/or CD related corticosteroids during the entire study is prohibited.  Decreasing doses of 
corticosteroids is prohibited during the 12-week induction period, except in the event of moderate-to-
severe treatment related toxicities and after discussion with the AbbVie TA MD.
Subjects who enter Induction Period 2 will be allowed to taper their corticosteroids at the discretion of 
the Investigator.  Increasing doses above the Baseline dose is prohibited.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
7
Methodology (Continued):
Dose Selection
This study will evaluate two IV doses of risankizumab (600 mg and 1200 mg).  The selection of the 
doses in this study is informed by the analysis of the safety and efficacy data, as well as the 
exposure-response relationship of efficacy, of a Phase 2 study in subjects with CD that explored 200 mg 
and 600 mg doses.  The results from the Phase 2 study suggest a potential for increased benefit with 
1200 mg administration.
Induction Period 2 will evaluate IV (1200 mg Q4w) or SC (180 mg or 360 mg Q8w; maintenance dosing 
regimen) risankizumab.  The purpose of Induction Period 2 is to evaluate the efficacy and safety of re-
induction of risankizumab (1200 mg IV at Weeks 12, 16, and 20) versus starting maintenance dosing on 
clinical response status.  Data from the Phase 2 study in subjects with CD suggested that re-induction 
with 600 mg IV increased both clinical response and clinical remission in subjects with inadequate 
response at Week 12.  The selection of the SC doses is informed by the analysis of the safety and 
efficacy data, as well as the exposure-response relationship of efficacy, of the maintenance period during 
the Phase 2 study in subjects with CD that evaluated 180 mg SC risankizumab for maintenance.  The 
results from the Phase 2 study suggest a potential for increased benefit with 360 mg SC administration 
for maintenance regimen. 
Data Monitoring Committee (DMC)
An external independent DMC will review unblinded safety data on a cohort level, at a minimum of 
6-month intervals throughout the course of the study.  At the timing of this amendment, the DMC has 
provided recommendation that the study may continue without modification and allowed enrollment to 
begin for 16 – 17 year-olds.  A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be provided to 
the patients at Screening so that any such events once occurred will be reported immediately by the 
patients to the investigator.  
A separate DMC charter will be prepared outside of the protocol and will describe the roles and 
responsibilities of the DMC members, frequency and triggers of data reviews, and relevant safety data to 
be assessed.  The cardiac adjudication committee (CAC) and anaphylaxis adjudication committee (AAC) 
adjudicates blinded data and the DMC reviews the data in an unblinded manner.  Unblinded adjudicated 
cardio-cerebrovascular events and anaphylactic reactions will be presented to the DMC for review on a 
periodic basis.  Communications from the DMC to the Study Teams will not contain information that 
could potentially unblind the team to subject treatment assignments.
Diagnosis and Main Criteria for Inclusion/Exclusion:  
Main Inclusion:  
1.
Male or female aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent according to local 
regulations, at the Baseline visit.  Where locally permissible, subjects 16 to < 18 years of age who 
meet the definition of Tanner stage 5 for development (refer to Appendix I), at the Baseline Visit 
(sites will be notified when adolescents may enroll).
2.
Confirmed diagnosis of CD for at least 3 months prior to Baseline.  Appropriate documentation of 
biopsy results consistent with the diagnosis of CD, in the assessment of the Investigator, must be 
available.
3.
Crohn's disease activity index (CDAI) score 220 – 450 at Baseline.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
8
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Inclusion (Continued):  
4.
Endoscopic evidence of mucosal inflammation as documented by an SES-CD of ≥ 3.  All eligible 
scores exclude the presence of narrowing component and are confirmed by a central reader.  (Once 
cap of no more than 58 subjects is reached, enrollment criterion will be an SES-CD of ≥ 6 for 
ileocolonic or colonic disease or SES-CD of ≥ 4 for isolated ileal disease.)
5.
Average daily SF ≥ 4 and/or average daily AP score ≥ 2 at Baseline.
6.
Demonstrated intolerance or inadequate response to one or more of the following biologic agents:  
infliximab, adalimumab, certolizumab pegol, natalizumab, ustekinumab and/or vedolizumab:
!
Demonstration of intolerance requires no minimum dose or duration of use
!
Inadequate response to biologic agents defined as signs and symptoms of persistently (in the 
opinion of the Investigator) active disease despite a history of one or more of the following:
o
At least one 6-week induction regimen of infliximab (≥ 5 mg/kg IV at Weeks 0, 2, and 6),
o
At least one 4-week induction regimen of adalimumab (one 160 mg SC dose at Week 0, 
followed by one 80 mg SC dose at Week 2 [or one 80 mg SC dose at Week 0, followed 
by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]),
o
At least one 4-week induction regimen of certolizumab pegol (400 mg SC at Weeks 0, 2, 
and 4)
o
At least one 6-week induction regimen of vedolizumab (300 mg IV at Weeks 0, 2, and 6)
o
At least one 12-week induction regimen of natalizumab (300 mg IV every 4 weeks)
o
At least one 8-week induction regimen of ustekinumab [260 mg (≤ 55 kg) or 390 mg 
(> 55 to ≤ 85 kg) or 520 mg (> 85 kg) IV, followed by 90 mg SC at Week 8] (Once cap 
of no more than 20% ustekinumab exposed subjects is reached, subjects with prior 
ustekinumab exposure will not be allowed to enroll.)  
!
Recurrence of symptoms during scheduled maintenance dosing following prior clinical benefit 
of the above biologic agents
!
Note:  Subjects who discontinued biologic agents for reasons other than inadequate response as 
defined above or intolerance (e.g., change of insurance) are not eligible to enroll
7.
If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol Contraception 
Recommendations.  Females of childbearing potential must have a negative serum pregnancy test 
result during Screening, and a negative urine pregnancy at Baseline.  Females of non-childbearing 
potential (either postmenopausal or permanently surgically sterile as defined in Section 5.2.4) 
during Screening do not require pregnancy testing at Baseline. 
Note:  Subjects with borderline serum pregnancy test at Screening must have a serum pregnancy test 
≥ 3 days later to document continued lack of a positive result.
8.
Subjects must be able and willing to give written informed consent and to comply with the 
requirements of this study protocol.
Main Exclusion:  
1.
Subject with a current diagnosis of ulcerative colitis or indeterminate colitis.
Concomitant Medications and Treatments 
2.
Subject on CD-related antibiotics who has not been on stable doses for greater than, or discontinued 
within, 14 days prior to Baseline.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
9
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
3.
Subject on oral aminosalicylates who has not been on stable doses for greater than, or discontinued 
within, at least 14 days prior to Baseline.
4.
Subject taking oral corticosteroids:
!
Budesonide > 9 mg/day
!
Beclomethasone > 5 mg/day
!
Prednisone or equivalent > 20 mg/day
!
Or has not been on the current course for ≥ 14 days prior to Baseline and on a stable dose for 
≥7 days prior to Baseline
5.
Subject on immunomodulators (AZA, 6-MP, MTX) who:
!
Has not been on the current course for ≥ 42 days prior to Baseline, and
!
Has not been on a stable dose for ≥ 35 days prior to Baseline
Medications and Treatments During the Screening Period
6.
Subject who received IV anti-infectives within 35 days prior to Baseline visit or oral/intramuscular 
anti-infectives (non-CD-related) within 14 days prior to the Baseline visit.  This does not apply to 
TB prophylaxis.
7.
Subject who received exclusive enteral nutrition or any parenteral nutrition within 35 days prior to 
Baseline.
8.
Subject who received any live bacterial or viral vaccination within 30 days prior to Screening or 
during the Screening period.
9.
Subject who received cyclosporine, tacrolimus, or mycophenolate mofetil within 35 days prior to 
Baseline.
10. Subject who received fecal microbial transplantation within 35 days prior to Baseline.
Prior Medications and Treatments
11. Subject who received any biologic agent:
!
Approved biologics: infliximab, adalimumab, certolizumab, natalizumab, vedolizumab within 
8 weeks prior to Baseline, or ustekinumab within 12 weeks prior to Baseline 
Note:  If there is proper documentation of an undetectable drug level measured by a 
commercially available assay for any of the approved biologics above, there is no minimum 
washout prior to Baseline.
!
Any investigational biologic or other agent or procedure within 35 days or 5 half-lives prior to 
Baseline, whichever is longer.
12. Subject with prior exposure to p19 inhibitors (e.g., risankizumab).
13. Subject has been taking combination of two or more of the following oral budesonide, or oral 
beclomethasone and/or oral prednisone (or equivalent) simultaneously, with the exception of 
inhalers, within 14 days prior to Screening or during the Screening period.
14. Subject who received IV/intramuscular corticosteroids within 14 days prior to Screening or during 
the Screening period.
15. Subject who received therapeutic enema or suppository, other than required for endoscopy, within 
14 days prior to endoscopy used for Screening or during the Screening period.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
10
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
16. Subject who received apheresis (e.g., Adacolumn apheresis) ≤ 60 days prior to Screening or during 
the Screening period.
17. Subject who has concomitant cannabis use either recreational or for medical reasons within 14 days 
of Baseline or any history of clinically significant drug, or alcohol abuse in the last 12 months.
CD Related
18. Subject with currently known complications of CD such as:
!
abscess (abdominal or perianal),
!
symptomatic bowel strictures,
!
> 2 missing segments of the following 5 segments:  terminal ileum, right colon, transverse 
colon, sigmoid and left colon, and rectum
!
fulminant colitis,
!
toxic megacolon,
!
or any other manifestation that might require surgery while enrolled in the study.
19. Subject with ostomy or ileoanal pouch.
20. Subject diagnosed with short gut or short bowel syndrome.
21. Subject with surgical bowel resection within the past 3 months prior to Baseline, or a history of 
≥3 bowel resections.
Safety
22. Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study 
drugs or the ingredients of Chinese hamster ovary (CHO).
23. Subjects with the following chronic or active infections: 
!
Active, chronic, or recurrent infection that based on the Investigator's clinical assessment makes 
the subject unsuitable candidate for the study, 
!
Infection with C. difficile toxin or other intestinal pathogen during Screening,
!
Are infected with human immunodeficiency virus (HIV),
!
QuantiFERON®-TB test or Purified Protein Derivative (PPD) skin test, or both, according to 
local guidelines, will be performed during Screening.  QuantiFERON®-TB test is preferred for 
subjects who received BCG vaccination or were exposed to other Mycobacteria species.  
Subjects with a positive test result (or indeterminate results that have been repeated) may 
participate in the study if further work up (according to local practice/guidelines) establishes 
conclusively that the subject has no evidence of active tuberculosis.  Subjects with a history of 
active TB who have documented completion of a full course of anti-TB therapy may be allowed 
to enter the study after consultation with the AbbVie TA MD.  If latent TB is established, TB 
prophylaxis/treatment should be initiated and maintained according to local country guidelines.
!
Have active hepatitis B or hepatitis C defined as:
o
HBV:  hepatitis B surface antigen (HBs Ag) positive (+), or detected sensitivity on the 
HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for 
hepatitis B core antibody (HBc Ab) positive subjects
o
HCV:  HCV ribonucleic acid (RNA) detectable in any subject with positive anti-HCV 
antibody (HCV Ab)


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
11
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
24. Subject with a previous history of dysplasia of the gastrointestinal tract or found to have dysplasia, 
other than completely removed low-grade dysplastic lesions, in any biopsy performed during the 
Screening endoscopy.
25. Subject with a known history of lymphoproliferative disease, including lymphoma, or signs and 
symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or 
splenomegaly.
26. Subject with current or previous history of malignancy other than a successfully treated 
non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of 
the cervix.
27. Subject who has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, 
disorder or symptoms thereof.
28. Female subjects who is pregnant, breastfeeding, or is considering becoming pregnant during the 
study or for approximately 140 days after the last dose of study drug.
29. Subject who has any condition, including any physical, psychological, or psychiatric condition, 
which in the opinion of the Investigator, would compromise the safety of the subject or the quality 
of the data and renders the subject an unsuitable candidate for the study.
30. Screening laboratory and other analyses show any of the following abnormal results:
!
Aspartate transaminase (AST), alanine transaminase (ALT) > 2 × upper limit of the reference 
range;
!
White blood cell (WBC) count < 3.0 × 109/L;
!
Total bilirubin ≥ 2 mg/dL; except for subjects with isolated elevation of indirect bilirubin 
relating to Gilbert syndrome;
!
Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal 
Disease (MDRD) formula < 30 ml/min/1.73 m2. 
!
Hemoglobin < 8 g/dL
!
Platelets < 100,000/μL
!
Positive serum pregnancy test at the Screening visit or positive urine pregnancy test at the 
Baseline visit
Laboratory values can be re-tested once during the screening period after discussion and clearance 
with the TAMD.  If the re-tested lab value(s) remain(s) exclusionary, the subject will be considered 
a screen failure.  Redrawing samples if previous samples were unable to be analyzed would not 
count as a retest since previous result was never obtained.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
12
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
31. No known active COVID-19 infection.  Subject must not have signs/symptoms associated with 
COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and may only rescreen 
after they meet the following COVID-19 viral clearance criteria:
!
Symptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since recovery, defined as resolution of fever without 
use of antipyretics and improvement in respiratory symptoms (e.g., cough, shortness of breath)
!
Asymptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (Note: subjects who develop 
symptoms will follow guidance above for symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the above viral clearance 
criteria may be adjusted to account for epidemiological trends, updated information regarding 
infectivity and local/institutional guidelines.
Investigational Product:
Risankizumab
Dose(s):
Risankizumab 1200 mg IV Q4W*
Risankizumab 600 mg IV Q4W
Risankizumab 180 mg SC Q8W
Risankizumab 360 mg SC Q8W
*If administration of the 1200 mg dose is halted for any reason, 
enrollment may continue for subjects into the risankizumab 600 mg, or 
placebo arms at a 1:1 ratio.  The ratio of randomization and final sample 
size may be further updated in an amendment to the protocol.  Subjects 
already randomized to treatment arms, including Induction Period 2, 
will receive blinded 600 mg risankizumab IV.
Mode of Administration:
Risankizumab solution for infusion (IV)
Risankizumab solution for injection (SC)
Reference Therapy:
Placebo for risankizumab 
Dose(s):
Placebo:  N/A
Mode of Administration:
Placebo solution for infusion (IV)
Placebo solution for injection (SC)
Duration of Treatment:  12 or 24 weeks.
The study will include a Screening period of 35 days and a double-blind induction period of 12 weeks.  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive risankizumab in 
Induction Period 2 over a subsequent 12 week period.  There will be a follow up call 140 days from the 
last dose of study drug to obtain information on any new or ongoing AEs for those subjects who do not 
roll over into Study M16-000 or discontinue from the study prematurely.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
13
Criteria for Evaluation:
Endpoint Definitions:
!
Clinical remission:  average daily SF ≤ 2.8 and not worse than Baseline AND average daily 
AP score ≤ 1 and not worse than Baseline
!
Enhanced clinical response:  ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in 
average daily AP score and both not worse than Baseline, and/or clinical remission
!
Clinical response:  ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in average daily 
AP score and both not worse than Baseline
!
Endoscopic response:  decrease in SES-CD > 50% from Baseline (or for subjects with isolated 
ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline), as scored 
by central reviewer
!
Ulcer-free endoscopy:  SES-CD ulcerated surface subscore of 0 in subjects with SES-CD 
ulcerated surface subscore ≥ 1 at Baseline, as scored by a central reviewer.
!
Endoscopic remission:  SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no 
subscore greater than 1 in any individual variable, as scored by a central reviewer
!
CDAI clinical response: reduction of CDAI ≥ 100 points from baseline
!
CDAI clinical remission: CDAI < 150
!
SF remission:  average daily SF ≤ 2.8 and not worse than baseline
!
AP remission:  average daily AP score ≤ 1 and not worse than baseline
Efficacy:
Co-Primary Endpoints:
!
Proportion of subjects with CDAI clinical remission at Week 12 
!
Proportion of subjects with endoscopic response at Week 12
Ranked Secondary Endpoints (Risankizumab vs Placebo):
1.
Proportion of subjects with clinical remission at Week 12
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with CDAI clinical response at Week 12
4.
Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-
fatigue) at Week 12
5.
Proportion of subjects with CDAI clinical remission at Week 4 
6.
Proportion of subjects with CDAI clinical response and endoscopic response at Week 12
7.
Proportion of subjects with SF remission at Week 12
8.
Proportion of subjects with AP remission at Week 12
9.
Proportion of subjects with endoscopic remission at Week 12
10. Proportion of subjects with enhanced clinical response at Week 4
11. Proportion of subjects with ulcer-free endoscopy at Week 12
12. Proportion of subjects with enhanced clinical response at Week 12
13. Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at Week 12, in 
subjects with any EIMs at Baseline
14. Proportion of subjects with CD-related hospitalization through Week 12


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
14
Criteria for Evaluation (Continued):
Efficacy (Continued):
Ranked Secondary Endpoints (Risankizumab vs Placebo) (Continued):
15. Proportion of subjects without draining fistulas at Week 12 in subjects with draining fistulas at 
Baseline
For further information, including non-ranked endpoints, refer to protocol.
Pharmacokinetics:
Serum risankizumab concentrations will be determined from samples collected just prior to dosing at 
Weeks 4, 8, and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Immunogenicity:
Serum ADAs will be determined from samples collected just prior to dosing at Baseline and Weeks 4, 8, 
and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Safety:
Safety analyses will be performed on safety set which includes all subjects who receive at least one dose 
of study drug.  Incidence of adverse events (AEs), changes in vital signs, physical examination results, 
and clinical laboratory data will be assessed throughout the study.  
Exploratory Research Variables and Validation Studies (Optional):
Prognostic, surrogate, predictive and pharmacodynamics biomarkers signatures may be investigated.  
Samples for different applications, potentially including but not limited to pharmacogenetic, epigenetic, 
transcriptomic, proteomic, metabolomic, metagenomic, phenotypic, functional and targeted 
investigations will be collected at various time points.  Assessments may include but may not be limited 
to nucleic acids, proteins, metabolites, lipids, or peripheral blood mononuclear cells (PBMC).
Statistical Methods:
Efficacy:
The co-primary endpoints are the proportion of subjects with CDAI clinical remission at Week 12 and 
the proportion of subjects who achieve endoscopic response at Week 12.  A total of approximately 
579 subjects will be randomized into two risankizumab treatment groups and the placebo group in a 
1:1:1 ratio (193 subjects/arm).  When all patients complete their Week 12/PD visit, the database will be 
locked for the final analysis of 12-week induction period.  When all the patients who enter the induction 
Period 2 finish Week 24/PD visit, the database will be locked for the whole study and all the planned 
analysis for the induction Period 2 will be performed.
Assuming the Week 12 CDAI clinical remission rate will be 34% for one of the risankizumab groups 
and 15% for the placebo group, a sample size of 193 subjects for each risankizumab group and 
193 subjects for the placebo group will have approximately 97% power to detect the treatment difference 
between risankizumab dose groups and placebo in CDAI clinical remission rates at Week 12 using 
Fisher's exact test at a 0.025 significant level (two sided).
The comparisons between each risankizumab dose versus placebo for the primary efficacy variable will 
be performed using the Cochran-Mantel-Haenszel (CMH) test adjusted by the number of prior biologics 
failed (1, > 1) and Baseline steroid use (yes, no).
Both of the primary efficacy endpoints will be tested at statistically significant of 0.025 for each of the 
risankizumab dose group versus placebo to adjust for multiplicity.  A CMH based two-sided 95% 
confidence interval for the difference between treatment groups will be calculated.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
15
Statistical Methods (Continued):
Efficacy (Continued):
The intent-to-treat (ITT) set includes all randomized subjects who have taken at least one dose of study 
drug.  The primary population for efficacy analysis are the subjects in the intent-to-treat analysis set who 
had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal disease).  Subjects who discontinue prior to 
Week 12 for any reason will be considered as "not-achieved" for CDAI clinical remission and 
endoscopic response endpoints.
In general, continuous secondary efficacy variables will be analyzed using a Mixed-Effect Model 
Repeated Measure (MMRM) model including factors for treatment group, visit, visit by treatment 
interaction, and stratification variables, for the longitudinal continuous endpoints.  The MMRM analysis 
is considered primary for inferential purposes.  
Pharmacokinetics and Immunogenicity:
Serum risankizumab concentrations will be summarized at each time point for each dosing regimen 
using descriptive statistics.  Population pharmacokinetic analyses combining the data from this study and 
other studies may be performed.  Relationships between risankizumab exposures and efficacy and safety 
variables of interest may be explored.  
ADA incidence will be summarized by cohorts and study visits.  ADA titers will be tabulated for each 
subject at the respective study visits.  The effect of ADA on risankizumab pharmacokinetics, efficacy 
and/or safety variable(s) and/or any additional analyses will be explored.
Safety:
Adverse events, laboratory data and vital signs are the primary safety parameters in this study.  All 
safety comparisons will be performed between treatment groups using the safety set.  Treatment 
emergent AEs are defined as events that begin or worsen either on or after the first dose of the study 
drug and within 140 days after the last dose of the study drug for subjects who do not participate in 
Study M16-000 or until first dose of study drug in Study M16-000 if the subject is enrolled in 
Study M16-000. 
An overview of treatment-emergent AEs, AEs leading to death and AEs leading to premature 
discontinuation (see details in the statistical analysis plan [SAP]), AEs by Medical Dictionary for Drug 
Regulatory Activities (MedDRA version) preferred term and system organ class, AEs by maximum 
relationship to study drug, and AEs by maximum severity will be summarized by number and 
percentage.  
Changes in laboratory data will be described using statistical characteristics and compared 
between-treatment groups will be performed using a one-way Analysis of Variance (ANOVA).  In 
addition, shift tables and listings will be provided for abnormal values, whereby the normal range of the 
analyzing laboratory will be used.  Vital signs will be analyzed similarly.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
16
1.3
List of Abbreviations and Definition of Terms
Abbreviations
6-MP
6-Mercaptopurine
AAC
Anaphylaxis adjudication committee
ADA
Anti-Drug Antibody
AE
Adverse event 
ALT
Alanine transaminase 
ANCOVA
Analysis of Covariance
ANOVA
Analysis of Variance
AP
Abdominal Pain
AST
Aspartate transaminase 
ATEMS
AbbVie Temperature Excursion Management System
AZA
Azathioprine
BCG
Bacillus Calmette-Guérin 
BUN
Blood urea nitrogen 
CAC
Cardiac Adjudication Committee
CD
Crohn's disease 
CDAI
Crohn's disease activity index
CHO
Chinese Hamster Ovary
CMH
Cochran-Mantel-Haenszel
COVID-19
Coronavirus Disease 2019
CRA
Clinical Research Associate
CSS
Crohn's Symptom Severity
CTCAE
Common Terminology Criteria for Adverse Events
CXR
Chest x-ray 
DILI
Drug-induced Liver Injury
DMC
Data Monitoring Committee
DNA
Deoxyribonucleic acid 
ECG
Electrocardiogram 
eCRF
Electronic Case Report Form
EDC
Electronic Data Capture
EIM
Extra-Intestinal Manifestations
ePRO
Electronic Patient Reported Outcome


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
17
EQ-5D-5L
European Quality of Life 5 Dimensions
FACIT-F
Functional Assessment of Chronic Illness Therapy-Fatigue
FCP
Fecal Calprotectin
FDA
Food and Drug Administration 
FSH
Follicle-Stimulating Hormone
GCP
Good Clinical Practice 
HBV
Hepatitis B virus
HBc Ab
Hepatitis B core antibody
Hbs Ab
Hepatitis B surface antibody
Hbs Ag
Hepatitis B surface antigen 
HCV
Hepatitis C virus
HCV Ab
Hepatitis C virus antibody
HCT
Hematocrit
HIV
Human immunodeficiency virus
hs-CRP
High-sensitivity C-Reactive Protein
IBDQ
Inflammatory Bowel Disease Questionnaire 
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
IGRA
Interferon-Gamma Release Assay
IL
Interleukin 
IM
Intramuscular
INR
International Normalized Ratio
IR
Inadequate response
IRB
Institutional Review Board 
IRT
Interactive Response Technologies
ITT
Intent-to-treat
IUD
Intrauterine device
IUS
Intrauterine hormone-releasing system
IV
Intravenous
MACE
Major Adverse Cardiovascular Events
MDRD
Modification of Diet in Renal Disease
MedDRA
Medical Dictionary for Drug Regulatory Activities
MI
Multiple Imputation
MMR
Measles Mumps-Rubella


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
18
MMRM
Mixed-Effect Model Repeated Measure
MMRV
Measles Mumps-Rubella Varicella
MTX
Methotrexate 
nAb
Neutralizing antibodies
NRI
Non-responder imputation
N/A
Not Applicable
OC
Observed Case
OL
Open-Label
OPV
Oral Polio Vaccine
PBMC
Peripheral blood mononuclear cell
PCR
Polymerase Chain Reaction
PD
Premature Discontinuation
PGIC
Patient Global Impression of Change
PGIS
Patient Global Impression of Severity
PK
Pharmacokinetics
PMM
Pattern Mixture Model
POR
Proof of Receipt 
PPD
Purified protein derivative 
QoL
Quality of Life
Q4w
Every 4 Weeks
Q8w
Every 8 Weeks
RBC
Red blood cell 
RNA
Ribonucleic Acid
RSI
Reference safety information
SAE
Serious adverse event 
SAP
Statistical Analysis Plan
SC
Subcutaneous 
SES-CD
Simple Endoscopic Score for Crohn's disease
SF
Stool Frequency
SF-36 
36-Item Short Form Health Survey
SUSAR
Suspected Unexpected Serious Adverse Reactions
TA MD
Therapeutic Area Medical Director
TB
Tuberculosis 
TNF
Tumor Necrosis Factor 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
19
ULN
Upper Limit of Normal
WBC
White blood cell
WOCBP
Women of Childbearing Potential
WPAI-CD
Work Productivity and Impairment Questionnaire – Crohn's disease


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
20
2.0
Table of Contents
1.0
Title Page..................................................................................1
1.1
Protocol Amendment:  Summary of Changes ...........................................2
1.2
Synopsis .....................................................................................................4
1.3
List of Abbreviations and Definition of Terms........................................16
2.0
Table of Contents...................................................................20
3.0
Introduction ...........................................................................25
3.1
Differences Statement..............................................................................26
3.2
Benefits and Risks....................................................................................26
4.0
Study Objective......................................................................29
5.0
Investigational Plan...............................................................29
5.1
Overall Study Design and Plan:  Description ..........................................29
5.2
Selection of Study Population..................................................................37
5.2.1
Inclusion Criteria .....................................................................................38
5.2.2
Exclusion Criteria ....................................................................................40
5.2.3
Prior and Concomitant Therapy...............................................................46
5.2.3.1
Prior Therapy ...........................................................................................46
5.2.3.2
Concomitant Therapy...............................................................................46
5.2.3.3
Prohibited Therapy...................................................................................48
5.2.4
Contraception Recommendations ............................................................49
5.3
Efficacy, Pharmacokinetic, Pharmacodynamic, Optional 
Exploratory Research/Validation Studies and Safety 
Assessments/Variables.............................................................................50
5.3.1
Efficacy and Safety Measurements Assessed and Flow Chart ................50
5.3.1.1
Study Procedures .....................................................................................50
5.3.1.2
Collection and Handling of Optional Exploratory 
Research/Validation Studies Samples......................................................67
5.3.2
Drug Concentration and Anti-Drug Antibody Measurements.................69
5.3.2.1
Collection of Samples for Analysis .........................................................69
5.3.2.2
Handling/Processing of Samples .............................................................69
5.3.2.3
Disposition of Samples ............................................................................69
5.3.2.4
Measurement Methods.............................................................................70


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
21
5.3.3
Efficacy Variables....................................................................................70
5.3.3.1
Primary Variable......................................................................................71
5.3.3.2
Secondary Variables ................................................................................71
5.3.3.3
Other Endpoints .......................................................................................72
5.3.4
Safety Variables.......................................................................................73
5.3.5
Pharmacokinetic Variables ......................................................................73
5.3.6
Optional Exploratory Research/Validation Variables..............................73
5.4
Removal of Subjects from Therapy or Assessment.................................74
5.4.1
Discontinuation of Individual Subjects....................................................74
5.4.2
Discontinuation of Entire Study...............................................................76
5.5
Treatments................................................................................................76
5.5.1
Treatments Administered.........................................................................76
5.5.2
Identity of Investigational Products.........................................................77
5.5.2.1
Packaging and Labeling...........................................................................78
5.5.2.2
Storage and Disposition of Study Drug(s) ...............................................78
5.5.2.3
Preparation/Reconstitution of Dosage Form(s)........................................79
5.5.3
Method of Assigning Subjects to Treatment Groups...............................79
5.5.4
Selection and Timing of Dose for Each Subject......................................80
5.5.5
Blinding....................................................................................................80
5.5.5.1
Blinding of Investigational Product.........................................................81
5.5.5.2
Data Monitoring Committee....................................................................81
5.5.6
Treatment Compliance.............................................................................82
5.5.7
Drug Accountability.................................................................................82
5.6
Discussion and Justification of Study Design..........................................83
5.6.1
Discussion of Study Design and Choice of Control Groups....................83
5.6.2
Appropriateness of Measurements...........................................................84
5.6.3
Suitability of Subject Population .............................................................84
5.6.4
Selection of Doses in the Study ...............................................................85
6.0
Complaints .............................................................................86
6.1
Medical Complaints.................................................................................86
6.1.1
Definitions................................................................................................87
6.1.1.1
Adverse Event..........................................................................................87
6.1.1.2
Serious Adverse Events ...........................................................................88


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
22
6.1.1.3
Areas of Safety Interest............................................................................90
6.1.2
Adverse Event Severity............................................................................91
6.1.3
Relationship to Study Drug......................................................................92
6.1.3.1
Lack of Efficacy or Worsening of Disease ..............................................93
6.1.4
Adverse Event Collection Period.............................................................93
6.1.5
Adverse Event Reporting.........................................................................94
6.1.5.1
Adverse Events Commonly Associated with CD in Study 
Population ................................................................................................95
6.1.6
Pregnancy.................................................................................................96
6.1.7
Cardiac Adjudication Committee ............................................................97
6.1.8
Anaphylaxis Adjudication Committee.....................................................97
6.2
Product Complaint ...................................................................................97
6.2.1
Definition .................................................................................................97
6.2.2
Reporting..................................................................................................98
7.0
Protocol Deviations................................................................98
8.0
Statistical Methods and Determination of Sample 
Size ..........................................................................................99
8.1
Statistical and Analytical Plans................................................................99
8.1.1
Datasets for Analysis ...............................................................................99
8.1.1.1
Intent-to-Treat Analysis Set.....................................................................99
8.1.1.2
Safety Analysis Set ................................................................................100
8.1.2
Definition of Missing Data Imputation..................................................100
8.1.3
Subject Disposition ................................................................................100
8.1.4
Demographics and Baseline Characteristics..........................................100
8.1.5
Prior and Concomitant Medications ......................................................101
8.1.6
Efficacy Analysis ...................................................................................101
8.1.6.1
Primary Efficacy Variables....................................................................101
8.1.6.2
Secondary Efficacy Variables................................................................102
8.1.7
Safety Analysis ......................................................................................103
8.1.8
Analysis of Optional Exploratory Variables..........................................103
8.1.9
Analysis of Pharmacokinetic and Pharmacodynamic Variables............104
8.2
Determination of Sample Size ...............................................................105
8.3
Randomization Methods ........................................................................106


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
23
9.0
Ethics.....................................................................................107
9.1
Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB) ...........................................................................................107
9.2
Ethical Conduct of the Study.................................................................107
9.3
Subject Information and Consent...........................................................108
10.0
Source Documents and Case Report Form 
Completion ...........................................................................110
10.1
Source Documents .................................................................................110
10.2
Case Report Forms.................................................................................110
10.3
Electronic Patient Reported Outcomes (ePRO).....................................111
11.0
Data Quality Assurance ......................................................113
12.0
Use of Information...............................................................114
13.0
Completion of the Study .....................................................115
14.0
Investigator's Agreement....................................................116
15.0
Reference List ......................................................................117
List of Tables
Table 1.
Clinical Laboratory Tests.........................................................................57
Table 2.
Identity of Investigational Product...........................................................78
Table 3.
Serious Adverse Events ...........................................................................89
Table 4.
Common Events Associated with CD......................................................96
List of Figures
Figure 1.
Study M15-991 Study Schematic ............................................................32
Figure 2.
Adverse Event Collection ........................................................................93
List of Appendices
Appendix A.
Responsibilities of the Clinical Investigator ..........................................120
Appendix B.
List of Protocol Signatories....................................................................122
Appendix C.
Study Activities......................................................................................123


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
24
Appendix D.
Study Activities – Optional Exploratory Research Samples .................127
Appendix E.
Sample SES-CD Scoring .......................................................................128
Appendix F.
Crohn's Disease Activity Index (CDAI) ................................................129
Appendix G.
Standard Weights...................................................................................130
Appendix H.
Clinical Criteria for Diagnosing Anaphylaxis .......................................133
Appendix I.
Tanner Stage 5 for Development ...........................................................135
Appendix J.
Protocol Amendment:  List of Changes.................................................138


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
25
3.0
Introduction
Crohn's disease (CD) encompasses a spectrum of clinical and pathological processes 
manifested by focal asymmetric, transmural, and occasionally granulomatous 
inflammation that can affect any segment of the gastrointestinal tract and presents with 
symptoms of fatigue, prolonged diarrhea with or without gross bleeding, abdominal pain, 
weight loss, and fever.1  The disease can affect persons of any age, and its onset is most 
common in the second and third decades.  Females are affected slightly more than males, 
and the risk for disease is higher in some ethnic groups.2,3  The incidence of CD has 
steadily increased in developed countries over the past 3 decades4 with recent estimates 
varying from 12.7 and 20.2 cases/100,000, and a prevalence of 319 and 322 cases/100,000 
in North America and Europe, respectively.5  In Asia, the incidence of CD is estimated to 
be 0.5 to 1.0 cases per 100,000 persons, with a prevalence rate ranging from 3.6 to 7.7.6,7
The exact cause of CD is still unknown, but is hypothesized to be the result of a 
dysregulated immune system in the context of a genetically susceptible individual.  It is 
thought that a combination of a patient's genetics, microbiome, immune response, and the 
environment result in an excessive and abnormal immune response in the gut that results 
in pathology seen in CD.2
The aim of medical treatment in CD has been focused on controlling inflammation and 
reducing symptoms.8  In addition to improving symptoms, an emerging goal of therapy is 
to heal the gut mucosa.  Resolution of intestinal ulcers, also known as mucosal healing 
has been associated with positive clinical benefits, including higher rates of clinical 
remission, fewer hospitalizations, and fewer abdominal surgeries.9,10  However, 
improvement of the appearance of the intestinal mucosa may be more difficult to achieve 
than symptomatic improvement alone.
Conventional pharmaceutical therapies (e.g., corticosteroids, aminosalicylates, 
thiopurines, methotrexate) are limited, do not always completely abate the inflammatory 
process, and have significant adverse effects.1,11  The advent of anti-TNFα agents 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
26
(e.g., adalimumab) and integrin inhibitors (e.g., vedolizumab) have been shown to achieve 
clinical remission in patients refractory to conventional therapies.9-13
Despite the benefits of available biologic therapies, many patients do not respond to initial 
treatment (primary loss of response) or lose treatment over time (secondary loss of 
response).  Regarding anti-TNF agents, approximately 40% of patients will experience 
primary non-response and secondary non-response occurs in 38% of patients at 6 months 
and 50% of patients at 1 year.12,14-17  Additionally, some patients are not candidates for 
available biologic therapies.  Therefore new therapeutic options are required in order to 
continue to improve the outcome of patients with CD.
Risankizumab is a fully humanized mAb of the IgG1 subclass directed towards IL-23p19.  
The antibody has been engineered to reduce Fcγ receptor and complement binding and 
potential charge heterogeneity.  Risankizumab binds with high affinity to human IL-23 
and inhibits IL-23 stimulated IL-17 production at inhibitory concentration (IC) 50 
concentrations below 10 pM, as compared with 167 pM for ustekinumab in the same 
system.  Risankizumab does not affect IL-12 at a maximum tested concentration (33 nM) 
and it does not inhibit IL-12 stimulated IFN-γ production.
3.1
Differences Statement
This study is designed to evaluate the efficacy and safety of two risankizumab induction 
doses versus placebo during induction therapy in subjects with moderately to severely 
active CD.  The primary difference between Study M15-991 and the prior phase 2 study 
of risankizumab in CD is that this study will test a higher dosing of 1200 mg.  
Additionally, the endpoints in this study are different to reflect the changing regulatory 
requirements for pivotal registrational studies for new agents for the treatment of CD.
3.2
Benefits and Risks
Data suggest that altered immune regulation at the epithelial barrier, leads to an 
overproduction of inflammatory cytokines, tissue destruction, and aberrant tissue repair in 
CD.  Among the cytokines implicated in CD pathogenesis, data at the genetic, human 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
27
biology and clinical level strongly implicate IL-23 in this disease.18,19  The preclinical and 
clinical profiles of risankizumab suggest that it may have the potential to address unmet 
medical need in CD.  The data observed in the Phase 2 study suggest that risankizumab 
will alleviate signs and symptoms of active CD and reduce mucosal inflammation.  
Participation in this study may help to generate future benefit for subjects with CD. 
Though there are no serious adverse drug reactions known to be associated with 
risankizumab therapy, risks of participating in this study include risk of infection and risks 
related to the study specific procedures of blood sampling, infusion and injection of study 
drug, and colonoscopy with biopsy.
Blood sampling, intravenous (IV) infusions and subcutaneous (SC) injections can cause 
local bruising, inflammation, and pain.  Colonoscopy and biopsy, although generally well 
tolerated, can be associated with diarrhea, abdominal pain, and in more severe cases, 
perforation, bleeding, effects from anaesthetic medications, and infection.
Local reactions to IV or SC administered biologic therapies are uncommon, and are 
usually limited to redness, swelling or induration at the injection site.  Manifestations of 
systemic hypersensitivity reactions include anaphylaxis, pruritus, hypotension, and 
respiratory distress.  Both local and systemic hypersensitivity reactions are readily 
detectable, transient in nature, and manageable with standard medical treatment.  Subjects 
will be closely monitored during drug administration.
As with any immune modulating agent, risankizumab has the potential to impair immune 
function resulting in a risk of infection.  This will be addressed by clinical monitoring for 
adverse events (AEs) during the treatment and follow up periods.  Subjects with positive 
screening for M. Tuberculosis (TB) (skin/interferon-gamma release assay [IGRA] test 
positive) will be further worked up for signs and symptoms of active TB (e.g., chest x-ray 
[CXR]).  Subjects with active TB will be excluded from enrolling in the study.  Subjects 
with latent TB will be allowed to enroll in line with local guidelines.  If latent TB is 
established, TB prophylaxis/treatment should be initiated and maintained according to 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
28
local country guidelines.  Subjects with current signs or symptoms of infection or history
of serious infection will not be included in the study.
The role of IL-23 in tumor immunity is not well established at this time, but an increased 
risk of cancer from an IL-23 antagonist, though considered small, cannot be excluded.
Although rare, a potential for drug-induced liver injury (DILI) is under constant 
surveillance by sponsors and regulators.  Therefore, though there is no known DILI risk 
with risankizumab, this study requires timely detection, evaluation, and follow-up of 
laboratory alterations of selected liver laboratory parameters to ensure subjects' safety.
An independent Data Monitoring Committee (DMC) will be assessing all potential safety 
signals and will be unblinded to treatment allocation.  The DMC will review unblinded 
safety data on a cohort level, at a minimum of 6 month intervals throughout the course of 
the study.  At the timing of this amendment, the DMC has provided recommendation that 
the study may continue without modification and allowed enrollment to begin for 16 –
17 year-olds.  A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be 
provided to the patients at Screening so that any such events once occurred will be 
reported immediately by the patients to the investigator.
Increases in major adverse cardiovascular events (MACE) including myocardial 
infarction, cerebrovascular accident, and cardiovascular death have been reported in drugs 
with similar mechanism of action to risankizumab (e.g., p40 inhibitors).  However, the 
incidence of MACE has not been observed in longer term studies.  While the likelihood of 
increased MACE is small, all suspected cardiovascular events (serious or nonserious) 
observed in this study will be adjudicated by an independent adjudication committee.  An 
independent cardiac adjudication committee (CAC) will be adjudicating observed cardio-
and cerebro-vascular events and will remain blinded to treatment allocation.  In addition, 
an independent anaphylaxis adjudication committee (AAC) will be adjudicating observed 
potential anaphylactic events and will remain blinded to treatment allocation.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
29
The benefit-risk profile is considered appropriate for an experimental therapy at this stage 
of clinical development. 
In view of the COVID-19 pandemic, the benefit-risk profile of various 
immunomodulatory therapies on COVID-19 is being evaluated based on real world and 
clinical trial data.  At this time, the effects of risankizumab on the course of COVID-19 
are not well defined.
4.0
Study Objective
The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab 
versus placebo during induction therapy in subjects with moderately to severely active 
CD.  
5.0
Investigational Plan
5.1
Overall Study Design and Plan:  Description
The study was designed to enroll approximately 579 subjects to meet scientific and 
regulatory objectives without enrolling an undue number of subjects in alignment with 
ethical considerations.  Therefore, if the target number of subjects has been enrolled, there 
is a possibility that additional subjects in screening will not be enrolled.  In addition to the 
579 subjects, up to 58 subjects with a lower SES-CD, defined as an eligibility SES-CD of 
≥ 3 to < 6 for ileocolonic or colonic disease or SES-CD of 3 for isolated ileal disease will 
be enrolled in order to inform treatment effect in this patient population, but these subjects 
will not be included in the primary ITT population for efficacy analysis.
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled induction 
study to assess the efficacy and safety of risankizumab in subjects with moderately to 
severely active CD, defined as:
1.
average daily stool frequency (SF) ≥ 4 (when calculating SF, only the number of 
liquid or very soft stools should be recorded) and/or average daily abdominal pain 
(AP) score ≥ 2; plus 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
30
2.
endoscopic evidence of mucosal inflammation as measured by the Simple 
Endoscopic Score for CD (SES CD).  All eligible scores exclude the presence of 
narrowing component and are confirmed by a central reader.  Endoscopic activity 
is defined as SES-CD of ≥ 3. 
The number of subjects enrolled with a SES-CD of ≥ 3 to < 6 for ileocolonic or colonic 
disease or SES-CD of 3 for isolated ileal disease will be no more than 58 subjects.  Once 
cap of no more than 58 subjects is reached, enrollment criterion will be an eligibility 
SES-CD of ≥ 6 for ileocolonic or colonic disease, or eligibility SES-CD of ≥ 4 for isolated 
ileal disease.
All endoscopies will be centrally read to document eligibility and for assessment at the 
time points indicated in Appendix C.
The study will enroll subjects who have had a documented inadequate response (IR) or 
intolerance to use of an approved biologic agent (bio-IR), such as infliximab, 
adalimumab, certolizumab, natalizumab, ustekinumab and/or vedolizumab.  The percent
of subjects with exposure, including intolerance or inadequate response, to ustekinumab
will be no more than 20%.
The study duration may be up to 49 weeks, including a Screening period of 35 days, a 
12-week induction period, a 12-week Induction Period 2 for those subjects who do not 
achieve clinical response at Week 12, and a 140 days of follow up period from the last 
dose of study drug.
Visits for clinical evaluation will occur at Baseline Weeks 4, 8, and 12/PD.  Subjects, who 
do not achieve clinical response at Week 12, will be offered blinded risankizumab in 
Induction Period 2 with evaluation for clinical response at Week 24.
At the study visit indicated in Appendix C, all subjects will be provided with a subject 
diary where they will record CD related symptoms throughout the study.  Subjects will 
also be dispensed a patient information card during Screening.  Additionally, subjects will 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
31
complete symptom, quality of life (QoL) and work productivity questionnaires throughout 
the study as indicated in Appendix C.  Clinical labs including, but not limited to, 
urinalysis, chemistry and hematology, high-sensitivity C-reactive protein (hs-CRP), serum 
risankizumab concentrations, and serum anti-drug antibody (ADA) levels may be 
collected.  In addition, stool samples for calprotectin analysis will be collected and should 
be taken before starting bowel preparations for endoscopy.  All endoscopies will be 
evaluated using SES-CD and will be confirmed by a central reader.  Biopsy to confirm 
diagnosis (during Screening) or to rule out dysplasia/malignancy may be performed 
during the same time points as the endoscopy.  Optional exploratory research samples 
may be taken during the study.
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be 
enrolled into the study and randomized in a 1:1:1 ratio as shown in Figure 1.  At the 
timing of this amendment, the DMC has provided recommendation that the study may 
continue without modification and allowed enrollment to begin for 16 – 17 year-olds.   


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
32
Figure 1.
Study M15-991 Study Schematic
a.
12-Week Induction Period
b. Induction Period 2
DC = discontinued; IR = subjects with inadequate clinical response to induction; IV = intravenous; R = subjects with 
clinical response; RR = re-randomize; RZB = risankizumab


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
33
Screening Period
Within 35 days prior to the Baseline visit, subjects will receive a full explanation of the 
study design and study procedures, provide a written informed consent, and undergo the 
screening procedures as outlined in Appendix C.  Once written informed consent is 
obtained, subjects will undergo screening procedures.
The length of time between Screening and the Baseline visit must allow time for 
endoscopy central reading and lab results.  The Screening period (35 days ± 7 days is 
granted around all study visits) may be extended as necessary after consultation with the 
AbbVie Therapeutic Area Medical Director (TA MD) for subjects who require initiation 
of prophylactic anti-TB therapy, or in case of external circumstances (e.g., due to the 
delay of availability of screening test results).
Laboratory values that are exclusionary can be re-tested once during the screening period 
upon discussion and clearance with TA MD.  If the re-tested lab value(s) remain(s) 
exclusionary, the subject will be considered a screen failure.  Redrawing samples if 
previous samples were unable to be analyzed would not count as a retest since the 
previous result was never obtained.  
Clinical laboratory assessments as specified in Appendix C will only need to be repeated 
at Baseline if the time between Screening and Baseline is > 14 days, or if the subject's 
health status has changed to warrant a repeat test. 
All subjects need to have their average daily SF, average daily AP, and CDAI calculated 
and meeting eligibility criteria before randomization at Baseline.
12-Week Induction Period
At the Baseline visit, subjects who meet all the inclusion criteria and none of the 
exclusion criteria described in Section 5.2.1 and Section 5.2.2 will be enrolled into the 
study and randomized to the double-blind induction period where they will receive either 
risankizumab 1200 mg IV, risankizumab 600 mg IV, or placebo.  The randomization at 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
34
Baseline will be stratified by the number of prior biologics failed (1, > 1), steroid use at 
Baseline (yes, no), and Baseline SES-CD (original, alternative).
During this period of the study, subjects will visit the study site at Weeks 4, 8 and 12/PD.  
Subjects, who do not achieve clinical response at Week 12 and choose to continue in the 
study, will have additional visits at Weeks 16, 20 and 24 for blinded Induction Period 2 
with risankizumab.  A ± 7-day window is permitted around scheduled study visits.  An 
effort will be made to bring subjects back to their original scheduled visit (calculated from 
Baseline) if they are out of the visit window.
At the Week 12/PD visit, all subjects will undergo an endoscopy for evaluation of 
mucosal inflammation.  It is expected that all subjects who remain in the study through at 
least Week 8 will have a Week 12/PD endoscopy.  All subjects achieving clinical 
response, defined as ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in 
average daily AP score (both not worse than Baseline) at Week 12 may be eligible to 
enter Study M16-000.  Subjects are not eligible to enter Study M16-000 until endoscopy 
has been completed (local reader results will be used for stratification for 
Study M16-000).  
All subjects who do not achieve clinical response at Week 12 will be able to receive 
blinded risankizumab in Induction Period 2, as specified below.  Subjects are not eligible 
to receive blinded Induction Period 2 therapy until endoscopy has been completed.  
Induction Period 2
At Week 12, subjects who do not achieve clinical response will be randomized by 
Interactive Response Technologies (IRT) to Induction Period 2, a double-blind, double-
dummy 12-week treatment period.
Subjects who received risankizumab induction treatment will be randomized 1:1:1 to:
●
Group 1:  1200 mg IV risankizumab
●
Group 2:  360 mg SC risankizumab


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
35
●
Group 3:  180 mg SC risankizumab
Subjects who received placebo induction treatment will receive:
●
Group 4:  1200 mg IV risankizumab
The IV risankizumab dose or matching IV placebo will be given at Weeks 12, 16, and 20; 
The SC risankizumab dose or matching SC placebo will be given at Weeks 12, and 20
At Week 24, subjects who participated in the blinded Induction Period 2 will be 
reassessed and undergo a third endoscopy for evaluation of mucosal inflammation.  
Subjects who achieve clinical response at Week 24 may be eligible to enter 
Study M16-000.  Subjects without clinical response at Week 24, as well as all subjects 
who terminate the study early (including subjects who are eligible for but do not 
participate in the blinded Induction Period 2), will be discontinued and have a follow-up 
call 140 days from the last dose of study drug to obtain information on any new and/or 
ongoing AEs.
Concomitant Aminosalicylates, Immunomodulators (Azathioprine [AZA], 
6-Mercaptopurine [6-MP], Methotrexate [MTX]), and/or CD-Related Antibiotics
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at 
Baseline must continue their concomitant treatment for the duration of the study.  
Initiating and/or increasing doses of aminosalicylates, immunomodulators, and/or CD-
related antibiotics during the study is prohibited.  Decreasing doses of aminosalicylates, 
immunomodulators, and/or CD-related antibiotics is prohibited during the study, except in 
the event of moderate-to-severe treatment related toxicities and after discussion with the 
AbbVie TA MD.  CD-related antibiotics may be discontinued in Induction Period 2 at the 
discretion of the Investigator.
Note:  the duration of the study includes the Induction Period 2.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
36
Concomitant Corticosteroids
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at 
the Baseline dose for the duration of the 12-week induction period.  Initiation and/or 
increasing doses of systemic and/or CD related corticosteroids during the entire study is 
prohibited.  Decreasing doses of corticosteroids is prohibited during the 12-week 
induction period, except in the event of moderate-to-severe treatment related toxicities 
and after discussion with the AbbVie TA MD.  
Subjects who receive blinded therapy in Induction Period 2 during Weeks 12 to 24 will be 
allowed to taper their corticosteroids at the discretion of the Investigator.  While stopping 
the taper is permitted, increasing doses above the Baseline dose is prohibited.
Follow-Up Period/Premature Discontinuation (PD)
Subjects may discontinue treatment at any time during the study participation 
(Section 5.4).  Subjects who end study participation early will have a PD visit and 
complete the procedures outlined for the PD visit in Appendix C as soon as possible after 
the last dose of study drug and preferably prior to the administration of any new therapies.
Subjects who discontinue the study or subjects who complete the Week 12/Week 24 visit 
and do not roll-over into Study M16-000 will have a follow-up call 140 days from the last 
dose of study drug to obtain information on any new or ongoing AEs.
Re-Screen
Subjects who initially screen fail for the study may be permitted to re-screen following 
re-consent.  The subject must meet all the inclusion and none of the exclusion criteria at 
the time of re-screening in order to qualify for the study.  There is no minimum period of 
time a subject must wait to re-screen for the study.
If the subject had a complete initial screening evaluation including the TB test, hepatitis B 
virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and 
electrocardiogram (ECG), these tests will not be required to be repeated for re-screening 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
37
provided the conditions noted in Section 5.3.1.1 are met and no more than 90 days have 
passed since the collection date of the testing.
If a subject is being rescreened within 14 days (≤ 14 days have passed) from the date of 
the previous screening testing, it is not required to repeat testing for 
chemistry/hematology, urinalysis, serum pregnancy, and C. difficile provided that the 
subject's health status has not changed to warrant a repeat test.  In this case, all Baseline 
testing should be performed at the Baseline visit.
If rescreening occurs more than 14 days (> 14 days have passed) from the collection date 
of the previous screening testing then new samples (chemistry/hematology, urinalysis, 
serum pregnancy, and C. difficile) should be collected during Rescreening.  In this case, 
chemistry/hematology, urinalysis do not need to be repeated at the Baseline visit if 
Baseline occurs within 14 days (≤ 14 days) from the date of rescreening testing provided 
that the subject's health status has not changed to warrant a repeat test.
All subjects need to have their average daily SF, average daily AP, and CDAI calculated 
and meeting eligibility criteria before randomization at Baseline.
An endoscopy with biopsy will not be required to be repeated for re-screening provided 
the conditions noted in Section 5.3.1.1 are met and the endoscopy is within 45 days of the 
Baseline visit.  Sites are may contact the AbbVie TA MD if there are questions on if 
subjects should or should not be re-screened.
5.2
Selection of Study Population
It is anticipated that approximately 579 subjects with moderately to severely active CD 
will be enrolled at approximately 400 study sites worldwide.  The study will enroll 100% 
of subjects who have had an inadequate response or intolerance to prior biologic therapy 
(bio-IR).
A subject may be enrolled in this study provided that he/she has met all of the inclusion 
criteria and none of the exclusion criteria specified in this protocol.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
38
5.2.1
Inclusion Criteria
1.
Male or female aged ≥ 18 to ≤ 80 years, or minimum age of adult consent 
according to local regulations, at the Baseline visit.  Where locally permissible, 
subjects 16 to < 18 years of age who meet the definition of Tanner stage 5 for 
development (refer to Appendix I) at the Baseline Visit (sites will be notified when 
adolescents may enroll).
2.
Confirmed diagnosis of CD for at least 3 months prior to Baseline.  Appropriate 
documentation of biopsy results consistent with the diagnosis of CD, in the 
assessment of the Investigator, must be available.
3.
Crohn's disease activity index (CDAI) score 220 – 450 at Baseline.
4.
Endoscopic evidence of mucosal inflammation as documented by the SES-CD of 
≥3.  All eligible scores exclude the presence of narrowing component and are 
confirmed by a central reader.  (Once cap of no more than 58 subjects is reached, 
enrollment criterion will be an SES-CD of ≥ 6 for ileocolonic or colonic disease or 
SES-CD of ≥ 4 for isolated ileal disease.)
5.
Average daily SF ≥ 4 and/or average daily AP score ≥ 2 at Baseline.
6.
Demonstrated intolerance or inadequate response to one or more of the following 
biologic agents as defined below:  infliximab, adalimumab, certolizumab pegol, 
natalizumab, vedolizumab and/or ustekinumab:
●
Demonstration of intolerance requires no minimum dose or duration of use
●
Inadequate response to biologic agents defined as signs and symptoms of 
persistently (in the opinion of the Investigator) active disease despite a history 
of one or more of the following:
○
At least one 6-week induction regimen of infliximab (≥ 5 mg/kg IV at 
Weeks 0, 2, and 6),
○
At least one 4-week induction regimen of adalimumab (one 160 mg SC 
dose at Week 0, followed by one 80 mg SC dose at Week 2 [or one 80 mg 
SC dose at Week 0, followed by one 40 mg SC dose at Week 2, in 
countries where this dosing regimen is approved]),


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
39
○
At least one 4-week induction regimen of certolizumab pegol (400 mg SC 
at Weeks 0, 2, and 4)
○
At least one 6-week induction regimen of vedolizumab (300 mg IV at 
Weeks 0, 2, and 6),
○
At least one 12-week induction regimen of natalizumab (300 mg IV every 
4 weeks)
○
At least one 8-week induction regimen of ustekinumab [260 mg (≤ 55 kg) 
or 390 mg (> 55 to ≤ 85 kg) or 520 mg (> 85 kg) IV, followed by 90 mg 
SC at Week 8] (Once cap of no more than 20% ustekinumab exposed 
subjects is reached, subjects with prior ustekinumab exposure will not be 
allowed to enroll.)  
●
Recurrence of symptoms during scheduled maintenance dosing following prior 
clinical benefit of the above biologic agents
●
Note:  Subjects who discontinued biologic agents for reasons other than 
inadequate response as defined above or intolerance (e.g., change of insurance) 
are not eligible to enroll
7.
If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol 
Contraception Recommendations.  Females of childbearing potential must have a 
negative serum pregnancy test result during Screening, and a negative urine 
pregnancy at Baseline.  Females of non-childbearing potential (either 
postmenopausal or permanently surgically sterile as defined in Section 5.2.4) 
during Screening do not require pregnancy testing at Baseline.   
Note:  Subjects with borderline serum pregnancy test at Screening must have a 
serum pregnancy test ≥ 3 days later to document continued lack of a positive 
result.
8.
Subject must be able and willing to give written informed consent and to comply 
with the requirements of this study protocol.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
40
Rationale for Inclusion Criteria
1 – 6
To select the adequate subject population with a disease status representative 
of the target population for evaluation
7
The impact of risankizumab on pregnancy and reproduction is unknown
8
In accordance with harmonized Good Clinical Practice (GCP)
5.2.2
Exclusion Criteria
1.
Subject with a current diagnosis of ulcerative colitis or indeterminate colitis.
Concomitant Medications and Treatments
2.
Subject on CD-related antibiotics who has not been on stable doses for greater 
than, or discontinued within, 14 days prior to Baseline.
3.
Subject on oral aminosalicylates who has not been on stable doses for greater than, 
or discontinued within, at least 14 days prior to Baseline.
4.
Subject taking oral corticosteroids:
●
Budesonide > 9 mg/day
●
Beclomethasone > 5 mg/day
●
Prednisone or equivalent > 20 mg/day
●
Or has not been on the current course for ≥ 14 days prior to Baseline and on a 
stable dose for ≥ 7 days prior to Baseline 
5.
Subject on immunomodulators (AZA, 6-MP, MTX) who:
●
Has not been on the current course for ≥ 42 days prior to Baseline, and
●
Has not been on a stable dose for ≥ 35 days prior to Baseline


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
41
Medications and Treatments During the Screening Period
6.
Subject who received IV anti-infectives within 35 days prior to Baseline visit or 
oral/intramuscular anti-infectives (non-CD-related) within 14 days prior to the 
Baseline visit.  This does not apply to TB prophylaxis.
7.
Subject who received exclusive enteral nutrition or any parenteral nutrition within 
35 days prior to Baseline.
8.
Subject who received any live bacterial or viral vaccination within 30 days prior to 
Screening or during the Screening Period.
9.
Subject who received cyclosporine, tacrolimus, or mycophenolate mofetil within 
35 days prior to Baseline.
10.
Subject who received fecal microbial transplantation within 35 days prior to 
Baseline.
Prior Medications and Treatments 
11.
Subject who received any: 
●
approved biologic agent: infliximab, adalimumab, certolizumab, vedolizumab, 
natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks 
prior to Baseline
Note:  If there is proper documentation of an undetectable drug level measured 
by a commercially available assay for any of the approved biologics above, 
there is no minimum washout prior to Baseline.
●
any investigational biologic or other agent or procedure within 35 days or 
5 half-lives prior to Baseline, whichever is longer.
12.
Subject with prior exposure to p19 inhibitors (e.g., risankizumab).
13.
Subject has been taking combination of two or more of the following:  oral 
budesonide, or oral beclomethasone and/or oral prednisone (or equivalent) 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
42
simultaneously, with the exception of inhalers, within 14 days prior to Screening or 
during the Screening period.
14.
Subject who received IV/intramuscular corticosteroids within 14 days prior to 
Screening or during the Screening period.
15.
Subject who received therapeutic enema or suppository, other than required for 
endoscopy, within 14 days prior to endoscopy used for Screening or during the 
Screening period.
16.
Subject who received apheresis (e.g., Adacolumn apheresis) ≤ 60 days prior to 
Screening or during the Screening period.
17.
Subject who has concomitant cannabis use either recreational or for medical 
reasons within 14 days of Baseline or any history of clinically significant drug, or 
alcohol abuse in the last 12 months.
CD Related
18.
Subject with currently known complications of CD such as:
●
abscess (abdominal or perianal),
●
symptomatic bowel strictures,
●
> 2 missing segments of the following 5 segments: terminal ileum, right 
colon, transverse colon, sigmoid and left colon, and rectum
●
fulminant colitis,
●
toxic megacolon,
●
or any other manifestation that might require surgery while enrolled in the 
study.
19.
Subject with ostomy or ileoanal pouch.
20.
Subject diagnosed with short gut or short bowel syndrome.
21.
Subject with surgical bowel resection within the past 3 months prior to Baseline, or 
a history of ≥ 3 bowel resections.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
43
Safety
22.
Subject who has a known hypersensitivity to risankizumab or the excipients of any 
of the study drugs or the ingredients of Chinese hamster ovary (CHO).
23.
Subjects with the following chronic or active infections: 
●
Active, chronic, or recurrent infection that based on the Investigator's clinical 
assessment makes the subject unsuitable candidate for the study, 
●
Infection with C. difficile toxin or other intestinal pathogen during Screening, 
●
Are infected with human immunodeficiency virus (HIV), 
●
QuantiFERON®-TB test or Purified Protein Derivative (PPD) skin test, or 
both, according to local guidelines, will be performed during Screening.  
QuantiFERON®-TB test is preferred for subjects who received BCG 
vaccination or were exposed to other Mycobacteria species.  Subjects with a 
positive test result (or indeterminate results that have been repeated) may 
participate in the study if further work up (according to local 
practice/guidelines) establishes conclusively that the subject has no evidence 
of active tuberculosis.  Subjects with a history of active TB who have 
documented completion of a full course of anti-TB therapy may be allowed to 
enter the study after consultation with the AbbVie TA MD.  If latent TB is 
established, TB prophylaxis/treatment should be initiated and maintained 
according to local country guidelines.
●
Have active hepatitis B or hepatitis C defined as:
a.
HBV:  hepatitis B surface antigen (HBs Ag) positive (+), or detected 
sensitivity on the HBV deoxyribonucleic acid (DNA) polymerase chain 
reaction (PCR) qualitative test for hepatitis B core antibody (HBc Ab) 
positive subjects;
b. HCV:  HCV ribonucleic acid (RNA) detectable in any subject with 
positive anti-HCV antibody (HCV Ab)
24.
Subject with a previous history of dysplasia of the gastrointestinal tract or found to 
have dysplasia, other than completely removed low-grade dysplastic lesions, in any 
biopsy performed during the Screening endoscopy.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
44
25.
Subject with a known history of lymphoproliferative disease, including lymphoma, 
or signs and symptoms suggestive of possible lymphoproliferative disease, such as 
lymphadenopathy and/or splenomegaly.
26.
Subject with current or previous history of malignancy other than a successfully 
treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized 
carcinoma in situ of the cervix.
27.
Subject who has severe, progressive, or uncontrolled renal, hepatic, hematological, 
endocrine, disorder or symptoms thereof.
28.
Female subjects who is pregnant, breastfeeding, or is considering becoming 
pregnant during the study or for approximately 140 days after the last dose of study 
drug.
29.
Subject who has any condition, including any physical, psychological, or 
psychiatric condition, which in the opinion of the Investigator, would compromise 
the safety of the subject or the quality of the data and renders the subject an 
unsuitable candidate for the study.
30.
Screening laboratory and other analyses show any of the following abnormal 
results:
●
Aspartate transaminase (AST), alanine transaminase (ALT) > 2 × upper limit 
of the reference range;
●
White blood cell (WBC) count < 3.0 × 109/L;
●
Total bilirubin ≥ 2 mg/dL; except for subjects with isolated elevation of 
indirect bilirubin relating to Gilbert syndrome;
●
Estimated glomerular filtration rate by simplified 4-variable Modification of 
Diet in Renal Disease (MDRD) formula < 30 ml/min/1.73 m2. 
●
Hemoglobin < 8 g/dL
●
Platelets < 100,000/μL
●
Positive serum pregnancy test at the Screening visit or positive urine 
pregnancy test at the Baseline visit


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
45
Laboratory values can be re-tested once during the screening period after 
discussion and clearance with TA MD.  If the re-tested lab value(s) remain(s) 
exclusionary, the subject will be considered a screen failure.  Redrawing 
samples if previous samples were unable to be analyzed would not count as a 
retest since the previous result was never obtained.
31.
No known active COVID-19 infection.  Subject must not have signs/symptoms 
associated with COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and 
may only rescreen after they meet the following COVID-19 viral clearance criteria: 
●
Symptomatic subjects:  At least 2 negative viral tests in a row completed
locally, ≥ 24 hours apart after at least 10 days have passed since recovery,
defined as resolution of fever without use of antipyretics and improvement in 
respiratory symptoms (e.g., cough, shortness of breath)
●
Asymptomatic subjects:  At least 2 negative viral tests in a row completed 
locally, ≥ 24 hours apart after at least 10 days have passed since prior positive 
result (Note:  subjects who develop symptoms will follow guidance above for 
symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the 
above viral clearance criteria may be adjusted to account for epidemiological 
trends, updated information regarding infectivity and local/institutional guidelines.
Rationale for Exclusion Criteria
1
To avoid medical conditions that may compromise the ability to 
identify subjects with the correct diagnosis or to interpret medical 
importance of clinical results
2 – 16
To avoid bias for the evaluation of efficacy and safety by 
concomitant use of other medications or treatments and to ensure 
the safety of the subject
17 – 20
To avoid complications of CD that may compromise the 
evaluations of efficacy and safety
21 – 31
To ensure the safety of the subject and/or others


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
46
5.2.3
Prior and Concomitant Therapy
5.2.3.1
Prior Therapy
Any medication or vaccine (including over-the-counter or prescription medicines, 
vitamins and/or herbal supplements) that the subject has received within 35 days prior to 
Baseline, is receiving at the time of enrollment, or continues during the study, must be 
recorded along with the reason for use, date(s) of administration including start and end 
dates, and dosage information including dose, route and frequency in source documents 
and the electronic case report forms (eCRFs).
CD specific medications (including but not limited to corticosteroids, aminosalicylates, 
immunomodulators [AZA, 6-MP, or MTX], and CD-related antibiotics) that the subject 
has received within 90 days of Baseline should be recorded on the appropriate page of the 
eCRF and should include the dates of administration and dosages.  In addition, if a subject 
has ever received AZA, 6-MP, or MTX (oral or IM/SC), the duration of therapy, 
maximum dose, reason for use and reason(s) for termination of treatment will also be 
recorded in the appropriate eCRF.  
For all subjects with a history of biologic use for inflammatory bowel disease, the history 
of previous use including the names of biologic therapy used, duration of therapy, the 
highest known dose taken, reason for use and reason(s) for termination of treatment of the 
biologic agent will be recorded in the appropriate eCRF.
The AbbVie TA MD identified in Section 6.1.5 should be contacted if there are any 
questions regarding concomitant or prior therapy(ies).
5.2.3.2
Concomitant Therapy
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at 
Baseline must continue their concomitant treatment for the duration of the study.  
Initiating and/or increasing doses of aminosalicylates, immunomodulators, and/or 
CD-related antibiotics during the study is prohibited.  Decreasing doses of 
aminosalicylates, immunomodulators, and/or CD-related antibiotics is prohibited during 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
47
the study, except in the event of moderate-to-severe treatment related toxicities and after 
discussion with the AbbVie TA MD.  CD-related antibiotics may be discontinued in the 
blinded Induction Period 2 at the discretion of the Investigator.
Note:  the duration of the study includes the Induction Period 2.
Concomitant Corticosteroids 
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at 
the Baseline dose for the duration of the 12-week induction period.  Initiation and/or 
increasing doses of systemic and/or CD related corticosteroids during the entire study is 
prohibited.  Decreasing doses of corticosteroids is prohibited during the 12-week 
induction period, except in the event of moderate-to-severe treatment related toxicities 
and after discussion with the AbbVie TA MD.
Subjects who receive blinded therapy in Induction Period 2 during Weeks 12 to 24 will be 
allowed to taper their corticosteroids at the discretion of the Investigator.  While stopping 
the taper is permitted, increasing doses above the Baseline dose is prohibited.
Subjects may not be on both budesonide and prednisone (or equivalent) simultaneously, 
with exception of inhalers within 14 days prior to Screening.
Setons are authorized as concomitant therapy in subjects with perianal fistulas and should 
be documented in the eCRF under concomitant medications.
Changes in all concomitant medications will be assessed at each study visit from Baseline 
through Week 12/PD and during Weeks 12 to 24 visits for subjects who participate in the 
blinded Induction Period 2.  Any changes will be documented in the source documents 
and captured on the appropriate eCRF page.
Subjects should not be routinely pre-medicated prior to infusion of study drug.  If in the 
Investigator's judgment the subject requires pre-medication based on prior medical history 
or symptoms with prior infusions of study drug in the current study, the AbbVie TA MD 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
48
should be contacted regarding possible permitted pre-medication with diphenhydramine 
hydrochloride and acetaminophen (or equivalents).  Individual dosage, timing, and route 
of administration would be determined by the Investigator.  Any pre-medications 
administered must be recorded on the appropriate eCRF.
The AbbVie TA MD identified in Section 6.1.5 should be contacted if there are any 
questions regarding concomitant or prior therapy(ies).
5.2.3.3
Prohibited Therapy
The following are prohibited medications during the study:
●
All biologic therapy with a potential therapeutic impact on the disease being 
studied including but not limited to the following:
○
Abatacept (Orencia®);
○
Adalimumab (Humira®);
○
Anakinra (Kineret®);
○
Belimumab (Benlysta®);
○
Certolizumab pegol (Cimzia®)
○
Etanercept (Enbrel®);
○
Golimumab (Simponi®);
○
Infliximab (Remicade®);
○
Natalizumab (Tysabri®);
○
Rituximab (Rituxan®);
○
Tocilizumab (Actemra®);
○
Ustekinumab (Stelara®);
○
Vedolizumab (Entyvio®);
●
Investigational agents (e.g., tofacitinib, baracitinib, filgotinib)
●
Live or attenuated vaccines are NOT allowed during the study and for 
140 days after the last dose of study drug.  Examples of such vaccines include 
but are not limited to the following:
○
live attenuated influenza


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
49
○
herpes zoster (e.g., Zostavax®)
○
rotavirus
○
varicella (chicken pox)
○
measles-mumps-rubella (MMR) or measles mumps rubella varicella 
(MMRV)
○
oral polio vaccine (OPV)
○
smallpox
○
yellow fever
○
Bacille Calmette-Guérin (BCG)
○
oral typhoid
●
Cyclosporine, tacrolimus, or mycophenolate mofetil.
●
Concomitant cannabis use either recreational or for medical reasons.
●
Rectal therapy with any therapeutic enemas or suppositories, with the 
exception of those required for endoscopy, is prohibited during the study.
●
Apheresis (e.g., Adacolumn apheresis).
●
Exclusive enteral nutrition or any parenteral nutrition.
The AbbVie TA MD identified in Section 6.1.5 should be contacted if there are any 
questions regarding prohibited therapy.
5.2.4
Contraception Recommendations
If female, subject must be either postmenopausal defined as:
●
Age ≥ 55 years with no menses for 12 or more months without an alternative 
medical cause.
●
Age < 55 years with no menses for 12 or more months without an alternative 
medical cause AND an FSH level > 40 IU/L.
OR,
●
Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy 
or hysterectomy).
OR, for women of childbearing potential (WOCBP):


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
50
●
Practicing at least one of the following methods of birth control, prior to 
Baseline through at least 140 days after the last dose of study drug.
○
Combined (estrogen and progestogen containing) hormonal contraception 
(oral, intravaginal, transdermal, injectable) associated with the inhibition of 
ovulation, (must start at least 1 month prior to study).
○
Progestogen-only hormonal contraception (oral, injectable, implantable) 
associated with inhibition of ovulation (must start at least 1 month prior to 
study)
○
Bilateral tubal occlusion/ligation (can be via hysteroscopy, provided a 
hysterosalpingogram confirms success of the procedure).
○
Vasectomized sexual partner(s) (the vasectomized partner should have 
received medical assessment of the surgical success and is the sole sexual 
partner of the trial participant).
○
Intrauterine device (IUD).
○
Intrauterine hormone-releasing system (IUS).
○
True abstinence: Refraining from heterosexual intercourse when this is in 
line with the preferred and usual lifestyle of the subject (periodic 
abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation 
methods] and withdrawal are not acceptable).
5.3
Efficacy, Pharmacokinetic, Pharmacodynamic, Optional 
Exploratory Research/Validation Studies and Safety 
Assessments/Variables
5.3.1
Efficacy and Safety Measurements Assessed and Flow 
Chart
Study procedures described are listed in the following section of this protocol and are 
summarized in tabular format in Appendix C.
5.3.1.1
Study Procedures
The study procedures outlined in Appendix C are discussed in detail in this section, with 
the exception of optional exploratory research/validation studies (discussed in 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
51
Section 5.3.1.2 and Appendix D), pharmacokinetics and pharmacodynamics (discussed in 
Section 5.3.2) and the collection of AE information (discussed in Section 6.1.4).  All 
study data will be recorded in source documents and on the appropriate eCRFs.
Study visits may be impacted by changes in local regulations due to the COVID-19 
pandemic.  This may include changes such as phone or virtual visits, visits at alternative 
locations, or changes in the visit frequency and timing of study procedures, among others.  
Every effort should be made to ensure the safety of subjects and site staff, while 
maintaining the integrity of the study.
Informed Consent
At the Screening visit, the subject will sign and date a study specific, Independent Ethics 
Committee (IEC)/Independent Review Board (IRB) approved, informed consent form 
before any study procedures are performed or any medications are withheld from the 
subject in order to participate in this study.  A separate informed consent will be required 
for each subject in order to participate in the optional exploratory research/validation 
studies.  Details regarding how informed consent will be obtained and documented are 
provided in Section 9.3.
Due to the COVID-19 pandemic, modifications to the protocol may be necessary.  
Subjects should be informed of the changes to the conduct of the study relevant to their 
participation (e.g., cancellation of visits, change in laboratory testing site, etc.).  
Documentation of this notification or verbal consent should be maintained at the site as 
required per local regulatory requirements.  A signed and dated informed consent form 
should be obtained from the subject afterwards as soon as possible.
Inclusion/Exclusion Criteria
Subjects will be evaluated to ensure they meet all inclusion criteria and have none of the 
exclusion criteria at both Screening and Baseline visits.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
52
Medical and Surgical History
A complete medical and surgical history, including CD-onset date, history of CD 
medication use, and history of alcohol and tobacco use will be obtained from each subject 
at the Screening visit.  An updated medical history will be obtained prior to study drug 
administration at Baseline, to ensure the subject is still eligible for enrollment, and 
updated as necessary.
Information on prior biologic, corticosteroid, immunomodulators (i.e., AZA, 6-MP, 
MTX), CD-related antibiotics, aminosalicylates or any other physician prescribed therapy 
for CD use will be obtained as outlined in Section 5.2.3.1.  
A detailed medical history with respect to TB exposure will be documented.  This 
information will include BCG vaccination, cohabitation with individuals who have had 
TB, and residence or work in TB endemic locations.  Subjects with active TB (during 
Screening) or documented history of active TB who have documented completion of a full 
course of anti-TB therapy may be allowed to enter the study after consultation with the 
AbbVie TA MD.  TB history and anti-TB therapy needs to be documented in the source 
documents and eCRFs.
Physical Examination
A physical examination including evaluation of extra intestinal manifestations (EIMs) will 
be performed at the designated study visits as specified in Appendix C.
A full physical examination will be performed as outlined in Appendix C.  Physical 
examinations at all other visits (including unscheduled visits) are symptom based and 
should include the assessment of EIMs as part of calculating the Crohn's disease activity 
index (CDAI).  The number of cutaneous fistulas should be recorded, including the 
number of fistulas draining upon gentle compression.  Fistulas will be classified as 
abdominal or perianal/anal.  Physical exam abnormalities noted by the Investigator at 
Baseline (including fistulas and fissures) will be recorded in the subject's medical history.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
53
Abnormalities noted after the Baseline visit will be evaluated and documented by the 
Investigator as to whether they are AEs.
Additionally, physical examination findings that are related to or part of each subject's 
medical history will be captured on the appropriate medical history eCRFs.
Vital Signs
Vital sign determinations of systolic and diastolic blood pressure in sitting position, pulse 
rate, respiratory rate, and body temperature will be obtained at each visit.  Blood pressure, 
pulse rate, and respiratory rate should be measured before blood draws are performed.
Height will be measured at the Screening visit only (with shoes off) for subjects 
≥18 years of age.  Height will be re-measured at Week 12 and Week 24 for subjects 
< 18 years of age at Baseline.  Body weight will be measured at all scheduled visits, as 
specified in Appendix C.  All measurements will be recorded in metric units where 
applicable.
TB Testing
All subjects will be tested for TB by either the QuantiFERON-TB Gold Test (or 
equivalent) or a TB Skin Test (PPD), or both, according to local guideline, as specified in 
Appendix C.
For subjects treated with corticosteroids (equivalent to Prednisone 5 mg or above – with 
ongoing treatment or treatment within 1 month prior to TB screening), an Interferon-
Gamma Release Assay (IGRA; QuantiFERON-TB Gold In-Tube test) must be performed 
during the Screening Period for all subjects including those with a prior history of Bacille 
Calmette-Guérin (BCG) administration or who were exposed to other Mycobacteria 
species.
For subjects NOT treated with corticosteroids (equivalent to Prednisone 5 mg or above –
with ongoing treatment or treatment within 1 month prior to TB screening), a PPD skin 
test (alternatively, also known as tuberculin skin test) must be placed, or alternatively an 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
54
Interferon-Gamma Release Assay (IGRA; QuantiFERON-TB Gold In-Tube test or 
T-SPOT TB test) must be performed during the Screening Period for all subjects.  IGRA 
is preferred for subjects with a prior history of Bacille Calmette-Guérin (BCG) 
administration or who were exposed to other Mycobacteria species.
If PPD and/or the QuantiFERON®-TB Gold test (IGRA equivalent) is positive, or if there 
is a repeat indeterminate (note:  the first indeterminate results must be repeated) 
QuantiFERON®-TB Gold test (or IGRA equivalent) upon retesting, subjects may 
participate in the study if further work up (according to local practice/guidelines) 
establishes conclusively that the subject has no evidence of active tuberculosis.  Subjects 
with a history of active TB who have documented completion of a full course of anti-TB 
therapy may be allowed to enter the study after consultation with the AbbVie TA MD.  If 
active TB is diagnosed, the subject may not enroll in the study.  If presence of latent 
tuberculosis is established, then tuberculosis prophylaxis should be initiated and 
maintained according to local country guidelines.  It is also necessary to report the latent 
TB or positive TB testing in the source documents and eCRFs.
●
QuantiFERON®-TB Gold Test is the preferred method which will be analyzed 
by the central laboratory (QuantiFERON test is preferred over TB Skin Test).  
However, if other IGRA equivalent tests are used, these may be performed by 
a certified local laboratory at the Investigator's discretion.
●
If the QuantiFERON®-TB Gold Test is NOT possible (or if both the 
QuantiFERON®-TB Gold Test and the PPD Skin Test are required per local 
guidelines) the PPD Skin Test will be performed according to standard clinical 
practice.  
●
The PPD Skin Test should be read by a licensed healthcare professional 
between 48 and 72 hours after administration.  A subject who does not return 
within 72 hours will need to be rescheduled for another skin test.
●
The reaction will be measured in millimeters (mm) of induration and 
induration ≥ 5 mm is considered a positive reaction.  The absence of induration 
will be recorded as "0 mm" not "negative."


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
55
●
If PPD and/or the QuantiFERON®-TB Gold test (or IGRA equivalent) is 
positive, or if there is a repeat indeterminate QuantiFERON®-TB Gold test (or 
IGRA equivalent) upon retesting, subjects may continue in the study if further 
work up (according to local practice/guidelines) establishes conclusively that 
the subject has no evidence of active tuberculosis.
●
If presence of latent tuberculosis is established, TB prophylaxis/treatment 
should be initiated and maintained according to local country guidelines.
●
Subjects who have had an ulcerating reaction to the TB Skin Test in the past 
should not be re-exposed and should not be tested by a PPD skin test.
●
In the case of a tuberculosis-related AE, a supplemental eCRF that provides 
additional information should be completed by the Investigator or designee.
●
If a CXR or other diagnostic tests are required to be performed to assess TB 
per local guidelines, this information will also be captured on the appropriate 
eCRF.
12-Lead Electrocardiogram (ECG)
A resting 12-lead ECG will be performed during Screening as specified in Appendix C.  
A qualified physician will interpret the clinical significance of any abnormal finding, sign, 
and date each ECG.  ECG findings, including any clinically significant findings will be 
documented in the source documents and later transcribed on to the appropriate eCRF.  
Each signed original ECG will be monitored by the responsible clinical research associate 
(CRA) and kept with subject's source documents onsite.
For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at 
Screening will not be required, provided source documentation is available.  If there are 
other findings that are clinically significant, the Investigator must bring this to the 
attention of the AbbVie TA MD before the subject can be enrolled.
Subjects can have a repeat ECG at any time during the study as warranted, based on the 
opinion of the Investigator.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
56
Clinical Laboratory Tests
Blood samples will be obtained for the laboratory tests listed in Table 1.  Blood draws 
should be performed, as much as possible, after vital signs, efficacy assessments and 
questionnaires (CDAI, IBDQ, etc.), are obtained and before study drug administration 
during a visit.
A certified central laboratory will be utilized to process and provide results for the clinical 
laboratory tests.  All abnormal laboratory tests that are considered clinically significant by 
the Investigator will be followed to a satisfactory resolution.
The central laboratory chosen for this study will provide instructions regarding the 
collection, processing and shipping of these samples.
For serum chemistry tests and some exploratory biomarker tests, it is preferred that the 
subject has fasted (8 hours, except for water) prior to sample collection, however it is not 
required.  It must be recorded whether the subject has fasted or not at the time of 
collection in the laboratory request, source document, and eCRF.
If travel restrictions or other changes in local regulations in light of the COVID-19 
pandemic prevent the subject from having blood drawn for laboratory testing at the study 
site, if possible, arrange for subjects to have laboratory work done at a local lab, hospital, 
or other facility.  Local lab results should be obtained along with reference ranges and 
kept within the subjects' source documentation.  Local lab results should be reviewed by 
the investigator as soon as possible.
If laboratory samples cannot be obtained, study drug administration may be continued 
provided the investigator has reviewed all prior laboratory results and confirms and 
discusses with the subject that there is no safety concern for the subject to continue use of 
the study drug in the absence of current labs.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
57
Table 1.
Clinical Laboratory Tests
Hematology
Clinical Chemistrya
Screening Blood Tests
Hematocrit
Hemoglobin
Red Blood Cell (RBC) 
count
White Blood Cell (WBC) 
count
WBC Differential
Platelets
Coagulation:
INRc
General:
Sodium
Potassium 
Chloride 
Bicarbonate (CO2)
Urea (BUN)
Creatinine
Glucose
Additional Chemistry Tests:
Calcium
Phosphate
Total Protein
Albumin
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Alkaline Phosphatase
Gamma-Glutamyl Transferase 
(GGT/γ-GT)
Bilirubin Total and Direct
Lipid Panel:
Cholesterol (total, LDL, and HDL)
Triglycerides
Additional Calculations:
Estimated glomerular filtration 
rate by simplified 4-MDRDd
HBs Ag
HBs Ab
HBc Ab
HBV DNA PCR reflex only
HCV Ab
HCV RNA reflex only
QuantiFERON-TB Gold or PPD Test
HIV-1 and HIV-2
Other Laboratory Tests:
Urinalysisb
Serum pregnancy (bHCG) test
Urine pregnancy test (Local)
Optional:  FSH, if needed to confirm 
postmenopausal status
Tryptasee
Histaminee
Leukocyte esterase
Nitrite
pH
Protein
Blood 
Specific Gravity 
Ketones
Glucose
Bilirubin
Biomarkers:
High-Sensitivity C-Reactive Protein 
(hs-CRP)
Optional Biomarkers:
Blood, tissue and stool will be 
collected for optional exploratory 
research/validation studiesa
Stool Samples:
C. difficile toxin
Fecal calprotectin (FCP)
PK/Immunogenicity:
Serum risankizumabe
Serum anti-drug 
antibodies (ADA)e
Serum neutralizing 
antibodies (nAb)e
a.
It is preferred that the subject has fasted (8 hours, except for water) prior to sample collection, however it is not 
required.
b.
A microscopic analysis will be performed by the central laboratory in the event the dipstick results show 
leukocytes, nitrite, protein, ketones, or blood greater than negative or glucose greater than normal.
c.
INR test only drawn if ALT or AST > 3 × ULN (upper limit of normal) and Total Bilirubin ≤ 2 × ULN (Refer to 
Section 5.4.1, for additional information).
d.
Only done at screening and calculated by the central laboratory.
e.
To be done with the occurrence of a suspected anaphylactic reaction (an additional sample of tryptase to be 
collected if possible at least 2 weeks post-reaction or at the next study visit); for ADA these samples are collected 
in addition to those specified in Appendix C.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
58
Hepatitis B Testing
All subjects will be tested for the presence of the HBV at Screening.  A positive result for 
the Hepatitis B surface antigen (HBs Ag) will be exclusionary.  Samples that are negative 
for HBs Ag will be tested for surface antibodies (HBs Ab) and core antibodies (HBc Ab 
Total).  Subjects with HBs Ag (–), HBs Ab (–), and HBc Ab Total (+) require PCR 
qualitative testing for HBV DNA.  Any HBV DNA PCR result that meets or exceeds 
detection sensitivity will be exclusionary.
Subjects with a negative HBs Ag test and tests showing the results below do not require 
HBV DNA PCR qualitative testing: 
●
HBc Ab Total (–) and HBs Ab (–)
●
HBc Ab Total (–) and HBs Ab (+)
●
HBc Ab Total (+) and HBs Ab (+)
Hepatitis C Testing
All subjects will be tested for the presence of the hepatitis C Virus (HCV) antibody at 
Screening.  Subjects with positive HCV antibody will have an HCV RNA test.  If the 
HCV RNA is positive then the subject will be excluded.
HIV
Subjects with a known history of HIV infection are excluded from study participation. 
HIV testing will be conducted as part of the infection screening at the Screening visit.  
The Investigator must discuss any local reporting requirements to local health agencies 
with the subject.  The site will report these results to their health agency per local 
regulations, if necessary.  If a subject has a confirmed positive result, the Investigator 
must discuss with the subject the potential implications to the subject's health and subject 
should be referred for clinical care promptly.  A subject will not be eligible for study 
participation if test results indicate a positive HIV infection.  AbbVie will not receive 
results from the testing.  This testing is to be done at the central lab.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
59
Anaphylaxis Testing 
In the event of a suspected systemic post-dose hypersensitivity reaction, a serum 
risankizumab, ADA, and neutralizing antibody (nAb) sample should be collected once 
within 24 hours of the reaction.  In addition to serum risankizumab, ADA, and nAb 
assays, blood tests to be conducted in the event of a systemic hypersensitivity reaction are:
●
Tryptase:  Optimally, measurement needs to be obtained from within 
15 minutes to 3 hours of symptom onset, and no later than 6 hours (as tryptase 
may remain elevated for 6 or more hours after the onset and therefore may still 
be informative if obtained after 3 hours); it is also requested to collect a 
follow-up tryptase level a minimum of 2 weeks after the recorded event or at 
the next study visit.
●
Plasma histamine: optimally, within 5 to 15 minutes of the onset of 
symptoms, and no later than 1 hour.
Stool Samples Collected
Fecal Calprotectin (FCP)
Fecal calprotectin will be performed for all subjects as indicated in Appendix C.  If 
subjects are unable to provide a sample at the site visit, subjects will be sent home with a 
stool sample supply kit and the site will give instructions to assist with collection 
procedures.  All stool samples should be collected before any bowel preparation for 
endoscopy is started and returned to the site per the instructions provided outside of this 
protocol.
The FCP results will remain blinded to Investigator, study site personnel and the subject 
throughout the study.
The central laboratory will be utilized to process and provide results for these laboratory 
tests.  In order to maintain the study blind, local laboratory testing for FCP for routine 
subject monitoring should not be performed.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
60
C. Difficile Stool Testing
During the Screening period a stool sample will be collected and sent to the central 
laboratory for testing.  The sample will be assessed for the presence of C. difficile toxin.
The sample must be shipped to the central laboratory using dry ice.  Additional 
information is available in the laboratory manual provided by the central laboratory.
Subjects who are positive for C. difficile toxin may be treated appropriately and 
re-screened.
Urinalysis
Dipstick urinalysis will be completed by the sites at all required visits as listed in 
Appendix C.  A microscopic urinalysis will only be performed by the central laboratory if 
the dipstick urinalysis results are abnormal, where abnormal is defined as leukocytes, 
nitrite, ketone, protein, blood or glucose value of greater than a trace.
Pregnancy Testing
A serum pregnancy test will be performed for all female subjects of childbearing potential 
during Screening. 
The serum pregnancy test will be sent to and performed by the central laboratory.  If the 
serum pregnancy test is positive the subject is considered a screen failure.  If the serum 
pregnancy test is borderline, it should be repeated to determine eligibility ≥ 3 days later.  
If the repeat serum pregnancy test is:
●
Positive, the subject is considered a screen failure;
●
Negative, the subject can be enrolled into the study;
●
Still borderline ≥ 3 days later, this will be considered documentation of 
continued lack of a positive result and the subject can be enrolled into the 
study (unless prohibited locally) in the absence of clinical suspicion of 
pregnancy and other pathological causes of borderline results.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
61
A urine pregnancy test will be performed for all WOCBP as indicated in Appendix C, 
prior to study drug administration.  More frequent pregnancy tests will be performed 
throughout the study if required per local/country requirements.
●
If the Baseline urine pregnancy test performed at the site is negative, then 
dosing with study drug may begin.  If the baseline urine pregnancy test 
performed at the site is positive, dosing with study drug must be withheld and 
a serum pregnancy test is required.  The serum pregnancy test will be sent to 
and performed by the central laboratory.  If the serum pregnancy test is 
negative, study drug may be started.  If the serum pregnancy test is positive, 
study drug must be withheld and the subject must be discontinued from the 
study.  In the event a pregnancy test result is borderline, a repeat test is 
required.
●
If a urine pregnancy test post-baseline is positive, study drug will be 
temporarily discontinued and a serum pregnancy test is required.  The serum 
pregnancy test will be sent to and performed by the central laboratory.  If the 
serum pregnancy test is negative, study drug may be restarted.  If the serum 
pregnancy test is positive, study drug will be permanently discontinued.
A pregnant or breastfeeding female will not be eligible for participation or continuation in 
this study or be allowed to continue study drug.
High-Sensitivity C-Reactive Protein (hs-CRP)
Blood samples for hs-CRP will be obtained per Appendix C.  The hs-CRP results will 
remain blinded to Investigator, study site personnel and the subject.
Blood draws should be performed, as much as possible, after all efficacy assessments, 
questionnaires (CDAI, IBDQ, etc.), and vital sign determinations are obtained and before 
study drug administration during a visit.  In order to maintain the study blind, local 
routine laboratory testing should not be performed.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
62
Crohn's Disease Activity Index (CDAI) 
Average daily SF, average daily AP score, and well-being will be calculated from the 
subject diary.  During screening subjects will be instructed on how to calculate the 
number of very soft and liquid stools, including a visual depiction.  Physical exam and 
appropriate laboratory values will be calculated at all study visits beginning at Baseline.  
The Screening period will be a minimum of 7 days to calculate the Baseline scores.
The CDAI scores must be calculated using a central laboratory hematocrit (Hct) value 
from the same visit for all visits, except Baseline, where the most recent Screening Hct 
value will be used.  The final CDAI for all other visits will be calculated once the 
hematocrit value is received from the central lab.  If the Hct is missing due to technical 
issues (e.g., lost sample, clotted sample, etc.), the Hct value from the preceding visit may 
be used.
Instructions to calculate CDAI
●
To answer questions one (1) through three (3), entries from the 7 days prior 
to the visit should be used as recorded by the subject from the diary.
●
Diary entries should not be included in the 7 days evaluated prior to the visit 
if:  (1) the day the subject received medication for bowel preparation prior to 
endoscopy, (2) the day the subject underwent an endoscopy, and (3) 2 days 
following the endoscopy.  Diary entries, up to 14 days prior to the visit, will be 
used accordingly in order to provide the most recent data for 7 days prior to the 
respective study visit.  The 7 days do not need to be consecutive.
●
In question four (4), for the section regarding presence of anal fistulas and 
other fistulas, all fistulas detectable on physical examination (draining and 
non-draining) should be captured on the CDAI and calculated into the CDAI 
score.
●
And the evaluation for fever should include all the days that are taken into 
account for the calculation of the CDAI.
●
When completing question five (5) ("Taking 
Lomotil/Imodium/Loperamide/opiates for diarrhea, 0 = no, 1 = yes") on the 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
63
CDAI, "no" should be answered if a subject is taking an opiate(s) solely for 
pain.  The use of these medications takes into account only the day of the 
scheduled visit and is only assessing their use as anti-diarrheals
●
For question seven (7), hematocrit results from central laboratory will be used 
for the CDAI calculation.  If the hematocrit value contains more than 
one decimal point, the rounding will be allowed to the tenths decimal (e.g., Hct 
value 33.44 will be captured as 33.4, Hct value of 33.45 will be captured as 
33.5).  The Hct values either prior to completing the calculation or at the 
subtotal box 7 of the CDAI should not be rounded to a whole number.
●
For question eight (8), the height obtained at Screening should be used when 
selecting the standard weight in Appendix G, and this standard weight should 
be used for calculating every CDAI throughout subject participation in the 
study. 
●
Standard height is calculated by using the height obtained at Screening 
(without shoes) adding 1 inch or 2.5 cm.  For subjects < 18 years of age at 
Baseline, height will be re-measured at Week 12 and Week 24 (if applicable) 
and standard height should be recalculated.
●
If the body weight obtained at the time of assessment is not captured in 
kilograms (kg), then when converting into kg, rounding should occur using the 
second digit after the decimal (also known as the hundredth place) where if the 
number is 0 – 4, then keep the first digit after the decimal (also known as the 
tenth place) unchanged.  If the second digit after the decimal is 5 – 9, then 
round up the first digit after the decimal (e.g., 90.246 would be captured as 
90.2 and 97.687 would be captured as 97.7).
●
The subtotal of box 8 should not be rounded to a whole number.
The calculation of the CDAI score is in Appendix F.
Endoscopy
An endoscopy will be performed on the following visits:
●
During Screening*
●
Week 12/PD


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
64
●
Week 24 
The same endoscopist, where possible, should perform all endoscopies.  In addition, 
where possible, the Investigator or sub-Investigator should be the endoscopist for the 
study.  It is expected that all subjects who remain in the study through at least Weeks 8 
will have a Week 12/PD endoscopy.
*
An endoscopy performed before the Screening visit, independently of the study, may 
be used as the Screening endoscopy, with the approval of the AbbVie TA MD, if the 
following conditions are met:
1.
Biopsy confirmation of the diagnosis is available according to section "Biopsy 
During Endoscopy" below, as applicable.
2.
The endoscopy took place within 45 days prior to Baseline visit.
3.
The endoscopy was recorded in a video format as the endoscopic eligibility will be 
determined by the central reviewers. 
All ileocolonoscopies will be performed and recorded at the site in a video format.  Sites 
should also perform the SES-CD assessment and record the findings on the SES-CD score 
sheet (Appendix E) and in the appropriate eCRF.
All endoscopies will be reviewed by a central reviewer who is blinded.  Endoscopies 
completed at Week 12 and Week 24, for those subjects who undergo blinded therapy in 
Induction Period 2, will use the local reader results for stratification for Study M16-000.
There will be a window of ± 7 days to conduct the ileocolonoscopy.  This window may be 
extended as necessary after consultation with the AbbVie TA MD in case of external 
circumstances.
The endoscopies performed at the time points described above will be used to provide the 
endoscopy subscores to calculate the SES-CD.  All attempts should be made by the 
endoscopist to explore all segments of the colon and terminal ileum, including intubation 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
65
of the terminal ileum, at every endoscopy visit.  The endoscopy subscores by segment will 
be noted in the subject's source documents and in the database but the central reviewer's 
endoscopy subscore will be used for the efficacy analyses.
Biopsy During Endoscopy
Appropriate documentation of biopsy results consistent with the diagnosis of CD, in the 
assessment of the Investigator, must be available in order to confirm the subject's 
eligibility for the study.  Biopsies may be done when performing the endoscopy to 
confirm CD diagnosis (if appropriate documentation for confirmation of the diagnosis 
does not exist), and/or to rule out dysplasia and colon cancer at the Investigator's 
discretion.  These biopsies will be processed and evaluated locally and the histology 
report should be available in the subject's medical records.
If any biopsy sample(s) are obtained, it should also be recorded on the video.  
Any biopsy sample(s) will be collected from the respective bowel segment during the 
withdrawal of the endoscope and after sufficient recording for the central reader to 
calculate the SES-CD.
The signed pathology report will be monitored by the responsible CRA and kept with the 
subject's source documents onsite.  Subjects should not be enrolled if high grade colonic 
dysplasia or colon cancer is discovered at Screening endoscopy or endoscopy performed 
within 45 days prior to Baseline visit.  Subjects may be enrolled if low grade colonic 
dysplasia is discovered during endoscopy and is completely removed.
If a diagnosis of high grade colonic dysplasia or colon cancer is discovered during any 
subsequent endoscopic evaluation during the course of the study, the findings should be 
recorded as an AE and the subject should be discontinued from the study.  If low grade 
colonic dysplasia is discovered during any subsequent endoscopic evaluation during the 
course of the study, the findings should be entered as an AE and the subject can continue 
in the study if the lesion has been completely removed. 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
66
Subject Diary 
Subjects will be dispensed an electronic diary at Screening and will be trained on how to 
complete the diary by site staff during the Screening visit.  All subjects should complete 
their subject diary on a daily basis throughout the entire study.  The diary will be reviewed 
by site personnel with the subject at each visit and collected at the Final/PD visit, unless 
the subject continues into Study M16-000.  Subjects will also be dispensed a patient 
information card at Screening.
Completion will be reinforced during study visits as necessary.
Outcomes and Questionnaires
Subjects will be asked to complete the following electronic questionnaires/outcomes at the 
time points indicated in Appendix C.
●
Inflammatory Bowel Disease Questionnaire (IBDQ)
●
Work Productivity and Impairment Questionnaire – CD (WPAI-CD)
●
Crohn's Symptom Severity (CSS)
●
Patient Global Impression of Change (PGIC)
●
Patient Global Impression of Severity (PGIS)
●
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
●
European Quality of Life 5 Dimensions (EQ-5D-5L) 
●
36-Item Short Form Health Survey (SF-36)
Due to the COVID-19 pandemic and any local restrictions, sites may administer PRO 
instruments over the phone as needed. Sites may read the PRO questions and response 
options to the subject and record the subject's responses. Sites may send the 
questionnaires (email or hard copy) to the subjects to allow them to read/understand the 
questions and responses when the subject is providing responses over the phone. The date 
and time of PRO data collection should be recorded along with who collected the 
information.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
67
Study Drug Dispensing/Administration
Intravenous and SC study drug will be administered to all subjects on-site.  For WOCBP 
subjects, the urine pregnancy test needs to be negative prior to receiving study drug.  The 
site will be provided administration instructions.  Also, the initial 20 subjects enrolled 
between the Phase 3 induction trials will be monitored on site for 2 hours after completion 
of each infusion.  Subjects should be observed after study drug administration until judged 
clinically stable by the study personnel.  If an anaphylactic reaction or other serious 
allergic reaction occurs, administration of study drug should be discontinued immediately, 
appropriate laboratory testing samples drawn and appropriate therapy initiated.
Study drug kits are assigned by the IRT following the subjects randomized treatment 
schedule.  (Refer to Section 5.5 for additional information.)
During the Study Drug Dosing Period, a subject with confirmed (viral test positive) or 
suspected COVID-19 infection can only be dosed with study drug if the following 
COVID-19 viral clearance criteria are met:
●
Symptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours apart 
after at least 10 days have passed since recovery, defined as resolution of fever 
without use of antipyretics and improvement in respiratory symptoms (e.g., 
cough, shortness of breath)
●
Asymptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (note:  
subjects who develop symptoms will follow guidance above for symptomatic 
subjects)
5.3.1.2
Collection and Handling of Optional Exploratory 
Research/Validation Studies Samples
Subjects will have the option to provide samples for exploratory research and validation 
studies.  Subjects may still participate in the study even if they decide not to participate in 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
68
the optional exploratory research/validation.  The procedures for obtaining and 
documenting informed consent are discussed in Section 9.3.
Exploratory research can help to improve our understanding of how individuals respond 
to drugs and our ability to predict which patients would benefit from receiving specific 
therapies.  In addition, exploratory research may help to improve our understanding of 
how to diagnose and assess/monitor CD by assessing associations between disease 
characteristics, outcomes data and biomarkers of interests. 
Validation studies, including those related to the development of potential in vitro 
diagnostic tests, may be carried out retrospectively in order to assess associations between 
events of interest (i.e., efficacy and/or safety events) and candidate biomarkers.
AbbVie (or people or companies working with AbbVie) will store the biomarker 
exploratory research/validation studies samples in a secure storage space with adequate 
measures to protect confidentiality.  The samples will be retained while research on 
risankizumab (or drugs of this class) or this disease and related conditions continues, but 
for no longer than 20 years after study completion.
It is preferred that the subject has fasted (8 hours, except for water) prior to sample 
collection, however it is not required.  It must be recorded whether the subject has fasted 
or not at the time of collection in the laboratory request, source document, and eCRF.  The 
following samples will be collected according to Appendix D from each subject who 
consents to provide samples for exploratory research/validation studies:
●
DNA samples for pharmacogenetic or epigenetic analyses.
●
RNA samples for transcriptomic and/or epigenetic analyses.
●
Serum and plasma samples for systemic analyses including, but not limited to, 
proteomics and metabolomics.
●
Peripheral blood mononuclear cell (PBMC) samples for analyses including, 
but not limited to, immune cell profiling and assessment of functional activity


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
69
●
Stool samples for investigations including, but not limited to, proteomics, 
metabolomics, transcriptomics and metagenomics.
●
Intestinal biopsies for pathological and biological investigations, including but 
not limited to, transcriptomic analyses and immunohistochemistry.  Biopsy for 
histologic assessment by central review will be conducted at each visit with 
endoscopy.
Samples will be shipped to AbbVie or a designated laboratory for DNA/RNA extraction, 
if applicable, and/or analyses or long-term storage.  Instructions for the preparation and 
shipment of the samples will be provided in the laboratory manual.
5.3.2
Drug Concentration and Anti-Drug Antibody Measurements
5.3.2.1
Collection of Samples for Analysis
Serum risankizumab concentrations, ADA, and neutralizing antibodies (nAb) will be 
determined from blood collected by venipuncture just prior to dosing as indicated in 
Appendix C.  The time that each blood sample is collected will be recorded to the nearest 
minute in the source document and on the appropriate eCRF.
5.3.2.2
Handling/Processing of Samples
Specific instructions for collection of blood/serum samples and subsequent preparation 
and storage of the samples for the assays will be provided by the central laboratory, 
AbbVie, or its designee.
Refer to the study specific laboratory manual for detailed instructions on sample 
collection, processing, and shipment.
5.3.2.3
Disposition of Samples
Frozen samples will be packed in dry ice (pellet form) sufficient to last 3 days during 
transport.  Samples will be shipped pursuant to instructions from the onsite CRA.  An 
inventory of the samples will be included in the package for shipment.  Arrangements will 
be made with the central lab for the transfer of samples. 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
70
5.3.2.4
Measurement Methods
Serum concentrations of risankizumab and relative titers of risankizumab ADA will be 
determined using validated methods under the supervision of the Bioanalysis department 
at AbbVie.  Any additional analytes may be analyzed using non-validated methods.  
Serum samples collected for risankizumab and risankizumab ADA and risankizumab nAb 
analysis may be used for future assay development or validation activities.  
The nAb samples upon request may be used for the analysis of neutralizing anti-drug 
antibodies in a validated assay.
5.3.3
Efficacy Variables
Endpoint Definitions:
●
Clinical remission:  average daily SF ≤ 2.8 and not worse than Baseline AND 
average daily AP score ≤ 1 and not worse than Baseline
●
Enhanced clinical response:  ≥ 60% decrease in average daily SF and/or 
≥35% decrease in average daily AP score and both not worse than Baseline, 
and/or clinical remission
●
Clinical response:  ≥ 30% decrease in average daily SF and/or ≥ 30% 
decrease in average daily AP score and both not worse than Baseline
●
Endoscopic response:  decrease in SES-CD > 50% from Baseline (or for 
subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 
2 point reduction from Baseline), as scored by central reviewer
●
Ulcer-free endoscopy:  SES-CD ulcerated surface subscore of 0 in subjects 
with SES-CD ulcerated surface subscore ≥ 1 at Baseline, as scored by a central 
reviewer
●
Endoscopic remission:  SES-CD ≤ 4 and at least a 2 point reduction versus 
baseline and no subscore greater than 1 in any individual variable, as scored by 
a central reviewer
●
CDAI clinical response:  reduction of CDAI ≥ 100 points from baseline
●
CDAI clinical remission: CDAI < 150


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
71
●
SF remission:  average daily SF ≤ 2.8 and not worse than baseline
●
AP remission:  average daily AP score ≤ 1 and not worse than baseline
5.3.3.1
Primary Variable
Co-Primary Endpoints:  
●
Proportion of subjects with CDAI clinical remission at Week 12
●
Proportion of subjects with endoscopic response at Week 12 
5.3.3.2
Secondary Variables
Ranked Secondary Endpoints:
1.
Proportion of subjects with clinical remission at Week 12
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with CDAI clinical response at Week 12
4.
Change from baseline of Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT fatigue) at Week 12 
5.
Proportion of subjects with CDAI clinical remission at Week 4 
6.
Proportion of subjects with CDAI clinical response and endoscopic response at 
Week 12
7.
Proportion of subjects with SF remission at Week 12
8.
Proportion of subjects with AP remission at Week 12
9.
Proportion of subjects with endoscopic remission at Week 12
10.
Proportion of subjects with enhanced clinical response at Week 4
11.
Proportion of subjects with ulcer-free endoscopy at Week 12
12.
Proportion of subjects with enhanced clinical response at Week 12


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
72
13.
Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at 
Week 12, in subjects with any EIMs at Baseline
14.
Proportion of subjects with CD-related hospitalization through Week 12
15.
Proportion of subjects without draining fistulas at Week 12 in subjects with 
draining fistulas at Baseline
5.3.3.3
Other Endpoints
●
Change from Baseline in IBDQ over time
●
Change from Baseline in individual IBDQ domain scores (bowel, emotional, 
social, systemic) over time
●
Proportion of subjects with IBDQ remission (IBDQ > 170 points) over time 
●
Proportion of subjects with IBDQ response (increase in IBDQ > 16 points 
from Baseline) over time 
●
Change from Baseline in WPAI-CD over time
●
Change from Baseline in EQ-5D-5L over time
●
Change from Baseline in FACIT-Fatigue total score and individual item score 
over time
●
Change from Baseline in SF-36 over time
●
Change from Baseline in FCP over time
●
Change from Baseline in hs-CRP over time 
●
Change from Baseline in average daily AP score over time
●
Change from Baseline in average daily SF over time
●
Proportion of subjects with clinical remission over time
●
Proportion of subjects with enhanced clinical response over time
●
Proportion of subjects with clinical response over time
●
Change from Baseline in SES-CD at Week 12
●
Proportion of subjects with a SES-CD ulcerated surface subscore ≤ 1 in each 
segment at Week 12 in subjects with a SES-CD ulcerated surface subscore ≥ 2 
at Baseline


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
73
●
Change from baseline in PGIS over time
●
PGIC over time
●
Proportion of subjects with endoscopic remission over time
●
Proportion of subjects with endoscopic response over time
●
Proportion of subjects with CD-related surgeries through Week 12
●
Proportion of subjects with any reduction in SES-CD at Week 12
●
Proportion of subjects with CDAI clinical remission over time
●
Proportion of subjects with CDAI clinical response over time
●
Change from Baseline in CDAI over time
●
Change from Baseline in CSS over time
Of note, over time will be measured at each study visit as specified in the study activity 
table.
5.3.4
Safety Variables
Safety analyses will be performed on safety set which includes all subjects who receive at 
least one dose of study drug.  Incidence of AEs, changes in vital signs, physical 
examination results, and clinical laboratory data will be assessed throughout the study.  
5.3.5
Pharmacokinetic Variables
Serum risankizumab concentrations will be determined during the treatment period and at 
the follow-up visit as outlined in Appendix C.  Serum risankizumab concentrations will be 
summarized at each time point for each dosing regimen using descriptive statistics.  
Population pharmacokinetic analyses combining the data from this study and other studies 
may be performed.  Relationships between risankizumab exposures and efficacy and 
safety variables of interest may be explored.
5.3.6
Optional Exploratory Research/Validation Variables
Optional samples may be collected to conduct exploratory investigations into known and 
novel biomarkers.  The types of biomarkers to be analyzed may include, but are not 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
74
limited to, nucleic acids, proteins, lipids, metabolites or cellular markers/functions.  
Biomarker assessments may be used to assess and generate prognostic, predictive, 
pharmacodynamic, or surrogate biomarker signatures.  These assessments may be 
explored in the context of CD or related conditions and/or risankizumab or drugs of 
similar classes.
The samples may also be used to develop new diagnostic tests, therapies, research 
methods or technologies.  In addition, samples from this study may be banked for future 
use.  Samples may then be used to validate putative biomarker signatures obtained from a 
prospective study, leading to the development of diagnostic tests.  The results from these 
analyses are exploratory in nature and may not be included with the study report.
5.4
Removal of Subjects from Therapy or Assessment
5.4.1
Discontinuation of Individual Subjects
A subject may withdraw from the study at any time.  The Investigator may discontinue 
any subject's participation for any reason, including an AE, safety concerns or failure to 
comply with the protocol.
Subjects will be withdrawn from the study immediately if any one of the following 
occurs:
●
Clinically significant abnormal laboratory result(s) or AE(s), which rule out 
continuation of the study drug, as determined by the Investigator in 
consultation with the AbbVie TA MD.
●
The Investigator believes it is in the best interest of the subject, including 
subjects with no improvement to study drug at Week 12 for whom the 
investigator believes it is in the best interest of the subject not to enter 
Induction Period 2.
●
Subjects who experience a severe systemic hypersensitivity infusion/injection 
reaction or anaphylaxis
●
The subject requests withdrawal from the study.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
75
●
Inclusion and exclusion criteria violation was noted after the subject started 
study drug, when continuation of the study would place the subject at risk as 
determined by the AbbVie TA MD.
●
Introduction of prohibited medications or dosages when continuation of the 
study drug would place the subject at risk as determined by the AbbVie TA 
MD.
●
The subject becomes pregnant while on study drug.
●
Subject has a malignancy, except for localized non-melanoma skin cancer.  
Discontinuation for carcinoma in-situ of the cervix is at the discretion of the 
Investigator.  
●
Subject is significantly non-compliant with study procedures which would put 
the subject at risk for continued participation in the study, as determined by the 
Investigator, in consultation with the AbbVie TA MD.
●
Occurrence of following hepatic test abnormalities considered by the 
Investigator to be related to study drug (retesting for ALT, AST, and TBL may 
be needed to confirm):
○
Confirmed ALT or AST > 8 × Upper Limit of Normal (ULN)
○
Confirmed ALT or AST > 5 × ULN for more than 2 weeks 
○
Confirmed ALT or AST > 3 × ULN and (TBL > 2 × ULN or INR > 1.5) 
○
Confirmed ALT or AST > 3 × ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (> 5%)
If, during the course of study drug administration, the subject prematurely discontinues 
study drug use, the procedures outlined for the PD visit must be completed within 2 weeks 
of the last dose of study drug, and preferably prior to the initiation of another therapy.  
However, these procedures should not interfere with the initiation of any new treatments 
or therapeutic modalities that the Investigator feels are necessary to treat the subject's 
condition.  Following discontinuation of the study drug, the subject will be treated in 
accordance with the Investigator's best clinical judgment.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
76
A final visit will occur for all subjects, approximately 140 days after the last dose of study 
drug to determine the status of any ongoing AEs/SAEs or the occurrence of any new 
AEs/SAEs, except for those who are rolled over to the Study M16-000.
All attempts must be made to determine the date of the last dose of study drug and the 
primary reason for premature discontinuation.  The information will be recorded on the 
appropriate eCRF page.
For subjects who are considered lost to follow-up, reasonable attempts must be made to 
obtain information on the final status of the subject.  At a minimum, two phone calls must 
be made and one certified letter must be sent and documented in the subject's source 
documentation. 
Subjects who discontinue the study prematurely will not be replaced. 
5.4.2
Discontinuation of Entire Study
AbbVie may terminate this study prematurely, either in its entirety or at any study site, for 
reasonable cause provided that written notice is submitted in advance of the intended 
termination.  The Investigator may also terminate the study at his/her site for reasonable 
cause, after providing written notice to AbbVie in advance of the intended termination.  
Advance notice is not required by either party if the study is stopped due to safety 
concerns.  If AbbVie terminates the study for safety reasons, AbbVie will immediately 
notify the Investigator by telephone and subsequently provide written instructions for 
study termination.
5.5
Treatments 
5.5.1
Treatments Administered
Each dose of blinded study drug (1200 mg risankizumab, 600 mg risankizumab, or 
placebo) will be administered intravenously to the subject during the 12-Week Induction 
Period.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
77
Each dose of blinded study drug (1200 mg risankizumab, 360 mg risankizumab, or 
180 mg risankizumab) will be administered intravenously or subcutaneously in Induction 
Period 2.
If the 1200 mg dose is discontinued due to any reason, subjects will continue to enroll into 
the study and be randomized to either 600 mg risankizumab or placebo at 1:1 ratio.  In 
this case, the randomization ratio and sample size may be further updated in an 
amendment to the protocol.  In addition, for subjects already randomized and for future 
randomization, 600 mg will be administered during Induction Period 2.
Subjects should not be routinely pre-medicated prior to infusion of study drug.  If in the 
Investigator's judgment the subject requires pre-medication based on prior medical history 
or symptoms with prior infusions of study drug in the current study, the AbbVie TA MD 
should be contacted regarding possible permitted pre-medication with diphenhydramine 
hydrochloride and acetaminophen (or equivalents).  Individual dosage, timing, and route 
of administration would be determined by the Investigator.  Any pre-medications 
administered must be recorded on the appropriate eCRF.
Subjects who do not achieve clinical response at Week 12 will be eligible for Induction 
Period 2 with blinded risankizumab.  Blinded risankizumab will be administered either 
intravenously at Weeks 12, 16, and 20 or subcutaneously at Weeks 12 and 20.
5.5.2
Identity of Investigational Products
The individual study drug information is presented in Table 2.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
78
Table 2.
Identity of Investigational Product
Study Drug
Strength
Route of 
Administration
Manufacturer
Risankizumab
(ABBV-066)
90 mg/mL
IV
Boehringer Ingelheim 
Pharma GmbH & Co. KG
Placebo for Risankizumab
(ABBV-066)
N/A
IV
Boehringer Ingelheim 
Pharma GmbH & Co. KG
Risankizumab
(ABBV-066)
90 mg/mL
SC
Boehringer Ingelheim 
Pharma GmbH & Co. KG
Placebo for Risankizumab
(ABBV-066)
N/A
SC
Boehringer Ingelheim 
Pharma GmbH & Co. KG
AbbVie will not provide 5% dextrose to be used as a diluent for administration for 
risankizumab or placebo and it should be sourced locally from approved marketed 
products from various commercial manufacturers depending on availability.
5.5.2.1
Packaging and Labeling
Risankizumab or placebo will be provided as one (1) vial per carton or one (1) prefilled 
syringe per carton to accommodate the study design.   
Each kit label will contain a unique kit number.  This kit number is assigned to a subject 
via IRT and encodes the appropriate study drug to be dispensed at the subjects 
corresponding study visit.  Each kit will be labeled as required per country requirements.  
Labels must remain affixed to the kits.  All blank spaces on the label will be completed by 
site staff prior to dispensing to the subjects.
5.5.2.2
Storage and Disposition of Study Drug(s)
Study drug must be kept protected from light in the original packaging, in a refrigerator 
between 2° to 8°C (36° to 46°F).  Study drug must not be frozen at any time.
The investigational products are for investigational use only and are to be used only 
within context of this study.  The study drug supplied for this study must be maintained 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
79
under adequate security and stored under the conditions specified on the label until 
dispensed for subject use or destroyed as appropriate.  A temperature log must be 
maintained for documentation. 
The refrigerator temperature must be recorded each business day.  Malfunctions or any 
temperature excursion must be reported to the Sponsor immediately.  Sites are responsible 
to report temperature excursions into the AbbVie Temperature Excursion Management 
System (ATEMS).  Study drug should be quarantined and not dispensed until AbbVie or 
ATEMS deems the drug as acceptable. 
Upon receipt of the study drugs, the site will acknowledge receipt within the IRT system.
5.5.2.3
Preparation/Reconstitution of Dosage Form(s)
Administration Instructions and Dose Preparation Instructions will be provided as 
separate documents outside of this protocol.  Dose preparation will be performed by a 
licensed unblinded pharmacist or qualified designee as appropriate.
5.5.3
Method of Assigning Subjects to Treatment Groups
All subjects will be assigned a unique identification number by the IRT at the Screening 
visit and will keep the same unique subject identification number throughout the study.  
Subjects who meet the inclusion and none of the exclusion criteria defined in 
Section 5.2.1 and Section 5.2.2 will be centrally randomized 1:1:1 to one of 
three treatment arms at Baseline during the 12-Week Induction Period of the study in a 
double-blind manner.  The randomization will be stratified by the number of prior 
biologics failed (1, > 1), Baseline steroid use (yes, no), and Baseline SES-CD (original, 
alternative).  The IRT will assign a randomization number that will encode the subject's 
treatment group assignment according to the randomization schedule generated by the 
Statistics Department at AbbVie.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
80
IRT will provide the appropriate medication kit number(s) to dispense to each subject.  
Study drug will be administered at the study visits as summarized in Section 5.5.  
Returned study drug should not be re-dispensed to any subject.
At Week 12, subjects who do not achieve clinical response will be eligible for Induction 
Period 2 where subjects receiving blinded IV risankizumab will be re-randomized 1:1:1 to 
receive blinded risankizumab in one of three groups and subjects who are receiving 
blinded placebo will receive blinded IV risankizumab as summarized in Section 5.5.
5.5.4
Selection and Timing of Dose for Each Subject
Subject will be administered study drug at the clinical site as outlined in Section 5.5.1.   
5.5.5
Blinding
All AbbVie personnel with direct oversight of the conduct and management of the study 
(with the exception of AbbVie's Drug Supply Management Team and unblinded 
CRA/monitor (as applicable)), as well as the Investigator, the blinded study site personnel 
(with the exception of the unblinded site staff), and the subject will remain blinded to each 
subject's treatment throughout the study.  The IRT will provide access to blinded subject 
treatment information in the case of medical emergency.
In the event of a medical emergency in which the Investigator believes that knowledge of 
study drug treatment is required, reasonable efforts must be made to contact the AbbVie 
TA MD (see Section 6.1.5) prior to breaking the blind, as long as it does not compromise 
subject safety.  However, if an urgent therapeutic intervention is necessary which warrants 
breaking the blind prior to contacting AbbVie TA MD, the Investigator can directly 
access the IRT system to break the blind without AbbVie agreement.  In the event that the 
blind is broken before notification to AbbVie TA MD, it is requested that the AbbVie TA 
MD be notified within 24 hours of the blind being broken.  Also, the date and reason that 
the blind was broken must be recorded in the source document and eCRF, as applicable.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
81
5.5.5.1
Blinding of Investigational Product
In order to maintain the blind, it is necessary to have unblinded site staff (unblinded 
licensed pharmacist or qualified designee) to prepare the IV solutions and blind the doses.  
Study personnel who administer the infusions to the subjects must remain blinded.  
The Administration Instructions and Dose Preparation Instructions are to be checked for 
the staff requirements for all activities concerning handling of study kits, including IRT 
transactions.
5.5.5.2
Data Monitoring Committee
An external independent DMC will review unblinded safety data on a cohort level, at a 
minimum of 6-month intervals throughout the course of the study.  
A separate DMC charter will be prepared outside of the protocol and approved by AbbVie 
and the DMC members before a subject is initiated into the study.  The DMC charter will 
describe the composition of the DMC, the roles and responsibilities of the DMC 
members, frequency and triggers of data reviews, relevant safety data to be assessed, 
meeting occasions, and communication with AbbVie as well as relevant competent 
authorities, if necessary.  The DMC is responsible for monitoring safety data, alerting 
AbbVie to possible safety concerns related to the conduct of the study, and recommending 
appropriate actions for the study conduct.
At the timing of this amendment, the DMC has provided recommendation that the study 
may continue without modification and allowed enrollment to begin for 16 – 17 year-olds.  
A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be 
provided to the patients at Screening so that any such events once occurred will be 
reported immediately by the patients to the investigator.  
The DMC will review safety data at a minimum of 6-month intervals throughout the 
course of the study.  The DMC will determine if more frequent DMC meetings are 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
82
required based on review of the accumulating safety data.  In addition, ad-hoc DMC 
meetings will be scheduled in the event of any significant safety concerns.  Based on these 
reviews, the DMC will make recommendations, as appropriate, regarding the conduct and 
management of the study.
The CAC and AAC adjudicate blinded data and the DMC reviews the data in an 
unblinded manner.  Unblinded adjudicated cardio-cerebrovascular events and 
anaphylactic reactions will be presented to the DMC for review on a periodic basis.
Communications from the DMC to the Study Teams will not contain information that 
could potentially unblind the team to subject treatment assignments.
5.5.6
Treatment Compliance
The Investigator or his/her designated and qualified representatives will 
administer/dispense study drug only to subjects enrolled in the study in accordance with 
the protocol.  The study drug must not be used for reasons other than that described in the 
protocol.
5.5.7
Drug Accountability
The Investigator or designee (blinded or unblinded as applicable) will verify that study 
drug supplies are received intact, at the appropriate temperature, and in the correct 
amounts from the depot.  This will be accomplished by documenting the condition of the 
shipment, verifying the kit numbers in the package against the Proof of Receipt (POR) or 
similar document included with each drug shipment, and documenting this verification by 
signing and dating the POR or similar document and via direct reporting in IRT.  The 
original POR note or similar document will be kept in the site files as a record of what 
was received.
In addition, IRT will be used to document investigational product accountability including 
date received, the lot number, kit number(s), date and number of vials and syringes 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
83
dispensed, and subject number.  For this study, unless otherwise prohibited locally, these 
records will be maintained electronically as part of the IRT system.
An overall accountability of the study drug will be performed by the site and 
reconciliation will be performed by the CRA/monitor (blinded or unblinded according to 
the monitoring plan) throughout the study and at the site close-out visit.
After verification of drug accountability, used study drug must be destroyed at the site 
according to local regulations governing biohazardous waste.  Destruction of used study 
supplies must be completed and documented in such a way that blinding is maintained for 
all blinded study personnel.  All unused supplies must be inventoried, accounted for and 
destroyed on site according to local procedures or regulation or returned to a destruction
facility.  A copy of the Return Consignment Form from IRT, in accordance with 
instructions provided by the monitor/CRA (blinded or unblinded according to the 
monitoring plan), will be included in the return shipments.
The use of a third party vendor for drug destruction must be pre-approved by AbbVie.  
For sites performing on-site drug destruction or using a third party vendor for drug 
destruction, a copy of the destruction methodology and date of destruction should be 
maintained at the site's facility.  
5.6
Discussion and Justification of Study Design
5.6.1
Discussion of Study Design and Choice of Control Groups
Risankizumab is a selective IL-23 inhibitor that may provide improved clinical benefit to 
risk profile in CD patients.  The proposed study is a Phase 3, randomized, double-blind, 
placebo-controlled study to evaluate the safety and efficacy of risankizumab compared to 
placebo in subjects with moderately to severely active CD, who have had inadequate 
response or intolerance to biologic agents such as infliximab, adalimumab, certolizumab, 
natalizumab, ustekinumab and/or vedolizumab.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
84
The study consists of a 12 week induction period to evaluate the efficacy and safety of 
two different IV risankizumab doses (600 mg or 1200 mg, Q4w) versus placebo.  For 
subjects who do not achieve clinical response at Week 12, an optional blinded Induction 
Period 2 (IV, 1200 mg, Q4w; SC, 360 mg, Q8w; SC, 180 mg, Q8w) for an additional 
12 weeks will be offered.  Subjects with clinical response at the end of induction or 
Induction Period 2 can enter Study M16-000 for an additional 52 weeks of treatment, with 
additional OL treatment being offered through approval.
At this time, a 12-week placebo controlled study is necessary for registrational purposes.  
A comparative study utilizing placebo provides an unbiased assessment of the efficacy 
and safety profile of risankizumab.  Furthermore, as approved biologics for CD are 
increasing, comparisons versus active drugs are important for market access.  To ensure 
all subjects are given the opportunity to receive potentially efficacious therapy, all 
subjects not responding after 12 weeks can participate in the blinded Induction Period 2 
with risankizumab.
5.6.2
Appropriateness of Measurements
Standard statistical, clinical, endoscopy-related and laboratory procedures will be utilized 
in this study.  All efficacy measurements in this study are standard for assessing disease 
activity in subjects with CD.  All clinical and laboratory procedures in this study are 
standard and generally accepted.  Central reading of endoscopy will increase study rigor 
and ensure enrollment of subjects with moderately to severely active CD.
5.6.3
Suitability of Subject Population
Adult male and female subjects with moderately to severely active CD who meet all of the 
inclusion criteria and none of the exclusion criteria are eligible for enrollment in this 
study.  The specific population chosen was based on the unmet medical need of those 
subjects with a history of inadequate response or intolerance to biologic therapies.   


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
85
5.6.4
Selection of Doses in the Study
AbbVie plans to evaluate two doses of risankizumab (600 mg and 1200 mg) via IV 
administration every 4 weeks (Q4w; Weeks 0, 4, 8) through induction (12-Week 
Induction Period) and an additional three doses of 1200 mg of risankizumab via IV 
administration (Q4w; Weeks 12, 16, 20) or two doses of 180 or 360 mg SC (Q8W, 
Weeks 12 and 20; Induction Period 2) for subjects who do not achieve clinical response at 
Week 12.  The selection of the doses in this study is informed by the analysis of safety 
and efficacy data, as well as the exposure-response relationship of efficacy, of a Phase 2 
study in subjects with CD (Study 1311.6) and the pharmacokinetic data from the 
completed studies in subjects with psoriasis (Studies 1311.1 and 1311.2). 
Results from the placebo controlled Study 1311.6 that evaluated 200 mg and 600 mg IV 
doses of risankizumab at Weeks 0, 4, 8 weeks for induction suggests increasing trend of 
clinical response and remission (for both CDAI and PRO-2 based measures) at Week 12 
with increasing risankizumab dose and exposure, indicating a potential for further 
improvement in proportion of subjects with response and remission with evaluation of 
higher doses.  Preliminary model predictions suggest further incremental benefit in CDAI 
remission in subjects with CD at 1200 mg IV Q4w dose compared to 600 mg IV Q4w 
dose.  The evaluation of higher dose data (1200 mg IV Q4w) will facilitate a more robust 
characterization of the dose-response and exposure-response relationship for these 
efficacy endpoints.  Inclusion of 1200 mg IV dose in this study is further supported by the 
safety results from the 12 week blinded induction period in Study 1311.6.  The safety 
profile of the 600 mg risankizumab group compared favorably with the placebo group and 
no overall safety concerns were identified which would preclude evaluation of IV 
induction doses higher than 600 mg risankizumab in patients with CD.  Furthermore, the 
projected steady state exposures for the 1200 mg IV risankizumab Q4w regimen in 
subjects with CD are covered by safety margins of ~1.6 and ~3.6 for Cmax and AUC0-28 days
respectively (relative to NOAEL identified in the 26 week GLP toxicology study).
Induction Period 2 will evaluate IV (1200 mg Q4w) or SC (180 mg or 360 mg Q8w) 
risankizumab. The purpose of Induction Period 2 is to evaluate the efficacy and safety of 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
86
re-induction of risankizumab versus starting maintenance dosing on clinical response.  
Data from the Phase 2 study in subjects with CD suggested that re-induction with 600 mg 
IV increased both clinical response and clinical remission.  The selection of the SC doses 
is informed by the analysis of the safety and efficacy data, as well as the exposure-
response relationship of efficacy, of the maintenance period during the Phase 2 study in 
subjects with CD that evaluated 180 mg SC risankizumab for maintenance.  The results 
from the Phase 2 study suggest a potential for increased benefit with 360 mg SC 
administration for maintenance regimen.
6.0
Complaints
A Complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the physical characteristics, identity, quality, purity, potency, durability, 
reliability, safety, effectiveness, or performance of a product/device after it is released for 
distribution.
The investigational product in this study contains: 
●
Biologic compound(s) 
Complaints associated with any component of this investigational product must be 
reported to the Sponsor (Section 6.2.2).  For adverse events, please refer to Sections 6.1
through 6.1.7.  For product complaints, please refer to Section 6.2.
6.1
Medical Complaints
The Investigator will monitor each subject for clinical and laboratory evidence of adverse 
events on a routine basis throughout the study.  The Investigator will assess and record 
any adverse event in detail including the date of onset, event diagnosis (if known) or 
sign/symptom, severity, time course (end date, ongoing, intermittent), relationship of the 
adverse event to study drug, and any action(s) taken.  For serious adverse events 
considered as having "no reasonable possibility" of being associated with study drug, the 
Investigator will provide an "Other" cause of the event.  For adverse events to be 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
87
considered intermittent, the events must be of similar nature and severity.  Adverse 
events, whether in response to a query, observed by site personnel, or reported 
spontaneously by the subject will be recorded.
All adverse events will be followed to a satisfactory conclusion.
6.1.1
Definitions
6.1.1.1
Adverse Event
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment.  An adverse event can therefore 
be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not the event is considered causally related to the use of the product.
Such an event can result from use of the drug as stipulated in the protocol or labeling, as 
well as from accidental or intentional overdose, drug abuse, or drug withdrawal.  Any 
worsening of a pre-existing condition or illness is considered an adverse event.  
Worsening in severity of a reported adverse event should be reported as a new adverse 
event.  Laboratory abnormalities and changes in vital signs are considered to be adverse 
events only if they result in discontinuation from the study, necessitate therapeutic 
medical intervention, and/or if the Investigator considers them to be adverse events.
An elective surgery/procedure scheduled to occur during a study will not be considered an 
adverse event if the surgery/procedure is being performed for a pre-existing condition and 
the surgery/procedure has been pre planned prior to study entry.  However, if the 
pre-existing condition deteriorates unexpectedly during the study (e.g., surgery performed 
earlier than planned), then the deterioration of the condition for which the elective 
surgery/procedure is being done will be considered an adverse event.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
88
Supplemental study case report forms should be completed in the event of COVID-19 
related missed/virtual visits, study drug interruptions or discontinuations, or adverse 
events (including capture of specific signs/symptoms of infection and testing results).
COVID-19 infections should be captured as adverse events.  If the event meets the criteria 
for a serious adverse event (SAE), then follow the SAE reporting directions per the 
protocol and above.  The following COVID-19 related supplemental eCRFs should be 
completed:
●
COVID-19 Supplemental Signs/ Symptoms 
●
COVID-19 Status Form
If a subject has a confirmed or suspected COVID-19 infection and study drug was 
interrupted, the investigator should contact the sponsor emergency medical contact listed 
above before reintroducing study drug.
6.1.1.2
Serious Adverse Events
If an adverse event meets any of the following criteria, it is to be reported to AbbVie as a 
serious adverse event (SAE) within 24 hours of the site being made aware of the serious 
adverse event.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
89
Table 3.
Serious Adverse Events
Death of Subject
An event that results in the death of a subject.
Life-Threatening
An event that, in the opinion of the Investigator, would have 
resulted in immediate fatality if medical intervention had not 
been taken.  This does not include an event that would have 
been fatal if it had occurred in a more severe form.
Hospitalization or 
Prolongation of 
Hospitalization
An event that results in an admission to the hospital for any 
length of time or prolongs the subject's hospital stay.  This 
does not include an emergency room visit or admission to an 
outpatient facility.
Congenital Anomaly
An anomaly detected at or after birth, or any anomaly that 
results in fetal loss.
Persistent or 
Significant 
Disability/Incapacity
An event that results in a condition that substantially interferes 
with the activities of daily living of a study subject.  Disability 
is not intended to include experiences of relatively minor 
medical significance such as headache, nausea, vomiting, 
diarrhea, influenza, and accidental trauma (e.g., sprained 
ankle).
Important Medical 
Event Requiring 
Medical or Surgical 
Intervention to 
Prevent Serious 
Outcome
An important medical event that may not be immediately life-
threatening or result in death or hospitalization, but based on 
medical judgment may jeopardize the subject and may require 
medical or surgical intervention to prevent any of the 
outcomes listed above (i.e., death of subject, life threatening, 
hospitalization, prolongation of hospitalization, congenital 
anomaly, or persistent or significant disability/incapacity).  
Additionally, any elective or spontaneous abortion or stillbirth 
is considered an important medical event.  Examples of such 
events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospitalization, or 
the development of drug dependency or drug abuse.
For serious adverse events with the outcome of death, the date and cause of death will be 
recorded on the appropriate eCRF.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
90
6.1.1.3
Areas of Safety Interest
Additional information may be collected for the following events.
Hepatic Events 
In the case of any of the following AEs, the appropriate supplemental eCRFs should be 
completed:
●
Discontinuation or interruption of study drug due to any hepatic related AE 
●
Any hepatic related SAE 
●
A subject experiencing an ALT/AST > 8 × ULN 
●
A subject experiencing an ALT/AST > 3 × ULN in conjunction with a total 
bilirubin > 2 × ULN.
Systemic Hypersensitivity/Anaphylactic Reactions
Therapeutic protein products, such as biologics, may elicit a range of acute effects, from 
symptomatic discomfort to sudden, fatal reactions that have often been grouped as 
'infusion reactions' in the past.  Although the term implies a certain temporal relationship, 
infusion reactions are otherwise not well defined and may encompass a wide range of 
clinical events, including anaphylaxis and other event that may not be directly related to 
antibody responses, such as cytokine release syndrome. 
In the event of a suspected systemic hypersensitivity/anaphylactic reaction, in addition to 
the standard AE eCRF, a supplemental eCRF should also be completed by the site.  The 
clinical criterion for diagnosing anaphylaxis is provided in Appendix H for reference; 
symptoms of anaphylactic reaction usually occur within 24 hours after exposure to an 
allergen.  These are guidelines that are used to help diagnose anaphylaxis.  The 
investigator is encouraged to report any suspected reactions.
All intravenous and subcutaneous doses of risankizumab will be administered by study-
site personnel under the direction of the Investigator.  Subjects will be monitored 
throughout the study for signs and symptoms suggestive of hypersensitivity reactions, 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
91
including allergic reactions and anaphylaxis.  A medical person qualified in the treatment 
of acute hypersensitivity reactions must be present during the infusions.  All appropriate 
medical support measures (e.g., diphenhydramine, steroids, epinephrine, oxygen) for the
treatment of suspected hypersensitivity reactions should be available for immediate use in 
the event that a suspected hypersensitivity reaction occurs.  Subjects who manifest any 
new signs or symptoms during the infusion should be monitored for appropriate resolution 
prior to leaving the site.  Subjects are encouraged to report any symptoms related to a 
possible infusion related reactions or local injection site reaction or late phase reactions to 
the site any time during the study.  A patient information card listing the symptoms of 
these reactions will be provided to the participants.
Cardiac Events/Procedures 
In the case of any of the following reported MACE, the appropriate supplemental eCRFs 
should be completed:
●
Cardiac events;
●
Myocardial infarction or unstable angina;
●
Cerebral vascular accident and transient ischemic attack;
●
Cardiovascular procedures
Tuberculosis (TB)
In the case of any positive TB test or diagnosis of active TB, the appropriate supplemental 
eCRFs should be completed.
6.1.2
Adverse Event Severity
When criteria are available, events should be graded as described in the National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03,20
which can be accessed at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
92
If no specific criteria are provided to grade the reported event, the event should be graded 
as follows.  
Mild 
(Grade 1)
Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.
Moderate 
(Grade 2)
Minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental activities of daily living (ADL)
Severe 
(Grade 3)
Severe or medically significant but not immediately life threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care ADL 
Severe 
(Grade 4)
Life-threatening consequences; urgent intervention indicated.
Severe 
(Grade 5)
Death related to AE
Use the following guidelines when entering the severity grading criteria into the electronic 
data capture (EDC) system.
Grade 1 as Mild; Grade 2 as Moderate; and Grade 3 to 5 as Severe.
6.1.3
Relationship to Study Drug
The Investigator will use the following definitions to assess the relationship of the adverse 
event to the use of study drug:
Reasonable 
Possibility
After consideration of factors including timing of the event, biologic 
plausibility, clinical judgment, and potential alternative causes, there 
is sufficient evidence (information) to suggest a causal relationship.
No Reasonable 
Possibility
After consideration of factors including timing of the event biologic 
plausibility, clinical judgment and potential alternative causes, there 
is insufficient evidence (information) to suggest a causal 
relationship.
For causality assessments, events assessed as having a reasonable possibility of being 
related to the study drug will be considered "associated."  Events assessed as having no 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
93
reasonable possibility of being related to study drug will be considered "not associated."  
In addition, when the Investigator has not reported a causality or deemed it not assessable, 
AbbVie will consider the event associated.
If an Investigator's opinion of no reasonable possibility of being related to study drug is 
given, an "Other" cause of event must be provided by the Investigator for the serious 
adverse event.
6.1.3.1
Lack of Efficacy or Worsening of Disease
Events that are clearly consistent with progression of the underlying disease (CD) are 
considered an expected outcome for this study and will not be subject to expedited 
reporting.
6.1.4
Adverse Event Collection Period
All adverse events reported from the time of study drug administration until 140 days 
from the last dose of study drugs have elapsed will be collected, whether solicited or 
spontaneously reported by the subject.  In addition, serious adverse events and protocol-
related nonserious adverse events will be collected from the time the subject signed the 
study-specific informed consent.
Adverse event information will be collected as shown in Figure 2.
Figure 2.
Adverse Event Collection


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
94
6.1.5
Adverse Event Reporting
In the event of a serious adverse event, whether associated with study drug or not, the 
Investigator will notify Clinical Pharmacovigilance within 24 hours of the site being made 
aware of the serious adverse event by entering the serious adverse event data into the 
electronic data capture (EDC) system.  Serious adverse events that occur prior to the site 
having access to the RAVE® system, or if RAVE® is not operable, should be documented 
on the SAE Non-CRF forms and emailed (preferred route) or faxed to Clinical 
Pharmacovigilance within 24 hours of the site being made aware of the serious adverse 
event.
Email:  PPDINDPharmacovigilance@abbvie.com
FAX to:  +1 (847) 938-0660
For safety concerns, contact the Immunology Safety Team at:
Immunology Safety Team
Dept. R48S, Bldg. AP31-2
1 North Waukegan Road
North Chicago, IL 60064
Safety Hotline:
+1 847-938-8737
Email:
GPRD_SafetyManagement_Immunology @abbvie.com


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
95
For any subject safety concerns, please contact the physician listed below:
Primary Therapeutic Area Medical Director:
1 North Waukegan Road
North Chicago, IL 60064
United States
Telephone Contact Information:
Office:
Mobile
Email:
In emergency situations involving study subjects when the primary AbbVie TA MD is not 
available by phone, please contact the 24-hour AbbVie Medical Escalation Hotline where 
your call will be re-directed to a designated backup AbbVie TA MD:
Phone:  +1 (973) 784-6402
AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions 
(SUSAR) reporting for the investigational medicinal product (IMP) in accordance with 
global and local guidelines and Appendix A of the Investigator Brochure will serve as the 
Reference Safety Information (RSI).  The RSI in effect at the start of a DSUR reporting 
period serves as the RSI during the reporting period.  For follow up report, the RSI in 
place at the time of occurrence of the suspected Serious Adverse Reaction will be used to 
assess expectedness.  
6.1.5.1
Adverse Events Commonly Associated with CD in Study 
Population
Certain events are anticipated to occur in the study population as known consequences of 
CD (e.g., as symptoms or due to disease progression) independent of drug exposure.  
These events are listed in Table 4.  These AEs, captured on the appropriate eCRF, are 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
96
considered expected for reporting purposes for this protocol.  Although exempt from 
expedited reporting to certain Health Authorities and ECs/IRBs as individual cases, if any 
of these events meets seriousness criteria, it must be reported to AbbVie within 24 hours 
of the site being made aware of the SAE (as defined in Section 6.1.5).
Events commonly associated with CD population hence considered expected for 
reporting.
Table 4.
Common Events Associated with CD 
Fistulae
Abscesses
Stenoses/Obstruction
!
Anal fistula
!
Colovaginal fistula
!
Colovesical fistula
!
Enterocolonic fistula
!
Enterocutaneous fistula
!
Enterovaginal fistula
!
Female genital-digestive tract 
fistula
!
Ileal fistula
!
Ileorectal fistula
!
Ileovaginal fistula
!
Perineal fistula
!
Rectal fistula
!
Rectovaginal fistula
!
Anal abscess
!
Anorectal abscess
!
Rectal abscess
!
Anal stenosis
!
Ileal stenosis
!
Intestinal obstruction
!
Small intestine obstruction
Others
!
Anal fissure
!
Worsening of 
Crohn's disease
!
Intestinal perforation
6.1.6
Pregnancy
Pregnancy in a study subject must be reported to AbbVie within 24 hours of the site 
becoming aware of the pregnancy.  Subjects who become pregnant during the study must 
be discontinued from study drug (Section 5.4.1).
Information regarding a pregnancy occurrence in a study subject and the outcome of the 
pregnancy will be collected.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
97
Pregnancy in a study subject is not considered an adverse event.  The medical outcome for 
either mother or infant, meeting any serious criteria including an elective or spontaneous 
abortion is considered a serious adverse event and must be reported to AbbVie within 
24 hours of the site becoming aware of the event.
6.1.7
Cardiac Adjudication Committee
The independent external CAC will be adjudicating observed cardio- and cerebro-vascular 
events and will remain blinded to treatment allocation.  The events that are adjudicated 
and the adjudication process will be detailed in the Cardiac Adjudication Committee 
Charter.  Dedicated eCRFs will be used for events of myocardial infarction-unstable 
angina, stroke-transient ischemic attack, and death.  In addition, the site may be contacted 
for additional source documentation for relevant events.
6.1.8
Anaphylaxis Adjudication Committee
The independent external AAC will be adjudicating observed potential anaphylactic 
events and will remain blinded to treatment allocation.  The events that are adjudicated 
and the adjudication process will be detailed in the Anaphylaxis Adjudication Committee 
Charter.  A supplemental eCRF will be used to collect information pertinent to the events.  
In addition, the site may be contacted for additional source documentation for relevant 
events.
6.2
Product Complaint
6.2.1
Definition
A Product Complaint is any Complaint (see Section 6.0 for the definition) related to the 
biologic or drug component of the product.
For a product this may include, but is not limited to, damaged/broken product or 
packaging, product appearance whose color/markings do not match the labeling, labeling 
discrepancies/inadequacies in the labeling/instructions (example:  printing illegible), 
missing components/product, or packaging issues.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
98
Any information available to help in the determination of causality to the events outlined 
directly above should be captured.
6.2.2
Reporting
Product Complaints concerning the investigational product must be reported to the 
Sponsor within 24 hours of the study site's knowledge of the event via the Product 
Complaint form.  Product Complaints occurring during the study will be followed-up to a 
satisfactory conclusion.  All follow-up information is to be reported to the Sponsor (or an 
authorized representative) and documented in source as required by the Sponsor.  Product 
Complaints associated with AEs will be reported in the study summary.  All other 
complaints will be monitored on an ongoing basis.
Product Complaints may require return of the product with the alleged complaint 
condition.  In instances where a return is requested, every effort should be made by the 
Investigator to return the product within 30 days.  If returns cannot be accommodated 
within 30 days, the site will need to provide justification and an estimated date of return.
The description of the complaint is important for AbbVie in order to enable AbbVie to 
investigate and determine if any corrective actions are required.
7.0
Protocol Deviations
AbbVie does not allow intentional/prospective deviations from the protocol unless when 
necessary to eliminate an immediate hazard to study subjects.  The principal Investigator 
is responsible for complying with all protocol requirements, and applicable global and 
local laws regarding protocol deviations.  If a protocol deviation occurs (or is identified, 
including those that may be due to the COVID-19 pandemic) after a subject has been 
enrolled, the principal Investigator is responsible for notifying IEC/IRB regulatory 
authorities (as applicable), and AbbVie.
Such contact must be made as soon as possible to permit a review by AbbVie to 
determine the impact of the deviation on the subject and/or the study.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
99
8.0
Statistical Methods and Determination of Sample 
Size
8.1
Statistical and Analytical Plans
The primary objective of the statistical analyses is to evaluate the efficacy and safety of 
two risankizumab induction doses versus placebo in subjects with moderately to severely 
active CD who had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal disease).  
When all patients complete their Week 12/PD visit, the database will be locked and un-
blinded for the 12-week induction period.  The planned analysis for the 12-week induction 
period will be performed.  This is the only and final analysis for co-primary endpoints of 
the 12-week induction period.  When all the patients who enter the induction Period 2 
finish Week 24/PD visit, the database will be locked for the whole study and all the 
planned analyses for the induction Period 2 will be performed.
Complete, specific details of the statistical analyses will be described and fully 
documented in the study Statistical Analysis Plan (SAP).  The SAP will be finalized prior 
to the study database lock.
The impact of missing data due to COVID-19 will be monitored and appropriate 
modifications to the analysis of primary and key secondary endpoints for handling such 
missing data will be reflected and incorporated in the final SAP.
8.1.1
Datasets for Analysis 
8.1.1.1
Intent-to-Treat Analysis Set
The intent-to-treat (ITT) analysis set includes all randomized subjects who received at 
least one dose of study drug.  The primary population for efficacy analysis are the subjects 
in the intent-to-treat set who had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal 
disease).  The ITT subjects will be analyzed as randomized.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
100
8.1.1.2
Safety Analysis Set
The safety analysis set consists of all subjects who received at least one dose of the study 
drug.  The safety set will be analyzed as treated, according to treatment the subject 
actually received.  The safety set will be used for safety analysis.
8.1.2
Definition of Missing Data Imputation 
Missing data will be imputed using one or more of the following methods:
Non-Responder Imputation (NRI):  In NRI analyses, subjects who prematurely 
discontinue the study prior to efficacy assessment at Week 12 will be considered non-
responders with respect to the efficacy endpoint. 
Observed Cases (OC):  The OC analysis will not impute values for missing evaluations, 
and thus a subject who does not have an evaluation on a scheduled visit will be excluded 
from the OC analysis for that visit.
8.1.3
Subject Disposition 
The number and percentage of subjects who are enrolled, randomized and received at 
least one dose of study drug, and the number of subjects who prematurely discontinued 
and the reason for premature discontinuation will be summarized by treatment group.  
Premature discontinuation of study drug will be summarized for each treatment group, as 
well as for all subjects combined, with frequencies and percentages overall and by reason 
for discontinuation for all randomized subjects who received at least one dose of study 
drug.  Subjects may have multiple reasons for prematurely discontinuing study drug, but 
will be counted no more than once for the total ("Any Reason").
8.1.4
Demographics and Baseline Characteristics
Demographics (where collection is allowed) and Baseline characteristics of the study 
subjects will be summarized using descriptive statistics.  Summary statistics for 
continuous variables will include the number of observations, mean, standard deviation, 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
101
median, and range for each treatment group.  For other categorical or discrete variables, 
frequencies and percentages will be computed in each category for each treatment group, 
as well as for all subjects combined.
8.1.5
Prior and Concomitant Medications
Prior therapy and medications will include all therapies and medications administered 
prior to the date of the first dose of study drug.  Prior therapy and medication will be 
summarized for all randomized subjects.  No statistical test will be performed.
Concomitant medications will be summarized for all randomized subjects.  Concomitant 
medications will be summarized using the World Health Organization Drug Dictionary 
with frequencies and percentages for each treatment group.  No statistical test will be 
performed. 
8.1.6
Efficacy Analysis
8.1.6.1
Primary Efficacy Variables
The co-primary endpoints are the proportion of subjects who achieve CDAI clinical 
remission at Week 12 and the proportion of subjects who achieve endoscopic response at 
Week 12. 
The comparisons between each risankizumab dose versus placebo for the primary efficacy 
variable will be performed using the Cochran-Mantel-Haenszel (CMH) test adjusted by 
number of prior biologics failed (1, > 1) and steroid use at Baseline (yes, no).  A multiple 
testing procedure will be used to provide strong control of the type 1 error rate at 
alpha = 0.05 (2-sided) across analyses comparing each risankizumab dose level to placebo 
with respect to the co-primary endpoints, and ranked secondary endpoints.  Specifically, 
testing will utilize a sequence of hypothesis testing for the co-primary endpoints followed 
by the ranked secondary endpoints, and will begin with testing each of the co-primary 
endpoints using α of 0.025 (2-sided) for each dose compared to placebo.  If both co-
primary endpoints achieve statistical significance within a dose level, continued testing 
will follow a pre-specified weight of α allocation between the single hypothesis within the 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
102
family, as well as between the families of hypotheses across the doses.  Details will be 
provided in the Statistical Analysis Plan.  A CMH based two-sided 95% confidence 
interval for the difference between treatment groups will be calculated.
Subjects who discontinue prior to Week 12 for any reason will be considered as "not-
achieved" for CDAI clinical remission and endoscopic response endpoints.  Sensitivity 
analyses for missing data handling using MI, PMM and OC will be performed for co-
primary endpoints and details will be outlined in the SAP.
8.1.6.2
Secondary Efficacy Variables 
The secondary efficacy variables are divided into two groups.  The first group includes 
ranked secondary endpoints, which are ranked by clinical importance.  Statistical 
significance is assessed at the pre-specified alpha level (two-sided) in ranked endpoint 
order until the significant level exceeds the pre-specified alpha level.  No additional 
statistically significant treatment differences could be declared if the preceding ranked 
endpoint fails to achieve the pre-specified alpha level.  The second group includes all 
other additional secondary variables.  All analyses of secondary endpoints will be 
performed using the ITT analysis set. 
In general, continuous secondary efficacy variables will be analyzed using a Mixed-Effect 
Model Repeated Measure (MMRM) model including factors for treatment group, visit, 
visit by treatment interaction, and stratification variables, for the longitudinal continuous 
endpoints.  The MMRM analysis is considered primary for inferential purposes. 
Categorical secondary efficacy variables will be analyzed using the CMH test controlling 
for stratification variables.  Non-responder imputation for missing data will be used for 
categorical secondary endpoints. 
Analysis of Pattern Mixture Model (PMM) will be performed as sensitivity analyses for 
ranked secondary endpoints.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
103
8.1.7
Safety Analysis 
Safety analyses will be carried out using the safety analysis sets, which includes all 
subjects who receive at least one dose of study drug.  Incidence of AEs, including those 
related to study drug, changes in vital signs, physical examination results, and clinical 
laboratory values will be analyzed.
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
dictionary.  Treatment-emergent AEs are defined as AEs that began or worsened in 
severity after initiation of study drug and within 140 days after the last dose of the study 
drug.  An overview of treatment-emergent AEs, including AEs leading to death and AEs 
leading to premature discontinuation (see details in the SAP), AEs by MedDRA preferred 
term and system organ class, AEs by maximum relationship to study drug, and AEs by 
maximum severity will be summarized by number and percentage.  
Continuous laboratory and vital sign parameters will be summarized for each treatment 
group by visit.  Treatment group differences between each of the risankizumab dosing 
groups and the placebo group for changes from Baseline may be analyzed using a 
one-way Analysis of Variance (ANOVA).  Vital signs and laboratory data will be 
described by statistical characteristics and frequency of abnormal values.  In addition, 
shift tables and listings will be provided for abnormal values, whereby the normal range 
of the analyzing laboratory will be used.  Analysis details will be specified in the SAP.
8.1.8
Analysis of Optional Exploratory Variables
For exploratory biomarkers that are measured, including but not limited to 
pharmacogenetic, epigenetic, transcriptomic, proteomic, and metabolomic and immune 
cell surface markers or functional biomarkers, the association of biomarkers to the 
efficacy and safety endpoints may be explored for each biomarker one at a time, and also 
for combinations of biomarkers via some multivariate predictive modeling algorithms.  
Optimal multivariate combinations of biomarkers that associate with efficacy endpoints, 
subject response/non-response (with respect to appropriate clinical endpoints), and also 
with safety endpoints may be explored via a variety of statistical predictive modeling 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
104
algorithms.  Cut-points for individual biomarkers and optimal combinations of biomarkers 
that differentiate the subject response with respect to efficacy/safety endpoints may be 
explored using the in-house developed subgroup identification algorithms: Sequential 
BATTing, PRIM, AIM BATTing, and AIM Rule.  The significance of these multivariate 
combinations of biomarkers may be assessed via at least 20 iterations of 5-fold cross-
validation.21,22
8.1.9
Analysis of Pharmacokinetic and Pharmacodynamic 
Variables
Serum risankizumab concentrations will be summarized at each time point for each 
dosing regimen using descriptive statistics.  In addition, ADA incidence will be 
summarized by cohorts and study visits.  ADA titers will be tabulated for each subject at 
the respective study visits.  Data from this study may be combined with data from other 
studies for the population pharmacokinetic and exposure-response analyses and may not 
be part of the clinical study report.  Population pharmacokinetic and exposure-response 
analyses of only data from this study may not be conducted.  The following general 
methodology will be used for the population pharmacokinetic analysis.
Population pharmacokinetic analyses of risankizumab will be performed using the actual 
sampling time relative to dosing.  Pharmacokinetic models will be build using a non-
linear mixed-effects modeling approach with NONMEM software (Version 7, or a higher 
version).  The structure of the starting pharmacokinetic model will be based on the 
pharmacokinetic analysis data from previous studies.  Systemic clearance and volume of 
distribution of risankizumab will be the pharmacokinetic parameters of major interest in 
the NONMEM analyses.  If necessary, other parameters, including the parameters 
describing absorption characteristics, may be estimated if useful in the analysis.
The evaluation criteria described below will be used to examine the performance of 
different models:
1.
The objective function of the best model is significantly smaller than the alternative 
model(s).


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
105
2.
The observed and predicted concentrations from the preferred model are more 
randomly distributed across the line of unity (a straight line with zero intercept and 
a slope of one) than the alternative model(s).
3.
Visual inspection of model fit, standard errors of model parameters and change in 
inter-subject and intra-subject error.
Once an appropriate base pharmacokinetic model (including inter- and intra-subject error 
structure) is developed, empirical Bayesian estimates of individual model parameters will 
be calculated by the posterior conditional estimation technique using NONMEM.  The 
relationship between these conditional estimates CL/F or Vss/F values with only 
potentially physiologically relevant or clinically meaningful covariates (such as ADA 
classification, subject age, sex, body weight, concomitant medications, possibly baseline 
inflammatory and disease markers) may be explored using stepwise forward selection 
method, or another suitable regression/smoothing method at a significance level of 0.01.
After identification of all relevant covariates, a stepwise backward elimination of 
covariates from the full model will be employed to evaluate the significance (at P < 0.001, 
corresponding to a decrease in objective function > 10.83 for one degree of freedom) of 
each covariate in the full model.
Linear or non-linear relationships of primary pharmacokinetic parameters with various 
covariates may also be explored.
Relationships between exposure and clinical observations (primary or secondary efficacy 
or safety variables of interest) may be explored.  Additional analyses will be performed if 
useful and appropriate.
8.2
Determination of Sample Size
The co-primary endpoints are the proportion of subjects with CDAI clinical remission at 
Week 12 and the proportion of subjects who achieve endoscopic response at Week 12.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
106
A total of approximately 579 subjects will be randomized into 2 risankizumab treatment 
groups and the placebo group in a 1:1:1 ratio with 193 subjects per treatment group).  
Assuming the Week 12 CDAI clinical remission rate will be 34% for one of the 
risankizumab dose groups and 15% for the placebo group, a sample size of 193 subjects 
for each risankizumab dose group and 193 subjects for the placebo group will have 
approximately 97% power to detect the treatment difference between risankizumab dose 
groups and placebo in CDAI clinical remission rates at Week 12 using Fisher's exact test 
at a 0.025 significant level (two-sided).  Assuming the Week 12 endoscopic response rate 
will be 17% for one of the risankizumab  groups and 5% for the placebo group, this 
sample size will have 93% power to detect the treatment difference between  
risankizumab and placebo in endoscopic response rates at Week 12 using a Fisher's exact 
test at a 0.025 significant level (two-sided).
8.3
Randomization Methods
A total of approximately 579 subjects will be randomized into two risankizumab dose 
groups and the placebo group in a 1:1:1 ratio.  Randomization will be stratified by the 
number of prior biologics failed (1, > 1), steroid use at Baseline (yes, no), and Baseline 
SES-CD (original, alternative), where the stratum of "original" includes the patients with 
baseline SES-CD of ≥ 6 (or ≥ 4 for subjects with isolated ileal disease), and the stratum of 
"alternative" includes the patients with baseline SES-CD of ≥ 3 to < 6 for ileaocolonic or 
colonic disease or SES-CD of 3 for isolated ileal disease.  
Subjects with clinical non-response to risankizumab at Week 12 will be re-randomized in 
a 1:1:1 ratio to 1200 mg IV dose group, 360 mg SC dose group, or 180 mg SC dose 
group.  Subjects with clinical non-response to placebo at Week 12 will blindly receive 
1200 mg risankizumab IV dose.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
107
9.0
Ethics
9.1
Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB)
Good Clinical Practice (GCP) requires that the clinical protocol, any protocol 
amendments, the Investigator's Brochure, the informed consent and all other forms of 
subject information related to the study (e.g., advertisements used to recruit subjects) and 
any other necessary documents be reviewed by an IEC/IRB.  The IEC/IRB will review the 
ethical, scientific and medical appropriateness of the study before it is conducted.  
IEC/IRB approval of the protocol, informed consent and subject information and/or 
advertising, as relevant, will be obtained prior to the authorization of drug shipment to a 
study site.
Following local regulation, substantial amendments may also be reviewed and approved 
by the national competent authority.
Any amendments to the protocol will require IEC/IRB approval prior to implementation 
of any changes made to the study design.  The Investigator will be required to submit, 
maintain and archive study essential documents according to International Conference on 
Harmonization (ICH) GCP and all other applicable regulatory requirements.
Any SAEs that meet the reporting criteria, as dictated by local regulations, will be 
reported to both responsible Ethics Committees and Regulatory Agencies, as required by 
local regulations.  During the conduct of the study, the Investigator should promptly 
provide written reports (e.g., ICH Expedited Reports, and any additional reports required 
by local regulations) to the IEC/IRB of any changes that affect the conduct of the study 
and/or increase the risk to subjects.  Written documentation of the submission to the 
IEC/IRB should also be provided to AbbVie.
9.2
Ethical Conduct of the Study
The study will be conducted in accordance with the protocol, ICH guidelines, applicable 
regulations and guidelines governing clinical study conduct and the ethical principles that 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
108
have their origin in the Declaration of Helsinki.  Responsibilities of the clinical 
Investigator are specified in Appendix A.
In the event of a state of emergency due to the COVID-19 pandemic leading to difficulties 
in performing protocol-specified procedures, AbbVie will engage with study site 
personnel in efforts to ensure the safety of subjects, maintain protocol compliance, and 
minimize risks to the integrity of the study while trying to best manage subject continuity 
of care.  This may include alternative methods for assessments (e.g., phone contacts or 
virtual site visits), alternative locations for data collection (e.g., use of a local lab instead 
of a central lab). In all cases, these alternative measures must be allowed by local 
regulations and permitted by IRB/IEC.  Investigators should notify AbbVie if any urgent 
safety measures are taken to protect the subjects against any immediate hazard.
9.3
Subject Information and Consent
For adult subjects the Investigator or his/her representative will explain the nature of the 
study to the subject, and answer all questions regarding this study.  Prior to any study-
related screening procedures being performed on the subject, the informed consent 
statement will be reviewed and signed and dated by the subject, the person who 
administered the informed consent, and any other signatories according to local 
requirements.  A copy of the informed consent form will be given to the subject and the 
original will be placed in the subject's medical record.  An entry must also be made in the 
subject's dated source documents to confirm that informed consent was obtained prior to 
any study-related procedures and that the subject received a signed copy.
Information regarding incentives for subjects and information regarding provisions for 
treating and/or compensating subjects who are harmed as a consequence of participation 
in the study can be found in the informed consent form.
Samples for exploratory research/validation studies will only be collected if the subject 
has voluntarily signed and dated the separate written consent for exploratory 
research/validation studies, approved by an IRB/IEC, after the nature of the testing has 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
109
been explained and the subject has had an opportunity to ask questions.  The separate 
written consent must be signed before the exploratory research/validation studies samples 
are collected and testing is performed.  If the subject does not consent to the exploratory 
research/validation studies, it will not impact the subject's participation in the study.
For adolescent subjects the investigator or his/her representative will explain the nature of 
the study to the subject and the subject's parent/legal guardian, and answer all questions 
regarding this study.  Adolescent subjects will be included in all discussions in order to 
obtain verbal or written assent.  Prior to any study-related screening procedures being 
performed on the subject, the informed consent statement will be reviewed and signed and 
dated by the subject's parent/legal guardian, the person who administered the informed 
consent, and any other signatories according to local requirements.  Additionally, in 
keeping with each institution's IRB/IEC requirements, an informed assent form may also 
be obtained by each subject prior to any study-related procedures being performed.  If a 
subject becomes of legal age during the course of the study, that subject will need to be 
re-consented.
A copy of the informed consent form and the assent form will be given to the subject and 
the subject's parent/legal guardian and the original will be placed in the subject's medical 
record.  An entry must also be made in the subject's dated source documents to confirm 
that informed consent was obtained prior to any study-related procedures and that the 
subject received a signed copy. 
Genetic and non-genetic biomarker analysis will only be performed if the subject's 
parent/legal guardian has voluntarily signed and dated a separate genetic and non-genetic 
biomarker informed consent, approved by an IRB/IEC, after the nature of the testing has 
been explained and the subject and subject's parent/legal guardian has had an opportunity 
to ask questions.  The separate genetic and non-genetic biomarker informed consent must 
be signed before the genetic and non-genetic biomarker testing is performed.  If the 
subject's parent/legal guardian does not consent to the genetic and non-genetic biomarker 
testing, it will not impact the subject's participation in the study.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
110
In the event a subject withdraws from the main study, optional exploratory research 
samples will continue to be stored and analyzed unless the subject specifically withdraws 
consent for the optional samples.  If consent is withdrawn for the optional sampling, the 
subject must inform their study doctor, and once AbbVie is informed, the optional 
samples will be destroyed.  However, if the subject withdraws his/her consent and the 
samples have already been tested, those results will still remain as part of the overall 
research data.
10.0
Source Documents and Case Report Form 
Completion
10.1
Source Documents
Source documents are defined as original documents, data and records.  This may include 
hospital records, clinical and office charts, ECGs, laboratory data/information, subjects' 
diaries or evaluation checklists, pharmacy dispensing and other records, recorded data 
from automated instruments, microfiches, photographic negatives, microfilm or magnetic 
media, and/or x-rays.  IRT may also be the source for drug accountability.  Data collected 
during this study must be recorded on the appropriate source documents.  The Investigator 
Awareness Date (SAE eCRF) may serve as the source for this data point.  This AE data 
point required for eCRF completion can be entered directly in the eCRF.
The Investigator(s)/institution(s) will permit study-related monitoring, audits, IEC/IRB 
review, and regulatory inspection(s), providing direct access to source data documents.
During the COVID-19 pandemic, remote monitoring of data may be employed if allowed 
by the local regulatory authority, IRB/IEC, and the study site.
10.2
Case Report Forms
Electronic case report forms (eCRF) must be completed for each subject screened/enrolled 
in this study.  These forms will be used to transmit information collected during the study 
to AbbVie and regulatory authorities, as applicable.  The eCRF data for this study are 
being collected with an EDC system called Rave® provided by the technology vendor 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
111
Medidata Solutions Incorporated, NY, USA.  The EDC system and the study-specific 
eCRFs will comply with Title 21 CFR Part 11.  The documentation related to the 
validation of the EDC system is available through the vendor, Medidata, while the 
validation of the study-specific eCRFs will be conducted by AbbVie and will be 
maintained in the Trial Master File at AbbVie.
The Investigator will document subject data in his/her own subject files.  These subject 
files will serve as source data for the study.  All eCRF data required by this protocol will 
be recorded by investigative site personnel in the EDC system.  All data entered into the 
eCRF will be supported by source documentation.
The Investigator or an authorized member of the Investigator's staff will make any 
necessary corrections to the eCRF.  All change information, including the date and person 
performing the corrections, will be available via the audit trail, which is part of the EDC 
system.  For any correction, a reason for the alteration will be provided.  The eCRFs will 
be reviewed periodically for completeness, legibility, and acceptability by AbbVie 
personnel (or their representatives).  AbbVie (or their representatives) will also be allowed 
access to all source documents pertinent to the study in order to verify eCRF entries.  The 
principal Investigator will review the eCRFs for completeness and accuracy and provide 
his or her electronic signature and date to eCRFs as evidence thereof.
Medidata will provide access to the EDC system for the duration of the study through a 
password-protected method of internet access.  Such access will be removed from 
Investigator sites at the end of the site's participation in the study.  Data from the EDC 
system will be archived on appropriate data media (CD-ROM, etc.) and provided to the 
Investigator at that time as a durable record of the site's eCRF data.  It will be possible for 
the Investigator to make paper printouts from that media.
10.3
Electronic Patient Reported Outcomes (ePRO)
Patient reported data must be completed for each subject screened/enrolled in this study.  
Some of these data are being collected with an ePRO system called Trialmax, provided by 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
112
the technology vendor CRF Health of Plymouth Meeting, PA, USA.  The ePRO system is 
in compliance with Title 21 CFR Part 11.  The documentation related to the system 
validation of the ePRO system is available through the vendor, CRF Health, while the 
user acceptance testing of the study specific PRO design will be conducted and 
maintained at AbbVie.
The subject will be entering the data on an electronic device; these data will be uploaded 
to a server.  The data on the server will be considered source, and maintained and 
managed by CRF Health.
Internet access to the ePRO data will be provided by CRF Health for the duration of the 
study.  This access will be available for the duration of the study to the site Investigator, 
as well as delegated personnel.  Such access will be removed from Investigator sites 
following the receipt of the study archive.  Data from the ePRO system will be archived 
on appropriate data media (CD-ROM, etc.) and provided to the Investigator at that time as 
a durable record of the site's ePRO data.  It will be possible for the Investigator to make 
paper print-outs from that media.
The ePRO data will be collected by the following methods:
Diary Based
The ePRO data (number of liquid or very soft stools, use of medications used for 
endoscopy preparation, abdominal pain, and general well-being) will be collected 
electronically via a handheld device into which the subject will record the required pieces 
of information on a daily basis.  The electronic device will be programmed to allow data 
entry once per day.  All data entered on the device will be immediately stored to the 
device itself and manually/automatically uploaded to a central server administrated by 
CRF Health.  The investigational site staff will be able to access all uploaded subject 
entered data via a password protected website, up until the generation, receipt and 
confirmation of the study archive.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
113
Tablet Based
The PROs listed below will be collected electronically via a Tablet device into which the 
subject will directly enter the required pieces of information while at the site.  The 
electronic device will be programmed to allow data entry for only the visits specified in 
the protocol and will not allow for subjects to complete more than one of the same 
assessment at any one visit.  All data entered on the device will be immediately stored to 
the device itself and (manually/automatically) uploaded to a central server administrated 
by CRF Health.  The investigational site staff will be able to access all uploaded subject 
entered data via a password protected website, up until the generation, receipt and 
confirmation of the study archive.
●
CSS
●
PGIC
●
PGIS
●
EQ-5D-5L
●
FACIT-F
●
IBDQ
●
SF-36
●
WPAI-CD
11.0
Data Quality Assurance
To ensure data integrity and subject safety, a study monitor will, throughout the study, 
verify that all subjects signed agreement of informed consent prior to any study-specific 
procedures being conducted.  The study monitor will confirm that the Investigator is 
conducting the study in compliance with the protocol, GCP and applicable regulations, 
and verify that the information reported in the eCRF is complete, accurate, and supported 
by information in source documents.
Computer logic and manual checks will be created to identify items such as inconsistent 
study dates.  Any necessary corrections will be made to the eCRF.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
114
12.0
Use of Information
All information concerning risankizumab and AbbVie operations, such as AbbVie patent 
applications, formulas, manufacturing processes, basic scientific data, or formulation 
information, supplied by AbbVie and not previously published is considered confidential 
information.
The information developed during the conduct of this clinical study is also considered 
confidential and will be used by AbbVie in connection with the development of 
risankizumab.  This information may be disclosed as deemed necessary by AbbVie to 
other clinical Investigators, other pharmaceutical companies, to the Food and Drug 
Administration (FDA) and to other governmental agencies.  To allow for the use of the 
information derived from this clinical study and to ensure complete and thorough analysis, 
the Investigator is obligated to provide AbbVie with complete test results and all data 
developed in this study and to provide direct access to source data/documents for study-
related monitoring, audits, IEC/IRB review, and regulatory inspection.
This confidential information shall remain the sole property of AbbVie, shall not be 
disclosed to others without the written consent of AbbVie, and shall not be used except in 
the performance of this study.
If this protocol or the information gained from the conduct of this study will be made 
public (disclosed/published), AbbVie will determine the information that is not yet in the 
public domain and if the disclosure of such information may undermine AbbVie's 
interests, will remain confidential at the time of disclosure/publication.
The Investigator will maintain a confidential subject identification code list of all subjects 
enrolled in the study (by name and subject number).  This list will be maintained at the 
site and will not be retrieved by AbbVie. 
Any exploratory research/validation studies that may be done using the samples from this 
study will be experimental in nature and the results will not be suitable for clinical 
decision making or patient management, hence, neither the Investigator, the subject, nor 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
115
the subject's physician (if different from the Investigator) will be informed of individual 
subject results, should analyses be performed, nor will anyone not directly involved in this 
research.  Correspondingly, researchers will have no access to subject identifiers.  
Individual results will not be reported to anyone not directly involved in this research 
other than for regulatory purposes.  Aggregate data from exploratory research/validation 
studies from this study may be used in scientific publications or presented at medical 
conventions.  Exploratory research/validation studies data will be published or presented 
only in a way that does not identify any individual subject.
13.0
Completion of the Study
The Investigator will conduct the study in compliance with the protocol and complete the 
study within the timeframe specified in the contract between the Investigator and AbbVie.  
Continuation of this study beyond this date must be mutually agreed upon in writing by 
both the Investigator and AbbVie.  The Investigator will provide a final report to the 
IEC/IRB following conclusion of the study, and will forward a copy of this report to 
AbbVie or their representative.
The Investigator must submit, maintain, and archive any records related to the study 
according to ICH GCP and all other applicable regulatory requirements.  If the 
Investigator is not able to retain the records, he/she must notify AbbVie to arrange 
alternative archiving options.
AbbVie will select the signatory Investigator from the Investigators who participate in the 
study.  Selection criteria for this Investigator will include level of participation as well as 
significant knowledge of the clinical research, investigational drug and study protocol.  
The signatory Investigator for the study will review and sign the final study report in 
accordance with the European Agency for the Evaluation of Medicinal Products Guidance 
on Investigator's Signature for Study Reports.
The end-of-study is defined as the date of the last subject's last visit.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
116
14.0
Investigator's Agreement
1.
I have received and reviewed the Investigator's Brochure for risankizumab.
2.
I have read this protocol and agree that the study is ethical.
3.
I agree to conduct the study as outlined and in accordance with all applicable 
regulations and guidelines.
4.
I agree to maintain the confidentiality of all information received or developed in 
connection with this protocol.
5.
I agree that all electronic signatures will be considered the equivalent of a 
handwritten signature and will be legally binding.
Protocol Title: 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 
Induction Study to Assess the Efficacy and Safety of Risankizumab 
in Subjects with Moderately to Severely Active Crohn's Disease 
Who Failed Prior Biologic Treatment
Protocol Date:
27 August 2020
Signature of Principal Investigator
Date
Name of Principal Investigator (printed or typed)


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
117
15.0
Reference List
1.
Hanauer SB, Sandborn W; Practice Parameters Committee of the American 
College of Gastroenterology.  Management of Crohn's disease in adults.  Am J 
Gastroenterol.  2001;96(3):635-43.
2.
Loftus EV Jr.  Clinical epidemiology of inflammatory bowel disease:  incidence, 
prevalence, and environmental influences.  Gastroenterology.  
2004;126(6):1504-17. 
3.
Probert CS, Jayanthi V, Rampton DS, et al.  Epidemiology of inflammatory bowel 
disease in different ethnic and religious groups:  limitations and aetiological clues.  
Int J Colorectal Dis.  1996;11(1):25-8. 
4.
Molodecky NA, Soon IS, Rabi DM, et al.  Increasing incidence and prevalence of 
the inflammatory bowel diseases with time, based on systematic review.  
Gastroenterology.  2012;142(1):46-54.
5.
Baumgart DC, Sandborn WJ.  Crohn's disease.  Lancet.  2012;380(9853):1590-605.
6.
Leong RW, Lau JY, Sung JJ.  The epidemiology and phenotype of Crohn's disease 
in the Chinese population.  Inflamm Bowel Dis.  2004;10(5):646-51.
7.
Lee YM, Fock K, See SJ, et al.  Racial differences in the prevalence of ulcerative 
colitis and Crohn's disease in Singapore.  J Gastroenterol Hepatol.  
2000;15(6):622-5.
8.
Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of 
American College of Gastroenterology.  Management of Crohn's disease in adults.  
Am J Gastroenterol.  2009;104(2):465-83.
9.
Froslie KF, Jahnsen J, Moum BA, et al.  Mucosal healing in inflammatory bowel 
disease:  results from a Norwegian population-based cohort.  Gastroenterology.  
2007;133(2):412-22.
10.
Kakkar A, Wasan SK, Farraye FA.  Targeting mucosal healing in Crohn's disease.  
Gastroenterol Hepatol (NY).  2011;7(6):374-80.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
118
11.
Dignass A, Van Assche G, Lindsay JO, et al; European Crohn's and Colitis 
Organisation (ECCO).  The second European evidence-based consensus on the 
diagnosis and management of Crohn's disease:  current management.  J Crohns 
Colitis.  2010;4(1):28-62.  
12.
Colombel JF, Sandborn WJ, Rutgeerts P, et al.  Adalimumab for maintenance of 
clinical response and remission in patients with Crohn's disease:  the CHARM trial.  
Gastroenterology.  2007;132(1):52-65.
13.
Sandborn WJ, Feagan BG, Rutgeerts P, et al.  Vedolizumab as induction and 
maintenance therapy for Crohn's disease.  N Engl J Med.  2013;369(8):711-21.
14.
Targan SR, Hanauer SB, van Deventer SJ, et al.  A short-term study of chimeric 
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.  
Crohn's disease cA2 study group.  N Engl J Med.  1997;337(15):1029-35.
15.
Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group.  
Maintenance infliximab for Crohn's disease:  the ACCENT I randomised trial.  
Lancet.  2002;359(9317):1541-9.
16.
Hanauer SB, Sandborn WJ, Rutgeerts P, et al.  Human anti-tumor necrosis factor 
monoclonal antibody (adalimumab) in Crohn's disease:  the CLASSIC-I trial.  
Gastroenterology.  2006;130(2):323-33.
17.
Sandborn WJ, Feagan BG, Stoinov S, et al; PRECISE 1 Study Investigators.  
Certolizumab pegol for the treatment of Crohn's disease.  N Engl J Med.  
2007;357(3):228-38.
18.
Siakavellas SI, Bamias G.  Role of the IL-23/IL-17 axis in Crohn's disease.  Discov 
Med.  2012;14(77):253-62.
19.
Boyapati R, Satsangi J, Ho GT.  Pathogenesis of Crohn's disease.  F1000Prime 
Rep.  2015;7:44.  eCollection 2015.
20.
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE).  Available from:  http://ctep.cancer.gov/protocolDevelopment/ 
electronic_applications/ctc.htm#ctc_40.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
119
21.
McKeegan EM, Ansell PJ, Davis G, et al.  Plasma biomarker signature associated 
with improved survival in advanced non-small cell lung cancer patients on 
linifanib.  Lung Cancer.  2015;90(2):296-301.
22.
Chen G, Zhong H, Belousov A, et al.  A PRIM approach to predictive-signature 
development for patient stratification.  Stat Med.  2015;34(2):317-42.
23.
Daperno M, D'Haens G, Van Assche G, et al.  Development and validation of a 
new, simplified endoscopic activity score for Crohn's disease:  the SES-CD.  
Gastrointest Endosc.  2004;60(4):505-12.
24.
Sampson HA, Muñoz-Furlong A, Campbell RL, et al.  Second symposium on the 
definition and management of anaphylaxis:  summary report - Second National 
Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium.  J Allergy Clin Immunol.  2006;117(2):391-7.
25.
Marshall WA, Tanner JM.  Variations in pattern of pubertal changes in girls.  Arch 
Dis Child.  1969;44(235):291-303.
26.
Marshall WA, Tanner JM.  Variations in the pattern of pubertal changes in boys.  
Arch Dis Child.  1970;45(239):13-23.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
120
Appendix A.
Responsibilities of the Clinical Investigator
Clinical research studies sponsored by AbbVie are subject to the Good Clinical Practices 
(GCP) and local regulations and guidelines governing the study at the site location.  In 
signing the Investigator Agreement in Section 14.0 of this protocol, the Investigator is 
agreeing to the following:
1.
Conducting the study in accordance with the relevant, current protocol, making 
changes in a protocol only after notifying AbbVie, except when necessary to 
protect the safety, rights or welfare of subjects.
2.
Personally conducting or supervising the described investigation(s).
3.
Informing all subjects, or persons used as controls, that the drugs are being used for 
investigational purposes and complying with the requirements relating to informed 
consent and ethics committees (e.g., independent ethics committee [IEC] or 
institutional review board [IRB]) review and approval of the protocol and 
amendments.
4.
Reporting adverse experiences that occur in the course of the investigation(s) to 
AbbVie and the site director.
5.
Reading the information in the Investigator's Brochure/safety material provided, 
including the instructions for use and the potential risks and side effects of the 
investigational product(s).
6.
Informing all associates, colleagues, and employees assisting in the conduct of the 
study about their obligations in meeting the above commitments.
7.
Maintaining adequate and accurate records of the conduct of the study, making
those records available for inspection by representatives of AbbVie and/or the 
appropriate regulatory agency, and retaining all study-related documents until 
notification from AbbVie.
8.
Maintaining records demonstrating that an ethics committee/competent authority 
reviewed and approved the initial clinical investigation and all amendments.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
121
9.
Reporting promptly, all changes in the research activity and all unanticipated 
problems involving risks to human subjects or others, to the appropriate individuals 
(e.g., coordinating investigator, institution director) and/or directly to the ethics 
committees and AbbVie.
10.
Following the protocol and not make any changes in the research without ethics 
committee approval, except where necessary to eliminate apparent immediate 
hazards to human subjects.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
122
Appendix B.
List of Protocol Signatories
Name
Title
Functional Area
Clinical Development, Immunology
Clinical Development, Immunology
Statistics
Statistics
Clinical Pharmacology and Pharmacometrics
Bioanalysis
Clinical Operations


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
123
Appendix C.
Study Activities
Screening Period
(35 Days)a
12-Week Double-Blind Induction
Induction Period 2
Unschb
140-Day
Follow-Upc
Activity
Screening
Baseline
Week 4
Week 8
Week 12/PD
Week 16
Week 20
Week 24
Informed consent
X
Inclusion/Exclusion
X
Xd
Medical/Surgery History
X
Xd
Previous and Concomitant 
Medication
X
Xd
X
X
X
X
X
X
X
Physical Exame/Vital Signsf
X
X
X
X
X
X
X
X
X
Adverse Event Assessmentg
X
X
X
X
X
X
X
X
X
X
TB Screeningh
Xx
ECGi
Xx
Hepatitis B, Hepatitis C 
Screeningj and HIV Testk
Xx
C. difficile toxin
Xw
Urinalysisl,m
Xw
Xn
X
X
Pregnancy Testm,o
Xw
X
X
X
X
X
X
X
Chemistry and Hematologym
Xw
Xn
X
X
X
X
X
X
Optional Blood Sample for 
Biologic Drug Level
X
COVID-19 Assessmenty
X
hs-CRPm
X
X
X
X
X
Serum Risankizumabp
X
X
X
X
X


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
124
Screening Period
(35 Days)a
12-Week Double-Blind Induction
Induction Period 2
Unschb
140-Day
Follow-Upc
Activity
Screening
Baseline
Week 4
Week 8
Week 12/PD
Week 16
Week 20
Week 24
Serum Anti-Drug Antibody 
(ADA)p, u and Neutralizing 
Anti-Drug Antibodies (nAb)p
X
X
X
X
X
X
Fecal calprotectin (FCP)m,q
X
X
X
X
Crohn's Disease Activity Index 
(CDAI)
Xr
X
X
X
X
X
X
X
Endoscopy/SES-CDs
X
X
X
Intestinal Biopsiest
X
X
X
Dispense Subject Diaryv
X
Subject Diary Review
X
X
X
X
X
X
X
X
Subject Questionnaire:
CSS
X
X
X
X
X
X
X
X
Subject Questionnaire:
PGIC and PGIS
X (PGIS 
only)
X
X
X
X
X
X
X
Subject Questionnaires:
  EQ-5D-5L
  FACIT-F
  IBDQ
  SF-36  
  WPAI-CD
X
X
X
X
Study Drug Administrationu
X
X
X
Xu
X
X
a.
The Screening period should be a minimum of 4 days, preferably 7 days for CDAI calculation, (refer to Section 5.3.1.1).  The Baseline CDAI will be calculated using the data 
collected during the Screening period.  Baseline visit date will serve as the reference for all subsequent visits.  A ± 7 day window is permitted around all study visits.
b.
Visits to retest a lab will not be considered an Unscheduled visit.  Unscheduled visits according to this table are for purposes when the subject is coming in a visit for 
evaluation and assessment.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
125
c.
Subjects will be contacted 140 days following last dose of study drug for an assessment of any new or ongoing AEs, except those subjects who roll-over into the 
Study M16-000 study after the end of study participation.
d.
Update inclusion/exclusion, prior and concomitant therapy, and medical/surgical history information to assure subject eligibility.
e.
Physical examinations are full physical examinations at Screening and Week 12 and Week 24 if the subject receives treatment in Induction Period 2.  Physical examinations at 
all other visits (including unscheduled visits) are symptom based and should include the assessment of EIMs and a count of the number of cutaneous fistulas as part of 
calculating the CDAI.
f.
Blood pressure, pulse rate, temperature, respiratory rate and weight should be performed before blood draws are performed.  Height will be measured at Screening only (with 
shoes off and then adding 1 inch or 2.5 cm) for subjects ≥ 18 years of age.  Height will be re-measured at Week 12 and Week 24 (if applicable) for subjects < 18 years of age 
at Baseline.
g.
Collection of SAEs and protocol-related nonserious AEs begins the day the subject signs the informed consent.  
h.
Subjects with negative QuantiFERON-TB Gold test and/or PPD test within 90 days of Screening will not require a repeat test (documentation must be available).  PPD skin 
test is to be read 48 to 72 hours after placement.  In case of positive PPD/positive or repeat indeterminate IGRA testing, subjects may participate in the study if further work 
up (according to local practice/guidelines) is negative for active TB.   
i.
For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at Screening will not be required, provided source documentation is available.  Subjects can 
have a repeat ECG at any time during the study as warranted based on the opinion of the Investigator. 
j.
Subjects will be tested for the presence of the HBV and HCV at Screening.  A positive result for the hepatitis B surface antigen (HBs Ag) or hepatitis C (HCV RNA 
detectable in any subject with anti-HCV Ab) will be exclusionary.  For subjects who are negative for HBs Ag but are positive for core antibodies (HBc Ab), HBV DNA PCR 
will be performed and any result that meets or exceeds detection sensitivity will be exclusionary.  
k.
HIV testing will be performed at the central laboratory, which will report the results directly to the sites.  AbbVie will not receive results from the testing.
l.
Dipstick urinalysis will be completed by the sites at required visits.  A microscopic analysis will be performed by the central laboratory, in the event the dipstick results show 
leukocytes, nitrite, protein, ketones or blood greater than negative or glucose greater than normal.  
m.
Urinalysis, chemistry and hematology, hs-CRP, and FCP may be collected at other scheduled and unscheduled visits than indicated in the table if they are warranted by the 
Investigator.
n.
Lab assessments will only need to be repeated at Baseline if the time between Screening and Baseline is greater than 14 days, or if the subject's health status has changed to 
warrant a repeat test.  
o.
Serum pregnancy test will be performed on all WOCBP at Screening.  Urine pregnancy test will be performed locally as indicated in the table for all WOCBP.  The urine 
pregnancy test must be negative to receive study drug.  If any urine pregnancy test is positive, a serum pregnancy test will be performed by the central laboratory.  FSH will 
be performed in all female subjects < 55 years old with no menses for 12 months.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
126
p.
Serum risankizumab concentrations and ADA will be determined from samples collected just prior to dosing at every visit.  The date and time of sample collection will be 
captured on the eCRF.
q.
Stool sample will be collected at each time point indicated in the table.  For the visit when endoscopy will be conducted, stool sample should be collected prior to bowel prep 
and should be returned to the site per the instructions provided outside of this protocol.  If a sample cannot be obtained during the site visit, the site will give instructions and a 
stool sample supply kit.  
r.
Diary information collected during Screening will serve to calculate Baseline CDAI.  During Screening, subjects will be instructed on how to calculate the number of very 
soft and liquid stools, including a visual depiction.  CDAI should be completed at Baseline visit, just prior to randomization.  
s.
Endoscopy at/during the Screening period or within 45 days of the Baseline visit will be used to calculate the SES-CD score at Baseline.  Endoscopic evaluations using 
SES-CD confirmed by central reader will be done at Screening.  Endoscopies completed at Week 12 and Week 24, for those subjects who receive treatment in Induction 
Period 2, will use the local reader results for stratification for Study M16-000.
t.
Biopsies may be done when performing the endoscopy to confirm CD diagnosis (if appropriate documentation for confirmation of the diagnosis does not exist), and/or to rule 
out dysplasia and colon cancer at the Investigator's discretion.  These samples will be processed and assessed locally.  Histology report should be available in the subject's 
source records.  
u.
Administration of drug will be performed after all assessments and examinations scheduled for that day have been completed, including endoscopy.  Completion of PROs are 
permitted during administration of study drug.  At Week 12, study drug will only be administered for subjects who are to receive treatment in Induction Period 2.  Subjects 
will also be dispensed a patient information card.  In the event of a suspected systemic post-dose hypersensitivity reaction, serum risankizumab, ADA, and nAb should be 
collected once within 24 hours of the reaction.  In addition, tryptase sample should be obtained between 15 minutes to 3 hours of symptom onset, and no later than 6 hours, 
and another sample is requested a minimum of 2 weeks after the recorded event or at the next study visit.  Also, plasma histamine sample should be obtained within 5 to 15 
minutes of the onset of symptoms and no later than 1 hour.
v.
Subjects should also be dispensed the patient information card.
w.
For Rescreening, if a subject is being rescreened within 14 days (≤ 14 days have passed) from the collection date of the previous screening testing, it is not required to repeat 
Screening testing for chemistry/hematology, urinalysis, serum pregnancy, and C. difficile provided that the subject's health status has not changed to warrant a repeat test.
x.
For Rescreening, if the subject had a complete initial screening evaluation including the TB test, hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency 
virus (HIV), and electrocardiogram (ECG), these tests will not be required to be repeated for re-screening provided the conditions noted in Section 5.3.1.1 are met and no 
more than 90 days have passed since the collection date of the testing.
y.
Assessment for signs/symptoms of COVID-19 infection.  If the investigator suspects the possibility of COVID-19 based on the signs, symptoms and medical complaint (chief 
complaint, history of exposure, etc.), local laboratory testing must be completed.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
127
Appendix D.
Study Activities – Optional Exploratory Research Samples
Screening Period (35 Days)a
12-Week Double-Blind Induction
Samples Collecteda
Screening
Baseline
Week 4
Week 12/PD
Pharmacogeneticb
X
Epigeneticb,c
X
X
X
Transcriptomicb,c
X
X
X
Proteomic and targeted protein investigations (plasma)b,c
X
X
X
Proteomic and targeted protein investigations (serum)b,c
X
X
X
PBMC (US sites only)d
X
X
Stoolb
X
X
X
Intestinal biopsies (RNA)b,e
X
X
Intestinal biopsies (IHC)b,e
X
X
a.
Collections to be performed only if subject provides separate written consent to collect the exploratory research/validation studies samples; if the separate consent is not 
signed, no samples can be collected.
b.
Based on the value of different technologies, samples may also be used to assess other biomarker signatures, including but not limited to metabolomics, lipidomics, and other 
approaches.
c.
It is preferred that the subject has fasted (8 hours, except for water) prior to sample collection, however it is not required.  It must be recorded whether the subject has fasted or 
not at the time of collection.
d.
Samples will be collected from US sites only.
e.
Biopsy may be done when performing the endoscopy.  Biopsy for histologic assessment by central review will be conducted at each visit with endoscopy.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
128
Appendix E.
Sample SES-CD Scoring
SES-CD Scoring23
Rectum
Sigmoid 
and 
Left 
Colon
Transverse 
Colon
Right 
Colon
Ileum
Total
Size of Ulcers 
Enter:
0 if none
1 if aphthous ulcers (Ø 0.1 to 0.5 cm)
2 if large ulcers (Ø 0.5 to 2 cm)
3 if very large ulcers (Ø > 2 cm)
Ulcerated Surface
Enter:
0 if none
1 if < 10%
2 if 10% – 30%
3 if > 30%
Affected Surface
Enter:
0 if unaffected segments
1 if < 50%
2 if 50% – 75%
3 if > 75%
Presence of Narrowing
Enter:
0 if none
1 if single, can be passed
2 if multiple, can be passed
3 if cannot be passed
TOTAL =


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
129
Appendix F.
Crohn's Disease Activity Index (CDAI)
Factor
Subtotal
1.
Number of liquid or very soft stools
(Record the frequency per day)
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
2
2.
Abdominal pain rating:
0 = none, 1 = mild, 2 = moderate,
3 = severe
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
5
3.
General well-being:
0 = generally well, 1 = slightly
underpar, 2 = poor, 3 = very poor,
4 = terrible
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
7
4.
Number of 6 listed categories the 
subject now has 
Check all items that apply:
☐
Arthritis/arthralgia
☐
Iritis/uveitis
☐
Erythema nodosum/pyoderma 
gangrenosum/aphthous 
stomatitis
☐
Fissure, abscess and/or anal 
fistula (draining/non-draining)
☐
Other cutaneous fistula
(draining/non-draining) Fistula
☐
Fever over 100°F (37.8°C)
during past week
_________________________________ 
_________________________________
Record "0" if no categories checked
×
20
5.
Taking Lomotil/Imodium/ 
Loperamide/opiates for diarrhea 
0 = no, 1 = yes
________
×
30
6.
Abdominal mass
0 = none, 2 = questionable,
5 = defined
________
×
10
7.
Hematocrit:  ___.__
Male:  (47 – hematocrit) =
Female:  (42 – hematocrit) =
Subtotal
If hematocrit > normal, enter "0"
×
6
8.
Body weight:  ___.__(kg)
Standard weight:  ___.__(kg)
100 × [1 – (Body wt/Standard wt)] =
Percent below standard weight:  ______
If body wt > std. wt, enter "0"
×
1
Total
NOTE:
During Screening subjects will be instructed on how to calculate the number of very soft and liquid stools, 
including a visual depiction.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
130
Appendix G.
Standard Weights
Standard Height and Weight Tables – Use to Calculate CDAI Score
Standard Height
cm (Inches)
Standard Weight (Men)
kg (Pounds)
Standard Weight (Women) kg 
(Pounds)
121.9 (48.0)
40.8 (89.9)
123.2 (48.5)
41.3 (91.0)
124.5 (49.0)
41.8 (92.1)
125.7 (49.5)
42.3 (93.3)
127.0 (50.0)
42.8 (94.4)
128.3 (50.5)
43.4 (95.6)
129.5 (51.0)
43.9 (96.8)
130.8 (51.5)
44.4 (98.0)
132.1 (52.0)
55.5 (122.4)
45.0 (99.2)
133.4 (52.5)
55.7 (122.7)
45.5 (100.4)
134.6 (53.0)
55.8 (123.1)
46.1 (101.6)
135.9 (53.5)
56.0 (123.5)
46.6 (102.8)
137.2 (54.0)
56.2 (123.9)
47.2 (104.1)
138.4 (54.5)
56.4 (124.4)
47.8 (105.3)
139.7 (55.0)
56.7 (124.9)
48.3 (106.6)
141.0 (55.5)
56.9 (125.5)
48.9 (107.9)
142.2 (56.0)
57.2 (126.1)
49.5 (109.1)
143.5 (56.5)
57.4 (126.7)
50.1 (110.4)
144.8 (57.0)
57.7 (127.3)
50.7 (111.7)
146.1 (57.5)
58.1 (128.0)
51.3 (113.0)
147.3 (58.0)
58.4 (128.7)
52.2 (115.0)
148.6 (58.5)
58.7 (129.5)
52.6 (116.0)
149.9 (59.0)
59.1 (130.3)
53.1 (117.0)
151.1 (59.5)
59.5 (131.1)
53.6 (118.3)
152.4 (60.0)
59.9 (132.0)
54.2 (119.5)
153.7 (60.5)
60.3 (132.9)
54.8 (120.8)
154.9 (61.0)
60.7 (133.8)
55.3 (122.0)
156.2 (61.5)
61.1 (134.8)
56.0 (123.5)
157.5 (62.0)
61.7 (136.0)
56.7 (125.0)


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
131
Standard Height and Weight Tables – Use to Calculate CDAI Score
Standard Height
cm (Inches)
Standard Weight (Men)
kg (Pounds)
Standard Weight (Women) kg 
(Pounds)
158.8 (62.5)
62.1 (137.0)
57.4 (126.5)
160.0 (63.0)
62.6 (138.0)
58.0 (128.0)
161.3 (63.5)
63.0 (139.0)
58.7 (129.5)
162.6 (64.0)
63.5 (140.0)
59.4 (131.0)
163.8 (64.5)
64.1 (141.3)
60.1 (132.5)
165.1 (65.0)
64.6 (142.5)
60.8 (134.0)
166.4 (65.5)
65.2 (143.8)
61.4 (135.5)
167.6 (66.0)
65.8 (145.0)
62.1 (137.0)
168.9 (66.5)
66.4 (146.5)
62.8 (138.5)
170.2 (67.0)
67.1 (148.0)
63.5 (140.0)
171.5 (67.5)
67.8 (149.5)
64.2 (141.5)
172.7 (68.0)
68.5 (151.0)
64.9 (143.0)
174.0 (68.5)
69.2 (152.5)
65.5 (144.5)
175.3 (69.0)
69.8 (154.0)
66.2 (146.0)
176.5 (69.5)
70.5 (155.5)
66.9 (147.5)
177.8 (70.0)
71.2 (157.0)
67.6 (149.0)
179.1 (70.5)
71.9 (158.5)
68.3 (150.5)
180.3 (71.0)
72.6 (160.0)
68.9 (152.0)
181.6 (71.5)
73.4 (161.8)
69.6 (153.5)
182.9 (72.0)
74.1 (163.5)
70.3 (155.0)
184.2 (72.5)
75.0 (165.3)
71.2 (156.9
185.4 (73.0)
75.7 (167.0)
71.9 (158.5)
186.7 (73.5)
76.6 (169.0)
72.6 (160.2)
188.0 (74.0)
77.5 (171.0)
73.4 (161.8)
189.2 (74.5)
78.4 (172.8)
74.1 (163.4)
190.5 (75.0)
79.1 (174.5)
74.9 (165.1)
191.8 (75.5)
80.2 (176.8)
75.6 (166.8)
193.0 (76.0)
81.2 (179.0)
76.4 (168.4)
194.3 (76.5)
82.0 (180.8)
77.2 (170.1)
195.6 (77.0)
82.9 (182.9)
77.9 (171.8)
196.9 (77.5)
83.9 (185.0)
78.7 (173.5)


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
132
Standard Height and Weight Tables – Use to Calculate CDAI Score
Standard Height
cm (Inches)
Standard Weight (Men)
kg (Pounds)
Standard Weight (Women) kg 
(Pounds)
198.1 (78.0)
84.9 (187.2)
79.5 (175.2)
199.4 (78.5)
85.9 (189.4)
80.3 (177.0)
200.7 (79.0)
86.9 (191.6)
81.0 (178.7)
201.9 (79.5)
87.9 (193.9)
81.8 (180.5)
203.2 (80.0)
89.0 (196.2)
82.6 (182.2)
204.5 (80.5)
90.0 (198.6)
*Standard height is calculated using 
actual height obtained at screening 
(without shoes) plus one inch
205.7 (81.0)
91.1 (200.9)
*Indoor clothing weighing 5 pounds 
for men and 3 pounds for women
207.0 (81.5)
92.2 (203.3)
*Centimeters × 0.3937 = inches
208.3 (82.0)
93.3 (205.8)
*Pounds × 0.4535 = kilograms


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
133
Appendix H.
Clinical Criteria for Diagnosing Anaphylaxis
Anaphylaxis24 is highly likely when any one of the following 3 criteria are fulfilled:
1.
Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen 
lips-tongue-uvula)
AND AT LEAST ONE OF THE FOLLOWING
a.
Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, 
reduced PEF, hypoxemia)
b. Reduced BP or associated symptoms of end-organ dysfunction (e.g., hypotonia 
[collapse], syncope, incontinence)
2.
Two or more of the following that occur rapidly after exposure to a likely allergen 
for that patient (minutes to several hours):
a.
Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, 
swollen lips tongue-uvula)
b. Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, 
reduced PEF, hypoxemia)
c.
Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, 
incontinence)
d. Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting)
3.
Reduced BP after exposure to known allergen for that patient (minutes to several 
hours):
a.
Infants and children:  low systolic BP (age specific) or greater than 30% 
decrease in systolic BP*
b. Adults:  systolic BP of less than 90 mm Hg or greater than 30% decrease from 
that person's baseline


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
134
PEF:  peak expiratory flow; BP:  blood pressure
*
low systolic BP for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg + 
[2 × age]) from 1 to 10 years, and less than 90 mg Hg from 11 to 17 years.
Serious Systemic Hypersensitivity Reaction:  A hypersensitivity reaction is a clinical 
sign or symptom, or constellation of signs or symptoms, caused by an inappropriate and 
excessive immunologic reaction to study drug administration.  A systemic 
hypersensitivity reaction is a hypersensitivity reaction that does not occur at the local site 
of study drug administration (e.g., not an injection site reaction).  A serious systemic 
hypersensitivity reaction is a systemic hypersensitivity reaction that fulfills criteria for a 
serious adverse event as specified in Section 6.1.1.2.
In the event of an anaphylactic reaction, blood samples will be drawn per Appendix C
after the onset of the reaction.  This will include: histamine and tryptase.  A blood sample 
for ADA assessment will also be collected along with 1 hour blood samples for above 
assessments.  Separate instructions for the collection, handling, storage and shipping of 
these labs will be provided outside of the study protocol.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
135
Appendix I.
Tanner Stage 5 for Development
Tanner Stage 5 for Development25,26
Puberty and the Tanner Stages – developed by Professor James M Tanner
Introduction
Adolescents experience several types of maturation, including cognitive (the development 
of formal operational thought), psychosocial (the stages of adolescence), and biologic.  
The complex series of biologic transitions are known as puberty, and these changes may 
impact psychosocial factors.
The most visible changes during puberty are growth in stature and development of 
secondary sexual characteristics.
Equally profound are changes in body composition; the achievement of fertility; and 
changes in most body systems, such as the neuroendocrine axis, bone size, and 
mineralization; and the cardiovascular system.  As an example, normal cardiovascular 
changes, including greater aerobic power reserve, electrocardiographic changes, and 
blood pressure changes, occur during puberty.
The normal sequence of pubertal events and perils of puberty are reviewed here.  This is 
within the normal ranges and does not take into account Precocious Puberty or Delayed 
Puberty.
Tanner Stages
Conceptually, pubertal maturation can be described in terms of sequence, timing, and 
tempo (Puberty consists of a series of predictable events, and the sequence of changes in 
secondary sexual characteristics has been categorized by several groups.  The staging 
system utilized most frequently is that published by Marshall and Tanner and the 
sequence of changes, commonly referred to as "Tanner stages," is described below.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
136
Boys – development of external genitalia
Stage 1:  Prepubertal
Stage 2:  Enlargement of scrotum and testes; scrotum skin reddens and changes in texture
Stage 3:  Enlargement of penis (length at first); further growth of testes
Stage 4:  Increased size of penis with growth in breadth and development of glans; testes 
and scrotum larger, scrotum skin darker
Stage 5:  Adult genitalia
Girls – breast development
Stage 1:  Prepubertal
Stage 2:  Breast bud stage with elevation of breast and papilla; enlargement of areola
Stage 3:  Further enlargement of breast and areola; no separation of their contour
Stage 4:  Areola and papilla form a secondary mound above level of breast
Stage 5:  Mature stage:  projection of papilla only, related to recession of areola
Boys and girls – pubic hair
Stage 1:  Prepubertal (can see velus hair similar to abdominal wall)
Stage 2:  Sparse growth of long, slightly pigmented hair, straight or curled, at base of 
penis or along labia
Stage 3:  Darker, coarser and more curled hair, spreading sparsely over junction of pubes
Stage 4:  Hair adult in type, but covering smaller area than in adult; no spread to medial 
surface of thighs


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
137
Stage 5:  Adult in type and quantity, with horizontal distribution ("feminine")
Boys Growth
●
Stage 1:  5 – 6 cm/year
●
Stage 2:  5 – 6 cm/year
●
Stage 3:  7 – 8 cm/year
●
Stage 4:  10 cm/year
●
Stage 5:  No further height increase after 17 years
Girls Growth
●
Stage 1:  5 – 6 cm/year
●
Stage 2:  7 – 8 cm/year
●
Stage 3:  8 cm/year
●
Stage 4:  7 cm/year
●
Stage 5:  No further height after 16 years


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
138
Appendix J.
Protocol Amendment:  List of Changes
The summary of changes is listed in Section 1.1.
Specific Protocol Changes
Section 1.2  Synopsis
Previously read:
AbbVie Inc.
Protocol Number:  M15-991
Name of Study Drug:  Risankizumab (ABBV-066)
Phase of Development:  3
Name of Active Ingredient:  Risankizumab
Date of Protocol Synopsis:  28 July 2020
Protocol Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to 
Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's 
Disease Who Failed Prior Biologic Treatment
Objectives:  The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab 
versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease 
(CD).
Investigators:  Multicenter
Study Sites:  Approximately 400 sites 
Study Population:  Males and females aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent 
according to local regulations at the Baseline visit, or aged 16 to < 18 years of age where locally 
permitted and who meet the definition of Tanner stage 5 development (refer to Appendix J), at the 
Baseline visit, with a diagnosis of moderately to severely active CD, defined as:
1.
average daily stool frequency (SF) ≥ 4 (when calculating SF, only the number of liquid or very soft 
stools should be recorded) and/or average daily abdominal pain (AP) score ≥ 2; plus 
2.
endoscopic evidence of mucosal inflammation measured by the Simple Endoscopic Score for CD 
(SES-CD).  All eligible scores exclude the presence of narrowing component and are confirmed by 
a central reader.  Endoscopic activity is defined as a SES-CD of ≥ 3.
The number of subjects enrolled with a SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or 
SES-CD of 3 for isolated ileal disease will be no more than 58 subjects.  Once cap of no more than 
58 subjects is reached, enrollment criterion will be an eligibility SES-CD of ≥ 6 for ileocolonic or 
colonic disease, or eligibility SES-CD of ≥ 4 for isolated ileal disease.
The study will enroll 100% of subjects who have had an inadequate response or intolerance to prior 
biologic therapy (bio-IR).  The bio-IR population is defined as subjects with documented intolerance or 
inadequate response to one or more of the approved biologic agents for CD (infliximab, adalimumab, 
certolizumab, natalizumab, ustekinumab and/or vedolizumab).  The percent of subjects with exposure, 
including intolerance or inadequate response to ustekinumab will be no more than 20%. 
Number of Subjects to be Enrolled:  Approximately 579 for the primary ITT population used for 
efficacy analysis; additionally, up to 58 subjects with lower SES-CD will be enrolled


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
139
Methodology:  
Study M15-991 is a randomized, double blind, placebo-controlled 12-week induction study.
Subjects (n = 579) will be randomized 1:1:1 to 1200 mg risankizumab or 600 mg risankizumab or 
placebo intravenous (IV) given at Baseline, Weeks 4, 8.  The randomization will be stratified by both the 
number of prior biologics failed (1, > 1), Baseline steroid use (yes, no), and Baseline SES-CD (original, 
alternative), where the stratum of "original" includes the patients with baseline SES-CD of ≥ 6 (or ≥ 4 
for subjects with isolated ileal disease), and the stratum of "alternative" includes the patients with 
baseline SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or SES-CD of 3 for isolated ileal 
disease.
Visits during the study will occur at Baseline and Weeks 4, 8, and 12/Premature Discontinuation (PD) to 
collect clinical and laboratory assessments of disease activity.  Subjects who do not achieve clinical 
response at Week 12 may be eligible for treatment with blinded risankizumab in Induction Period 2 with 
evaluation for clinical response at Week 24.
All subjects will be provided with a subject diary where they will record CD related symptoms 
throughout the study.  Subjects will also be dispensed a patient information card during Screening.  
Additionally, subjects will complete symptom, quality of life (QoL) and work productivity 
questionnaires throughout the study.  Clinical labs including, but not limited to, urinalysis, chemistry and 
hematology, high-sensitivity C-reactive protein (hs-CRP), serum risankizumab concentrations, and 
serum anti-drug antibody (ADA) levels will be collected throughout the study.  In addition, stool 
samples for calprotectin analysis will be collected and should be taken before starting bowel preparations 
for endoscopy.  All endoscopies will be evaluated using SES-CD and will be confirmed by a central 
reader.  Biopsy to confirm diagnosis (during Screening) or to rule out dysplasia/malignancy may be 
performed during the same time points as the endoscopy.  Optional exploratory research samples may be 
taken during the study.
At the Week 12/PD visit, all subjects will undergo an endoscopy for evaluation of mucosal 
inflammation.  It is expected that all subjects who remain in the study through at least Week 8 will have 
a Week 12/PD endoscopy.  All subjects achieving clinical response, defined as ≥ 30% decrease in 
average daily SF and/or ≥ 30% decrease in average daily AP score (both not worse than Baseline) at 
Week 12 may be eligible to enter Study M16-000.  Subjects are not eligible to enter Study M16-000 
until endoscopy has been completed (local reader results will be used for stratification for 
Study M16-000).  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive blinded 
treatment with risankizumab in Induction Period 2 as described below.  Subjects are not eligible to enter 
Induction Period 2 until Week 12 endoscopy has been completed.  


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
140
Methodology (Continued):
Induction Period 2
At Week 12, subjects who do not achieve clinical response will be randomized by Interactive Response 
Technologies (IRT) to Induction Period 2, a double-blind, double-dummy 12-week treatment period.
Subjects who received IV risankizumab induction treatment will be randomized 1:1:1 to:
!
Group 1:  1200 mg IV risankizumab
!
Group 2:  360 mg SC risankizumab
!
Group 3:  180 mg SC risankizumab
Subjects who received placebo induction treatment will receive:
!
Group 4:  1200 mg IV risankizumab
The IV risankizumab dose or matching IV placebo will be given at Weeks 12, 16, and 20; The SC 
risankizumab dose or matching SC placebo will be given at Weeks 12, and 20.
At Week 24, subjects who received treatment in Induction Period 2 will be reassessed and undergo a 
third endoscopy for evaluation of mucosal inflammation.  Subjects who achieve clinical response at 
Week 24 may be eligible to enter Study M16-000.  Subjects without clinical response at Week 24, as 
well as all subjects who terminate the study early (including subjects who are eligible for, but do not 
receive treatment during Induction Period 2) will be discontinued and have a follow-up call 140 days 
from the last dose of study drug to obtain information on any new or ongoing AEs.
Concomitant Aminosalicylates, Immunomodulators (Azathioprine [AZA], 6-Mercaptopurine 
[6-MP], Methotrexate [MTX]), and/or CD-Related Antibiotics
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at Baseline must 
continue these treatments for the duration of the study.  Initiating and/or increasing doses of 
aminosalicylates, immunomodulators, and/or CD-related antibiotics during the study is prohibited.  
Decreasing doses of aminosalicylates, immunomodulators, and/or CD-related antibiotics is prohibited 
during the study, except in the event of moderate-to-severe treatment related toxicities and after 
discussion with the AbbVie Therapeutic Area Medical Director (TA MD).  CD-related antibiotics may 
be discontinued in Induction Period 2 at the discretion of the Investigator.
Note:  the duration of the study includes Induction Period 2.
Concomitant Corticosteroids
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at the Baseline 
dose for the duration of the 12-week induction period.  Initiation and/or increasing doses of systemic 
and/or CD related corticosteroids during the entire study is prohibited.  Decreasing doses of 
corticosteroids is prohibited during the 12-week induction period, except in the event of moderate-to-
severe treatment related toxicities and after discussion with the AbbVie TA MD.
Subjects who enter Induction Period 2 will be allowed to taper their corticosteroids at the discretion of 
the Investigator.  Increasing doses above the Baseline dose is prohibited.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
141
Methodology (Continued):
Dose Selection
This study will evaluate two IV doses of risankizumab (600 mg and 1200 mg).  The selection of the 
doses in this study is informed by the analysis of the safety and efficacy data, as well as the 
exposure-response relationship of efficacy, of a Phase 2 study in subjects with CD that explored 200 mg 
and 600 mg doses.  The results from the Phase 2 study suggest a potential for increased benefit with 
1200 mg administration.
Induction Period 2 will evaluate IV (1200 mg Q4w) or SC (180 mg or 360 mg Q8w; maintenance dosing 
regimen) risankizumab.  The purpose of Induction Period 2 is to evaluate the efficacy and safety of re-
induction of risankizumab (1200 mg IV at Weeks 12, 16, and 20) versus starting maintenance dosing on 
clinical response status.  Data from the Phase 2 study in subjects with CD suggested that re-induction 
with 600 mg IV increased both clinical response and clinical remission in subjects with inadequate 
response at Week 12.  The selection of the SC doses is informed by the analysis of the safety and 
efficacy data, as well as the exposure-response relationship of efficacy, of the maintenance period during 
the Phase 2 study in subjects with CD that evaluated 180 mg SC risankizumab for maintenance.  The 
results from the Phase 2 study suggest a potential for increased benefit with 360 mg SC administration 
for maintenance regimen. 
Data Monitoring Committee (DMC)
An external independent DMC will review unblinded safety data on a cohort level, at a minimum of 
6-month intervals throughout the course of the study.  At the timing of this amendment, the DMC has 
provided recommendation that the study may continue without modification and allowed enrollment to 
begin for 16 – 17 year-olds.  A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be provided to 
the patients at Screening so that any such events once occurred will be reported immediately by the 
patients to the investigator.  
A separate DMC charter will be prepared outside of the protocol and will describe the roles and 
responsibilities of the DMC members, frequency and triggers of data reviews, and relevant safety data to 
be assessed.  The cardiac adjudication committee (CAC) and anaphylaxis adjudication committee (AAC) 
adjudicates blinded data and the DMC reviews the data in an unblinded manner.  Unblinded adjudicated 
cardio-cerebrovascular events and anaphylactic reactions will be presented to the DMC for review on a 
periodic basis.  Communications from the DMC to the Study Teams will not contain information that 
could potentially unblind the team to subject treatment assignments.
Diagnosis and Main Criteria for Inclusion/Exclusion:  
Main Inclusion:  
1.
Male or female aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent according to local 
regulations, at the Baseline visit.  Where locally permissible, subjects 16 to < 18 years of age who 
meet the definition of Tanner stage 5 for development (refer to Appendix I), at the Baseline Visit 
(sites will be notified when adolescents may enroll).
2.
Confirmed diagnosis of CD for at least 3 months prior to Baseline.  Appropriate documentation of 
biopsy results consistent with the diagnosis of CD, in the assessment of the Investigator, must be 
available.
3.
Crohn's disease activity index (CDAI) score 220 – 450 at Baseline.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
142
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Inclusion (Continued):  
4.
Endoscopic evidence of mucosal inflammation as documented by an SES-CD of ≥ 3.  All eligible 
scores exclude the presence of narrowing component and are confirmed by a central reader.  (Once 
cap of no more than 58 subjects is reached, enrollment criterion will be an SES-CD of ≥ 6 for 
ileocolonic or colonic disease or SES-CD of ≥ 4 for isolated ileal disease.)
5.
Average daily SF ≥ 4 and/or average daily AP score ≥ 2 at Baseline.
6.
Demonstrated intolerance or inadequate response to one or more of the following biologic agents:  
infliximab, adalimumab, certolizumab pegol, natalizumab, ustekinumab and/or vedolizumab:
!
Demonstration of intolerance requires no minimum dose or duration of use
!
Inadequate response to biologic agents defined as signs and symptoms of persistently (in the 
opinion of the Investigator) active disease despite a history of one or more of the following:
o
At least one 6-week induction regimen of infliximab (≥ 5 mg/kg IV at Weeks 0, 2, and 6),
o
At least one 4-week induction regimen of adalimumab (one 160 mg SC dose at Week 0, 
followed by one 80 mg SC dose at Week 2 [or one 80 mg SC dose at Week 0, followed 
by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]),
o
At least one 4-week induction regimen of certolizumab pegol (400 mg SC at Weeks 0, 2, 
and 4)
o
At least one 6-week induction regimen of vedolizumab (300 mg IV at Weeks 0, 2, and 6)
o
At least one 12-week induction regimen of natalizumab (300 mg IV every 4 weeks)
o
At least one 8-week induction regimen of ustekinumab [260 mg (≤ 55 kg) or 390 mg 
(> 55 to ≤ 85 kg) or 520 mg (> 85 kg) IV, followed by 90 mg SC at Week 8] (Once cap 
of no more than 20% ustekinumab exposed subjects is reached, subjects with prior 
ustekinumab exposure will not be allowed to enroll.)  
!
Recurrence of symptoms during scheduled maintenance dosing following prior clinical benefit 
of the above biologic agents
!
Note:  Subjects who discontinued biologic agents for reasons other than inadequate response as 
defined above or intolerance (e.g., change of insurance) are not eligible to enroll
7.
If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol Contraception 
Recommendations.  Females of childbearing potential must have a negative serum pregnancy test 
result during Screening, and a negative urine pregnancy at Baseline.  Females of non-childbearing 
potential (either postmenopausal or permanently surgically sterile as defined in Section 5.2.4) 
during Screening do not require pregnancy testing at Baseline. 
Note:  Subjects with borderline serum pregnancy test at Screening must have a serum pregnancy test 
≥ 3 days later to document continued lack of a positive result.
8.
Subjects must be able and willing to give written informed consent and to comply with the 
requirements of this study protocol.
Main Exclusion:  
1.
Subject with a current diagnosis of ulcerative colitis or indeterminate colitis.
Concomitant Medications and Treatments 
2.
Subject on CD-related antibiotics who has not been on stable doses for greater than, or discontinued 
within, 14 days prior to Baseline.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
143
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
3.
Subject on oral aminosalicylates who has not been on stable doses for greater than, or discontinued 
within, at least 14 days prior to Baseline.
4.
Subject taking oral corticosteroids:
!
Budesonide > 9 mg/day
!
Beclomethasone > 5 mg/day
!
Prednisone or equivalent > 20 mg/day
!
Or has not been on the current course for ≥ 14 days prior to Baseline and on a stable dose for 
≥7 days prior to Baseline
5.
Subject on immunomodulators (AZA, 6-MP, MTX) who:
!
Has not been on the current course for ≥ 42 days prior to Baseline, and
!
Has not been on a stable dose for ≥ 35 days prior to Baseline
Medications and Treatments During the Screening Period
6.
Subject who received IV anti-infectives within 35 days prior to Baseline visit or oral/intramuscular 
anti-infectives (non-CD-related) within 14 days prior to the Baseline visit.  This does not apply to 
TB prophylaxis.
7.
Subject who received exclusive enteral nutrition or any parenteral nutrition within 35 days prior to 
Baseline.
8.
Subject who received any live bacterial or viral vaccination within 30 days prior to Screening or 
during the Screening period.
9.
Subject who received cyclosporine, tacrolimus, or mycophenolate mofetil within 35 days prior to 
Baseline.
10. Subject who received fecal microbial transplantation within 35 days prior to Baseline.
Prior Medications and Treatments
11. Subject who received any biologic agent:
!
Approved biologics: infliximab, adalimumab, certolizumab, natalizumab, vedolizumab within 
8 weeks prior to Baseline, or ustekinumab within 12 weeks prior to Baseline 
Note:  If there is proper documentation of an undetectable drug level measured by a 
commercially available assay for any of the approved biologics above, there is no minimum 
washout prior to Baseline.
!
Any investigational biologic or other agent or procedure within 35 days or 5 half-lives prior to 
Baseline, whichever is longer.
12. Subject with prior exposure to p19 inhibitors (e.g., risankizumab).
13. Subject has been taking combination of two or more of the following oral budesonide, or oral 
beclomethasone and/or oral prednisone (or equivalent) simultaneously, with the exception of 
inhalers, within 14 days prior to Screening or during the Screening period.
14. Subject who received IV/intramuscular corticosteroids within 14 days prior to Screening or during 
the Screening period.
15. Subject who received therapeutic enema or suppository, other than required for endoscopy, within 
14 days prior to endoscopy used for Screening or during the Screening period.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
144
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
16. Subject who received apheresis (e.g., Adacolumn apheresis) ≤ 60 days prior to Screening or during 
the Screening period.
17. Subject who has concomitant cannabis use either recreational or for medical reasons within 14 days 
of Baseline or any history of clinically significant drug, or alcohol abuse in the last 12 months.
CD Related
18. Subject with currently known complications of CD such as:
!
abscess (abdominal or perianal),
!
symptomatic bowel strictures,
!
> 2 missing segments of the following 5 segments:  terminal ileum, right colon, transverse 
colon, sigmoid and left colon, and rectum
!
fulminant colitis,
!
toxic megacolon,
!
or any other manifestation that might require surgery while enrolled in the study.
19. Subject with ostomy or ileoanal pouch.
20. Subject diagnosed with short gut or short bowel syndrome.
21. Subject with surgical bowel resection within the past 3 months prior to Baseline, or a history of 
≥3 bowel resections.
Safety
22. Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study 
drugs or the ingredients of Chinese hamster ovary (CHO).
23. Subjects with the following chronic or active infections: 
!
Active, chronic, or recurrent infection that based on the Investigator's clinical assessment makes 
the subject unsuitable candidate for the study, 
!
Infection with C. difficile toxin or other intestinal pathogen during Screening,
!
Are infected with human immunodeficiency virus (HIV),
!
QuantiFERON®-TB test or Purified Protein Derivative (PPD) skin test, or both, according to 
local guidelines, will be performed during Screening.  QuantiFERON®-TB test is preferred for 
subjects who received BCG vaccination or were exposed to other Mycobacteria species.  
Subjects with a positive test result (or indeterminate results that have been repeated) may 
participate in the study if further work up (according to local practice/guidelines) establishes 
conclusively that the subject has no evidence of active tuberculosis.  Subjects with a history of 
active TB who have documented completion of a full course of anti-TB therapy may be allowed 
to enter the study after consultation with the AbbVie TA MD.  If latent TB is established, TB 
prophylaxis/treatment should be initiated and maintained according to local country guidelines.
!
Have active hepatitis B or hepatitis C defined as:
o
HBV: hepatitis B surface antigen (HBs Ag) positive (+), or detected sensitivity on the 
HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for 
hepatitis B core antibody (HBc Ab) positive subjects
o
HCV:  HCV ribonucleic acid (RNA) detectable in any subject with positive anti-HCV 
antibody (HCV Ab)


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
145
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
24. Subject with a previous history of dysplasia of the gastrointestinal tract or found to have dysplasia, 
other than completely removed low-grade dysplastic lesions, in any biopsy performed during the 
Screening endoscopy.
25. Subject with a known history of lymphoproliferative disease, including lymphoma, or signs and 
symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or 
splenomegaly.
26. Subject with current or previous history of malignancy other than a successfully treated 
non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of 
the cervix.
27. Subject who has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, 
disorder or symptoms thereof.
28. Female subjects who is pregnant, breastfeeding, or is considering becoming pregnant during the 
study or for approximately 140 days after the last dose of study drug.
29. Subject who has any condition, including any physical, psychological, or psychiatric condition, 
which in the opinion of the Investigator, would compromise the safety of the subject or the quality 
of the data and renders the subject an unsuitable candidate for the study.
30. Screening laboratory and other analyses show any of the following abnormal results:
!
Aspartate transaminase (AST), alanine transaminase (ALT) > 2 × upper limit of the reference 
range;
!
White blood cell (WBC) count < 3.0 × 109/L;
!
Total bilirubin ≥ 2 mg/dL; except for subjects with isolated elevation of indirect bilirubin 
relating to Gilbert syndrome;
!
Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal 
Disease (MDRD) formula < 30 ml/min/1.73 m2. 
!
Hemoglobin < 8 g/dL
!
Platelets < 100,000/μL
!
Positive serum pregnancy test at the Screening visit or positive urine pregnancy test at the 
Baseline visit
Laboratory values can be re-tested once during the screening period after discussion and clearance 
with the TAMD.  If the re-tested lab value(s) remain(s) exclusionary, the subject will be considered 
a screen failure.  Redrawing samples if previous samples were unable to be analyzed would not 
count as a retest since previous result was never obtained.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
146
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
31. No known active COVID-19 infection.  Subject must not have signs/symptoms associated with 
COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and may only rescreen 
after they meet the following COVID-19 viral clearance criteria:
!
Symptomatic subjects:  At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since recovery, defined as resolution of fever without 
use of antipyretics and improvement in respiratory symptoms (e.g., cough, shortness of breath)
!
Asymptomatic subjects:  At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (Note:  subjects who develop 
symptoms will follow guidance above for symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the above viral clearance 
criteria may be adjusted to account for epidemiological trends, updated information regarding 
infectivity and local/institutional guidelines.
Investigational Product:
Risankizumab
Dose(s):
Risankizumab 1200 mg IV Q4W*
Risankizumab 600 mg IV Q4W
Risankizumab 180 mg SC Q8W
Risankizumab 360 mg SC Q8W
*If administration of the 1200 mg dose is halted for any reason, 
enrollment may continue for subjects into the risankizumab 600 mg, or 
placebo arms at a 1:1 ratio.  The ratio of randomization and final sample 
size may be further updated in an amendment to the protocol.  Subjects 
already randomized to treatment arms, including Induction Period 2, 
will receive blinded 600 mg risankizumab IV.
Mode of Administration:
Risankizumab solution for infusion (IV)
Risankizumab solution for injection (SC)
Reference Therapy:
Placebo for risankizumab 
Dose(s):
Placebo:  N/A
Mode of Administration:
Placebo solution for infusion (IV)
Placebo solution for injection (SC)
Duration of Treatment:  12 or 24 weeks.
The study will include a Screening period of 35 days and a double-blind induction period of 12 weeks.  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive risankizumab in 
Induction Period 2 over a subsequent 12 week period.  There will be a follow up call 140 days from the 
last dose of study drug to obtain information on any new or ongoing AEs for those subjects who do not 
roll over into Study M16-000 or discontinue from the study prematurely.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
147
Criteria for Evaluation:
Endpoint Definitions:
!
Clinical remission:  average daily SF ≤ 2.8 and not worse than Baseline AND average daily 
AP score ≤ 1 and not worse than Baseline
!
Enhanced clinical response:  ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in 
average daily AP score and both not worse than Baseline, and/or clinical remission
!
Clinical response:  ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in average daily 
AP score and both not worse than Baseline
!
Endoscopic response:  decrease in SES-CD > 50% from Baseline (or for subjects with isolated 
ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline), as scored 
by central reviewer
!
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD 
ulcerated surface subscore ≥ 1 at Baseline, as scored by a central reviewer.
!
Endoscopic remission:  SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no 
subscore greater than 1 in any individual variable, as scored by a central reviewer
!
CDAI clinical response:  reduction of CDAI ≥ 100 points from baseline
!
CDAI clinical remission:  CDAI < 150
Efficacy:
Co-Primary Endpoints:  
!
Proportion of subjects with clinical remission at Week 12 
!
Proportion of subjects with endoscopic response at Week 12
Ranked Secondary Endpoints (Risankizumab vs Placebo):
1.
Proportion of subjects with CDAI clinical remission at Week 12
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with clinical remission at Week 4 
4.
Proportion of subjects with CDAI clinical response at Week 12 
5.
Mean change from baseline of induction in FACIT fatigue at Week 12 
6.
Mean change from baseline of induction in IBDQ total score at Week 12 
7.
Proportion of subjects with enhanced clinical response and endoscopic response at Week 12 
8.
Proportion of subjects with endoscopic remission at Week 12
9.
Proportion of subjects with enhanced clinical response at Week 4
10. Proportion of subjects with ulcer-free endoscopy at Week 12
11. Enhanced clinical response at Week 12
12. Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at Week 12, in 
subjects with any EIMs at Baseline 
13. Proportion of subjects with CD-related hospitalization through Week 12
14. Proportion of subjects without draining fistulas at Week 12 in subjects with draining fistulas at 
Baseline
For further information, including non-ranked endpoints, refer to protocol.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
148
Criteria for Evaluation (Continued):
Pharmacokinetics:
Serum risankizumab concentrations will be determined from samples collected just prior to dosing at 
Weeks 4, 8, and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Immunogenicity:
Serum ADAs will be determined from samples collected just prior to dosing at Baseline and Weeks 4, 8, 
and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Safety:
Safety analyses will be performed on safety set which includes all subjects who receive at least one dose 
of study drug.  Incidence of adverse events (AEs), changes in vital signs, physical examination results, 
and clinical laboratory data will be assessed throughout the study.  
Exploratory Research Variables and Validation Studies (Optional):
Prognostic, surrogate, predictive and pharmacodynamics biomarkers signatures may be investigated.  
Samples for different applications, potentially including but not limited to pharmacogenetic, epigenetic, 
transcriptomic, proteomic, metabolomic, metagenomic, phenotypic, functional and targeted 
investigations will be collected at various time points.  Assessments may include but may not be limited 
to nucleic acids, proteins, metabolites, lipids, or peripheral blood mononuclear cells (PBMC).
Statistical Methods:
Efficacy:
The co-primary endpoints are the proportion of subjects with clinical remission at Week 12 and the 
proportion of subjects who achieve endoscopic response at Week 12.  A total of approximately 
579 subjects will be randomized into two risankizumab treatment groups and the placebo group in a 
1:1:1 ratio (193 subjects/arm).  When all patients complete their Week 12/PD visit, the database will be 
locked for the final analysis of 12-week induction period.  When all the patients who enter the induction 
Period 2 finish Week 24/PD visit, the database will be locked for the whole study and all the planned 
analysis for the induction Period 2 will be performed.
Sample size calculation is based on the larger sample size needed to detect treatment difference for each 
of the co-primary endpoints.  Since historical data show slightly lower event rate and similar treatment 
difference versus placebo for the endoscopic response rate than the clinical remission rate at Week 12, 
clinical remission rates at Week 12 are used for power calculation.  Assuming the Week 12 clinical 
remission rate will be 23.5% for risankizumab groups and 10% for the placebo group, a sample size of 
193 subjects for each risankizumab group and 193 subjects for the placebo group will have 
approximately 89% power to detect the treatment difference between risankizumab and placebo in 
clinical remission rates at Week 12 using a Fisher's exact test at alpha level of 0.025 (two-sided).
The comparisons between each risankizumab dose versus placebo for the primary efficacy variable will 
be performed using the Cochran-Mantel-Haenszel (CMH) test adjusted by the number of prior biologics 
failed (1, > 1) and Baseline steroid use (yes, no).
Both of the primary efficacy endpoints will be tested at statistically significant of 0.025 for each of the 
risankizumab dose group versus placebo to adjust for multiplicity.  A CMH based two-sided 95% 
confidence interval for the difference between treatment groups will be calculated.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
149
Statistical Methods (Continued):
Efficacy (Continued):
The intent-to-treat (ITT) set includes all randomized subjects who have taken at least one dose of study 
drug.  The primary population for efficacy analysis are the subjects in the intent-to-treat analysis set who 
had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal disease).  If the average daily SF or average 
daily AP score at Week 12 are missing, the non-responder imputation (NRI) approach will be applied.  
Subjects who discontinue prior to Week 12 for any reason will be considered as "not-achieved" for 
clinical remission and endoscopic response endpoints.
In general, continuous secondary efficacy variables will be analyzed using a Mixed-Effect Model 
Repeated Measure (MMRM) model including factors for treatment group, visit, visit by treatment 
interaction, and stratification variables, for the longitudinal continuous endpoints.  The MMRM analysis 
is considered primary for inferential purposes.  
Pharmacokinetics and Immunogenicity:
Serum risankizumab concentrations will be summarized at each time point for each dosing regimen 
using descriptive statistics.  Population pharmacokinetic analyses combining the data from this study and 
other studies may be performed.  Relationships between risankizumab exposures and efficacy and safety 
variables of interest may be explored.  
ADA incidence will be summarized by cohorts and study visits.  ADA titers will be tabulated for each 
subject at the respective study visits.  The effect of ADA on risankizumab pharmacokinetics, efficacy 
and/or safety variable(s) and/or any additional analyses will be explored.
Safety:
Adverse events, laboratory data and vital signs are the primary safety parameters in this study.  All 
safety comparisons will be performed between treatment groups using the safety set.  Treatment 
emergent AEs are defined as events that begin or worsen either on or after the first dose of the study 
drug and within 140 days after the last dose of the study drug for subjects who do not participate in 
Study M16-000 or until first dose of study drug in Study M16-000 if the subject is enrolled in 
Study M16-000.  
An overview of treatment-emergent AEs, AEs leading to death and AEs leading to premature 
discontinuation (see details in the statistical analysis plan [SAP]), AEs by Medical Dictionary for Drug 
Regulatory Activities (MedDRA version) preferred term and system organ class, AEs by maximum 
relationship to study drug, and AEs by maximum severity will be summarized by number and 
percentage.  
Changes in laboratory data will be described using statistical characteristics and compared 
between-treatment groups will be performed using a one-way Analysis of Variance (ANOVA).  In 
addition, shift tables and listings will be provided for abnormal values, whereby the normal range of the 
analyzing laboratory will be used.  Vital signs will be analyzed similarly.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
150
Has been changed to read:
AbbVie Inc.
Protocol Number:  M15-991
Name of Study Drug:  Risankizumab (ABBV-066)
Phase of Development:  3
Name of Active Ingredient:  Risankizumab
Date of Protocol Synopsis:  27 August 2020
Protocol Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to 
Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's 
Disease Who Failed Prior Biologic Treatment
Objectives:  The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab 
versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease 
(CD).
Investigators:  Multicenter
Study Sites:  Approximately 400 sites 
Study Population:  Males and females aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent 
according to local regulations at the Baseline visit, or aged 16 to < 18 years of age where locally 
permitted and who meet the definition of Tanner stage 5 development (refer to Appendix J), at the 
Baseline visit, with a diagnosis of moderately to severely active CD, defined as:
1.
average daily stool frequency (SF) ≥ 4 (when calculating SF, only the number of liquid or very soft 
stools should be recorded) and/or average daily abdominal pain (AP) score ≥ 2; plus 
2.
endoscopic evidence of mucosal inflammation measured by the Simple Endoscopic Score for CD 
(SES-CD).  All eligible scores exclude the presence of narrowing component and are confirmed by 
a central reader.  Endoscopic activity is defined as a SES-CD of ≥ 3.
The number of subjects enrolled with a SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or 
SES-CD of 3 for isolated ileal disease will be no more than 58 subjects.  Once cap of no more than 
58 subjects is reached, enrollment criterion will be an eligibility SES-CD of ≥ 6 for ileocolonic or 
colonic disease, or eligibility SES-CD of ≥ 4 for isolated ileal disease.
The study will enroll 100% of subjects who have had an inadequate response or intolerance to prior 
biologic therapy (bio-IR).  The bio-IR population is defined as subjects with documented intolerance or 
inadequate response to one or more of the approved biologic agents for CD (infliximab, adalimumab, 
certolizumab, natalizumab, ustekinumab and/or vedolizumab).  The percent of subjects with exposure, 
including intolerance or inadequate response to ustekinumab will be no more than 20%. 
Number of Subjects to be Enrolled:  Approximately 579 for the primary ITT population used for 
efficacy analysis; additionally, up to 58 subjects with lower SES-CD will be enrolled


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
151
Methodology:  
Study M15-991 is a randomized, double blind, placebo-controlled 12-week induction study.
Subjects (n = 579) will be randomized 1:1:1 to 1200 mg risankizumab or 600 mg risankizumab or 
placebo intravenous (IV) given at Baseline, Weeks 4, 8.  The randomization will be stratified by both the 
number of prior biologics failed (1, > 1), Baseline steroid use (yes, no), and Baseline SES-CD (original, 
alternative), where the stratum of "original" includes the patients with baseline SES-CD of ≥ 6 (or ≥ 4 
for subjects with isolated ileal disease), and the stratum of "alternative" includes the patients with 
baseline SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or SES-CD of 3 for isolated ileal 
disease.
Visits during the study will occur at Baseline and Weeks 4, 8, and 12/Premature Discontinuation (PD) to 
collect clinical and laboratory assessments of disease activity.  Subjects who do not achieve clinical 
response at Week 12 may be eligible for treatment with blinded risankizumab in Induction Period 2 with 
evaluation for clinical response at Week 24.
All subjects will be provided with a subject diary where they will record CD related symptoms 
throughout the study.  Subjects will also be dispensed a patient information card during Screening.  
Additionally, subjects will complete symptom, quality of life (QoL) and work productivity 
questionnaires throughout the study.  Clinical labs including, but not limited to, urinalysis, chemistry and 
hematology, high-sensitivity C-reactive protein (hs-CRP), serum risankizumab concentrations, and 
serum anti-drug antibody (ADA) levels will be collected throughout the study.  In addition, stool 
samples for calprotectin analysis will be collected and should be taken before starting bowel preparations 
for endoscopy.  All endoscopies will be evaluated using SES-CD and will be confirmed by a central 
reader.  Biopsy to confirm diagnosis (during Screening) or to rule out dysplasia/malignancy may be 
performed during the same time points as the endoscopy.  Optional exploratory research samples may be 
taken during the study.
At the Week 12/PD visit, all subjects will undergo an endoscopy for evaluation of mucosal 
inflammation.  It is expected that all subjects who remain in the study through at least Week 8 will have 
a Week 12/PD endoscopy.  All subjects achieving clinical response, defined as ≥ 30% decrease in 
average daily SF and/or ≥ 30% decrease in average daily AP score (both not worse than Baseline) at 
Week 12 may be eligible to enter Study M16-000.  Subjects are not eligible to enter Study M16-000 
until endoscopy has been completed (local reader results will be used for stratification for 
Study M16-000).  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive blinded 
treatment with risankizumab in Induction Period 2 as described below.  Subjects are not eligible to enter 
Induction Period 2 until Week 12 endoscopy has been completed.  


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
152
Methodology (Continued):
Induction Period 2
At Week 12, subjects who do not achieve clinical response will be randomized by Interactive Response 
Technologies (IRT) to Induction Period 2, a double-blind, double-dummy 12-week treatment period.
Subjects who received IV risankizumab induction treatment will be randomized 1:1:1 to:
!
Group 1:  1200 mg IV risankizumab
!
Group 2:  360 mg SC risankizumab
!
Group 3:  180 mg SC risankizumab
Subjects who received placebo induction treatment will receive:
!
Group 4:  1200 mg IV risankizumab
The IV risankizumab dose or matching IV placebo will be given at Weeks 12, 16, and 20; The SC 
risankizumab dose or matching SC placebo will be given at Weeks 12, and 20.
At Week 24, subjects who received treatment in Induction Period 2 will be reassessed and undergo a 
third endoscopy for evaluation of mucosal inflammation.  Subjects who achieve clinical response at 
Week 24 may be eligible to enter Study M16-000.  Subjects without clinical response at Week 24, as 
well as all subjects who terminate the study early (including subjects who are eligible for, but do not 
receive treatment during Induction Period 2) will be discontinued and have a follow-up call 140 days 
from the last dose of study drug to obtain information on any new or ongoing AEs.
Concomitant Aminosalicylates, Immunomodulators (Azathioprine [AZA], 6-Mercaptopurine 
[6-MP], Methotrexate [MTX]), and/or CD-Related Antibiotics
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at Baseline must 
continue these treatments for the duration of the study.  Initiating and/or increasing doses of 
aminosalicylates, immunomodulators, and/or CD-related antibiotics during the study is prohibited.  
Decreasing doses of aminosalicylates, immunomodulators, and/or CD-related antibiotics is prohibited 
during the study, except in the event of moderate-to-severe treatment related toxicities and after 
discussion with the AbbVie Therapeutic Area Medical Director (TA MD).  CD-related antibiotics may 
be discontinued in Induction Period 2 at the discretion of the Investigator.
Note:  the duration of the study includes Induction Period 2.
Concomitant Corticosteroids
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at the Baseline 
dose for the duration of the 12-week induction period.  Initiation and/or increasing doses of systemic 
and/or CD related corticosteroids during the entire study is prohibited.  Decreasing doses of 
corticosteroids is prohibited during the 12-week induction period, except in the event of moderate-to-
severe treatment related toxicities and after discussion with the AbbVie TA MD.
Subjects who enter Induction Period 2 will be allowed to taper their corticosteroids at the discretion of 
the Investigator.  Increasing doses above the Baseline dose is prohibited.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
153
Methodology (Continued):
Dose Selection
This study will evaluate two IV doses of risankizumab (600 mg and 1200 mg).  The selection of the 
doses in this study is informed by the analysis of the safety and efficacy data, as well as the 
exposure-response relationship of efficacy, of a Phase 2 study in subjects with CD that explored 200 mg 
and 600 mg doses.  The results from the Phase 2 study suggest a potential for increased benefit with 
1200 mg administration.
Induction Period 2 will evaluate IV (1200 mg Q4w) or SC (180 mg or 360 mg Q8w; maintenance dosing 
regimen) risankizumab.  The purpose of Induction Period 2 is to evaluate the efficacy and safety of re-
induction of risankizumab (1200 mg IV at Weeks 12, 16, and 20) versus starting maintenance dosing on 
clinical response status.  Data from the Phase 2 study in subjects with CD suggested that re-induction 
with 600 mg IV increased both clinical response and clinical remission in subjects with inadequate 
response at Week 12.  The selection of the SC doses is informed by the analysis of the safety and 
efficacy data, as well as the exposure-response relationship of efficacy, of the maintenance period during 
the Phase 2 study in subjects with CD that evaluated 180 mg SC risankizumab for maintenance.  The 
results from the Phase 2 study suggest a potential for increased benefit with 360 mg SC administration 
for maintenance regimen. 
Data Monitoring Committee (DMC)
An external independent DMC will review unblinded safety data on a cohort level, at a minimum of 
6-month intervals throughout the course of the study.  At the timing of this amendment, the DMC has 
provided recommendation that the study may continue without modification and allowed enrollment to 
begin for 16 – 17 year-olds.  A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be provided to 
the patients at Screening so that any such events once occurred will be reported immediately by the 
patients to the investigator.  
A separate DMC charter will be prepared outside of the protocol and will describe the roles and 
responsibilities of the DMC members, frequency and triggers of data reviews, and relevant safety data to 
be assessed.  The cardiac adjudication committee (CAC) and anaphylaxis adjudication committee (AAC) 
adjudicates blinded data and the DMC reviews the data in an unblinded manner.  Unblinded adjudicated 
cardio-cerebrovascular events and anaphylactic reactions will be presented to the DMC for review on a 
periodic basis.  Communications from the DMC to the Study Teams will not contain information that 
could potentially unblind the team to subject treatment assignments.
Diagnosis and Main Criteria for Inclusion/Exclusion:  
Main Inclusion:  
1.
Male or female aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent according to local 
regulations, at the Baseline visit.  Where locally permissible, subjects 16 to < 18 years of age who 
meet the definition of Tanner stage 5 for development (refer to Appendix I), at the Baseline Visit 
(sites will be notified when adolescents may enroll).
2.
Confirmed diagnosis of CD for at least 3 months prior to Baseline.  Appropriate documentation of 
biopsy results consistent with the diagnosis of CD, in the assessment of the Investigator, must be 
available.
3.
Crohn's disease activity index (CDAI) score 220 – 450 at Baseline.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
154
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Inclusion (Continued):  
4.
Endoscopic evidence of mucosal inflammation as documented by an SES-CD of ≥ 3.  All eligible 
scores exclude the presence of narrowing component and are confirmed by a central reader.  (Once 
cap of no more than 58 subjects is reached, enrollment criterion will be an SES-CD of ≥ 6 for 
ileocolonic or colonic disease or SES-CD of ≥ 4 for isolated ileal disease.)
5.
Average daily SF ≥ 4 and/or average daily AP score ≥ 2 at Baseline.
6.
Demonstrated intolerance or inadequate response to one or more of the following biologic agents:  
infliximab, adalimumab, certolizumab pegol, natalizumab, ustekinumab and/or vedolizumab:
!
Demonstration of intolerance requires no minimum dose or duration of use
!
Inadequate response to biologic agents defined as signs and symptoms of persistently (in the 
opinion of the Investigator) active disease despite a history of one or more of the following:
o
At least one 6-week induction regimen of infliximab (≥ 5 mg/kg IV at Weeks 0, 2, and 6),
o
At least one 4-week induction regimen of adalimumab (one 160 mg SC dose at Week 0, 
followed by one 80 mg SC dose at Week 2 [or one 80 mg SC dose at Week 0, followed 
by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]),
o
At least one 4-week induction regimen of certolizumab pegol (400 mg SC at Weeks 0, 2, 
and 4)
o
At least one 6-week induction regimen of vedolizumab (300 mg IV at Weeks 0, 2, and 6)
o
At least one 12-week induction regimen of natalizumab (300 mg IV every 4 weeks)
o
At least one 8-week induction regimen of ustekinumab [260 mg (≤ 55 kg) or 390 mg 
(> 55 to ≤ 85 kg) or 520 mg (> 85 kg) IV, followed by 90 mg SC at Week 8] (Once cap 
of no more than 20% ustekinumab exposed subjects is reached, subjects with prior 
ustekinumab exposure will not be allowed to enroll.)  
!
Recurrence of symptoms during scheduled maintenance dosing following prior clinical benefit 
of the above biologic agents
!
Note:  Subjects who discontinued biologic agents for reasons other than inadequate response as 
defined above or intolerance (e.g., change of insurance) are not eligible to enroll
7.
If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol Contraception 
Recommendations.  Females of childbearing potential must have a negative serum pregnancy test 
result during Screening, and a negative urine pregnancy at Baseline.  Females of non-childbearing 
potential (either postmenopausal or permanently surgically sterile as defined in Section 5.2.4) 
during Screening do not require pregnancy testing at Baseline. 
Note:  Subjects with borderline serum pregnancy test at Screening must have a serum pregnancy test 
≥ 3 days later to document continued lack of a positive result.
8.
Subjects must be able and willing to give written informed consent and to comply with the 
requirements of this study protocol.
Main Exclusion:  
1.
Subject with a current diagnosis of ulcerative colitis or indeterminate colitis.
Concomitant Medications and Treatments 
2.
Subject on CD-related antibiotics who has not been on stable doses for greater than, or discontinued 
within, 14 days prior to Baseline.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
155
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
3.
Subject on oral aminosalicylates who has not been on stable doses for greater than, or discontinued 
within, at least 14 days prior to Baseline.
4.
Subject taking oral corticosteroids:
!
Budesonide > 9 mg/day
!
Beclomethasone > 5 mg/day
!
Prednisone or equivalent > 20 mg/day
!
Or has not been on the current course for ≥ 14 days prior to Baseline and on a stable dose for 
≥7 days prior to Baseline
5.
Subject on immunomodulators (AZA, 6-MP, MTX) who:
!
Has not been on the current course for ≥ 42 days prior to Baseline, and
!
Has not been on a stable dose for ≥ 35 days prior to Baseline
Medications and Treatments During the Screening Period
6.
Subject who received IV anti-infectives within 35 days prior to Baseline visit or oral/intramuscular 
anti-infectives (non-CD-related) within 14 days prior to the Baseline visit.  This does not apply to 
TB prophylaxis.
7.
Subject who received exclusive enteral nutrition or any parenteral nutrition within 35 days prior to 
Baseline.
8.
Subject who received any live bacterial or viral vaccination within 30 days prior to Screening or 
during the Screening period.
9.
Subject who received cyclosporine, tacrolimus, or mycophenolate mofetil within 35 days prior to 
Baseline.
10. Subject who received fecal microbial transplantation within 35 days prior to Baseline.
Prior Medications and Treatments
11. Subject who received any biologic agent:
!
Approved biologics: infliximab, adalimumab, certolizumab, natalizumab, vedolizumab within 
8 weeks prior to Baseline, or ustekinumab within 12 weeks prior to Baseline 
Note:  If there is proper documentation of an undetectable drug level measured by a 
commercially available assay for any of the approved biologics above, there is no minimum 
washout prior to Baseline.
!
Any investigational biologic or other agent or procedure within 35 days or 5 half-lives prior to 
Baseline, whichever is longer.
12. Subject with prior exposure to p19 inhibitors (e.g., risankizumab).
13. Subject has been taking combination of two or more of the following oral budesonide, or oral 
beclomethasone and/or oral prednisone (or equivalent) simultaneously, with the exception of 
inhalers, within 14 days prior to Screening or during the Screening period.
14. Subject who received IV/intramuscular corticosteroids within 14 days prior to Screening or during 
the Screening period.
15. Subject who received therapeutic enema or suppository, other than required for endoscopy, within 
14 days prior to endoscopy used for Screening or during the Screening period.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
156
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
16. Subject who received apheresis (e.g., Adacolumn apheresis) ≤ 60 days prior to Screening or during 
the Screening period.
17. Subject who has concomitant cannabis use either recreational or for medical reasons within 14 days 
of Baseline or any history of clinically significant drug, or alcohol abuse in the last 12 months.
CD Related
18. Subject with currently known complications of CD such as:
!
abscess (abdominal or perianal),
!
symptomatic bowel strictures,
!
> 2 missing segments of the following 5 segments:  terminal ileum, right colon, transverse 
colon, sigmoid and left colon, and rectum
!
fulminant colitis,
!
toxic megacolon,
!
or any other manifestation that might require surgery while enrolled in the study.
19. Subject with ostomy or ileoanal pouch.
20. Subject diagnosed with short gut or short bowel syndrome.
21. Subject with surgical bowel resection within the past 3 months prior to Baseline, or a history of 
≥3 bowel resections.
Safety
22. Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study 
drugs or the ingredients of Chinese hamster ovary (CHO).
23. Subjects with the following chronic or active infections: 
!
Active, chronic, or recurrent infection that based on the Investigator's clinical assessment makes 
the subject unsuitable candidate for the study, 
!
Infection with C. difficile toxin or other intestinal pathogen during Screening,
!
Are infected with human immunodeficiency virus (HIV),
!
QuantiFERON®-TB test or Purified Protein Derivative (PPD) skin test, or both, according to 
local guidelines, will be performed during Screening.  QuantiFERON®-TB test is preferred for 
subjects who received BCG vaccination or were exposed to other Mycobacteria species.  
Subjects with a positive test result (or indeterminate results that have been repeated) may 
participate in the study if further work up (according to local practice/guidelines) establishes 
conclusively that the subject has no evidence of active tuberculosis.  Subjects with a history of 
active TB who have documented completion of a full course of anti-TB therapy may be allowed 
to enter the study after consultation with the AbbVie TA MD.  If latent TB is established, TB 
prophylaxis/treatment should be initiated and maintained according to local country guidelines.
!
Have active hepatitis B or hepatitis C defined as:
o
HBV:  hepatitis B surface antigen (HBs Ag) positive (+), or detected sensitivity on the 
HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for 
hepatitis B core antibody (HBc Ab) positive subjects
o
HCV:  HCV ribonucleic acid (RNA) detectable in any subject with positive anti-HCV 
antibody (HCV Ab)


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
157
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
24. Subject with a previous history of dysplasia of the gastrointestinal tract or found to have dysplasia, 
other than completely removed low-grade dysplastic lesions, in any biopsy performed during the 
Screening endoscopy.
25. Subject with a known history of lymphoproliferative disease, including lymphoma, or signs and 
symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or 
splenomegaly.
26. Subject with current or previous history of malignancy other than a successfully treated 
non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of 
the cervix.
27. Subject who has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, 
disorder or symptoms thereof.
28. Female subjects who is pregnant, breastfeeding, or is considering becoming pregnant during the 
study or for approximately 140 days after the last dose of study drug.
29. Subject who has any condition, including any physical, psychological, or psychiatric condition, 
which in the opinion of the Investigator, would compromise the safety of the subject or the quality 
of the data and renders the subject an unsuitable candidate for the study.
30. Screening laboratory and other analyses show any of the following abnormal results:
!
Aspartate transaminase (AST), alanine transaminase (ALT) > 2 × upper limit of the reference 
range;
!
White blood cell (WBC) count < 3.0 × 109/L;
!
Total bilirubin ≥ 2 mg/dL; except for subjects with isolated elevation of indirect bilirubin 
relating to Gilbert syndrome;
!
Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal 
Disease (MDRD) formula < 30 ml/min/1.73 m2. 
!
Hemoglobin < 8 g/dL
!
Platelets < 100,000/μL
!
Positive serum pregnancy test at the Screening visit or positive urine pregnancy test at the 
Baseline visit
Laboratory values can be re-tested once during the screening period after discussion and clearance 
with the TAMD.  If the re-tested lab value(s) remain(s) exclusionary, the subject will be considered 
a screen failure.  Redrawing samples if previous samples were unable to be analyzed would not 
count as a retest since previous result was never obtained.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
158
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
31. No known active COVID-19 infection.  Subject must not have signs/symptoms associated with 
COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and may only rescreen 
after they meet the following COVID-19 viral clearance criteria:
!
Symptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since recovery, defined as resolution of fever without 
use of antipyretics and improvement in respiratory symptoms (e.g., cough, shortness of breath)
!
Asymptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (Note: subjects who develop 
symptoms will follow guidance above for symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the above viral clearance 
criteria may be adjusted to account for epidemiological trends, updated information regarding 
infectivity and local/institutional guidelines.
Investigational Product:
Risankizumab
Dose(s):
Risankizumab 1200 mg IV Q4W*
Risankizumab 600 mg IV Q4W
Risankizumab 180 mg SC Q8W
Risankizumab 360 mg SC Q8W
*If administration of the 1200 mg dose is halted for any reason, 
enrollment may continue for subjects into the risankizumab 600 mg, or 
placebo arms at a 1:1 ratio.  The ratio of randomization and final sample 
size may be further updated in an amendment to the protocol.  Subjects 
already randomized to treatment arms, including Induction Period 2, 
will receive blinded 600 mg risankizumab IV.
Mode of Administration:
Risankizumab solution for infusion (IV)
Risankizumab solution for injection (SC)
Reference Therapy:
Placebo for risankizumab 
Dose(s):
Placebo:  N/A
Mode of Administration:
Placebo solution for infusion (IV)
Placebo solution for injection (SC)
Duration of Treatment:  12 or 24 weeks.
The study will include a Screening period of 35 days and a double-blind induction period of 12 weeks.  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive risankizumab in 
Induction Period 2 over a subsequent 12 week period.  There will be a follow up call 140 days from the 
last dose of study drug to obtain information on any new or ongoing AEs for those subjects who do not 
roll over into Study M16-000 or discontinue from the study prematurely.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
159
Criteria for Evaluation:
Endpoint Definitions:
!
Clinical remission:  average daily SF ≤ 2.8 and not worse than Baseline AND average daily 
AP score ≤ 1 and not worse than Baseline
!
Enhanced clinical response:  ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in 
average daily AP score and both not worse than Baseline, and/or clinical remission
!
Clinical response:  ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in average daily 
AP score and both not worse than Baseline
!
Endoscopic response:  decrease in SES-CD > 50% from Baseline (or for subjects with isolated 
ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline), as scored 
by central reviewer
!
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD 
ulcerated surface subscore ≥ 1 at Baseline, as scored by a central reviewer.
!
Endoscopic remission:  SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no 
subscore greater than 1 in any individual variable, as scored by a central reviewer
!
CDAI clinical response: reduction of CDAI ≥ 100 points from baseline
!
CDAI clinical remission: CDAI < 150
!
SF remission:  average daily SF ≤ 2.8 and not worse than baseline
!
AP remission:  average daily AP score ≤ 1 and not worse than baseline
Efficacy:
Co-Primary Endpoints:
!
Proportion of subjects with CDAI clinical remission at Week 12 
!
Proportion of subjects with endoscopic response at Week 12
Ranked Secondary Endpoints (Risankizumab vs Placebo):
1.
Proportion of subjects with clinical remission at Week 12
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with CDAI clinical response at Week 12
4.
Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-
fatigue) at Week 12
5.
Proportion of subjects with CDAI clinical remission at Week 4 
6.
Proportion of subjects with CDAI clinical response and endoscopic response at Week 12
7.
Proportion of subjects with SF remission at Week 12
8.
Proportion of subjects with AP remission at Week 12
9.
Proportion of subjects with endoscopic remission at Week 12
10. Proportion of subjects with enhanced clinical response at Week 4
11. Proportion of subjects with ulcer-free endoscopy at Week 12
12. Proportion of subjects with enhanced clinical response at Week 12
13. Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at Week 12, in 
subjects with any EIMs at Baseline
14. Proportion of subjects with CD-related hospitalization through Week 12


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
160
Criteria for Evaluation (Continued):
Efficacy (Continued):
Ranked Secondary Endpoints (Risankizumab vs Placebo) (Continued):
15. Proportion of subjects without draining fistulas at Week 12 in subjects with draining fistulas at 
Baseline
For further information, including non-ranked endpoints, refer to protocol.
Pharmacokinetics:
Serum risankizumab concentrations will be determined from samples collected just prior to dosing at 
Weeks 4, 8, and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Immunogenicity:
Serum ADAs will be determined from samples collected just prior to dosing at Baseline and Weeks 4, 8, 
and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Safety:
Safety analyses will be performed on safety set which includes all subjects who receive at least one dose 
of study drug.  Incidence of adverse events (AEs), changes in vital signs, physical examination results, 
and clinical laboratory data will be assessed throughout the study.  
Exploratory Research Variables and Validation Studies (Optional):
Prognostic, surrogate, predictive and pharmacodynamics biomarkers signatures may be investigated.  
Samples for different applications, potentially including but not limited to pharmacogenetic, epigenetic, 
transcriptomic, proteomic, metabolomic, metagenomic, phenotypic, functional and targeted 
investigations will be collected at various time points.  Assessments may include but may not be limited 
to nucleic acids, proteins, metabolites, lipids, or peripheral blood mononuclear cells (PBMC).
Statistical Methods:
Efficacy:
The co-primary endpoints are the proportion of subjects with CDAI clinical remission at Week 12 and 
the proportion of subjects who achieve endoscopic response at Week 12.  A total of approximately 
579 subjects will be randomized into two risankizumab treatment groups and the placebo group in a 
1:1:1 ratio (193 subjects/arm).  When all patients complete their Week 12/PD visit, the database will be 
locked for the final analysis of 12-week induction period.  When all the patients who enter the induction 
Period 2 finish Week 24/PD visit, the database will be locked for the whole study and all the planned 
analysis for the induction Period 2 will be performed.
Assuming the Week 12 CDAI clinical remission rate will be 34% for one of the risankizumab groups 
and 15% for the placebo group, a sample size of 193 subjects for each risankizumab group and 
193 subjects for the placebo group will have approximately 97% power to detect the treatment difference 
between risankizumab dose groups and placebo in CDAI clinical remission rates at Week 12 using 
Fisher's exact test at a 0.025 significant level (two sided).
The comparisons between each risankizumab dose versus placebo for the primary efficacy variable will 
be performed using the Cochran-Mantel-Haenszel (CMH) test adjusted by the number of prior biologics 
failed (1, > 1) and Baseline steroid use (yes, no).
Both of the primary efficacy endpoints will be tested at statistically significant of 0.025 for each of the 
risankizumab dose group versus placebo to adjust for multiplicity.  A CMH based two-sided 95% 
confidence interval for the difference between treatment groups will be calculated.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
161
Statistical Methods (Continued):
Efficacy (Continued):
The intent-to-treat (ITT) set includes all randomized subjects who have taken at least one dose of study 
drug.  The primary population for efficacy analysis are the subjects in the intent-to-treat analysis set who 
had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal disease).  Subjects who discontinue prior to 
Week 12 for any reason will be considered as "not-achieved" for CDAI clinical remission and 
endoscopic response endpoints.
In general, continuous secondary efficacy variables will be analyzed using a Mixed-Effect Model 
Repeated Measure (MMRM) model including factors for treatment group, visit, visit by treatment 
interaction, and stratification variables, for the longitudinal continuous endpoints.  The MMRM analysis 
is considered primary for inferential purposes.  
Pharmacokinetics and Immunogenicity:
Serum risankizumab concentrations will be summarized at each time point for each dosing regimen 
using descriptive statistics.  Population pharmacokinetic analyses combining the data from this study and 
other studies may be performed.  Relationships between risankizumab exposures and efficacy and safety 
variables of interest may be explored.  
ADA incidence will be summarized by cohorts and study visits.  ADA titers will be tabulated for each 
subject at the respective study visits.  The effect of ADA on risankizumab pharmacokinetics, efficacy 
and/or safety variable(s) and/or any additional analyses will be explored.
Safety:
Adverse events, laboratory data and vital signs are the primary safety parameters in this study.  All 
safety comparisons will be performed between treatment groups using the safety set.  Treatment 
emergent AEs are defined as events that begin or worsen either on or after the first dose of the study 
drug and within 140 days after the last dose of the study drug for subjects who do not participate in 
Study M16-000 or until first dose of study drug in Study M16-000 if the subject is enrolled in 
Study M16-000. 
An overview of treatment-emergent AEs, AEs leading to death and AEs leading to premature 
discontinuation (see details in the statistical analysis plan [SAP]), AEs by Medical Dictionary for Drug 
Regulatory Activities (MedDRA version) preferred term and system organ class, AEs by maximum 
relationship to study drug, and AEs by maximum severity will be summarized by number and 
percentage.  
Changes in laboratory data will be described using statistical characteristics and compared 
between-treatment groups will be performed using a one-way Analysis of Variance (ANOVA).  In 
addition, shift tables and listings will be provided for abnormal values, whereby the normal range of the 
analyzing laboratory will be used.  Vital signs will be analyzed similarly.
Section 3.2  Benefits and Risks
Last paragraph previously read:
Considering the coronavirus (COVID-19) pandemic, the benefit and risk to subjects 
participating in this study have been re-evaluated.  Based on the limited information to 
date, no additional risk to study participants is anticipated with the use of risankizumab.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
162
Has been changed to read:
In view of the COVID-19 pandemic, the benefit-risk profile of various 
immunomodulatory therapies on COVID-19 is being evaluated based on real world and 
clinical trial data.  At this time, the effects of risankizumab on the course of COVID-19 
are not well defined.
Section 5.2.1  Inclusion Criteria
Subsection Rationale for Inclusion Criteria
Previously read:
1 – 5
To select the adequate subject population with a disease status representative 
of the target population for evaluation
6
The impact of risankizumab on pregnancy and reproduction is unknown
7
In accordance with harmonized Good Clinical Practice (GCP)
Has been changed to read:
1 – 6
To select the adequate subject population with a disease status representative 
of the target population for evaluation
7
The impact of risankizumab on pregnancy and reproduction is unknown
8
In accordance with harmonized Good Clinical Practice (GCP)
Section 5.2.2  Exclusion Criteria
Subsection Rationale for Exclusion Criteria
Previously read:
1
To avoid medical conditions that may compromise the ability to 
identify subjects with the correct diagnosis or to interpret medical 
importance of clinical results
2 – 16
To avoid bias for the evaluation of efficacy and safety by 
concomitant use of other medications or treatments and to ensure 
the safety of the subject
17 – 20
To avoid complications of CD that may compromise the 
evaluations of efficacy and safety


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
163
21 – 30
To ensure the safety of the subject and/or others
Has been changed to read:
1
To avoid medical conditions that may compromise the ability to 
identify subjects with the correct diagnosis or to interpret medical 
importance of clinical results
2 – 16
To avoid bias for the evaluation of efficacy and safety by 
concomitant use of other medications or treatments and to ensure 
the safety of the subject
17 – 20
To avoid complications of CD that may compromise the 
evaluations of efficacy and safety
21 – 31
To ensure the safety of the subject and/or others
Section 5.3.3  Efficacy Variables
Subsection Endpoint Definitions:
Add:  new ninth and tenth bullet
●
SF remission:  average daily SF ≤ 2.8 and not worse than baseline
●
AP remission:  average daily AP score ≤ 1 and not worse than baseline
Section 5.3.3.1  Primary Variable
Subsection Co-Primary Endpoints:
First bullet previously read:
Proportion of subjects with clinical remission at Week 12
Has been changed to read:
Proportion of subjects with CDAI clinical remission at Week 12
Section 5.3.3.2  Secondary Variables
Subsection Ranked Secondary Endpoints:
Previously read:
1.
Proportion of subjects with CDAI remission at Week 12


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
164
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with clinical remission at Week 4 
4.
Proportion of subjects with CDAI clinical response at Week 12 
5.
Mean change from baseline of induction in FACIT fatigue at Week 12 
6.
Mean change from baseline of induction in IBDQ total score at Week 12 
7.
Proportion of subjects with enhanced clinical response and endoscopic response at 
Week 12 
8.
Proportion of subjects with endoscopic remission at Week 12
9.
Proportion of subjects with enhanced clinical response at Week 4 
10.
Proportion of subjects with ulcer-free endoscopy at Week 12
11.
Enhanced clinical response at Week 12
12.
Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at 
Week 12, in subjects with any EIMs at Baseline 
13.
Proportion of subjects with CD-related hospitalization through Week 12
14.
Proportion of subjects without draining fistulas at Week 12 in subjects with 
draining fistulas at Baseline
Has been changed to read:
1.
Proportion of subjects with clinical remission at Week 12
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with CDAI clinical response at Week 12
4.
Change from baseline of Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT fatigue) at Week 12 
5.
Proportion of subjects with CDAI clinical remission at Week 4 


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
165
6.
Proportion of subjects with CDAI clinical response and endoscopic response at 
Week 12
7.
Proportion of subjects with SF remission at Week 12
8.
Proportion of subjects with AP remission at Week 12
9.
Proportion of subjects with endoscopic remission at Week 12
10.
Proportion of subjects with enhanced clinical response at Week 4
11.
Proportion of subjects with ulcer-free endoscopy at Week 12
12.
Proportion of subjects with enhanced clinical response at Week 12
13.
Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at 
Week 12, in subjects with any EIMs at Baseline
14.
Proportion of subjects with CD-related hospitalization through Week 12
15.
Proportion of subjects without draining fistulas at Week 12 in subjects with 
draining fistulas at Baseline
Section 5.3.3.3  Other Endpoints
Subsection Non-Ranked Endpoints
Delete:  subsection title
Non-Ranked Endpoints
Section 5.3.3.3  Other Endpoints
Subsection Non-Ranked Endpoints
Delete:  third bullet
Change from Baseline individual IBDQ item under Bowel Symptom domain (for Q1, Q5, 
Q9, Q13, Q17, Q20, Q22, Q24, Q26, and Q29) over time


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
166
Section 5.3.3.3  Other Endpoints
Subsection Non-Ranked Endpoints
Eighth bullet previously read:
Change from Baseline in FACIT-Fatigue over time
Has been changed to read:
Change from Baseline in FACIT-Fatigue total score and individual item score over time
Section 5.3.3.3  Other Endpoints
Subsection Non-Ranked Endpoints
Add:  new last paragraph
Of note, over time will be measured at each study visit as specified in the study activity 
table.
Section 8.1.6.1  Primary Efficacy Variables
First paragraph previously read:
The co-primary endpoints are the proportion of subjects who achieve clinical remission at 
Week 12 and the proportion of subjects who achieve endoscopic response at Week 12.
Has been changed to read:
The co-primary endpoints are the proportion of subjects who achieve CDAI clinical 
remission at Week 12 and the proportion of subjects who achieve endoscopic response at 
Week 12.
Section 8.1.6.1  Primary Efficacy Variables
Last paragraph, first and second sentence previously read:
If average daily SF or average daily AP score or endoscopic data at Week 12 are missing, 
the NRI approach will be applied.  Subjects who discontinue prior to Week 12 for any 
reason will be considered as "not-achieved" for clinical remission and endoscopic 
response endpoints.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
167
Has been changed to read:
Subjects who discontinue prior to Week 12 for any reason will be considered as "not-
achieved" for CDAI clinical remission and endoscopic response endpoints.
Section 8.2  Determination of Sample Size
Previously read:
The co-primary endpoints are the proportion of subjects with clinical remission at 
Week 12 and the proportion of subjects who achieve endoscopic response at Week 12.  
Sample size calculation is based on the larger sample size needed to detect treatment 
difference for each of the co-primary endpoints.  Since historical data show slightly lower 
event rate and similar treatment difference versus placebo for the endoscopic response 
rate than the clinical remission rate at Week 12, clinical remission rates at Week 12 are 
used for power calculation.  A total of approximately 579 subjects will be randomized into 
2 risankizumab treatment groups and the placebo group in a 1:1:1 ratio with 193 subjects 
per treatment group).  The sample size for this study is based on the expected proportion 
of subjects who achieve clinical remission at Week 12 between risankizumab and placebo.  
Assuming the Week 12 clinical remission rate will be 23.5% for risankizumab groups and 
10% for the placebo group, a sample size of 193 subjects for each risankizumab group and 
193 subjects for the placebo group will have approximately 89% power to detect the 
treatment difference between risankizumab and placebo in clinical remission rates at 
Week 12 using a Fisher's exact test at alpha level of 0.025 (two-sided).  Assuming the 
Week 12 endoscopic response rate will be 17% for one of the risankizumab dose groups 
and 5% for the placebo group, this sample size will have 93% power to detect the 
treatment difference between the risankizumab dose groups and placebo in endoscopic 
response rates at Week 12 using a Fisher's exact test at alpha of 0.025 (two-sided).
Has been changed to read:
The co-primary endpoints are the proportion of subjects with CDAI clinical remission at 
Week 12 and the proportion of subjects who achieve endoscopic response at Week 12.


Risankizumab
M15-991 Protocol Amendment 7.01 (US Only)
EudraCT 2016-003190-17
168
A total of approximately 579 subjects will be randomized into 2 risankizumab treatment 
groups and the placebo group in a 1:1:1 ratio with 193 subjects per treatment group).  
Assuming the Week 12 CDAI clinical remission rate will be 34% for one of the 
risankizumab dose groups and 15% for the placebo group, a sample size of 193 subjects 
for each risankizumab dose group and 193 subjects for the placebo group will have 
approximately 97% power to detect the treatment difference between risankizumab dose 
groups and placebo in CDAI clinical remission rates at Week 12 using Fisher's exact test 
at a 0.025 significant level (two-sided).  Assuming the Week 12 endoscopic response rate 
will be 17% for one of the risankizumab  groups and 5% for the placebo group, this 
sample size will have 93% power to detect the treatment difference between  
risankizumab and placebo in endoscopic response rates at Week 12 using a Fisher's exact 
test at a 0.025 significant level (two-sided).


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
1
1.0
Title Page
Clinical Study Protocol M15-991
A Multicenter, Randomized, Double-Blind, 
Placebo-Controlled Induction Study to Assess the 
Efficacy and Safety of Risankizumab in Subjects 
with Moderately to Severely Active Crohn's Disease 
Who Failed Prior Biologic Treatment
Incorporating Administrative Change 1 and 
Amendments 1, 2, 3, 4, 5, 6, and 7
AbbVie Investigational
  Product:
Risankizumab
Date:
28 July 2020
Development Phase:
3
Study Design:
Randomized, Double-Blind, Placebo-Controlled Parallel Group Design
EudraCT Number:
2016-003190-17
Investigator(s):
Multicenter Study (Investigator information is on file at AbbVie)
*Sponsor:
Non-European Countries:
AbbVie
1 North Waukegan Road
North Chicago, IL 60064 USA
European Countries:
AbbVie Deutschland GmbH & Co KG
Knollstrasse 50
Ludwigshafen 67061
Germany
Sponsor/Emergency 
  Contact:
Pharmaceutical Development
1 North Waukegan Road
North Chicago, IL 60064 USA
Phone:
Mobile:
Fax:
Email:
* The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country are provided 
within the clinical trial agreement with the Investigator/Institution and in the Clinical Trial Application with the 
Competent Authority.
This study will be conducted in compliance with the protocol, Good Clinical Practice and all other applicable regulatory 
requirements, including the archiving of essential documents.
Confidential Information
No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
2
1.1
Protocol Amendment:  Summary of Changes
Previous Protocol Versions
Protocol 
Date
Original
17 February 2017
Amendment 1
29 March 2017
Amendment 2
05 July 2017
Amendment 3
29 September 2017
Amendment 4
09 July 2018
Amendment 5
22 February 2019
Amendment 6
19 December 2019
The purpose of this amendment is to:
●
Addition of language on the re-evaluation of the benefit and risk in light of the 
COVID-19 pandemic, to subject participating in the study in Section 3.2
Rationale:  To clarify the updated benefit-risk balance to participating 
subjects
●
Addition of exclusion criteria language in Section 5.2.2
Rationale:  To exclude subjects with active COVID-19 infection from 
enrollment into study
●
Addition of study procedure language in Section 5.3.1.1 and Section 9.2
Rationale:  To modify study visits/protocol-specific procedures impacted by 
changes in local regulations due to COVID-19 pandemic, as necessary to 
ensure the safety of subjects, including visit frequency, alternative methods of 
assessments, locations for data collection permitted by IRB/IEC
●
Addition of protocol language regarding site responsibility in Section 5.5.2.2
and Section 5.5.7
Rationale:  To align with study-related training materials and documented 
study processes regarding site responsibility for reporting temperature 
excursions and for drug accountability/destruction
●
Addition of adverse event language in Section 6.1.1.1


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
3
Rationale:  To align AbbVie approved COVID-19 infection adverse event data 
collection processes
●
Addition of protocol deviation language in Section 7.0
Rationale:  To clarify that deviations include deviations occurring due to 
COVID-19
●
Addition of language to address missing data due to COVID-19 in the 
statistical analysis plan in Section 8.1
Rationale:  To clarify that modifications to the analysis for missing data due 
to COVID-19 infection will be incorporated into the statistical analysis plan
●
Addition of protocol modification language regarding data monitoring during 
COVID-19 in Section 10.1
Rationale:  To clarify that due to the COVID-19 infection, remote source data 
verification will be allowed if necessary and permitted by the local regulatory 
authority, IRB/IEC, and the study site
●
Clarification of HIV results language throughout the protocol
Rationale:  To align with study-related training materials regarding the 
handling of subject HIV results during screening
●
Addition of event in Study Activities Table in Appendix C
Rationale:  The addition of COVID-19 testing during subject study screening 
period
An itemized list of all changes made to this protocol under this amendment can be found 
in Appendix J.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
4
1.2
Synopsis
AbbVie Inc.
Protocol Number:  M15-991
Name of Study Drug:  Risankizumab (ABBV-066)
Phase of Development:  3
Name of Active Ingredient:  Risankizumab
Date of Protocol Synopsis:  28 July 2020
Protocol Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to 
Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's 
Disease Who Failed Prior Biologic Treatment
Objectives:  The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab 
versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease 
(CD).
Investigators:  Multicenter
Study Sites:  Approximately 400 sites 
Study Population:  Males and females aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent 
according to local regulations at the Baseline visit, or aged 16 to < 18 years of age where locally 
permitted and who meet the definition of Tanner stage 5 development (refer to Appendix J), at the 
Baseline visit, with a diagnosis of moderately to severely active CD, defined as:
1.
average daily stool frequency (SF) ≥ 4 (when calculating SF, only the number of liquid or very soft 
stools should be recorded) and/or average daily abdominal pain (AP) score ≥ 2; plus 
2.
endoscopic evidence of mucosal inflammation measured by the Simple Endoscopic Score for CD 
(SES-CD).  All eligible scores exclude the presence of narrowing component and are confirmed by 
a central reader.  Endoscopic activity is defined as a SES-CD of ≥ 3.
The number of subjects enrolled with a SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or 
SES-CD of 3 for isolated ileal disease will be no more than 58 subjects.  Once cap of no more than 
58 subjects is reached, enrollment criterion will be an eligibility SES-CD of ≥ 6 for ileocolonic or 
colonic disease, or eligibility SES-CD of ≥ 4 for isolated ileal disease.
The study will enroll 100% of subjects who have had an inadequate response or intolerance to prior 
biologic therapy (bio-IR).  The bio-IR population is defined as subjects with documented intolerance or 
inadequate response to one or more of the approved biologic agents for CD (infliximab, adalimumab, 
certolizumab, natalizumab, ustekinumab and/or vedolizumab).  The percent of subjects with exposure, 
including intolerance or inadequate response to ustekinumab will be no more than 20%. 
Number of Subjects to be Enrolled:  Approximately 579 for the primary ITT population used for 
efficacy analysis; additionally, up to 58 subjects with lower SES-CD will be enrolled


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
5
Methodology:  
Study M15-991 is a randomized, double blind, placebo-controlled 12-week induction study.
Subjects (n = 579) will be randomized 1:1:1 to 1200 mg risankizumab or 600 mg risankizumab or 
placebo intravenous (IV) given at Baseline, Weeks 4, 8.  The randomization will be stratified by both the 
number of prior biologics failed (1, > 1), Baseline steroid use (yes, no), and Baseline SES-CD (original, 
alternative), where the stratum of "original" includes the patients with baseline SES-CD of ≥ 6 (or ≥ 4 
for subjects with isolated ileal disease), and the stratum of "alternative" includes the patients with 
baseline SES-CD of ≥ 3 to < 6 for ileocolonic or colonic disease or SES-CD of 3 for isolated ileal 
disease.
Visits during the study will occur at Baseline and Weeks 4, 8, and 12/Premature Discontinuation (PD) to 
collect clinical and laboratory assessments of disease activity.  Subjects who do not achieve clinical 
response at Week 12 may be eligible for treatment with blinded risankizumab in Induction Period 2 with 
evaluation for clinical response at Week 24.
All subjects will be provided with a subject diary where they will record CD related symptoms 
throughout the study.  Subjects will also be dispensed a patient information card during Screening.  
Additionally, subjects will complete symptom, quality of life (QoL) and work productivity 
questionnaires throughout the study.  Clinical labs including, but not limited to, urinalysis, chemistry and 
hematology, high-sensitivity C-reactive protein (hs-CRP), serum risankizumab concentrations, and 
serum anti-drug antibody (ADA) levels will be collected throughout the study.  In addition, stool 
samples for calprotectin analysis will be collected and should be taken before starting bowel preparations 
for endoscopy.  All endoscopies will be evaluated using SES-CD and will be confirmed by a central 
reader.  Biopsy to confirm diagnosis (during Screening) or to rule out dysplasia/malignancy may be 
performed during the same time points as the endoscopy.  Optional exploratory research samples may be 
taken during the study.
At the Week 12/PD visit, all subjects will undergo an endoscopy for evaluation of mucosal 
inflammation.  It is expected that all subjects who remain in the study through at least Week 8 will have 
a Week 12/PD endoscopy.  All subjects achieving clinical response, defined as ≥ 30% decrease in 
average daily SF and/or ≥ 30% decrease in average daily AP score (both not worse than Baseline) at 
Week 12 may be eligible to enter Study M16-000.  Subjects are not eligible to enter Study M16-000 
until endoscopy has been completed (local reader results will be used for stratification for 
Study M16-000).  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive blinded 
treatment with risankizumab in Induction Period 2 as described below.  Subjects are not eligible to enter 
Induction Period 2 until Week 12 endoscopy has been completed.  


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
6
Methodology (Continued):
Induction Period 2
At Week 12, subjects who do not achieve clinical response will be randomized by Interactive Response 
Technologies (IRT) to Induction Period 2, a double-blind, double-dummy 12-week treatment period.
Subjects who received IV risankizumab induction treatment will be randomized 1:1:1 to:
!
Group 1:  1200 mg IV risankizumab
!
Group 2:  360 mg SC risankizumab
!
Group 3:  180 mg SC risankizumab
Subjects who received placebo induction treatment will receive:
!
Group 4:  1200 mg IV risankizumab
The IV risankizumab dose or matching IV placebo will be given at Weeks 12, 16, and 20; The SC 
risankizumab dose or matching SC placebo will be given at Weeks 12, and 20.
At Week 24, subjects who received treatment in Induction Period 2 will be reassessed and undergo a 
third endoscopy for evaluation of mucosal inflammation.  Subjects who achieve clinical response at 
Week 24 may be eligible to enter Study M16-000.  Subjects without clinical response at Week 24, as 
well as all subjects who terminate the study early (including subjects who are eligible for, but do not 
receive treatment during Induction Period 2) will be discontinued and have a follow-up call 140 days 
from the last dose of study drug to obtain information on any new or ongoing AEs.
Concomitant Aminosalicylates, Immunomodulators (Azathioprine [AZA], 6-Mercaptopurine 
[6-MP], Methotrexate [MTX]), and/or CD-Related Antibiotics
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at Baseline must 
continue these treatments for the duration of the study.  Initiating and/or increasing doses of 
aminosalicylates, immunomodulators, and/or CD-related antibiotics during the study is prohibited.  
Decreasing doses of aminosalicylates, immunomodulators, and/or CD-related antibiotics is prohibited 
during the study, except in the event of moderate-to-severe treatment related toxicities and after 
discussion with the AbbVie Therapeutic Area Medical Director (TA MD).  CD-related antibiotics may 
be discontinued in Induction Period 2 at the discretion of the Investigator.
Note:  the duration of the study includes Induction Period 2.
Concomitant Corticosteroids
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at the Baseline 
dose for the duration of the 12-week induction period.  Initiation and/or increasing doses of systemic 
and/or CD related corticosteroids during the entire study is prohibited.  Decreasing doses of 
corticosteroids is prohibited during the 12-week induction period, except in the event of moderate-to-
severe treatment related toxicities and after discussion with the AbbVie TA MD.
Subjects who enter Induction Period 2 will be allowed to taper their corticosteroids at the discretion of 
the Investigator.  Increasing doses above the Baseline dose is prohibited.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
7
Methodology (Continued):
Dose Selection
This study will evaluate two IV doses of risankizumab (600 mg and 1200 mg).  The selection of the 
doses in this study is informed by the analysis of the safety and efficacy data, as well as the 
exposure-response relationship of efficacy, of a Phase 2 study in subjects with CD that explored 200 mg 
and 600 mg doses.  The results from the Phase 2 study suggest a potential for increased benefit with 
1200 mg administration.
Induction Period 2 will evaluate IV (1200 mg Q4w) or SC (180 mg or 360 mg Q8w; maintenance dosing 
regimen) risankizumab.  The purpose of Induction Period 2 is to evaluate the efficacy and safety of re-
induction of risankizumab (1200 mg IV at Weeks 12, 16, and 20) versus starting maintenance dosing on 
clinical response status.  Data from the Phase 2 study in subjects with CD suggested that re-induction 
with 600 mg IV increased both clinical response and clinical remission in subjects with inadequate 
response at Week 12.  The selection of the SC doses is informed by the analysis of the safety and 
efficacy data, as well as the exposure-response relationship of efficacy, of the maintenance period during 
the Phase 2 study in subjects with CD that evaluated 180 mg SC risankizumab for maintenance.  The 
results from the Phase 2 study suggest a potential for increased benefit with 360 mg SC administration 
for maintenance regimen. 
Data Monitoring Committee (DMC)
An external independent DMC will review unblinded safety data on a cohort level, at a minimum of
6-month intervals throughout the course of the study.  At the timing of this amendment, the DMC has 
provided recommendation that the study may continue without modification and allowed enrollment to 
begin for 16 – 17 year-olds.  A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be provided to 
the patients at Screening so that any such events once occurred will be reported immediately by the 
patients to the investigator.  
A separate DMC charter will be prepared outside of the protocol and will describe the roles and 
responsibilities of the DMC members, frequency and triggers of data reviews, and relevant safety data to 
be assessed.  The cardiac adjudication committee (CAC) and anaphylaxis adjudication committee (AAC) 
adjudicates blinded data and the DMC reviews the data in an unblinded manner.  Unblinded adjudicated 
cardio-cerebrovascular events and anaphylactic reactions will be presented to the DMC for review on a 
periodic basis.  Communications from the DMC to the Study Teams will not contain information that 
could potentially unblind the team to subject treatment assignments.
Diagnosis and Main Criteria for Inclusion/Exclusion:  
Main Inclusion:  
1.
Male or female aged ≥ 18 to ≤ 80 years of age, or minimum age of adult consent according to local 
regulations, at the Baseline visit.  Where locally permissible, subjects 16 to < 18 years of age who 
meet the definition of Tanner stage 5 for development (refer to Appendix I), at the Baseline Visit 
(sites will be notified when adolescents may enroll).
2.
Confirmed diagnosis of CD for at least 3 months prior to Baseline.  Appropriate documentation of 
biopsy results consistent with the diagnosis of CD, in the assessment of the Investigator, must be 
available.
3.
Crohn's disease activity index (CDAI) score 220 – 450 at Baseline.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
8
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Inclusion (Continued):  
4.
Endoscopic evidence of mucosal inflammation as documented by an SES-CD of ≥ 3.  All eligible 
scores exclude the presence of narrowing component and are confirmed by a central reader.  (Once 
cap of no more than 58 subjects is reached, enrollment criterion will be an SES-CD of ≥ 6 for 
ileocolonic or colonic disease or SES-CD of ≥ 4 for isolated ileal disease.)
5.
Average daily SF ≥ 4 and/or average daily AP score ≥ 2 at Baseline.
6.
Demonstrated intolerance or inadequate response to one or more of the following biologic agents: 
infliximab, adalimumab, certolizumab pegol, natalizumab, ustekinumab and/or vedolizumab:
!
Demonstration of intolerance requires no minimum dose or duration of use
!
Inadequate response to biologic agents defined as signs and symptoms of persistently (in the 
opinion of the Investigator) active disease despite a history of one or more of the following:
o
At least one 6-week induction regimen of infliximab (≥ 5 mg/kg IV at Weeks 0, 2, and 6),
o
At least one 4-week induction regimen of adalimumab (one 160 mg SC dose at Week 0, 
followed by one 80 mg SC dose at Week 2 [or one 80 mg SC dose at Week 0, followed 
by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]),
o
At least one 4-week induction regimen of certolizumab pegol (400 mg SC at Weeks 0, 2, 
and 4)
o
At least one 6-week induction regimen of vedolizumab (300 mg IV at Weeks 0, 2, and 6)
o
At least one 12-week induction regimen of natalizumab (300 mg IV every 4 weeks)
o
At least one 8-week induction regimen of ustekinumab [260 mg (≤ 55 kg) or 390 mg 
(> 55 to ≤ 85 kg) or 520 mg (> 85 kg) IV, followed by 90 mg SC at Week 8] (Once cap 
of no more than 20% ustekinumab exposed subjects is reached, subjects with prior 
ustekinumab exposure will not be allowed to enroll.)  
!
Recurrence of symptoms during scheduled maintenance dosing following prior clinical benefit 
of the above biologic agents
!
Note:  Subjects who discontinued biologic agents for reasons other than inadequate response as 
defined above or intolerance (e.g., change of insurance) are not eligible to enroll
7.
If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol Contraception 
Recommendations.  Females of childbearing potential must have a negative serum pregnancy test 
result during Screening, and a negative urine pregnancy at Baseline.  Females of non-childbearing 
potential (either postmenopausal or permanently surgically sterile as defined in Section 5.2.4) 
during Screening do not require pregnancy testing at Baseline. 
Note:  Subjects with borderline serum pregnancy test at Screening must have a serum pregnancy test 
≥ 3 days later to document continued lack of a positive result.
8.
Subjects must be able and willing to give written informed consent and to comply with the 
requirements of this study protocol.
Main Exclusion:  
1.
Subject with a current diagnosis of ulcerative colitis or indeterminate colitis.
Concomitant Medications and Treatments 
2.
Subject on CD-related antibiotics who has not been on stable doses for greater than, or discontinued 
within, 14 days prior to Baseline.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
9
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
3.
Subject on oral aminosalicylates who has not been on stable doses for greater than, or discontinued 
within, at least 14 days prior to Baseline.
4.
Subject taking oral corticosteroids:
!
Budesonide > 9 mg/day
!
Beclomethasone > 5 mg/day
!
Prednisone or equivalent > 20 mg/day
!
Or has not been on the current course for ≥ 14 days prior to Baseline and on a stable dose for 
≥7 days prior to Baseline
5.
Subject on immunomodulators (AZA, 6-MP, MTX) who:
!
Has not been on the current course for ≥ 42 days prior to Baseline, and
!
Has not been on a stable dose for ≥ 35 days prior to Baseline
Medications and Treatments During the Screening Period
6.
Subject who received IV anti-infectives within 35 days prior to Baseline visit or oral/intramuscular 
anti-infectives (non-CD-related) within 14 days prior to the Baseline visit.  This does not apply to 
TB prophylaxis.
7.
Subject who received exclusive enteral nutrition or any parenteral nutrition within 35 days prior to 
Baseline.
8.
Subject who received any live bacterial or viral vaccination within 30 days prior to Screening or 
during the Screening period.
9.
Subject who received cyclosporine, tacrolimus, or mycophenolate mofetil within 35 days prior to 
Baseline.
10. Subject who received fecal microbial transplantation within 35 days prior to Baseline.
Prior Medications and Treatments
11. Subject who received any biologic agent:
!
Approved biologics: infliximab, adalimumab, certolizumab, natalizumab, vedolizumab within 
8 weeks prior to Baseline, or ustekinumab within 12 weeks prior to Baseline 
Note:  If there is proper documentation of an undetectable drug level measured by a 
commercially available assay for any of the approved biologics above, there is no minimum 
washout prior to Baseline.
!
Any investigational biologic or other agent or procedure within 35 days or 5 half-lives prior to 
Baseline, whichever is longer.
12. Subject with prior exposure to p19 inhibitors (e.g., risankizumab).
13. Subject has been taking combination of two or more of the following oral budesonide, or oral 
beclomethasone and/or oral prednisone (or equivalent) simultaneously, with the exception of 
inhalers, within 14 days prior to Screening or during the Screening period.
14. Subject who received IV/intramuscular corticosteroids within 14 days prior to Screening or during 
the Screening period.
15. Subject who received therapeutic enema or suppository, other than required for endoscopy, within 
14 days prior to endoscopy used for Screening or during the Screening period.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
10
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
16. Subject who received apheresis (e.g., Adacolumn apheresis) ≤ 60 days prior to Screening or during 
the Screening period.
17. Subject who has concomitant cannabis use either recreational or for medical reasons within 14 days 
of Baseline or any history of clinically significant drug, or alcohol abuse in the last 12 months.
CD Related
18. Subject with currently known complications of CD such as:
!
abscess (abdominal or perianal),
!
symptomatic bowel strictures,
!
> 2 missing segments of the following 5 segments:  terminal ileum, right colon, transverse 
colon, sigmoid and left colon, and rectum
!
fulminant colitis,
!
toxic megacolon,
!
or any other manifestation that might require surgery while enrolled in the study.
19. Subject with ostomy or ileoanal pouch.
20. Subject diagnosed with short gut or short bowel syndrome.
21. Subject with surgical bowel resection within the past 3 months prior to Baseline, or a history of 
≥3 bowel resections.
Safety
22. Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study 
drugs or the ingredients of Chinese hamster ovary (CHO).
23. Subjects with the following chronic or active infections: 
!
Active, chronic, or recurrent infection that based on the Investigator's clinical assessment makes 
the subject unsuitable candidate for the study, 
!
Infection with C. difficile toxin or other intestinal pathogen during Screening,
!
Are infected with human immunodeficiency virus (HIV),
!
QuantiFERON®-TB test or Purified Protein Derivative (PPD) skin test, or both, according to 
local guidelines, will be performed during Screening.  QuantiFERON®-TB test is preferred for 
subjects who received BCG vaccination or were exposed to other Mycobacteria species.  
Subjects with a positive test result (or indeterminate results that have been repeated) may 
participate in the study if further work up (according to local practice/guidelines) establishes 
conclusively that the subject has no evidence of active tuberculosis.  Subjects with a history of 
active TB who have documented completion of a full course of anti-TB therapy may be allowed 
to enter the study after consultation with the AbbVie TA MD.  If latent TB is established, TB 
prophylaxis/treatment should be initiated and maintained according to local country guidelines.
!
Have active hepatitis B or hepatitis C defined as:
o
HBV:  hepatitis B surface antigen (HBs Ag) positive (+), or detected sensitivity on the 
HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for 
hepatitis B core antibody (HBc Ab) positive subjects
o
HCV:  HCV ribonucleic acid (RNA) detectable in any subject with positive anti-HCV 
antibody (HCV Ab)


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
11
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):  
Main Exclusion (Continued):
24. Subject with a previous history of dysplasia of the gastrointestinal tract or found to have dysplasia, 
other than completely removed low-grade dysplastic lesions, in any biopsy performed during the 
Screening endoscopy.
25. Subject with a known history of lymphoproliferative disease, including lymphoma, or signs and 
symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or 
splenomegaly.
26. Subject with current or previous history of malignancy other than a successfully treated
non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of 
the cervix.
27. Subject who has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, 
disorder or symptoms thereof.
28. Female subjects who is pregnant, breastfeeding, or is considering becoming pregnant during the 
study or for approximately 140 days after the last dose of study drug.
29. Subject who has any condition, including any physical, psychological, or psychiatric condition, 
which in the opinion of the Investigator, would compromise the safety of the subject or the quality 
of the data and renders the subject an unsuitable candidate for the study.
30. Screening laboratory and other analyses show any of the following abnormal results:
!
Aspartate transaminase (AST), alanine transaminase (ALT) > 2 × upper limit of the reference 
range;
!
White blood cell (WBC) count < 3.0 × 109/L;
!
Total bilirubin ≥ 2 mg/dL; except for subjects with isolated elevation of indirect bilirubin 
relating to Gilbert syndrome;
!
Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal 
Disease (MDRD) formula < 30 ml/min/1.73 m2. 
!
Hemoglobin < 8 g/dL
!
Platelets < 100,000/μL
!
Positive serum pregnancy test at the Screening visit or positive urine pregnancy test at the 
Baseline visit
Laboratory values can be re-tested once during the screening period after discussion and clearance 
with the TAMD.  If the re-tested lab value(s) remain(s) exclusionary, the subject will be considered 
a screen failure.  Redrawing samples if previous samples were unable to be analyzed would not 
count as a retest since previous result was never obtained.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
12
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
31. No known active COVID-19 infection.  Subject must not have signs/symptoms associated with 
COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and may only rescreen 
after they meet the following COVID-19 viral clearance criteria:
!
Symptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since recovery, defined as resolution of fever without 
use of antipyretics and improvement in respiratory symptoms (e.g., cough, shortness of breath)
!
Asymptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (Note: subjects who develop 
symptoms will follow guidance above for symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the above viral clearance 
criteria may be adjusted to account for epidemiological trends, updated information regarding 
infectivity and local/institutional guidelines.
Investigational Product:
Risankizumab
Dose(s):
Risankizumab 1200 mg IV Q4W*
Risankizumab 600 mg IV Q4W
Risankizumab 180 mg SC Q8W
Risankizumab 360 mg SC Q8W
*If administration of the 1200 mg dose is halted for any reason, 
enrollment may continue for subjects into the risankizumab 600 mg, or 
placebo arms at a 1:1 ratio.  The ratio of randomization and final sample 
size may be further updated in an amendment to the protocol.  Subjects 
already randomized to treatment arms, including Induction Period 2, 
will receive blinded 600 mg risankizumab IV.
Mode of Administration:
Risankizumab solution for infusion (IV)
Risankizumab solution for injection (SC)
Reference Therapy:
Placebo for risankizumab 
Dose(s):
Placebo:  N/A
Mode of Administration:
Placebo solution for infusion (IV)
Placebo solution for injection (SC)
Duration of Treatment:  12 or 24 weeks.
The study will include a Screening period of 35 days and a double-blind induction period of 12 weeks.  
All subjects who do not achieve clinical response at Week 12 may be eligible to receive risankizumab in 
Induction Period 2 over a subsequent 12 week period.  There will be a follow up call 140 days from the 
last dose of study drug to obtain information on any new or ongoing AEs for those subjects who do not 
roll over into Study M16-000 or discontinue from the study prematurely.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
13
Criteria for Evaluation:
Endpoint Definitions:
!
Clinical remission:  average daily SF ≤ 2.8 and not worse than Baseline AND average daily 
AP score ≤ 1 and not worse than Baseline
!
Enhanced clinical response:  ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in 
average daily AP score and both not worse than Baseline, and/or clinical remission
!
Clinical response:  ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in average daily 
AP score and both not worse than Baseline
!
Endoscopic response:  decrease in SES-CD > 50% from Baseline (or for subjects with isolated 
ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline), as scored 
by central reviewer
!
Ulcer-free endoscopy:  SES-CD ulcerated surface subscore of 0 in subjects with SES-CD 
ulcerated surface subscore ≥ 1 at Baseline, as scored by a central reviewer.
!
Endoscopic remission:  SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no 
subscore greater than 1 in any individual variable, as scored by a central reviewer
!
CDAI clinical response: reduction of CDAI ≥ 100 points from baseline
!
CDAI clinical remission: CDAI < 150
Efficacy:
Co-Primary Endpoints:  
!
Proportion of subjects with clinical remission at Week 12 
!
Proportion of subjects with endoscopic response at Week 12
Ranked Secondary Endpoints (Risankizumab vs Placebo):
1.
Proportion of subjects with CDAI clinical remission at Week 12
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with clinical remission at Week 4 
4.
Proportion of subjects with CDAI clinical response at Week 12 
5.
Mean change from baseline of induction in FACIT fatigue at Week 12 
6.
Mean change from baseline of induction in IBDQ total score at Week 12 
7.
Proportion of subjects with enhanced clinical response and endoscopic response at Week 12 
8.
Proportion of subjects with endoscopic remission at Week 12
9.
Proportion of subjects with enhanced clinical response at Week 4
10. Proportion of subjects with ulcer-free endoscopy at Week 12
11. Enhanced clinical response at Week 12
12. Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at Week 12, in 
subjects with any EIMs at Baseline 
13. Proportion of subjects with CD-related hospitalization through Week 12
14. Proportion of subjects without draining fistulas at Week 12 in subjects with draining fistulas at 
Baseline
For further information, including non-ranked endpoints, refer to protocol.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
14
Criteria for Evaluation (Continued):
Pharmacokinetics:
Serum risankizumab concentrations will be determined from samples collected just prior to dosing at 
Weeks 4, 8, and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Immunogenicity:
Serum ADAs will be determined from samples collected just prior to dosing at Baseline and Weeks 4, 8, 
and 12/PD, and at Week 24 for subjects who enter Induction Period 2.
Safety:
Safety analyses will be performed on safety set which includes all subjects who receive at least one dose 
of study drug.  Incidence of adverse events (AEs), changes in vital signs, physical examination results, 
and clinical laboratory data will be assessed throughout the study.  
Exploratory Research Variables and Validation Studies (Optional):
Prognostic, surrogate, predictive and pharmacodynamics biomarkers signatures may be investigated.  
Samples for different applications, potentially including but not limited to pharmacogenetic, epigenetic, 
transcriptomic, proteomic, metabolomic, metagenomic, phenotypic, functional and targeted 
investigations will be collected at various time points.  Assessments may include but may not be limited 
to nucleic acids, proteins, metabolites, lipids, or peripheral blood mononuclear cells (PBMC).
Statistical Methods:
Efficacy:
The co-primary endpoints are the proportion of subjects with clinical remission at Week 12 and the 
proportion of subjects who achieve endoscopic response at Week 12.  A total of approximately 
579 subjects will be randomized into two risankizumab treatment groups and the placebo group in a 
1:1:1 ratio (193 subjects/arm).  When all patients complete their Week 12/PD visit, the database will be 
locked for the final analysis of 12-week induction period.  When all the patients who enter the induction 
Period 2 finish Week 24/PD visit, the database will be locked for the whole study and all the planned 
analysis for the induction Period 2 will be performed.
Sample size calculation is based on the larger sample size needed to detect treatment difference for each 
of the co-primary endpoints.  Since historical data show slightly lower event rate and similar treatment 
difference versus placebo for the endoscopic response rate than the clinical remission rate at Week 12, 
clinical remission rates at Week 12 are used for power calculation.  Assuming the Week 12 clinical 
remission rate will be 23.5% for risankizumab groups and 10% for the placebo group, a sample size of 
193 subjects for each risankizumab group and 193 subjects for the placebo group will have 
approximately 89% power to detect the treatment difference between risankizumab and placebo in 
clinical remission rates at Week 12 using a Fisher's exact test at alpha level of 0.025 (two-sided).
The comparisons between each risankizumab dose versus placebo for the primary efficacy variable will 
be performed using the Cochran-Mantel-Haenszel (CMH) test adjusted by the number of prior biologics 
failed (1, > 1) and Baseline steroid use (yes, no).
Both of the primary efficacy endpoints will be tested at statistically significant of 0.025 for each of the 
risankizumab dose group versus placebo to adjust for multiplicity.  A CMH based two-sided 95%
confidence interval for the difference between treatment groups will be calculated.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
15
Statistical Methods (Continued):
Efficacy (Continued):
The intent-to-treat (ITT) set includes all randomized subjects who have taken at least one dose of study 
drug.  The primary population for efficacy analysis are the subjects in the intent-to-treat analysis set who 
had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal disease).  If the average daily SF or average 
daily AP score at Week 12 are missing, the non-responder imputation (NRI) approach will be applied.  
Subjects who discontinue prior to Week 12 for any reason will be considered as "not-achieved" for 
clinical remission and endoscopic response endpoints.
In general, continuous secondary efficacy variables will be analyzed using a Mixed-Effect Model 
Repeated Measure (MMRM) model including factors for treatment group, visit, visit by treatment 
interaction, and stratification variables, for the longitudinal continuous endpoints.  The MMRM analysis 
is considered primary for inferential purposes.  
Pharmacokinetics and Immunogenicity:
Serum risankizumab concentrations will be summarized at each time point for each dosing regimen 
using descriptive statistics.  Population pharmacokinetic analyses combining the data from this study and 
other studies may be performed.  Relationships between risankizumab exposures and efficacy and safety 
variables of interest may be explored.  
ADA incidence will be summarized by cohorts and study visits.  ADA titers will be tabulated for each 
subject at the respective study visits.  The effect of ADA on risankizumab pharmacokinetics, efficacy 
and/or safety variable(s) and/or any additional analyses will be explored.
Safety:
Adverse events, laboratory data and vital signs are the primary safety parameters in this study.  All 
safety comparisons will be performed between treatment groups using the safety set.  Treatment 
emergent AEs are defined as events that begin or worsen either on or after the first dose of the study 
drug and within 140 days after the last dose of the study drug for subjects who do not participate in 
Study M16-000 or until first dose of study drug in Study M16-000 if the subject is enrolled in 
Study M16-000.  
An overview of treatment-emergent AEs, AEs leading to death and AEs leading to premature 
discontinuation (see details in the statistical analysis plan [SAP]), AEs by Medical Dictionary for Drug 
Regulatory Activities (MedDRA version) preferred term and system organ class, AEs by maximum 
relationship to study drug, and AEs by maximum severity will be summarized by number and 
percentage.  
Changes in laboratory data will be described using statistical characteristics and compared 
between-treatment groups will be performed using a one-way Analysis of Variance (ANOVA).  In 
addition, shift tables and listings will be provided for abnormal values, whereby the normal range of the 
analyzing laboratory will be used.  Vital signs will be analyzed similarly.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
16
1.3
List of Abbreviations and Definition of Terms
Abbreviations
6-MP
6-Mercaptopurine
AAC
Anaphylaxis adjudication committee
ADA
Anti-Drug Antibody
AE
Adverse event 
ALT
Alanine transaminase 
ANCOVA
Analysis of Covariance
ANOVA
Analysis of Variance
AP
Abdominal Pain
AST
Aspartate transaminase 
ATEMS
AbbVie Temperature Excursion Management System
AZA
Azathioprine
BCG
Bacillus Calmette-Guérin 
BUN
Blood urea nitrogen 
CAC
Cardiac Adjudication Committee
CD
Crohn's disease 
CDAI
Crohn's disease activity index
CHO
Chinese Hamster Ovary
CMH
Cochran-Mantel-Haenszel
COVID-19
Coronavirus Disease 2019
CRA
Clinical Research Associate
CSS
Crohn's Symptom Severity
CTCAE
Common Terminology Criteria for Adverse Events
CXR
Chest x-ray 
DILI
Drug-induced Liver Injury
DMC
Data Monitoring Committee
DNA
Deoxyribonucleic acid 
ECG
Electrocardiogram 
eCRF
Electronic Case Report Form
EDC
Electronic Data Capture
EIM
Extra-Intestinal Manifestations
ePRO
Electronic Patient Reported Outcome


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
17
EQ-5D-5L
European Quality of Life 5 Dimensions
FACIT-F
Functional Assessment of Chronic Illness Therapy-Fatigue
FCP
Fecal Calprotectin
FDA
Food and Drug Administration 
FSH
Follicle-Stimulating Hormone
GCP
Good Clinical Practice 
HBV
Hepatitis B virus
HBc Ab
Hepatitis B core antibody
Hbs Ab
Hepatitis B surface antibody
Hbs Ag
Hepatitis B surface antigen 
HCV
Hepatitis C virus
HCV Ab
Hepatitis C virus antibody
HCT
Hematocrit
HIV
Human immunodeficiency virus
hs-CRP
High-sensitivity C-Reactive Protein
IBDQ
Inflammatory Bowel Disease Questionnaire 
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
IGRA
Interferon-Gamma Release Assay
IL
Interleukin 
IM
Intramuscular
INR
International Normalized Ratio
IR
Inadequate response
IRB
Institutional Review Board 
IRT
Interactive Response Technologies
ITT
Intent-to-treat
IUD
Intrauterine device
IUS
Intrauterine hormone-releasing system
IV
Intravenous
MACE
Major Adverse Cardiovascular Events
MDRD
Modification of Diet in Renal Disease
MedDRA
Medical Dictionary for Drug Regulatory Activities
MI
Multiple Imputation
MMR
Measles Mumps-Rubella


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
18
MMRM
Mixed-Effect Model Repeated Measure
MMRV
Measles Mumps-Rubella Varicella
MTX
Methotrexate 
nAb
Neutralizing antibodies
NRI
Non-responder imputation
N/A
Not Applicable
OC
Observed Case
OL
Open-Label
OPV
Oral Polio Vaccine
PBMC
Peripheral blood mononuclear cell
PCR
Polymerase Chain Reaction
PD
Premature Discontinuation
PGIC
Patient Global Impression of Change
PGIS
Patient Global Impression of Severity
PK
Pharmacokinetics
PMM
Pattern Mixture Model
POR
Proof of Receipt 
PPD
Purified protein derivative 
QoL
Quality of Life
Q4w
Every 4 Weeks
Q8w
Every 8 Weeks
RBC
Red blood cell 
RNA
Ribonucleic Acid
RSI
Reference safety information
SAE
Serious adverse event 
SAP
Statistical Analysis Plan
SC
Subcutaneous 
SES-CD
Simple Endoscopic Score for Crohn's disease
SF
Stool Frequency
SF-36 
36-Item Short Form Health Survey
SUSAR
Suspected Unexpected Serious Adverse Reactions
TA MD
Therapeutic Area Medical Director
TB
Tuberculosis 
TNF
Tumor Necrosis Factor 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
19
ULN
Upper Limit of Normal
WBC
White blood cell
WOCBP
Women of Childbearing Potential
WPAI-CD
Work Productivity and Impairment Questionnaire – Crohn's disease


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
20
2.0
Table of Contents
1.0
Title Page..................................................................................1
1.1
Protocol Amendment:  Summary of Changes ...........................................2
1.2
Synopsis .....................................................................................................4
1.3
List of Abbreviations and Definition of Terms........................................16
2.0
Table of Contents...................................................................20
3.0
Introduction ...........................................................................25
3.1
Differences Statement..............................................................................26
3.2
Benefits and Risks....................................................................................26
4.0
Study Objective......................................................................29
5.0
Investigational Plan...............................................................29
5.1
Overall Study Design and Plan:  Description ..........................................29
5.2
Selection of Study Population..................................................................37
5.2.1
Inclusion Criteria .....................................................................................38
5.2.2
Exclusion Criteria ....................................................................................40
5.2.3
Prior and Concomitant Therapy...............................................................46
5.2.3.1
Prior Therapy ...........................................................................................46
5.2.3.2
Concomitant Therapy...............................................................................46
5.2.3.3
Prohibited Therapy...................................................................................48
5.2.4
Contraception Recommendations ............................................................49
5.3
Efficacy, Pharmacokinetic, Pharmacodynamic, Optional 
Exploratory Research/Validation Studies and Safety 
Assessments/Variables.............................................................................50
5.3.1
Efficacy and Safety Measurements Assessed and Flow Chart ................50
5.3.1.1
Study Procedures .....................................................................................50
5.3.1.2
Collection and Handling of Optional Exploratory 
Research/Validation Studies Samples......................................................67
5.3.2
Drug Concentration and Anti-Drug Antibody Measurements.................69
5.3.2.1
Collection of Samples for Analysis .........................................................69
5.3.2.2
Handling/Processing of Samples .............................................................69
5.3.2.3
Disposition of Samples ............................................................................69
5.3.2.4
Measurement Methods.............................................................................70


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
21
5.3.3
Efficacy Variables....................................................................................70
5.3.3.1
Primary Variable......................................................................................71
5.3.3.2
Secondary Variables ................................................................................71
5.3.3.3
Other Endpoints .......................................................................................72
5.3.4
Safety Variables.......................................................................................73
5.3.5
Pharmacokinetic Variables ......................................................................73
5.3.6
Optional Exploratory Research/Validation Variables..............................73
5.4
Removal of Subjects from Therapy or Assessment.................................74
5.4.1
Discontinuation of Individual Subjects....................................................74
5.4.2
Discontinuation of Entire Study...............................................................76
5.5
Treatments................................................................................................76
5.5.1
Treatments Administered.........................................................................76
5.5.2
Identity of Investigational Products.........................................................77
5.5.2.1
Packaging and Labeling...........................................................................78
5.5.2.2
Storage and Disposition of Study Drug(s) ...............................................78
5.5.2.3
Preparation/Reconstitution of Dosage Form(s)........................................79
5.5.3
Method of Assigning Subjects to Treatment Groups...............................79
5.5.4
Selection and Timing of Dose for Each Subject......................................79
5.5.5
Blinding....................................................................................................80
5.5.5.1
Blinding of Investigational Product.........................................................80
5.5.5.2
Data Monitoring Committee....................................................................80
5.5.6
Treatment Compliance.............................................................................82
5.5.7
Drug Accountability.................................................................................82
5.6
Discussion and Justification of Study Design..........................................83
5.6.1
Discussion of Study Design and Choice of Control Groups....................83
5.6.2
Appropriateness of Measurements...........................................................84
5.6.3
Suitability of Subject Population .............................................................84
5.6.4
Selection of Doses in the Study ...............................................................84
6.0
Complaints .............................................................................85
6.1
Medical Complaints.................................................................................86
6.1.1
Definitions................................................................................................86
6.1.1.1
Adverse Event..........................................................................................86
6.1.1.2
Serious Adverse Events ...........................................................................88


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
22
6.1.1.3
Areas of Safety Interest............................................................................90
6.1.2
Adverse Event Severity............................................................................91
6.1.3
Relationship to Study Drug......................................................................92
6.1.3.1
Lack of Efficacy or Worsening of Disease ..............................................93
6.1.4
Adverse Event Collection Period.............................................................93
6.1.5
Adverse Event Reporting.........................................................................94
6.1.5.1
Adverse Events Commonly Associated with CD in Study 
Population ................................................................................................95
6.1.6
Pregnancy.................................................................................................96
6.1.7
Cardiac Adjudication Committee ............................................................97
6.1.8
Anaphylaxis Adjudication Committee.....................................................97
6.2
Product Complaint ...................................................................................97
6.2.1
Definition .................................................................................................97
6.2.2
Reporting..................................................................................................98
7.0
Protocol Deviations................................................................98
8.0
Statistical Methods and Determination of Sample 
Size ..........................................................................................99
8.1
Statistical and Analytical Plans................................................................99
8.1.1
Datasets for Analysis ...............................................................................99
8.1.1.1
Intent-to-Treat Analysis Set.....................................................................99
8.1.1.2
Safety Analysis Set ................................................................................100
8.1.2
Definition of Missing Data Imputation..................................................100
8.1.3
Subject Disposition ................................................................................100
8.1.4
Demographics and Baseline Characteristics..........................................100
8.1.5
Prior and Concomitant Medications ......................................................101
8.1.6
Efficacy Analysis ...................................................................................101
8.1.6.1
Primary Efficacy Variables....................................................................101
8.1.6.2
Secondary Efficacy Variables................................................................102
8.1.7
Safety Analysis ......................................................................................103
8.1.8
Analysis of Optional Exploratory Variables..........................................103
8.1.9
Analysis of Pharmacokinetic and Pharmacodynamic Variables............104
8.2
Determination of Sample Size ...............................................................105
8.3
Randomization Methods ........................................................................106


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
23
9.0
Ethics.....................................................................................107
9.1
Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB) ...........................................................................................107
9.2
Ethical Conduct of the Study.................................................................107
9.3
Subject Information and Consent...........................................................108
10.0
Source Documents and Case Report Form 
Completion ...........................................................................110
10.1
Source Documents .................................................................................110
10.2
Case Report Forms.................................................................................110
10.3
Electronic Patient Reported Outcomes (ePRO).....................................111
11.0
Data Quality Assurance ......................................................113
12.0
Use of Information...............................................................114
13.0
Completion of the Study .....................................................115
14.0
Investigator's Agreement....................................................116
15.0
Reference List ......................................................................117
List of Tables
Table 1.
Clinical Laboratory Tests.........................................................................57
Table 2.
Identity of Investigational Product...........................................................77
Table 3.
Serious Adverse Events ...........................................................................89
Table 4.
Common Events Associated with CD......................................................96
List of Figures
Figure 1.
Study M15-991 Study Schematic ............................................................32
Figure 2.
Adverse Event Collection ........................................................................93
List of Appendices
Appendix A.
Responsibilities of the Clinical Investigator ..........................................120
Appendix B.
List of Protocol Signatories....................................................................122
Appendix C.
Study Activities......................................................................................123


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
24
Appendix D.
Study Activities – Optional Exploratory Research Samples .................127
Appendix E.
Sample SES-CD Scoring .......................................................................128
Appendix F.
Crohn's Disease Activity Index (CDAI) ................................................129
Appendix G.
Standard Weights...................................................................................130
Appendix H.
Clinical Criteria for Diagnosing Anaphylaxis .......................................133
Appendix I.
Tanner Stage 5 for Development ...........................................................135
Appendix J.
Protocol Amendment:  List of Changes.................................................138


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
25
3.0
Introduction
Crohn's disease (CD) encompasses a spectrum of clinical and pathological processes 
manifested by focal asymmetric, transmural, and occasionally granulomatous 
inflammation that can affect any segment of the gastrointestinal tract and presents with 
symptoms of fatigue, prolonged diarrhea with or without gross bleeding, abdominal pain, 
weight loss, and fever.1  The disease can affect persons of any age, and its onset is most 
common in the second and third decades.  Females are affected slightly more than males, 
and the risk for disease is higher in some ethnic groups.2,3  The incidence of CD has 
steadily increased in developed countries over the past 3 decades4 with recent estimates 
varying from 12.7 and 20.2 cases/100,000, and a prevalence of 319 and 322 cases/100,000 
in North America and Europe, respectively.5  In Asia, the incidence of CD is estimated to 
be 0.5 to 1.0 cases per 100,000 persons, with a prevalence rate ranging from 3.6 to 7.7.6,7
The exact cause of CD is still unknown, but is hypothesized to be the result of a 
dysregulated immune system in the context of a genetically susceptible individual.  It is 
thought that a combination of a patient's genetics, microbiome, immune response, and the 
environment result in an excessive and abnormal immune response in the gut that results 
in pathology seen in CD.2
The aim of medical treatment in CD has been focused on controlling inflammation and 
reducing symptoms.8  In addition to improving symptoms, an emerging goal of therapy is 
to heal the gut mucosa.  Resolution of intestinal ulcers, also known as mucosal healing 
has been associated with positive clinical benefits, including higher rates of clinical 
remission, fewer hospitalizations, and fewer abdominal surgeries.9,10  However, 
improvement of the appearance of the intestinal mucosa may be more difficult to achieve 
than symptomatic improvement alone.
Conventional pharmaceutical therapies (e.g., corticosteroids, aminosalicylates, 
thiopurines, methotrexate) are limited, do not always completely abate the inflammatory 
process, and have significant adverse effects.1,11  The advent of anti-TNFα agents 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
26
(e.g., adalimumab) and integrin inhibitors (e.g., vedolizumab) have been shown to achieve 
clinical remission in patients refractory to conventional therapies.9-13
Despite the benefits of available biologic therapies, many patients do not respond to initial 
treatment (primary loss of response) or lose treatment over time (secondary loss of 
response).  Regarding anti-TNF agents, approximately 40% of patients will experience 
primary non-response and secondary non-response occurs in 38% of patients at 6 months 
and 50% of patients at 1 year.12,14-17  Additionally, some patients are not candidates for 
available biologic therapies.  Therefore new therapeutic options are required in order to 
continue to improve the outcome of patients with CD.
Risankizumab is a fully humanized mAb of the IgG1 subclass directed towards IL-23p19.  
The antibody has been engineered to reduce Fcγ receptor and complement binding and 
potential charge heterogeneity.  Risankizumab binds with high affinity to human IL-23 
and inhibits IL-23 stimulated IL-17 production at inhibitory concentration (IC) 50 
concentrations below 10 pM, as compared with 167 pM for ustekinumab in the same 
system.  Risankizumab does not affect IL-12 at a maximum tested concentration (33 nM) 
and it does not inhibit IL-12 stimulated IFN-γ production.
3.1
Differences Statement
This study is designed to evaluate the efficacy and safety of two risankizumab induction 
doses versus placebo during induction therapy in subjects with moderately to severely 
active CD.  The primary difference between Study M15-991 and the prior phase 2 study 
of risankizumab in CD is that this study will test a higher dosing of 1200 mg.  
Additionally, the endpoints in this study are different to reflect the changing regulatory 
requirements for pivotal registrational studies for new agents for the treatment of CD.
3.2
Benefits and Risks
Data suggest that altered immune regulation at the epithelial barrier, leads to an 
overproduction of inflammatory cytokines, tissue destruction, and aberrant tissue repair in 
CD.  Among the cytokines implicated in CD pathogenesis, data at the genetic, human 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
27
biology and clinical level strongly implicate IL-23 in this disease.18,19  The preclinical and 
clinical profiles of risankizumab suggest that it may have the potential to address unmet 
medical need in CD.  The data observed in the Phase 2 study suggest that risankizumab 
will alleviate signs and symptoms of active CD and reduce mucosal inflammation.  
Participation in this study may help to generate future benefit for subjects with CD. 
Though there are no serious adverse drug reactions known to be associated with 
risankizumab therapy, risks of participating in this study include risk of infection and risks 
related to the study specific procedures of blood sampling, infusion and injection of study 
drug, and colonoscopy with biopsy.
Blood sampling, intravenous (IV) infusions and subcutaneous (SC) injections can cause 
local bruising, inflammation, and pain.  Colonoscopy and biopsy, although generally well 
tolerated, can be associated with diarrhea, abdominal pain, and in more severe cases, 
perforation, bleeding, effects from anaesthetic medications, and infection.
Local reactions to IV or SC administered biologic therapies are uncommon, and are 
usually limited to redness, swelling or induration at the injection site.  Manifestations of 
systemic hypersensitivity reactions include anaphylaxis, pruritus, hypotension, and 
respiratory distress.  Both local and systemic hypersensitivity reactions are readily 
detectable, transient in nature, and manageable with standard medical treatment.  Subjects 
will be closely monitored during drug administration.
As with any immune modulating agent, risankizumab has the potential to impair immune 
function resulting in a risk of infection.  This will be addressed by clinical monitoring for 
adverse events (AEs) during the treatment and follow up periods.  Subjects with positive 
screening for M. Tuberculosis (TB) (skin/interferon-gamma release assay [IGRA] test 
positive) will be further worked up for signs and symptoms of active TB (e.g., chest x-ray 
[CXR]).  Subjects with active TB will be excluded from enrolling in the study.  Subjects 
with latent TB will be allowed to enroll in line with local guidelines.  If latent TB is 
established, TB prophylaxis/treatment should be initiated and maintained according to 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
28
local country guidelines.  Subjects with current signs or symptoms of infection or history
of serious infection will not be included in the study.
The role of IL-23 in tumor immunity is not well established at this time, but an increased 
risk of cancer from an IL-23 antagonist, though considered small, cannot be excluded.
Although rare, a potential for drug-induced liver injury (DILI) is under constant 
surveillance by sponsors and regulators.  Therefore, though there is no known DILI risk 
with risankizumab, this study requires timely detection, evaluation, and follow-up of 
laboratory alterations of selected liver laboratory parameters to ensure subjects' safety.
An independent Data Monitoring Committee (DMC) will be assessing all potential safety 
signals and will be unblinded to treatment allocation.  The DMC will review unblinded 
safety data on a cohort level, at a minimum of 6 month intervals throughout the course of 
the study.  At the timing of this amendment, the DMC has provided recommendation that 
the study may continue without modification and allowed enrollment to begin for 16 –
17 year-olds.  A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be 
provided to the patients at Screening so that any such events once occurred will be 
reported immediately by the patients to the investigator.
Increases in major adverse cardiovascular events (MACE) including myocardial 
infarction, cerebrovascular accident, and cardiovascular death have been reported in drugs 
with similar mechanism of action to risankizumab (e.g., p40 inhibitors).  However, the 
incidence of MACE has not been observed in longer term studies.  While the likelihood of 
increased MACE is small, all suspected cardiovascular events (serious or nonserious) 
observed in this study will be adjudicated by an independent adjudication committee.  An 
independent cardiac adjudication committee (CAC) will be adjudicating observed cardio-
and cerebro-vascular events and will remain blinded to treatment allocation.  In addition, 
an independent anaphylaxis adjudication committee (AAC) will be adjudicating observed 
potential anaphylactic events and will remain blinded to treatment allocation.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
29
The benefit-risk profile is considered appropriate for an experimental therapy at this stage 
of clinical development. 
Considering the coronavirus (COVID-19) pandemic, the benefit and risk to subjects 
participating in this study have been re-evaluated.  Based on the limited information to 
date, no additional risk to study participants is anticipated with the use of risankizumab.
4.0
Study Objective
The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab 
versus placebo during induction therapy in subjects with moderately to severely active 
CD.  
5.0
Investigational Plan
5.1
Overall Study Design and Plan:  Description
The study was designed to enroll approximately 579 subjects to meet scientific and 
regulatory objectives without enrolling an undue number of subjects in alignment with 
ethical considerations.  Therefore, if the target number of subjects has been enrolled, there 
is a possibility that additional subjects in screening will not be enrolled.  In addition to the 
579 subjects, up to 58 subjects with a lower SES-CD, defined as an eligibility SES-CD of 
≥ 3 to < 6 for ileocolonic or colonic disease or SES-CD of 3 for isolated ileal disease will 
be enrolled in order to inform treatment effect in this patient population, but these subjects 
will not be included in the primary ITT population for efficacy analysis.
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled induction 
study to assess the efficacy and safety of risankizumab in subjects with moderately to 
severely active CD, defined as:
1.
average daily stool frequency (SF) ≥ 4 (when calculating SF, only the number of 
liquid or very soft stools should be recorded) and/or average daily abdominal pain 
(AP) score ≥ 2; plus 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
30
2.
endoscopic evidence of mucosal inflammation as measured by the Simple 
Endoscopic Score for CD (SES CD).  All eligible scores exclude the presence of 
narrowing component and are confirmed by a central reader.  Endoscopic activity 
is defined as SES-CD of ≥ 3. 
The number of subjects enrolled with a SES-CD of ≥ 3 to < 6 for ileocolonic or colonic 
disease or SES-CD of 3 for isolated ileal disease will be no more than 58 subjects.  Once 
cap of no more than 58 subjects is reached, enrollment criterion will be an eligibility 
SES-CD of ≥ 6 for ileocolonic or colonic disease, or eligibility SES-CD of ≥ 4 for isolated 
ileal disease.
All endoscopies will be centrally read to document eligibility and for assessment at the 
time points indicated in Appendix C.
The study will enroll subjects who have had a documented inadequate response (IR) or 
intolerance to use of an approved biologic agent (bio-IR), such as infliximab, 
adalimumab, certolizumab, natalizumab, ustekinumab and/or vedolizumab.  The percent
of subjects with exposure, including intolerance or inadequate response, to ustekinumab
will be no more than 20%.
The study duration may be up to 49 weeks, including a Screening period of 35 days, a 
12-week induction period, a 12-week Induction Period 2 for those subjects who do not 
achieve clinical response at Week 12, and a 140 days of follow up period from the last 
dose of study drug.
Visits for clinical evaluation will occur at Baseline Weeks 4, 8, and 12/PD.  Subjects, who 
do not achieve clinical response at Week 12, will be offered blinded risankizumab in 
Induction Period 2 with evaluation for clinical response at Week 24.
At the study visit indicated in Appendix C, all subjects will be provided with a subject 
diary where they will record CD related symptoms throughout the study.  Subjects will 
also be dispensed a patient information card during Screening.  Additionally, subjects will 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
31
complete symptom, quality of life (QoL) and work productivity questionnaires throughout 
the study as indicated in Appendix C.  Clinical labs including, but not limited to, 
urinalysis, chemistry and hematology, high-sensitivity C-reactive protein (hs-CRP), serum 
risankizumab concentrations, and serum anti-drug antibody (ADA) levels may be 
collected.  In addition, stool samples for calprotectin analysis will be collected and should 
be taken before starting bowel preparations for endoscopy.  All endoscopies will be 
evaluated using SES-CD and will be confirmed by a central reader.  Biopsy to confirm 
diagnosis (during Screening) or to rule out dysplasia/malignancy may be performed 
during the same time points as the endoscopy.  Optional exploratory research samples 
may be taken during the study.
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be 
enrolled into the study and randomized in a 1:1:1 ratio as shown in Figure 1.  At the 
timing of this amendment, the DMC has provided recommendation that the study may 
continue without modification and allowed enrollment to begin for 16 – 17 year-olds.   


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
32
Figure 1.
Study M15-991 Study Schematic
a.
12-Week Induction Period
b. Induction Period 2
DC = discontinued; IR = subjects with inadequate clinical response to induction; IV = intravenous; R = subjects with 
clinical response; RR = re-randomize; RZB = risankizumab


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
33
Screening Period
Within 35 days prior to the Baseline visit, subjects will receive a full explanation of the 
study design and study procedures, provide a written informed consent, and undergo the 
screening procedures as outlined in Appendix C.  Once written informed consent is 
obtained, subjects will undergo screening procedures.
The length of time between Screening and the Baseline visit must allow time for 
endoscopy central reading and lab results.  The Screening period (35 days ± 7 days is 
granted around all study visits) may be extended as necessary after consultation with the 
AbbVie Therapeutic Area Medical Director (TA MD) for subjects who require initiation 
of prophylactic anti-TB therapy, or in case of external circumstances (e.g., due to the 
delay of availability of screening test results).
Laboratory values that are exclusionary can be re-tested once during the screening period 
upon discussion and clearance with TA MD.  If the re-tested lab value(s) remain(s) 
exclusionary, the subject will be considered a screen failure.  Redrawing samples if 
previous samples were unable to be analyzed would not count as a retest since the 
previous result was never obtained.  
Clinical laboratory assessments as specified in Appendix C will only need to be repeated 
at Baseline if the time between Screening and Baseline is > 14 days, or if the subject's 
health status has changed to warrant a repeat test. 
All subjects need to have their average daily SF, average daily AP, and CDAI calculated 
and meeting eligibility criteria before randomization at Baseline.
12-Week Induction Period
At the Baseline visit, subjects who meet all the inclusion criteria and none of the 
exclusion criteria described in Section 5.2.1 and Section 5.2.2 will be enrolled into the 
study and randomized to the double-blind induction period where they will receive either 
risankizumab 1200 mg IV, risankizumab 600 mg IV, or placebo.  The randomization at 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
34
Baseline will be stratified by the number of prior biologics failed (1, > 1), steroid use at 
Baseline (yes, no), and Baseline SES-CD (original, alternative).
During this period of the study, subjects will visit the study site at Weeks 4, 8 and 12/PD.  
Subjects, who do not achieve clinical response at Week 12 and choose to continue in the 
study, will have additional visits at Weeks 16, 20 and 24 for blinded Induction Period 2 
with risankizumab.  A ± 7-day window is permitted around scheduled study visits.  An 
effort will be made to bring subjects back to their original scheduled visit (calculated from 
Baseline) if they are out of the visit window.
At the Week 12/PD visit, all subjects will undergo an endoscopy for evaluation of 
mucosal inflammation.  It is expected that all subjects who remain in the study through at 
least Week 8 will have a Week 12/PD endoscopy.  All subjects achieving clinical 
response, defined as ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in 
average daily AP score (both not worse than Baseline) at Week 12 may be eligible to 
enter Study M16-000.  Subjects are not eligible to enter Study M16-000 until endoscopy 
has been completed (local reader results will be used for stratification for 
Study M16-000).  
All subjects who do not achieve clinical response at Week 12 will be able to receive 
blinded risankizumab in Induction Period 2, as specified below.  Subjects are not eligible 
to receive blinded Induction Period 2 therapy until endoscopy has been completed.  
Induction Period 2
At Week 12, subjects who do not achieve clinical response will be randomized by 
Interactive Response Technologies (IRT) to Induction Period 2, a double-blind, double-
dummy 12-week treatment period.
Subjects who received risankizumab induction treatment will be randomized 1:1:1 to:
●
Group 1:  1200 mg IV risankizumab
●
Group 2:  360 mg SC risankizumab


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
35
●
Group 3:  180 mg SC risankizumab
Subjects who received placebo induction treatment will receive:
●
Group 4:  1200 mg IV risankizumab
The IV risankizumab dose or matching IV placebo will be given at Weeks 12, 16, and 20; 
The SC risankizumab dose or matching SC placebo will be given at Weeks 12, and 20
At Week 24, subjects who participated in the blinded Induction Period 2 will be 
reassessed and undergo a third endoscopy for evaluation of mucosal inflammation.  
Subjects who achieve clinical response at Week 24 may be eligible to enter 
Study M16-000.  Subjects without clinical response at Week 24, as well as all subjects 
who terminate the study early (including subjects who are eligible for but do not 
participate in the blinded Induction Period 2), will be discontinued and have a follow-up 
call 140 days from the last dose of study drug to obtain information on any new and/or 
ongoing AEs.
Concomitant Aminosalicylates, Immunomodulators (Azathioprine [AZA], 
6-Mercaptopurine [6-MP], Methotrexate [MTX]), and/or CD-Related Antibiotics
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at 
Baseline must continue their concomitant treatment for the duration of the study.  
Initiating and/or increasing doses of aminosalicylates, immunomodulators, and/or CD-
related antibiotics during the study is prohibited.  Decreasing doses of aminosalicylates, 
immunomodulators, and/or CD-related antibiotics is prohibited during the study, except in 
the event of moderate-to-severe treatment related toxicities and after discussion with the 
AbbVie TA MD.  CD-related antibiotics may be discontinued in Induction Period 2 at the 
discretion of the Investigator.
Note:  the duration of the study includes the Induction Period 2.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
36
Concomitant Corticosteroids
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at 
the Baseline dose for the duration of the 12-week induction period.  Initiation and/or 
increasing doses of systemic and/or CD related corticosteroids during the entire study is 
prohibited.  Decreasing doses of corticosteroids is prohibited during the 12-week 
induction period, except in the event of moderate-to-severe treatment related toxicities 
and after discussion with the AbbVie TA MD.  
Subjects who receive blinded therapy in Induction Period 2 during Weeks 12 to 24 will be 
allowed to taper their corticosteroids at the discretion of the Investigator.  While stopping 
the taper is permitted, increasing doses above the Baseline dose is prohibited.
Follow-Up Period/Premature Discontinuation (PD)
Subjects may discontinue treatment at any time during the study participation 
(Section 5.4).  Subjects who end study participation early will have a PD visit and 
complete the procedures outlined for the PD visit in Appendix C as soon as possible after 
the last dose of study drug and preferably prior to the administration of any new therapies.
Subjects who discontinue the study or subjects who complete the Week 12/Week 24 visit 
and do not roll-over into Study M16-000 will have a follow-up call 140 days from the last 
dose of study drug to obtain information on any new or ongoing AEs.
Re-Screen
Subjects who initially screen fail for the study may be permitted to re-screen following 
re-consent.  The subject must meet all the inclusion and none of the exclusion criteria at 
the time of re-screening in order to qualify for the study.  There is no minimum period of 
time a subject must wait to re-screen for the study.
If the subject had a complete initial screening evaluation including the TB test, hepatitis B 
virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and 
electrocardiogram (ECG), these tests will not be required to be repeated for re-screening 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
37
provided the conditions noted in Section 5.3.1.1 are met and no more than 90 days have 
passed since the collection date of the testing.
If a subject is being rescreened within 14 days (≤ 14 days have passed) from the date of 
the previous screening testing, it is not required to repeat testing for 
chemistry/hematology, urinalysis, serum pregnancy, and C. difficile provided that the 
subject's health status has not changed to warrant a repeat test.  In this case, all Baseline 
testing should be performed at the Baseline visit.
If rescreening occurs more than 14 days (> 14 days have passed) from the collection date 
of the previous screening testing then new samples (chemistry/hematology, urinalysis, 
serum pregnancy, and C. difficile) should be collected during Rescreening.  In this case, 
chemistry/hematology, urinalysis do not need to be repeated at the Baseline visit if 
Baseline occurs within 14 days (≤ 14 days) from the date of rescreening testing provided 
that the subject's health status has not changed to warrant a repeat test.
All subjects need to have their average daily SF, average daily AP, and CDAI calculated 
and meeting eligibility criteria before randomization at Baseline.
An endoscopy with biopsy will not be required to be repeated for re-screening provided 
the conditions noted in Section 5.3.1.1 are met and the endoscopy is within 45 days of the 
Baseline visit.  Sites are may contact the AbbVie TA MD if there are questions on if 
subjects should or should not be re-screened.
5.2
Selection of Study Population
It is anticipated that approximately 579 subjects with moderately to severely active CD 
will be enrolled at approximately 400 study sites worldwide.  The study will enroll 100% 
of subjects who have had an inadequate response or intolerance to prior biologic therapy 
(bio-IR).
A subject may be enrolled in this study provided that he/she has met all of the inclusion 
criteria and none of the exclusion criteria specified in this protocol.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
38
5.2.1
Inclusion Criteria
1.
Male or female aged ≥ 18 to ≤ 80 years, or minimum age of adult consent 
according to local regulations, at the Baseline visit.  Where locally permissible, 
subjects 16 to < 18 years of age who meet the definition of Tanner stage 5 for 
development (refer to Appendix I) at the Baseline Visit (sites will be notified when 
adolescents may enroll).
2.
Confirmed diagnosis of CD for at least 3 months prior to Baseline.  Appropriate 
documentation of biopsy results consistent with the diagnosis of CD, in the 
assessment of the Investigator, must be available.
3.
Crohn's disease activity index (CDAI) score 220 – 450 at Baseline.
4.
Endoscopic evidence of mucosal inflammation as documented by the SES-CD of 
≥3.  All eligible scores exclude the presence of narrowing component and are 
confirmed by a central reader.  (Once cap of no more than 58 subjects is reached, 
enrollment criterion will be an SES-CD of ≥ 6 for ileocolonic or colonic disease or 
SES-CD of ≥ 4 for isolated ileal disease.)
5.
Average daily SF ≥ 4 and/or average daily AP score ≥ 2 at Baseline.
6.
Demonstrated intolerance or inadequate response to one or more of the following 
biologic agents as defined below:  infliximab, adalimumab, certolizumab pegol, 
natalizumab, vedolizumab and/or ustekinumab:
●
Demonstration of intolerance requires no minimum dose or duration of use
●
Inadequate response to biologic agents defined as signs and symptoms of 
persistently (in the opinion of the Investigator) active disease despite a history 
of one or more of the following:
○
At least one 6-week induction regimen of infliximab (≥ 5 mg/kg IV at 
Weeks 0, 2, and 6),
○
At least one 4-week induction regimen of adalimumab (one 160 mg SC 
dose at Week 0, followed by one 80 mg SC dose at Week 2 [or one 80 mg 
SC dose at Week 0, followed by one 40 mg SC dose at Week 2, in 
countries where this dosing regimen is approved]),


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
39
○
At least one 4-week induction regimen of certolizumab pegol (400 mg SC 
at Weeks 0, 2, and 4)
○
At least one 6-week induction regimen of vedolizumab (300 mg IV at 
Weeks 0, 2, and 6),
○
At least one 12-week induction regimen of natalizumab (300 mg IV every 
4 weeks)
○
At least one 8-week induction regimen of ustekinumab [260 mg (≤ 55 kg) 
or 390 mg (> 55 to ≤ 85 kg) or 520 mg (> 85 kg) IV, followed by 90 mg 
SC at Week 8] (Once cap of no more than 20% ustekinumab exposed 
subjects is reached, subjects with prior ustekinumab exposure will not be 
allowed to enroll.)  
●
Recurrence of symptoms during scheduled maintenance dosing following prior 
clinical benefit of the above biologic agents
●
Note:  Subjects who discontinued biologic agents for reasons other than 
inadequate response as defined above or intolerance (e.g., change of insurance) 
are not eligible to enroll
7.
If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol 
Contraception Recommendations.  Females of childbearing potential must have a 
negative serum pregnancy test result during Screening, and a negative urine 
pregnancy at Baseline.  Females of non-childbearing potential (either 
postmenopausal or permanently surgically sterile as defined in Section 5.2.4) 
during Screening do not require pregnancy testing at Baseline.   
Note:  Subjects with borderline serum pregnancy test at Screening must have a 
serum pregnancy test ≥ 3 days later to document continued lack of a positive 
result.
8.
Subject must be able and willing to give written informed consent and to comply 
with the requirements of this study protocol.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
40
Rationale for Inclusion Criteria
1 – 5
To select the adequate subject population with a disease status representative 
of the target population for evaluation
6
The impact of risankizumab on pregnancy and reproduction is unknown
7
In accordance with harmonized Good Clinical Practice (GCP)
5.2.2
Exclusion Criteria
1.
Subject with a current diagnosis of ulcerative colitis or indeterminate colitis.
Concomitant Medications and Treatments
2.
Subject on CD-related antibiotics who has not been on stable doses for greater 
than, or discontinued within, 14 days prior to Baseline.
3.
Subject on oral aminosalicylates who has not been on stable doses for greater than, 
or discontinued within, at least 14 days prior to Baseline.
4.
Subject taking oral corticosteroids:
●
Budesonide > 9 mg/day
●
Beclomethasone > 5 mg/day
●
Prednisone or equivalent > 20 mg/day
●
Or has not been on the current course for ≥ 14 days prior to Baseline and on a 
stable dose for ≥ 7 days prior to Baseline 
5.
Subject on immunomodulators (AZA, 6-MP, MTX) who:
●
Has not been on the current course for ≥ 42 days prior to Baseline, and
●
Has not been on a stable dose for ≥ 35 days prior to Baseline


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
41
Medications and Treatments During the Screening Period
6.
Subject who received IV anti-infectives within 35 days prior to Baseline visit or 
oral/intramuscular anti-infectives (non-CD-related) within 14 days prior to the 
Baseline visit.  This does not apply to TB prophylaxis.
7.
Subject who received exclusive enteral nutrition or any parenteral nutrition within 
35 days prior to Baseline.
8.
Subject who received any live bacterial or viral vaccination within 30 days prior to 
Screening or during the Screening Period.
9.
Subject who received cyclosporine, tacrolimus, or mycophenolate mofetil within 
35 days prior to Baseline.
10.
Subject who received fecal microbial transplantation within 35 days prior to 
Baseline.
Prior Medications and Treatments 
11.
Subject who received any: 
●
approved biologic agent: infliximab, adalimumab, certolizumab, vedolizumab, 
natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks 
prior to Baseline
Note:  If there is proper documentation of an undetectable drug level measured 
by a commercially available assay for any of the approved biologics above, 
there is no minimum washout prior to Baseline.
●
any investigational biologic or other agent or procedure within 35 days or 
5 half-lives prior to Baseline, whichever is longer.
12.
Subject with prior exposure to p19 inhibitors (e.g., risankizumab).
13.
Subject has been taking combination of two or more of the following:  oral 
budesonide, or oral beclomethasone and/or oral prednisone (or equivalent) 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
42
simultaneously, with the exception of inhalers, within 14 days prior to Screening or 
during the Screening period.
14.
Subject who received IV/intramuscular corticosteroids within 14 days prior to 
Screening or during the Screening period.
15.
Subject who received therapeutic enema or suppository, other than required for 
endoscopy, within 14 days prior to endoscopy used for Screening or during the 
Screening period.
16.
Subject who received apheresis (e.g., Adacolumn apheresis) ≤ 60 days prior to 
Screening or during the Screening period.
17.
Subject who has concomitant cannabis use either recreational or for medical 
reasons within 14 days of Baseline or any history of clinically significant drug, or 
alcohol abuse in the last 12 months.
CD Related
18.
Subject with currently known complications of CD such as:
●
abscess (abdominal or perianal),
●
symptomatic bowel strictures,
●
> 2 missing segments of the following 5 segments: terminal ileum, right 
colon, transverse colon, sigmoid and left colon, and rectum
●
fulminant colitis,
●
toxic megacolon,
●
or any other manifestation that might require surgery while enrolled in the 
study.
19.
Subject with ostomy or ileoanal pouch.
20.
Subject diagnosed with short gut or short bowel syndrome.
21.
Subject with surgical bowel resection within the past 3 months prior to Baseline, or 
a history of ≥ 3 bowel resections.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
43
Safety
22.
Subject who has a known hypersensitivity to risankizumab or the excipients of any 
of the study drugs or the ingredients of Chinese hamster ovary (CHO).
23.
Subjects with the following chronic or active infections: 
●
Active, chronic, or recurrent infection that based on the Investigator's clinical 
assessment makes the subject unsuitable candidate for the study, 
●
Infection with C. difficile toxin or other intestinal pathogen during Screening, 
●
Are infected with human immunodeficiency virus (HIV), 
●
QuantiFERON®-TB test or Purified Protein Derivative (PPD) skin test, or
both, according to local guidelines, will be performed during Screening.  
QuantiFERON®-TB test is preferred for subjects who received BCG 
vaccination or were exposed to other Mycobacteria species.  Subjects with a 
positive test result (or indeterminate results that have been repeated) may 
participate in the study if further work up (according to local 
practice/guidelines) establishes conclusively that the subject has no evidence 
of active tuberculosis.  Subjects with a history of active TB who have 
documented completion of a full course of anti-TB therapy may be allowed to 
enter the study after consultation with the AbbVie TA MD.  If latent TB is 
established, TB prophylaxis/treatment should be initiated and maintained 
according to local country guidelines.
●
Have active hepatitis B or hepatitis C defined as:
a.
HBV:  hepatitis B surface antigen (HBs Ag) positive (+), or detected 
sensitivity on the HBV deoxyribonucleic acid (DNA) polymerase chain 
reaction (PCR) qualitative test for hepatitis B core antibody (HBc Ab) 
positive subjects;
b. HCV:  HCV ribonucleic acid (RNA) detectable in any subject with 
positive anti-HCV antibody (HCV Ab)
24.
Subject with a previous history of dysplasia of the gastrointestinal tract or found to 
have dysplasia, other than completely removed low-grade dysplastic lesions, in any 
biopsy performed during the Screening endoscopy.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
44
25.
Subject with a known history of lymphoproliferative disease, including lymphoma, 
or signs and symptoms suggestive of possible lymphoproliferative disease, such as 
lymphadenopathy and/or splenomegaly.
26.
Subject with current or previous history of malignancy other than a successfully 
treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized 
carcinoma in situ of the cervix.
27.
Subject who has severe, progressive, or uncontrolled renal, hepatic, hematological, 
endocrine, disorder or symptoms thereof.
28.
Female subjects who is pregnant, breastfeeding, or is considering becoming 
pregnant during the study or for approximately 140 days after the last dose of study 
drug.
29.
Subject who has any condition, including any physical, psychological, or 
psychiatric condition, which in the opinion of the Investigator, would compromise 
the safety of the subject or the quality of the data and renders the subject an 
unsuitable candidate for the study.
30.
Screening laboratory and other analyses show any of the following abnormal 
results:
●
Aspartate transaminase (AST), alanine transaminase (ALT) > 2 × upper limit 
of the reference range;
●
White blood cell (WBC) count < 3.0 × 109/L;
●
Total bilirubin ≥ 2 mg/dL; except for subjects with isolated elevation of 
indirect bilirubin relating to Gilbert syndrome;
●
Estimated glomerular filtration rate by simplified 4-variable Modification of 
Diet in Renal Disease (MDRD) formula < 30 ml/min/1.73 m2. 
●
Hemoglobin < 8 g/dL
●
Platelets < 100,000/μL
●
Positive serum pregnancy test at the Screening visit or positive urine 
pregnancy test at the Baseline visit


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
45
Laboratory values can be re-tested once during the screening period after 
discussion and clearance with TA MD.  If the re-tested lab value(s) remain(s) 
exclusionary, the subject will be considered a screen failure.  Redrawing 
samples if previous samples were unable to be analyzed would not count as a 
retest since the previous result was never obtained.
31.
No known active COVID-19 infection.  Subject must not have signs/symptoms 
associated with COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and 
may only rescreen after they meet the following COVID-19 viral clearance criteria: 
●
Symptomatic subjects:  At least 2 negative viral tests in a row completed
locally, ≥ 24 hours apart after at least 10 days have passed since recovery,
defined as resolution of fever without use of antipyretics and improvement in 
respiratory symptoms (e.g., cough, shortness of breath)
●
Asymptomatic subjects:  At least 2 negative viral tests in a row completed 
locally, ≥ 24 hours apart after at least 10 days have passed since prior positive 
result (Note:  subjects who develop symptoms will follow guidance above for 
symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the 
above viral clearance criteria may be adjusted to account for epidemiological 
trends, updated information regarding infectivity and local/institutional guidelines.
Rationale for Exclusion Criteria
1
To avoid medical conditions that may compromise the ability to 
identify subjects with the correct diagnosis or to interpret medical 
importance of clinical results
2 – 16
To avoid bias for the evaluation of efficacy and safety by 
concomitant use of other medications or treatments and to ensure 
the safety of the subject
17 – 20
To avoid complications of CD that may compromise the 
evaluations of efficacy and safety
21 – 30
To ensure the safety of the subject and/or others


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
46
5.2.3
Prior and Concomitant Therapy
5.2.3.1
Prior Therapy
Any medication or vaccine (including over-the-counter or prescription medicines, 
vitamins and/or herbal supplements) that the subject has received within 35 days prior to 
Baseline, is receiving at the time of enrollment, or continues during the study, must be 
recorded along with the reason for use, date(s) of administration including start and end 
dates, and dosage information including dose, route and frequency in source documents 
and the electronic case report forms (eCRFs).
CD specific medications (including but not limited to corticosteroids, aminosalicylates, 
immunomodulators [AZA, 6-MP, or MTX], and CD-related antibiotics) that the subject 
has received within 90 days of Baseline should be recorded on the appropriate page of the 
eCRF and should include the dates of administration and dosages.  In addition, if a subject 
has ever received AZA, 6-MP, or MTX (oral or IM/SC), the duration of therapy, 
maximum dose, reason for use and reason(s) for termination of treatment will also be 
recorded in the appropriate eCRF.  
For all subjects with a history of biologic use for inflammatory bowel disease, the history 
of previous use including the names of biologic therapy used, duration of therapy, the 
highest known dose taken, reason for use and reason(s) for termination of treatment of the 
biologic agent will be recorded in the appropriate eCRF.
The AbbVie TA MD identified in Section 6.1.5 should be contacted if there are any 
questions regarding concomitant or prior therapy(ies).
5.2.3.2
Concomitant Therapy
Subjects taking aminosalicylates, immunomodulators, and/or CD-related antibiotics at 
Baseline must continue their concomitant treatment for the duration of the study.  
Initiating and/or increasing doses of aminosalicylates, immunomodulators, and/or 
CD-related antibiotics during the study is prohibited.  Decreasing doses of 
aminosalicylates, immunomodulators, and/or CD-related antibiotics is prohibited during 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
47
the study, except in the event of moderate-to-severe treatment related toxicities and after 
discussion with the AbbVie TA MD.  CD-related antibiotics may be discontinued in the 
blinded Induction Period 2 at the discretion of the Investigator.
Note:  the duration of the study includes the Induction Period 2.
Concomitant Corticosteroids 
Subjects taking corticosteroids at Baseline must continue their concomitant treatment at 
the Baseline dose for the duration of the 12-week induction period.  Initiation and/or 
increasing doses of systemic and/or CD related corticosteroids during the entire study is 
prohibited.  Decreasing doses of corticosteroids is prohibited during the 12-week 
induction period, except in the event of moderate-to-severe treatment related toxicities 
and after discussion with the AbbVie TA MD.
Subjects who receive blinded therapy in Induction Period 2 during Weeks 12 to 24 will be 
allowed to taper their corticosteroids at the discretion of the Investigator.  While stopping 
the taper is permitted, increasing doses above the Baseline dose is prohibited.
Subjects may not be on both budesonide and prednisone (or equivalent) simultaneously, 
with exception of inhalers within 14 days prior to Screening.
Setons are authorized as concomitant therapy in subjects with perianal fistulas and should 
be documented in the eCRF under concomitant medications.
Changes in all concomitant medications will be assessed at each study visit from Baseline 
through Week 12/PD and during Weeks 12 to 24 visits for subjects who participate in the 
blinded Induction Period 2.  Any changes will be documented in the source documents 
and captured on the appropriate eCRF page.
Subjects should not be routinely pre-medicated prior to infusion of study drug.  If in the 
Investigator's judgment the subject requires pre-medication based on prior medical history 
or symptoms with prior infusions of study drug in the current study, the AbbVie TA MD 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
48
should be contacted regarding possible permitted pre-medication with diphenhydramine 
hydrochloride and acetaminophen (or equivalents).  Individual dosage, timing, and route 
of administration would be determined by the Investigator.  Any pre-medications 
administered must be recorded on the appropriate eCRF.
The AbbVie TA MD identified in Section 6.1.5 should be contacted if there are any 
questions regarding concomitant or prior therapy(ies).
5.2.3.3
Prohibited Therapy
The following are prohibited medications during the study:
●
All biologic therapy with a potential therapeutic impact on the disease being 
studied including but not limited to the following:
○
Abatacept (Orencia®);
○
Adalimumab (Humira®);
○
Anakinra (Kineret®);
○
Belimumab (Benlysta®);
○
Certolizumab pegol (Cimzia®)
○
Etanercept (Enbrel®);
○
Golimumab (Simponi®);
○
Infliximab (Remicade®);
○
Natalizumab (Tysabri®);
○
Rituximab (Rituxan®);
○
Tocilizumab (Actemra®);
○
Ustekinumab (Stelara®);
○
Vedolizumab (Entyvio®);
●
Investigational agents (e.g., tofacitinib, baracitinib, filgotinib)
●
Live or attenuated vaccines are NOT allowed during the study and for 
140 days after the last dose of study drug.  Examples of such vaccines include 
but are not limited to the following:
○
live attenuated influenza


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
49
○
herpes zoster (e.g., Zostavax®)
○
rotavirus
○
varicella (chicken pox)
○
measles-mumps-rubella (MMR) or measles mumps rubella varicella 
(MMRV)
○
oral polio vaccine (OPV)
○
smallpox
○
yellow fever
○
Bacille Calmette-Guérin (BCG)
○
oral typhoid
●
Cyclosporine, tacrolimus, or mycophenolate mofetil.
●
Concomitant cannabis use either recreational or for medical reasons.
●
Rectal therapy with any therapeutic enemas or suppositories, with the 
exception of those required for endoscopy, is prohibited during the study.
●
Apheresis (e.g., Adacolumn apheresis).
●
Exclusive enteral nutrition or any parenteral nutrition.
The AbbVie TA MD identified in Section 6.1.5 should be contacted if there are any 
questions regarding prohibited therapy.
5.2.4
Contraception Recommendations
If female, subject must be either postmenopausal defined as:
●
Age ≥ 55 years with no menses for 12 or more months without an alternative 
medical cause.
●
Age < 55 years with no menses for 12 or more months without an alternative 
medical cause AND an FSH level > 40 IU/L.
OR,
●
Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy 
or hysterectomy).
OR, for women of childbearing potential (WOCBP):


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
50
●
Practicing at least one of the following methods of birth control, prior to 
Baseline through at least 140 days after the last dose of study drug.
○
Combined (estrogen and progestogen containing) hormonal contraception 
(oral, intravaginal, transdermal, injectable) associated with the inhibition of 
ovulation, (must start at least 1 month prior to study).
○
Progestogen-only hormonal contraception (oral, injectable, implantable) 
associated with inhibition of ovulation (must start at least 1 month prior to 
study)
○
Bilateral tubal occlusion/ligation (can be via hysteroscopy, provided a 
hysterosalpingogram confirms success of the procedure).
○
Vasectomized sexual partner(s) (the vasectomized partner should have 
received medical assessment of the surgical success and is the sole sexual 
partner of the trial participant).
○
Intrauterine device (IUD).
○
Intrauterine hormone-releasing system (IUS).
○
True abstinence: Refraining from heterosexual intercourse when this is in 
line with the preferred and usual lifestyle of the subject (periodic 
abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation 
methods] and withdrawal are not acceptable).
5.3
Efficacy, Pharmacokinetic, Pharmacodynamic, Optional 
Exploratory Research/Validation Studies and Safety 
Assessments/Variables
5.3.1
Efficacy and Safety Measurements Assessed and Flow 
Chart
Study procedures described are listed in the following section of this protocol and are 
summarized in tabular format in Appendix C.
5.3.1.1
Study Procedures
The study procedures outlined in Appendix C are discussed in detail in this section, with 
the exception of optional exploratory research/validation studies (discussed in 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
51
Section 5.3.1.2 and Appendix D), pharmacokinetics and pharmacodynamics (discussed in 
Section 5.3.2) and the collection of AE information (discussed in Section 6.1.4).  All 
study data will be recorded in source documents and on the appropriate eCRFs.
Study visits may be impacted by changes in local regulations due to the COVID-19 
pandemic.  This may include changes such as phone or virtual visits, visits at alternative 
locations, or changes in the visit frequency and timing of study procedures, among others.  
Every effort should be made to ensure the safety of subjects and site staff, while 
maintaining the integrity of the study.
Informed Consent
At the Screening visit, the subject will sign and date a study specific, Independent Ethics 
Committee (IEC)/Independent Review Board (IRB) approved, informed consent form 
before any study procedures are performed or any medications are withheld from the 
subject in order to participate in this study.  A separate informed consent will be required 
for each subject in order to participate in the optional exploratory research/validation 
studies.  Details regarding how informed consent will be obtained and documented are 
provided in Section 9.3.
Due to the COVID-19 pandemic, modifications to the protocol may be necessary.  
Subjects should be informed of the changes to the conduct of the study relevant to their 
participation (e.g., cancellation of visits, change in laboratory testing site, etc.).  
Documentation of this notification or verbal consent should be maintained at the site as 
required per local regulatory requirements.  A signed and dated informed consent form 
should be obtained from the subject afterwards as soon as possible.
Inclusion/Exclusion Criteria
Subjects will be evaluated to ensure they meet all inclusion criteria and have none of the 
exclusion criteria at both Screening and Baseline visits.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
52
Medical and Surgical History
A complete medical and surgical history, including CD-onset date, history of CD 
medication use, and history of alcohol and tobacco use will be obtained from each subject 
at the Screening visit.  An updated medical history will be obtained prior to study drug 
administration at Baseline, to ensure the subject is still eligible for enrollment, and 
updated as necessary.
Information on prior biologic, corticosteroid, immunomodulators (i.e., AZA, 6-MP, 
MTX), CD-related antibiotics, aminosalicylates or any other physician prescribed therapy 
for CD use will be obtained as outlined in Section 5.2.3.1.  
A detailed medical history with respect to TB exposure will be documented.  This 
information will include BCG vaccination, cohabitation with individuals who have had 
TB, and residence or work in TB endemic locations.  Subjects with active TB (during 
Screening) or documented history of active TB who have documented completion of a full 
course of anti-TB therapy may be allowed to enter the study after consultation with the 
AbbVie TA MD.  TB history and anti-TB therapy needs to be documented in the source 
documents and eCRFs.
Physical Examination
A physical examination including evaluation of extra intestinal manifestations (EIMs) will 
be performed at the designated study visits as specified in Appendix C.
A full physical examination will be performed as outlined in Appendix C.  Physical 
examinations at all other visits (including unscheduled visits) are symptom based and 
should include the assessment of EIMs as part of calculating the Crohn's disease activity 
index (CDAI).  The number of cutaneous fistulas should be recorded, including the 
number of fistulas draining upon gentle compression.  Fistulas will be classified as 
abdominal or perianal/anal.  Physical exam abnormalities noted by the Investigator at 
Baseline (including fistulas and fissures) will be recorded in the subject's medical history.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
53
Abnormalities noted after the Baseline visit will be evaluated and documented by the 
Investigator as to whether they are AEs.
Additionally, physical examination findings that are related to or part of each subject's 
medical history will be captured on the appropriate medical history eCRFs.
Vital Signs
Vital sign determinations of systolic and diastolic blood pressure in sitting position, pulse 
rate, respiratory rate, and body temperature will be obtained at each visit.  Blood pressure, 
pulse rate, and respiratory rate should be measured before blood draws are performed.
Height will be measured at the Screening visit only (with shoes off) for subjects 
≥18 years of age.  Height will be re-measured at Week 12 and Week 24 for subjects 
< 18 years of age at Baseline.  Body weight will be measured at all scheduled visits, as 
specified in Appendix C.  All measurements will be recorded in metric units where 
applicable.
TB Testing
All subjects will be tested for TB by either the QuantiFERON-TB Gold Test (or 
equivalent) or a TB Skin Test (PPD), or both, according to local guideline, as specified in 
Appendix C.
For subjects treated with corticosteroids (equivalent to Prednisone 5 mg or above – with 
ongoing treatment or treatment within 1 month prior to TB screening), an Interferon-
Gamma Release Assay (IGRA; QuantiFERON-TB Gold In-Tube test) must be performed 
during the Screening Period for all subjects including those with a prior history of Bacille 
Calmette-Guérin (BCG) administration or who were exposed to other Mycobacteria 
species.
For subjects NOT treated with corticosteroids (equivalent to Prednisone 5 mg or above –
with ongoing treatment or treatment within 1 month prior to TB screening), a PPD skin 
test (alternatively, also known as tuberculin skin test) must be placed, or alternatively an 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
54
Interferon-Gamma Release Assay (IGRA; QuantiFERON-TB Gold In-Tube test or 
T-SPOT TB test) must be performed during the Screening Period for all subjects.  IGRA 
is preferred for subjects with a prior history of Bacille Calmette-Guérin (BCG) 
administration or who were exposed to other Mycobacteria species.
If PPD and/or the QuantiFERON®-TB Gold test (IGRA equivalent) is positive, or if there 
is a repeat indeterminate (note:  the first indeterminate results must be repeated) 
QuantiFERON®-TB Gold test (or IGRA equivalent) upon retesting, subjects may 
participate in the study if further work up (according to local practice/guidelines) 
establishes conclusively that the subject has no evidence of active tuberculosis.  Subjects 
with a history of active TB who have documented completion of a full course of anti-TB 
therapy may be allowed to enter the study after consultation with the AbbVie TA MD.  If 
active TB is diagnosed, the subject may not enroll in the study.  If presence of latent 
tuberculosis is established, then tuberculosis prophylaxis should be initiated and 
maintained according to local country guidelines.  It is also necessary to report the latent 
TB or positive TB testing in the source documents and eCRFs.
●
QuantiFERON®-TB Gold Test is the preferred method which will be analyzed 
by the central laboratory (QuantiFERON test is preferred over TB Skin Test).  
However, if other IGRA equivalent tests are used, these may be performed by 
a certified local laboratory at the Investigator's discretion.
●
If the QuantiFERON®-TB Gold Test is NOT possible (or if both the 
QuantiFERON®-TB Gold Test and the PPD Skin Test are required per local 
guidelines) the PPD Skin Test will be performed according to standard clinical 
practice.  
●
The PPD Skin Test should be read by a licensed healthcare professional 
between 48 and 72 hours after administration.  A subject who does not return 
within 72 hours will need to be rescheduled for another skin test.
●
The reaction will be measured in millimeters (mm) of induration and 
induration ≥ 5 mm is considered a positive reaction.  The absence of induration 
will be recorded as "0 mm" not "negative."


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
55
●
If PPD and/or the QuantiFERON®-TB Gold test (or IGRA equivalent) is 
positive, or if there is a repeat indeterminate QuantiFERON®-TB Gold test (or 
IGRA equivalent) upon retesting, subjects may continue in the study if further 
work up (according to local practice/guidelines) establishes conclusively that 
the subject has no evidence of active tuberculosis.
●
If presence of latent tuberculosis is established, TB prophylaxis/treatment 
should be initiated and maintained according to local country guidelines.
●
Subjects who have had an ulcerating reaction to the TB Skin Test in the past 
should not be re-exposed and should not be tested by a PPD skin test.
●
In the case of a tuberculosis-related AE, a supplemental eCRF that provides 
additional information should be completed by the Investigator or designee.
●
If a CXR or other diagnostic tests are required to be performed to assess TB 
per local guidelines, this information will also be captured on the appropriate 
eCRF.
12-Lead Electrocardiogram (ECG)
A resting 12-lead ECG will be performed during Screening as specified in Appendix C.  
A qualified physician will interpret the clinical significance of any abnormal finding, sign, 
and date each ECG.  ECG findings, including any clinically significant findings will be 
documented in the source documents and later transcribed on to the appropriate eCRF.  
Each signed original ECG will be monitored by the responsible clinical research associate 
(CRA) and kept with subject's source documents onsite.
For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at 
Screening will not be required, provided source documentation is available.  If there are 
other findings that are clinically significant, the Investigator must bring this to the 
attention of the AbbVie TA MD before the subject can be enrolled.
Subjects can have a repeat ECG at any time during the study as warranted, based on the 
opinion of the Investigator.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
56
Clinical Laboratory Tests
Blood samples will be obtained for the laboratory tests listed in Table 1.  Blood draws 
should be performed, as much as possible, after vital signs, efficacy assessments and 
questionnaires (CDAI, IBDQ, etc.), are obtained and before study drug administration 
during a visit.
A certified central laboratory will be utilized to process and provide results for the clinical 
laboratory tests.  All abnormal laboratory tests that are considered clinically significant by 
the Investigator will be followed to a satisfactory resolution.
The central laboratory chosen for this study will provide instructions regarding the 
collection, processing and shipping of these samples.
For serum chemistry tests and some exploratory biomarker tests, it is preferred that the 
subject has fasted (8 hours, except for water) prior to sample collection, however it is not 
required.  It must be recorded whether the subject has fasted or not at the time of 
collection in the laboratory request, source document, and eCRF.
If travel restrictions or other changes in local regulations in light of the COVID-19 
pandemic prevent the subject from having blood drawn for laboratory testing at the study 
site, if possible, arrange for subjects to have laboratory work done at a local lab, hospital, 
or other facility.  Local lab results should be obtained along with reference ranges and 
kept within the subjects' source documentation.  Local lab results should be reviewed by 
the investigator as soon as possible.
If laboratory samples cannot be obtained, study drug administration may be continued 
provided the investigator has reviewed all prior laboratory results and confirms and 
discusses with the subject that there is no safety concern for the subject to continue use of 
the study drug in the absence of current labs.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
57
Table 1.
Clinical Laboratory Tests
Hematology
Clinical Chemistrya
Screening Blood Tests
Hematocrit
Hemoglobin
Red Blood Cell (RBC) 
count
White Blood Cell (WBC) 
count
WBC Differential
Platelets
Coagulation:
INRc
General:
Sodium
Potassium 
Chloride 
Bicarbonate (CO2)
Urea (BUN)
Creatinine
Glucose
Additional Chemistry Tests:
Calcium
Phosphate
Total Protein
Albumin
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Alkaline Phosphatase
Gamma-Glutamyl Transferase 
(GGT/γ-GT)
Bilirubin Total and Direct
Lipid Panel:
Cholesterol (total, LDL, and HDL)
Triglycerides
Additional Calculations:
Estimated glomerular filtration 
rate by simplified 4-MDRDd
HBs Ag
HBs Ab
HBc Ab
HBV DNA PCR reflex only
HCV Ab
HCV RNA reflex only
QuantiFERON-TB Gold or PPD Test
HIV-1 and HIV-2
Other Laboratory Tests:
Urinalysisb
Serum pregnancy (bHCG) test
Urine pregnancy test (Local)
Optional:  FSH, if needed to confirm 
postmenopausal status
Tryptasee
Histaminee
Leukocyte esterase
Nitrite
pH
Protein
Blood 
Specific Gravity 
Ketones
Glucose
Bilirubin
Biomarkers:
High-Sensitivity C-Reactive Protein 
(hs-CRP)
Optional Biomarkers:
Blood, tissue and stool will be 
collected for optional exploratory 
research/validation studiesa
Stool Samples:
C. difficile toxin
Fecal calprotectin (FCP)
PK/Immunogenicity:
Serum risankizumabe
Serum anti-drug 
antibodies (ADA)e
Serum neutralizing 
antibodies (nAb)e
a.
It is preferred that the subject has fasted (8 hours, except for water) prior to sample collection, however it is not 
required.
b.
A microscopic analysis will be performed by the central laboratory in the event the dipstick results show 
leukocytes, nitrite, protein, ketones, or blood greater than negative or glucose greater than normal.
c.
INR test only drawn if ALT or AST > 3 × ULN (upper limit of normal) and Total Bilirubin ≤ 2 × ULN (Refer to 
Section 5.4.1, for additional information).
d.
Only done at screening and calculated by the central laboratory.
e.
To be done with the occurrence of a suspected anaphylactic reaction (an additional sample of tryptase to be 
collected if possible at least 2 weeks post-reaction or at the next study visit); for ADA these samples are collected 
in addition to those specified in Appendix C.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
58
Hepatitis B Testing
All subjects will be tested for the presence of the HBV at Screening.  A positive result for 
the Hepatitis B surface antigen (HBs Ag) will be exclusionary.  Samples that are negative 
for HBs Ag will be tested for surface antibodies (HBs Ab) and core antibodies (HBc Ab 
Total).  Subjects with HBs Ag (–), HBs Ab (–), and HBc Ab Total (+) require PCR 
qualitative testing for HBV DNA.  Any HBV DNA PCR result that meets or exceeds 
detection sensitivity will be exclusionary.
Subjects with a negative HBs Ag test and tests showing the results below do not require 
HBV DNA PCR qualitative testing: 
●
HBc Ab Total (–) and HBs Ab (–)
●
HBc Ab Total (–) and HBs Ab (+)
●
HBc Ab Total (+) and HBs Ab (+)
Hepatitis C Testing
All subjects will be tested for the presence of the hepatitis C Virus (HCV) antibody at 
Screening.  Subjects with positive HCV antibody will have an HCV RNA test.  If the 
HCV RNA is positive then the subject will be excluded.
HIV
Subjects with a known history of HIV infection are excluded from study participation. 
HIV testing will be conducted as part of the infection screening at the Screening visit.  
The Investigator must discuss any local reporting requirements to local health agencies 
with the subject.  The site will report these results to their health agency per local 
regulations, if necessary.  If a subject has a confirmed positive result, the Investigator 
must discuss with the subject the potential implications to the subject's health and subject 
should be referred for clinical care promptly.  A subject will not be eligible for study 
participation if test results indicate a positive HIV infection.  AbbVie will not receive 
results from the testing.  This testing is to be done at the central lab.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
59
Anaphylaxis Testing 
In the event of a suspected systemic post-dose hypersensitivity reaction, a serum 
risankizumab, ADA, and neutralizing antibody (nAb) sample should be collected once 
within 24 hours of the reaction.  In addition to serum risankizumab, ADA, and nAb 
assays, blood tests to be conducted in the event of a systemic hypersensitivity reaction are:
●
Tryptase:  Optimally, measurement needs to be obtained from within 
15 minutes to 3 hours of symptom onset, and no later than 6 hours (as tryptase 
may remain elevated for 6 or more hours after the onset and therefore may still 
be informative if obtained after 3 hours); it is also requested to collect a 
follow-up tryptase level a minimum of 2 weeks after the recorded event or at 
the next study visit.
●
Plasma histamine: optimally, within 5 to 15 minutes of the onset of 
symptoms, and no later than 1 hour.
Stool Samples Collected
Fecal Calprotectin (FCP)
Fecal calprotectin will be performed for all subjects as indicated in Appendix C.  If 
subjects are unable to provide a sample at the site visit, subjects will be sent home with a 
stool sample supply kit and the site will give instructions to assist with collection 
procedures.  All stool samples should be collected before any bowel preparation for 
endoscopy is started and returned to the site per the instructions provided outside of this 
protocol.
The FCP results will remain blinded to Investigator, study site personnel and the subject 
throughout the study.
The central laboratory will be utilized to process and provide results for these laboratory 
tests.  In order to maintain the study blind, local laboratory testing for FCP for routine 
subject monitoring should not be performed.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
60
C. Difficile Stool Testing
During the Screening period a stool sample will be collected and sent to the central 
laboratory for testing.  The sample will be assessed for the presence of C. difficile toxin.
The sample must be shipped to the central laboratory using dry ice.  Additional 
information is available in the laboratory manual provided by the central laboratory.
Subjects who are positive for C. difficile toxin may be treated appropriately and 
re-screened.
Urinalysis
Dipstick urinalysis will be completed by the sites at all required visits as listed in 
Appendix C.  A microscopic urinalysis will only be performed by the central laboratory if 
the dipstick urinalysis results are abnormal, where abnormal is defined as leukocytes, 
nitrite, ketone, protein, blood or glucose value of greater than a trace.
Pregnancy Testing
A serum pregnancy test will be performed for all female subjects of childbearing potential 
during Screening. 
The serum pregnancy test will be sent to and performed by the central laboratory.  If the 
serum pregnancy test is positive the subject is considered a screen failure.  If the serum 
pregnancy test is borderline, it should be repeated to determine eligibility ≥ 3 days later.  
If the repeat serum pregnancy test is:
●
Positive, the subject is considered a screen failure;
●
Negative, the subject can be enrolled into the study;
●
Still borderline ≥ 3 days later, this will be considered documentation of 
continued lack of a positive result and the subject can be enrolled into the 
study (unless prohibited locally) in the absence of clinical suspicion of 
pregnancy and other pathological causes of borderline results.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
61
A urine pregnancy test will be performed for all WOCBP as indicated in Appendix C, 
prior to study drug administration.  More frequent pregnancy tests will be performed 
throughout the study if required per local/country requirements.
●
If the Baseline urine pregnancy test performed at the site is negative, then 
dosing with study drug may begin.  If the baseline urine pregnancy test 
performed at the site is positive, dosing with study drug must be withheld and 
a serum pregnancy test is required.  The serum pregnancy test will be sent to 
and performed by the central laboratory.  If the serum pregnancy test is 
negative, study drug may be started.  If the serum pregnancy test is positive, 
study drug must be withheld and the subject must be discontinued from the 
study.  In the event a pregnancy test result is borderline, a repeat test is 
required.
●
If a urine pregnancy test post-baseline is positive, study drug will be 
temporarily discontinued and a serum pregnancy test is required.  The serum 
pregnancy test will be sent to and performed by the central laboratory.  If the 
serum pregnancy test is negative, study drug may be restarted.  If the serum 
pregnancy test is positive, study drug will be permanently discontinued.
A pregnant or breastfeeding female will not be eligible for participation or continuation in 
this study or be allowed to continue study drug.
High-Sensitivity C-Reactive Protein (hs-CRP)
Blood samples for hs-CRP will be obtained per Appendix C.  The hs-CRP results will 
remain blinded to Investigator, study site personnel and the subject.
Blood draws should be performed, as much as possible, after all efficacy assessments, 
questionnaires (CDAI, IBDQ, etc.), and vital sign determinations are obtained and before 
study drug administration during a visit.  In order to maintain the study blind, local 
routine laboratory testing should not be performed.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
62
Crohn's Disease Activity Index (CDAI) 
Average daily SF, average daily AP score, and well-being will be calculated from the 
subject diary.  During screening subjects will be instructed on how to calculate the 
number of very soft and liquid stools, including a visual depiction.  Physical exam and 
appropriate laboratory values will be calculated at all study visits beginning at Baseline.  
The Screening period will be a minimum of 7 days to calculate the Baseline scores.
The CDAI scores must be calculated using a central laboratory hematocrit (Hct) value 
from the same visit for all visits, except Baseline, where the most recent Screening Hct 
value will be used.  The final CDAI for all other visits will be calculated once the 
hematocrit value is received from the central lab. If the Hct is missing due to technical 
issues (e.g., lost sample, clotted sample, etc.), the Hct value from the preceding visit may 
be used.
Instructions to calculate CDAI
●
To answer questions one (1) through three (3), entries from the 7 days prior 
to the visit should be used as recorded by the subject from the diary.
●
Diary entries should not be included in the 7 days evaluated prior to the visit 
if:  (1) the day the subject received medication for bowel preparation prior to 
endoscopy, (2) the day the subject underwent an endoscopy, and (3) 2 days 
following the endoscopy.  Diary entries, up to 14 days prior to the visit, will be 
used accordingly in order to provide the most recent data for 7 days prior to the 
respective study visit.  The 7 days do not need to be consecutive.
●
In question four (4), for the section regarding presence of anal fistulas and 
other fistulas, all fistulas detectable on physical examination (draining and 
non-draining) should be captured on the CDAI and calculated into the CDAI 
score.
●
And the evaluation for fever should include all the days that are taken into 
account for the calculation of the CDAI.
●
When completing question five (5) ("Taking 
Lomotil/Imodium/Loperamide/opiates for diarrhea, 0 = no, 1 = yes") on the 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
63
CDAI, "no" should be answered if a subject is taking an opiate(s) solely for 
pain.  The use of these medications takes into account only the day of the 
scheduled visit and is only assessing their use as anti-diarrheals
●
For question seven (7), hematocrit results from central laboratory will be used 
for the CDAI calculation.  If the hematocrit value contains more than 
one decimal point, the rounding will be allowed to the tenths decimal (e.g., Hct 
value 33.44 will be captured as 33.4, Hct value of 33.45 will be captured as 
33.5).  The Hct values either prior to completing the calculation or at the 
subtotal box 7 of the CDAI should not be rounded to a whole number.
●
For question eight (8), the height obtained at Screening should be used when 
selecting the standard weight in Appendix G, and this standard weight should 
be used for calculating every CDAI throughout subject participation in the 
study. 
●
Standard height is calculated by using the height obtained at Screening 
(without shoes) adding 1 inch or 2.5 cm.  For subjects < 18 years of age at 
Baseline, height will be re-measured at Week 12 and Week 24 (if applicable) 
and standard height should be recalculated.
●
If the body weight obtained at the time of assessment is not captured in 
kilograms (kg), then when converting into kg, rounding should occur using the 
second digit after the decimal (also known as the hundredth place) where if the 
number is 0 – 4, then keep the first digit after the decimal (also known as the 
tenth place) unchanged.  If the second digit after the decimal is 5 – 9, then 
round up the first digit after the decimal (e.g., 90.246 would be captured as 
90.2 and 97.687 would be captured as 97.7).
●
The subtotal of box 8 should not be rounded to a whole number.
The calculation of the CDAI score is in Appendix F.
Endoscopy
An endoscopy will be performed on the following visits:
●
During Screening*
●
Week 12/PD


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
64
●
Week 24 
The same endoscopist, where possible, should perform all endoscopies.  In addition, 
where possible, the Investigator or sub-Investigator should be the endoscopist for the 
study.  It is expected that all subjects who remain in the study through at least Weeks 8 
will have a Week 12/PD endoscopy.
*
An endoscopy performed before the Screening visit, independently of the study, may 
be used as the Screening endoscopy, with the approval of the AbbVie TA MD, if the 
following conditions are met:
1.
Biopsy confirmation of the diagnosis is available according to section "Biopsy 
During Endoscopy" below, as applicable.
2.
The endoscopy took place within 45 days prior to Baseline visit.
3.
The endoscopy was recorded in a video format as the endoscopic eligibility will be 
determined by the central reviewers. 
All ileocolonoscopies will be performed and recorded at the site in a video format.  Sites 
should also perform the SES-CD assessment and record the findings on the SES-CD score 
sheet (Appendix E) and in the appropriate eCRF.
All endoscopies will be reviewed by a central reviewer who is blinded.  Endoscopies 
completed at Week 12 and Week 24, for those subjects who undergo blinded therapy in 
Induction Period 2, will use the local reader results for stratification for Study M16-000.
There will be a window of ± 7 days to conduct the ileocolonoscopy.  This window may be 
extended as necessary after consultation with the AbbVie TA MD in case of external 
circumstances.
The endoscopies performed at the time points described above will be used to provide the 
endoscopy subscores to calculate the SES-CD.  All attempts should be made by the 
endoscopist to explore all segments of the colon and terminal ileum, including intubation 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
65
of the terminal ileum, at every endoscopy visit.  The endoscopy subscores by segment will 
be noted in the subject's source documents and in the database but the central reviewer's 
endoscopy subscore will be used for the efficacy analyses.
Biopsy During Endoscopy
Appropriate documentation of biopsy results consistent with the diagnosis of CD, in the 
assessment of the Investigator, must be available in order to confirm the subject's 
eligibility for the study.  Biopsies may be done when performing the endoscopy to 
confirm CD diagnosis (if appropriate documentation for confirmation of the diagnosis 
does not exist), and/or to rule out dysplasia and colon cancer at the Investigator's 
discretion.  These biopsies will be processed and evaluated locally and the histology 
report should be available in the subject's medical records.
If any biopsy sample(s) are obtained, it should also be recorded on the video.  
Any biopsy sample(s) will be collected from the respective bowel segment during the 
withdrawal of the endoscope and after sufficient recording for the central reader to 
calculate the SES-CD.
The signed pathology report will be monitored by the responsible CRA and kept with the 
subject's source documents onsite.  Subjects should not be enrolled if high grade colonic 
dysplasia or colon cancer is discovered at Screening endoscopy or endoscopy performed 
within 45 days prior to Baseline visit.  Subjects may be enrolled if low grade colonic 
dysplasia is discovered during endoscopy and is completely removed.
If a diagnosis of high grade colonic dysplasia or colon cancer is discovered during any 
subsequent endoscopic evaluation during the course of the study, the findings should be 
recorded as an AE and the subject should be discontinued from the study.  If low grade 
colonic dysplasia is discovered during any subsequent endoscopic evaluation during the 
course of the study, the findings should be entered as an AE and the subject can continue 
in the study if the lesion has been completely removed. 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
66
Subject Diary 
Subjects will be dispensed an electronic diary at Screening and will be trained on how to 
complete the diary by site staff during the Screening visit.  All subjects should complete 
their subject diary on a daily basis throughout the entire study.  The diary will be reviewed 
by site personnel with the subject at each visit and collected at the Final/PD visit, unless 
the subject continues into Study M16-000.  Subjects will also be dispensed a patient 
information card at Screening.
Completion will be reinforced during study visits as necessary.
Outcomes and Questionnaires
Subjects will be asked to complete the following electronic questionnaires/outcomes at the 
time points indicated in Appendix C.
●
Inflammatory Bowel Disease Questionnaire (IBDQ)
●
Work Productivity and Impairment Questionnaire – CD (WPAI-CD)
●
Crohn's Symptom Severity (CSS)
●
Patient Global Impression of Change (PGIC)
●
Patient Global Impression of Severity (PGIS)
●
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
●
European Quality of Life 5 Dimensions (EQ-5D-5L) 
●
36-Item Short Form Health Survey (SF-36)
Due to the COVID-19 pandemic and any local restrictions, sites may administer PRO 
instruments over the phone as needed. Sites may read the PRO questions and response 
options to the subject and record the subject's responses. Sites may send the 
questionnaires (email or hard copy) to the subjects to allow them to read/understand the 
questions and responses when the subject is providing responses over the phone. The date 
and time of PRO data collection should be recorded along with who collected the 
information.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
67
Study Drug Dispensing/Administration
Intravenous and SC study drug will be administered to all subjects on-site.  For WOCBP 
subjects, the urine pregnancy test needs to be negative prior to receiving study drug.  The 
site will be provided administration instructions.  Also, the initial 20 subjects enrolled 
between the Phase 3 induction trials will be monitored on site for 2 hours after completion 
of each infusion.  Subjects should be observed after study drug administration until judged 
clinically stable by the study personnel.  If an anaphylactic reaction or other serious 
allergic reaction occurs, administration of study drug should be discontinued immediately, 
appropriate laboratory testing samples drawn and appropriate therapy initiated.
Study drug kits are assigned by the IRT following the subjects randomized treatment 
schedule.  (Refer to Section 5.5 for additional information.)
During the Study Drug Dosing Period, a subject with confirmed (viral test positive) or 
suspected COVID-19 infection can only be dosed with study drug if the following 
COVID-19 viral clearance criteria are met:
●
Symptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours apart 
after at least 10 days have passed since recovery, defined as resolution of fever 
without use of antipyretics and improvement in respiratory symptoms (e.g., 
cough, shortness of breath)
●
Asymptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (note:  
subjects who develop symptoms will follow guidance above for symptomatic 
subjects)
5.3.1.2
Collection and Handling of Optional Exploratory 
Research/Validation Studies Samples
Subjects will have the option to provide samples for exploratory research and validation 
studies.  Subjects may still participate in the study even if they decide not to participate in 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
68
the optional exploratory research/validation.  The procedures for obtaining and 
documenting informed consent are discussed in Section 9.3.
Exploratory research can help to improve our understanding of how individuals respond 
to drugs and our ability to predict which patients would benefit from receiving specific 
therapies.  In addition, exploratory research may help to improve our understanding of 
how to diagnose and assess/monitor CD by assessing associations between disease 
characteristics, outcomes data and biomarkers of interests. 
Validation studies, including those related to the development of potential in vitro 
diagnostic tests, may be carried out retrospectively in order to assess associations between 
events of interest (i.e., efficacy and/or safety events) and candidate biomarkers.
AbbVie (or people or companies working with AbbVie) will store the biomarker 
exploratory research/validation studies samples in a secure storage space with adequate 
measures to protect confidentiality.  The samples will be retained while research on 
risankizumab (or drugs of this class) or this disease and related conditions continues, but 
for no longer than 20 years after study completion.
It is preferred that the subject has fasted (8 hours, except for water) prior to sample 
collection, however it is not required.  It must be recorded whether the subject has fasted 
or not at the time of collection in the laboratory request, source document, and eCRF.  The 
following samples will be collected according to Appendix D from each subject who 
consents to provide samples for exploratory research/validation studies:
●
DNA samples for pharmacogenetic or epigenetic analyses.
●
RNA samples for transcriptomic and/or epigenetic analyses.
●
Serum and plasma samples for systemic analyses including, but not limited to, 
proteomics and metabolomics.
●
Peripheral blood mononuclear cell (PBMC) samples for analyses including, 
but not limited to, immune cell profiling and assessment of functional activity


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
69
●
Stool samples for investigations including, but not limited to, proteomics, 
metabolomics, transcriptomics and metagenomics.
●
Intestinal biopsies for pathological and biological investigations, including but 
not limited to, transcriptomic analyses and immunohistochemistry.  Biopsy for 
histologic assessment by central review will be conducted at each visit with 
endoscopy.
Samples will be shipped to AbbVie or a designated laboratory for DNA/RNA extraction, 
if applicable, and/or analyses or long-term storage.  Instructions for the preparation and 
shipment of the samples will be provided in the laboratory manual.
5.3.2
Drug Concentration and Anti-Drug Antibody Measurements
5.3.2.1
Collection of Samples for Analysis
Serum risankizumab concentrations, ADA, and neutralizing antibodies (nAb) will be 
determined from blood collected by venipuncture just prior to dosing as indicated in 
Appendix C.  The time that each blood sample is collected will be recorded to the nearest 
minute in the source document and on the appropriate eCRF.
5.3.2.2
Handling/Processing of Samples
Specific instructions for collection of blood/serum samples and subsequent preparation 
and storage of the samples for the assays will be provided by the central laboratory, 
AbbVie, or its designee.
Refer to the study specific laboratory manual for detailed instructions on sample 
collection, processing, and shipment.
5.3.2.3
Disposition of Samples
Frozen samples will be packed in dry ice (pellet form) sufficient to last 3 days during 
transport.  Samples will be shipped pursuant to instructions from the onsite CRA.  An 
inventory of the samples will be included in the package for shipment.  Arrangements will 
be made with the central lab for the transfer of samples. 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
70
5.3.2.4
Measurement Methods
Serum concentrations of risankizumab and relative titers of risankizumab ADA will be 
determined using validated methods under the supervision of the Bioanalysis department 
at AbbVie.  Any additional analytes may be analyzed using non-validated methods.  
Serum samples collected for risankizumab and risankizumab ADA and risankizumab nAb 
analysis may be used for future assay development or validation activities.  
The nAb samples upon request may be used for the analysis of neutralizing anti-drug 
antibodies in a validated assay.
5.3.3
Efficacy Variables
Endpoint Definitions:
●
Clinical remission:  average daily SF ≤ 2.8 and not worse than Baseline AND 
average daily AP score ≤ 1 and not worse than Baseline
●
Enhanced clinical response:  ≥ 60% decrease in average daily SF and/or 
≥35% decrease in average daily AP score and both not worse than Baseline, 
and/or clinical remission
●
Clinical response:  ≥ 30% decrease in average daily SF and/or ≥ 30% 
decrease in average daily AP score and both not worse than Baseline
●
Endoscopic response:  decrease in SES-CD > 50% from Baseline (or for 
subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 
2 point reduction from Baseline), as scored by central reviewer
●
Ulcer-free endoscopy:  SES-CD ulcerated surface subscore of 0 in subjects 
with SES-CD ulcerated surface subscore ≥ 1 at Baseline, as scored by a central 
reviewer
●
Endoscopic remission:  SES-CD ≤ 4 and at least a 2 point reduction versus 
baseline and no subscore greater than 1 in any individual variable, as scored by 
a central reviewer
●
CDAI clinical response:  reduction of CDAI ≥ 100 points from baseline
●
CDAI clinical remission: CDAI < 150


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
71
5.3.3.1
Primary Variable
Co-Primary Endpoints:  
●
Proportion of subjects with clinical remission at Week 12  
●
Proportion of subjects with endoscopic response at Week 12 
5.3.3.2
Secondary Variables
Ranked Secondary Endpoints:
1.
Proportion of subjects with CDAI remission at Week 12
2.
Proportion of subjects with CDAI clinical response at Week 4
3.
Proportion of subjects with clinical remission at Week 4 
4.
Proportion of subjects with CDAI clinical response at Week 12 
5.
Mean change from baseline of induction in FACIT fatigue at Week 12 
6.
Mean change from baseline of induction in IBDQ total score at Week 12 
7.
Proportion of subjects with enhanced clinical response and endoscopic response at 
Week 12 
8.
Proportion of subjects with endoscopic remission at Week 12
9.
Proportion of subjects with enhanced clinical response at Week 4 
10.
Proportion of subjects with ulcer-free endoscopy at Week 12
11.
Enhanced clinical response at Week 12
12.
Proportion of subjects with resolution of extra-intestinal manifestations (EIMs) at 
Week 12, in subjects with any EIMs at Baseline 
13.
Proportion of subjects with CD-related hospitalization through Week 12
14.
Proportion of subjects without draining fistulas at Week 12 in subjects with 
draining fistulas at Baseline


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
72
5.3.3.3
Other Endpoints
Non-Ranked Endpoints
●
Change from Baseline in IBDQ over time
●
Change from Baseline in individual IBDQ domain scores (bowel, emotional, 
social, systemic) over time
●
Change from Baseline individual IBDQ item under Bowel Symptom domain 
(for Q1, Q5, Q9, Q13, Q17, Q20, Q22, Q24, Q26, and Q29) over time
●
Proportion of subjects with IBDQ remission (IBDQ > 170 points) over time 
●
Proportion of subjects with IBDQ response (increase in IBDQ > 16 points 
from Baseline) over time 
●
Change from Baseline in WPAI-CD over time
●
Change from Baseline in EQ-5D-5L over time
●
Change from Baseline in FACIT-Fatigue over time
●
Change from Baseline in SF-36 over time
●
Change from Baseline in FCP over time
●
Change from Baseline in hs-CRP over time 
●
Change from Baseline in average daily AP score over time
●
Change from Baseline in average daily SF over time
●
Proportion of subjects with clinical remission over time
●
Proportion of subjects with enhanced clinical response over time
●
Proportion of subjects with clinical response over time
●
Change from Baseline in SES-CD at Week 12
●
Proportion of subjects with a SES-CD ulcerated surface subscore ≤ 1 in each 
segment at Week 12 in subjects with a SES-CD ulcerated surface subscore ≥ 2 
at Baseline
●
Change from baseline in PGIS over time
●
PGIC over time
●
Proportion of subjects with endoscopic remission over time
●
Proportion of subjects with endoscopic response over time


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
73
●
Proportion of subjects with CD-related surgeries through Week 12
●
Proportion of subjects with any reduction in SES-CD at Week 12
●
Proportion of subjects with CDAI clinical remission over time
●
Proportion of subjects with CDAI clinical response over time
●
Change from Baseline in CDAI over time
●
Change from Baseline in CSS over time
5.3.4
Safety Variables
Safety analyses will be performed on safety set which includes all subjects who receive at 
least one dose of study drug.  Incidence of AEs, changes in vital signs, physical 
examination results, and clinical laboratory data will be assessed throughout the study.  
5.3.5
Pharmacokinetic Variables
Serum risankizumab concentrations will be determined during the treatment period and at 
the follow-up visit as outlined in Appendix C.  Serum risankizumab concentrations will be 
summarized at each time point for each dosing regimen using descriptive statistics.  
Population pharmacokinetic analyses combining the data from this study and other studies 
may be performed.  Relationships between risankizumab exposures and efficacy and 
safety variables of interest may be explored.
5.3.6
Optional Exploratory Research/Validation Variables
Optional samples may be collected to conduct exploratory investigations into known and 
novel biomarkers.  The types of biomarkers to be analyzed may include, but are not 
limited to, nucleic acids, proteins, lipids, metabolites or cellular markers/functions.  
Biomarker assessments may be used to assess and generate prognostic, predictive, 
pharmacodynamic, or surrogate biomarker signatures.  These assessments may be 
explored in the context of CD or related conditions and/or risankizumab or drugs of 
similar classes.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
74
The samples may also be used to develop new diagnostic tests, therapies, research 
methods or technologies.  In addition, samples from this study may be banked for future 
use.  Samples may then be used to validate putative biomarker signatures obtained from a 
prospective study, leading to the development of diagnostic tests.  The results from these 
analyses are exploratory in nature and may not be included with the study report.
5.4
Removal of Subjects from Therapy or Assessment
5.4.1
Discontinuation of Individual Subjects
A subject may withdraw from the study at any time.  The Investigator may discontinue 
any subject's participation for any reason, including an AE, safety concerns or failure to 
comply with the protocol.
Subjects will be withdrawn from the study immediately if any one of the following 
occurs:
●
Clinically significant abnormal laboratory result(s) or AE(s), which rule out 
continuation of the study drug, as determined by the Investigator in 
consultation with the AbbVie TA MD.
●
The Investigator believes it is in the best interest of the subject, including 
subjects with no improvement to study drug at Week 12 for whom the 
investigator believes it is in the best interest of the subject not to enter 
Induction Period 2.
●
Subjects who experience a severe systemic hypersensitivity infusion/injection 
reaction or anaphylaxis
●
The subject requests withdrawal from the study.
●
Inclusion and exclusion criteria violation was noted after the subject started 
study drug, when continuation of the study would place the subject at risk as 
determined by the AbbVie TA MD.
●
Introduction of prohibited medications or dosages when continuation of the 
study drug would place the subject at risk as determined by the AbbVie TA 
MD.
●
The subject becomes pregnant while on study drug.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
75
●
Subject has a malignancy, except for localized non-melanoma skin cancer.  
Discontinuation for carcinoma in-situ of the cervix is at the discretion of the 
Investigator.  
●
Subject is significantly non-compliant with study procedures which would put 
the subject at risk for continued participation in the study, as determined by the 
Investigator, in consultation with the AbbVie TA MD.
●
Occurrence of following hepatic test abnormalities considered by the 
Investigator to be related to study drug (retesting for ALT, AST, and TBL may 
be needed to confirm):
○
Confirmed ALT or AST > 8 × Upper Limit of Normal (ULN)
○
Confirmed ALT or AST > 5 × ULN for more than 2 weeks 
○
Confirmed ALT or AST > 3 × ULN and (TBL > 2 × ULN or INR > 1.5) 
○
Confirmed ALT or AST > 3 × ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (> 5%)
If, during the course of study drug administration, the subject prematurely discontinues 
study drug use, the procedures outlined for the PD visit must be completed within 2 weeks 
of the last dose of study drug, and preferably prior to the initiation of another therapy.  
However, these procedures should not interfere with the initiation of any new treatments 
or therapeutic modalities that the Investigator feels are necessary to treat the subject's 
condition.  Following discontinuation of the study drug, the subject will be treated in 
accordance with the Investigator's best clinical judgment.
A final visit will occur for all subjects, approximately 140 days after the last dose of study 
drug to determine the status of any ongoing AEs/SAEs or the occurrence of any new 
AEs/SAEs, except for those who are rolled over to the Study M16-000.
All attempts must be made to determine the date of the last dose of study drug and the 
primary reason for premature discontinuation.  The information will be recorded on the 
appropriate eCRF page.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
76
For subjects who are considered lost to follow-up, reasonable attempts must be made to 
obtain information on the final status of the subject.  At a minimum, two phone calls must 
be made and one certified letter must be sent and documented in the subject's source 
documentation. 
Subjects who discontinue the study prematurely will not be replaced. 
5.4.2
Discontinuation of Entire Study
AbbVie may terminate this study prematurely, either in its entirety or at any study site, for 
reasonable cause provided that written notice is submitted in advance of the intended 
termination.  The Investigator may also terminate the study at his/her site for reasonable 
cause, after providing written notice to AbbVie in advance of the intended termination.  
Advance notice is not required by either party if the study is stopped due to safety 
concerns.  If AbbVie terminates the study for safety reasons, AbbVie will immediately 
notify the Investigator by telephone and subsequently provide written instructions for 
study termination.
5.5
Treatments 
5.5.1
Treatments Administered
Each dose of blinded study drug (1200 mg risankizumab, 600 mg risankizumab, or 
placebo) will be administered intravenously to the subject during the 12-Week Induction 
Period.
Each dose of blinded study drug (1200 mg risankizumab, 360 mg risankizumab, or 
180 mg risankizumab) will be administered intravenously or subcutaneously in Induction 
Period 2.
If the 1200 mg dose is discontinued due to any reason, subjects will continue to enroll into 
the study and be randomized to either 600 mg risankizumab or placebo at 1:1 ratio.  In 
this case, the randomization ratio and sample size may be further updated in an 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
77
amendment to the protocol.  In addition, for subjects already randomized and for future 
randomization, 600 mg will be administered during Induction Period 2.
Subjects should not be routinely pre-medicated prior to infusion of study drug.  If in the 
Investigator's judgment the subject requires pre-medication based on prior medical history 
or symptoms with prior infusions of study drug in the current study, the AbbVie TA MD 
should be contacted regarding possible permitted pre-medication with diphenhydramine 
hydrochloride and acetaminophen (or equivalents).  Individual dosage, timing, and route 
of administration would be determined by the Investigator.  Any pre-medications 
administered must be recorded on the appropriate eCRF.
Subjects who do not achieve clinical response at Week 12 will be eligible for Induction 
Period 2 with blinded risankizumab.  Blinded risankizumab will be administered either 
intravenously at Weeks 12, 16, and 20 or subcutaneously at Weeks 12 and 20.
5.5.2
Identity of Investigational Products
The individual study drug information is presented in Table 2.
Table 2.
Identity of Investigational Product
Study Drug
Strength
Route of 
Administration
Manufacturer
Risankizumab
(ABBV-066)
90 mg/mL
IV
Boehringer Ingelheim 
Pharma GmbH & Co. KG
Placebo for Risankizumab
(ABBV-066)
N/A
IV
Boehringer Ingelheim 
Pharma GmbH & Co. KG
Risankizumab
(ABBV-066)
90 mg/mL
SC
Boehringer Ingelheim 
Pharma GmbH & Co. KG
Placebo for Risankizumab
(ABBV-066)
N/A
SC
Boehringer Ingelheim 
Pharma GmbH & Co. KG
AbbVie will not provide 5% dextrose to be used as a diluent for administration for 
risankizumab or placebo and it should be sourced locally from approved marketed 
products from various commercial manufacturers depending on availability.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
78
5.5.2.1
Packaging and Labeling
Risankizumab or placebo will be provided as one (1) vial per carton or one (1) prefilled 
syringe per carton to accommodate the study design.   
Each kit label will contain a unique kit number.  This kit number is assigned to a subject 
via IRT and encodes the appropriate study drug to be dispensed at the subjects 
corresponding study visit.  Each kit will be labeled as required per country requirements.  
Labels must remain affixed to the kits.  All blank spaces on the label will be completed by 
site staff prior to dispensing to the subjects.
5.5.2.2
Storage and Disposition of Study Drug(s)
Study drug must be kept protected from light in the original packaging, in a refrigerator 
between 2° to 8°C (36° to 46°F).  Study drug must not be frozen at any time.
The investigational products are for investigational use only and are to be used only 
within context of this study.  The study drug supplied for this study must be maintained 
under adequate security and stored under the conditions specified on the label until 
dispensed for subject use or destroyed as appropriate.  A temperature log must be 
maintained for documentation. 
The refrigerator temperature must be recorded each business day.  Malfunctions or any 
temperature excursion must be reported to the Sponsor immediately.  Sites are responsible 
to report temperature excursions into the AbbVie Temperature Excursion Management 
System (ATEMS).  Study drug should be quarantined and not dispensed until AbbVie or 
ATEMS deems the drug as acceptable. 
Upon receipt of the study drugs, the site will acknowledge receipt within the IRT system.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
79
5.5.2.3
Preparation/Reconstitution of Dosage Form(s)
Administration Instructions and Dose Preparation Instructions will be provided as 
separate documents outside of this protocol.  Dose preparation will be performed by a 
licensed unblinded pharmacist or qualified designee as appropriate.
5.5.3
Method of Assigning Subjects to Treatment Groups
All subjects will be assigned a unique identification number by the IRT at the Screening 
visit and will keep the same unique subject identification number throughout the study.  
Subjects who meet the inclusion and none of the exclusion criteria defined in 
Section 5.2.1 and Section 5.2.2 will be centrally randomized 1:1:1 to one of 
three treatment arms at Baseline during the 12-Week Induction Period of the study in a 
double-blind manner.  The randomization will be stratified by the number of prior 
biologics failed (1, > 1), Baseline steroid use (yes, no), and Baseline SES-CD (original, 
alternative).  The IRT will assign a randomization number that will encode the subject's 
treatment group assignment according to the randomization schedule generated by the 
Statistics Department at AbbVie.
IRT will provide the appropriate medication kit number(s) to dispense to each subject.  
Study drug will be administered at the study visits as summarized in Section 5.5.  
Returned study drug should not be re-dispensed to any subject.
At Week 12, subjects who do not achieve clinical response will be eligible for Induction 
Period 2 where subjects receiving blinded IV risankizumab will be re-randomized 1:1:1 to 
receive blinded risankizumab in one of three groups and subjects who are receiving 
blinded placebo will receive blinded IV risankizumab as summarized in Section 5.5.
5.5.4
Selection and Timing of Dose for Each Subject
Subject will be administered study drug at the clinical site as outlined in Section 5.5.1.   


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
80
5.5.5
Blinding
All AbbVie personnel with direct oversight of the conduct and management of the study 
(with the exception of AbbVie's Drug Supply Management Team and unblinded 
CRA/monitor (as applicable)), as well as the Investigator, the blinded study site personnel 
(with the exception of the unblinded site staff), and the subject will remain blinded to each 
subject's treatment throughout the study.  The IRT will provide access to blinded subject 
treatment information in the case of medical emergency.
In the event of a medical emergency in which the Investigator believes that knowledge of 
study drug treatment is required, reasonable efforts must be made to contact the AbbVie 
TA MD (see Section 6.1.5) prior to breaking the blind, as long as it does not compromise 
subject safety.  However, if an urgent therapeutic intervention is necessary which warrants 
breaking the blind prior to contacting AbbVie TA MD, the Investigator can directly 
access the IRT system to break the blind without AbbVie agreement.  In the event that the 
blind is broken before notification to AbbVie TA MD, it is requested that the AbbVie TA 
MD be notified within 24 hours of the blind being broken.  Also, the date and reason that 
the blind was broken must be recorded in the source document and eCRF, as applicable.
5.5.5.1
Blinding of Investigational Product
In order to maintain the blind, it is necessary to have unblinded site staff (unblinded 
licensed pharmacist or qualified designee) to prepare the IV solutions and blind the doses.  
Study personnel who administer the infusions to the subjects must remain blinded.  
The Administration Instructions and Dose Preparation Instructions are to be checked for 
the staff requirements for all activities concerning handling of study kits, including IRT 
transactions.
5.5.5.2
Data Monitoring Committee
An external independent DMC will review unblinded safety data on a cohort level, at a 
minimum of 6-month intervals throughout the course of the study.  


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
81
A separate DMC charter will be prepared outside of the protocol and approved by AbbVie 
and the DMC members before a subject is initiated into the study.  The DMC charter will 
describe the composition of the DMC, the roles and responsibilities of the DMC 
members, frequency and triggers of data reviews, relevant safety data to be assessed, 
meeting occasions, and communication with AbbVie as well as relevant competent 
authorities, if necessary.  The DMC is responsible for monitoring safety data, alerting 
AbbVie to possible safety concerns related to the conduct of the study, and recommending 
appropriate actions for the study conduct.
At the timing of this amendment, the DMC has provided recommendation that the study 
may continue without modification and allowed enrollment to begin for 16 – 17 year-olds.  
A patient information card with information of the symptoms and signs of 
hypersensitivity reactions, infusion related reactions as well as late stage reactions will be 
provided to the patients at Screening so that any such events once occurred will be 
reported immediately by the patients to the investigator.  
The DMC will review safety data at a minimum of 6-month intervals throughout the 
course of the study.  The DMC will determine if more frequent DMC meetings are 
required based on review of the accumulating safety data.  In addition, ad-hoc DMC 
meetings will be scheduled in the event of any significant safety concerns.  Based on these 
reviews, the DMC will make recommendations, as appropriate, regarding the conduct and 
management of the study.
The CAC and AAC adjudicate blinded data and the DMC reviews the data in an 
unblinded manner.  Unblinded adjudicated cardio-cerebrovascular events and 
anaphylactic reactions will be presented to the DMC for review on a periodic basis.
Communications from the DMC to the Study Teams will not contain information that 
could potentially unblind the team to subject treatment assignments.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
82
5.5.6
Treatment Compliance
The Investigator or his/her designated and qualified representatives will 
administer/dispense study drug only to subjects enrolled in the study in accordance with 
the protocol.  The study drug must not be used for reasons other than that described in the 
protocol.
5.5.7
Drug Accountability
The Investigator or designee (blinded or unblinded as applicable) will verify that study 
drug supplies are received intact, at the appropriate temperature, and in the correct 
amounts from the depot.  This will be accomplished by documenting the condition of the 
shipment, verifying the kit numbers in the package against the Proof of Receipt (POR) or 
similar document included with each drug shipment, and documenting this verification by 
signing and dating the POR or similar document and via direct reporting in IRT.  The 
original POR note or similar document will be kept in the site files as a record of what 
was received.
In addition, IRT will be used to document investigational product accountability including 
date received, the lot number, kit number(s), date and number of vials and syringes 
dispensed, and subject number.  For this study, unless otherwise prohibited locally, these 
records will be maintained electronically as part of the IRT system.
An overall accountability of the study drug will be performed by the site and 
reconciliation will be performed by the CRA/monitor (blinded or unblinded according to 
the monitoring plan) throughout the study and at the site close-out visit.
After verification of drug accountability, used study drug must be destroyed at the site 
according to local regulations governing biohazardous waste.  Destruction of used study 
supplies must be completed and documented in such a way that blinding is maintained for 
all blinded study personnel.  All unused supplies must be inventoried, accounted for and 
destroyed on site according to local procedures or regulation or returned to a destruction
facility.  A copy of the Return Consignment Form from IRT, in accordance with 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
83
instructions provided by the monitor/CRA (blinded or unblinded according to the 
monitoring plan), will be included in the return shipments.
The use of a third party vendor for drug destruction must be pre-approved by AbbVie.  
For sites performing on-site drug destruction or using a third party vendor for drug 
destruction, a copy of the destruction methodology and date of destruction should be 
maintained at the site's facility.  
5.6
Discussion and Justification of Study Design
5.6.1
Discussion of Study Design and Choice of Control Groups
Risankizumab is a selective IL-23 inhibitor that may provide improved clinical benefit to 
risk profile in CD patients.  The proposed study is a Phase 3, randomized, double-blind, 
placebo-controlled study to evaluate the safety and efficacy of risankizumab compared to 
placebo in subjects with moderately to severely active CD, who have had inadequate 
response or intolerance to biologic agents such as infliximab, adalimumab, certolizumab, 
natalizumab, ustekinumab and/or vedolizumab.
The study consists of a 12 week induction period to evaluate the efficacy and safety of 
two different IV risankizumab doses (600 mg or 1200 mg, Q4w) versus placebo.  For 
subjects who do not achieve clinical response at Week 12, an optional blinded Induction 
Period 2 (IV, 1200 mg, Q4w; SC, 360 mg, Q8w; SC, 180 mg, Q8w) for an additional 
12 weeks will be offered.  Subjects with clinical response at the end of induction or 
Induction Period 2 can enter Study M16-000 for an additional 52 weeks of treatment, with 
additional OL treatment being offered through approval.
At this time, a 12-week placebo controlled study is necessary for registrational purposes.  
A comparative study utilizing placebo provides an unbiased assessment of the efficacy 
and safety profile of risankizumab.  Furthermore, as approved biologics for CD are 
increasing, comparisons versus active drugs are important for market access.  To ensure 
all subjects are given the opportunity to receive potentially efficacious therapy, all 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
84
subjects not responding after 12 weeks can participate in the blinded Induction Period 2 
with risankizumab.
5.6.2
Appropriateness of Measurements
Standard statistical, clinical, endoscopy-related and laboratory procedures will be utilized 
in this study.  All efficacy measurements in this study are standard for assessing disease 
activity in subjects with CD.  All clinical and laboratory procedures in this study are 
standard and generally accepted.  Central reading of endoscopy will increase study rigor 
and ensure enrollment of subjects with moderately to severely active CD.
5.6.3
Suitability of Subject Population
Adult male and female subjects with moderately to severely active CD who meet all of the 
inclusion criteria and none of the exclusion criteria are eligible for enrollment in this 
study.  The specific population chosen was based on the unmet medical need of those 
subjects with a history of inadequate response or intolerance to biologic therapies.   
5.6.4
Selection of Doses in the Study
AbbVie plans to evaluate two doses of risankizumab (600 mg and 1200 mg) via IV 
administration every 4 weeks (Q4w; Weeks 0, 4, 8) through induction (12-Week 
Induction Period) and an additional three doses of 1200 mg of risankizumab via IV 
administration (Q4w; Weeks 12, 16, 20) or two doses of 180 or 360 mg SC (Q8W, 
Weeks 12 and 20; Induction Period 2) for subjects who do not achieve clinical response at 
Week 12.  The selection of the doses in this study is informed by the analysis of safety 
and efficacy data, as well as the exposure-response relationship of efficacy, of a Phase 2 
study in subjects with CD (Study 1311.6) and the pharmacokinetic data from the 
completed studies in subjects with psoriasis (Studies 1311.1 and 1311.2). 
Results from the placebo controlled Study 1311.6 that evaluated 200 mg and 600 mg IV 
doses of risankizumab at Weeks 0, 4, 8 weeks for induction suggests increasing trend of 
clinical response and remission (for both CDAI and PRO-2 based measures) at Week 12 
with increasing risankizumab dose and exposure, indicating a potential for further 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
85
improvement in proportion of subjects with response and remission with evaluation of 
higher doses.  Preliminary model predictions suggest further incremental benefit in CDAI 
remission in subjects with CD at 1200 mg IV Q4w dose compared to 600 mg IV Q4w 
dose.  The evaluation of higher dose data (1200 mg IV Q4w) will facilitate a more robust 
characterization of the dose-response and exposure-response relationship for these 
efficacy endpoints.  Inclusion of 1200 mg IV dose in this study is further supported by the 
safety results from the 12 week blinded induction period in Study 1311.6.  The safety 
profile of the 600 mg risankizumab group compared favorably with the placebo group and 
no overall safety concerns were identified which would preclude evaluation of IV 
induction doses higher than 600 mg risankizumab in patients with CD.  Furthermore, the 
projected steady state exposures for the 1200 mg IV risankizumab Q4w regimen in 
subjects with CD are covered by safety margins of ~1.6 and ~3.6 for Cmax and AUC0-28 days
respectively (relative to NOAEL identified in the 26 week GLP toxicology study).
Induction Period 2 will evaluate IV (1200 mg Q4w) or SC (180 mg or 360 mg Q8w) 
risankizumab. The purpose of Induction Period 2 is to evaluate the efficacy and safety of 
re-induction of risankizumab versus starting maintenance dosing on clinical response.  
Data from the Phase 2 study in subjects with CD suggested that re-induction with 600 mg 
IV increased both clinical response and clinical remission.  The selection of the SC doses 
is informed by the analysis of the safety and efficacy data, as well as the exposure-
response relationship of efficacy, of the maintenance period during the Phase 2 study in 
subjects with CD that evaluated 180 mg SC risankizumab for maintenance.  The results 
from the Phase 2 study suggest a potential for increased benefit with 360 mg SC 
administration for maintenance regimen.
6.0
Complaints
A Complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the physical characteristics, identity, quality, purity, potency, durability, 
reliability, safety, effectiveness, or performance of a product/device after it is released for 
distribution.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
86
The investigational product in this study contains: 
●
Biologic compound(s) 
Complaints associated with any component of this investigational product must be 
reported to the Sponsor (Section 6.2.2).  For adverse events, please refer to Sections 6.1
through 6.1.7.  For product complaints, please refer to Section 6.2.
6.1
Medical Complaints
The Investigator will monitor each subject for clinical and laboratory evidence of adverse 
events on a routine basis throughout the study.  The Investigator will assess and record 
any adverse event in detail including the date of onset, event diagnosis (if known) or 
sign/symptom, severity, time course (end date, ongoing, intermittent), relationship of the 
adverse event to study drug, and any action(s) taken.  For serious adverse events 
considered as having "no reasonable possibility" of being associated with study drug, the 
Investigator will provide an "Other" cause of the event.  For adverse events to be 
considered intermittent, the events must be of similar nature and severity.  Adverse 
events, whether in response to a query, observed by site personnel, or reported 
spontaneously by the subject will be recorded.
All adverse events will be followed to a satisfactory conclusion.
6.1.1
Definitions
6.1.1.1
Adverse Event
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment.  An adverse event can therefore 
be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not the event is considered causally related to the use of the product.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
87
Such an event can result from use of the drug as stipulated in the protocol or labeling, as 
well as from accidental or intentional overdose, drug abuse, or drug withdrawal.  Any 
worsening of a pre-existing condition or illness is considered an adverse event.  
Worsening in severity of a reported adverse event should be reported as a new adverse 
event.  Laboratory abnormalities and changes in vital signs are considered to be adverse 
events only if they result in discontinuation from the study, necessitate therapeutic 
medical intervention, and/or if the Investigator considers them to be adverse events.
An elective surgery/procedure scheduled to occur during a study will not be considered an 
adverse event if the surgery/procedure is being performed for a pre-existing condition and 
the surgery/procedure has been pre planned prior to study entry.  However, if the 
pre-existing condition deteriorates unexpectedly during the study (e.g., surgery performed 
earlier than planned), then the deterioration of the condition for which the elective 
surgery/procedure is being done will be considered an adverse event.
Supplemental study case report forms should be completed in the event of COVID-19 
related missed/virtual visits, study drug interruptions or discontinuations, or adverse 
events (including capture of specific signs/symptoms of infection and testing results).
COVID-19 infections should be captured as adverse events.  If the event meets the criteria 
for a serious adverse event (SAE), then follow the SAE reporting directions per the 
protocol and above.  The following COVID-19 related supplemental eCRFs should be 
completed:
●
COVID-19 Supplemental Signs/ Symptoms 
●
COVID-19 Status Form
If a subject has a confirmed or suspected COVID-19 infection and study drug was 
interrupted, the investigator should contact the sponsor emergency medical contact listed 
above before reintroducing study drug.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
88
6.1.1.2
Serious Adverse Events
If an adverse event meets any of the following criteria, it is to be reported to AbbVie as a 
serious adverse event (SAE) within 24 hours of the site being made aware of the serious 
adverse event.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
89
Table 3.
Serious Adverse Events
Death of Subject
An event that results in the death of a subject.
Life-Threatening
An event that, in the opinion of the Investigator, would have 
resulted in immediate fatality if medical intervention had not 
been taken.  This does not include an event that would have 
been fatal if it had occurred in a more severe form.
Hospitalization or 
Prolongation of 
Hospitalization
An event that results in an admission to the hospital for any 
length of time or prolongs the subject's hospital stay.  This 
does not include an emergency room visit or admission to an 
outpatient facility.
Congenital Anomaly
An anomaly detected at or after birth, or any anomaly that 
results in fetal loss.
Persistent or 
Significant 
Disability/Incapacity
An event that results in a condition that substantially interferes 
with the activities of daily living of a study subject.  Disability 
is not intended to include experiences of relatively minor 
medical significance such as headache, nausea, vomiting, 
diarrhea, influenza, and accidental trauma (e.g., sprained 
ankle).
Important Medical 
Event Requiring 
Medical or Surgical 
Intervention to 
Prevent Serious 
Outcome
An important medical event that may not be immediately life-
threatening or result in death or hospitalization, but based on 
medical judgment may jeopardize the subject and may require 
medical or surgical intervention to prevent any of the 
outcomes listed above (i.e., death of subject, life threatening, 
hospitalization, prolongation of hospitalization, congenital 
anomaly, or persistent or significant disability/incapacity).  
Additionally, any elective or spontaneous abortion or stillbirth 
is considered an important medical event.  Examples of such 
events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospitalization, or 
the development of drug dependency or drug abuse.
For serious adverse events with the outcome of death, the date and cause of death will be 
recorded on the appropriate eCRF.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
90
6.1.1.3
Areas of Safety Interest
Additional information may be collected for the following events.
Hepatic Events 
In the case of any of the following AEs, the appropriate supplemental eCRFs should be 
completed:
●
Discontinuation or interruption of study drug due to any hepatic related AE 
●
Any hepatic related SAE 
●
A subject experiencing an ALT/AST > 8 × ULN 
●
A subject experiencing an ALT/AST > 3 × ULN in conjunction with a total 
bilirubin > 2 × ULN.
Systemic Hypersensitivity/Anaphylactic Reactions
Therapeutic protein products, such as biologics, may elicit a range of acute effects, from 
symptomatic discomfort to sudden, fatal reactions that have often been grouped as 
'infusion reactions' in the past.  Although the term implies a certain temporal relationship, 
infusion reactions are otherwise not well defined and may encompass a wide range of 
clinical events, including anaphylaxis and other event that may not be directly related to 
antibody responses, such as cytokine release syndrome. 
In the event of a suspected systemic hypersensitivity/anaphylactic reaction, in addition to 
the standard AE eCRF, a supplemental eCRF should also be completed by the site.  The 
clinical criterion for diagnosing anaphylaxis is provided in Appendix H for reference; 
symptoms of anaphylactic reaction usually occur within 24 hours after exposure to an 
allergen.  These are guidelines that are used to help diagnose anaphylaxis.  The 
investigator is encouraged to report any suspected reactions.
All intravenous and subcutaneous doses of risankizumab will be administered by study-
site personnel under the direction of the Investigator.  Subjects will be monitored 
throughout the study for signs and symptoms suggestive of hypersensitivity reactions, 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
91
including allergic reactions and anaphylaxis.  A medical person qualified in the treatment 
of acute hypersensitivity reactions must be present during the infusions.  All appropriate 
medical support measures (e.g., diphenhydramine, steroids, epinephrine, oxygen) for the 
treatment of suspected hypersensitivity reactions should be available for immediate use in 
the event that a suspected hypersensitivity reaction occurs.  Subjects who manifest any 
new signs or symptoms during the infusion should be monitored for appropriate resolution 
prior to leaving the site.  Subjects are encouraged to report any symptoms related to a 
possible infusion related reactions or local injection site reaction or late phase reactions to 
the site any time during the study.  A patient information card listing the symptoms of 
these reactions will be provided to the participants.
Cardiac Events/Procedures 
In the case of any of the following reported MACE, the appropriate supplemental eCRFs 
should be completed:
●
Cardiac events;
●
Myocardial infarction or unstable angina;
●
Cerebral vascular accident and transient ischemic attack;
●
Cardiovascular procedures
Tuberculosis (TB)
In the case of any positive TB test or diagnosis of active TB, the appropriate supplemental 
eCRFs should be completed.
6.1.2
Adverse Event Severity
When criteria are available, events should be graded as described in the National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03,20
which can be accessed at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
92
If no specific criteria are provided to grade the reported event, the event should be graded 
as follows.  
Mild 
(Grade 1)
Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.
Moderate 
(Grade 2)
Minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental activities of daily living (ADL)
Severe 
(Grade 3)
Severe or medically significant but not immediately life threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care ADL 
Severe 
(Grade 4)
Life-threatening consequences; urgent intervention indicated.
Severe 
(Grade 5)
Death related to AE
Use the following guidelines when entering the severity grading criteria into the electronic 
data capture (EDC) system.
Grade 1 as Mild; Grade 2 as Moderate; and Grade 3 to 5 as Severe.
6.1.3
Relationship to Study Drug
The Investigator will use the following definitions to assess the relationship of the adverse 
event to the use of study drug:
Reasonable 
Possibility
After consideration of factors including timing of the event, biologic 
plausibility, clinical judgment, and potential alternative causes, there 
is sufficient evidence (information) to suggest a causal relationship.
No Reasonable 
Possibility
After consideration of factors including timing of the event biologic 
plausibility, clinical judgment and potential alternative causes, there 
is insufficient evidence (information) to suggest a causal 
relationship.
For causality assessments, events assessed as having a reasonable possibility of being 
related to the study drug will be considered "associated."  Events assessed as having no 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
93
reasonable possibility of being related to study drug will be considered "not associated."  
In addition, when the Investigator has not reported a causality or deemed it not assessable, 
AbbVie will consider the event associated.
If an Investigator's opinion of no reasonable possibility of being related to study drug is 
given, an "Other" cause of event must be provided by the Investigator for the serious 
adverse event.
6.1.3.1
Lack of Efficacy or Worsening of Disease
Events that are clearly consistent with progression of the underlying disease (CD) are 
considered an expected outcome for this study and will not be subject to expedited 
reporting.
6.1.4
Adverse Event Collection Period
All adverse events reported from the time of study drug administration until 140 days 
from the last dose of study drugs have elapsed will be collected, whether solicited or 
spontaneously reported by the subject.  In addition, serious adverse events and protocol-
related nonserious adverse events will be collected from the time the subject signed the 
study-specific informed consent.
Adverse event information will be collected as shown in Figure 2.
Figure 2.
Adverse Event Collection


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
94
6.1.5
Adverse Event Reporting
In the event of a serious adverse event, whether associated with study drug or not, the 
Investigator will notify Clinical Pharmacovigilance within 24 hours of the site being made 
aware of the serious adverse event by entering the serious adverse event data into the 
electronic data capture (EDC) system.  Serious adverse events that occur prior to the site 
having access to the RAVE® system, or if RAVE® is not operable, should be documented 
on the SAE Non-CRF forms and emailed (preferred route) or faxed to Clinical 
Pharmacovigilance within 24 hours of the site being made aware of the serious adverse 
event.
Email:  PPDINDPharmacovigilance@abbvie.com
FAX to:  +1 (847) 938-0660
For safety concerns, contact the Immunology Safety Team at:
Immunology Safety Team
Dept. R48S, Bldg. AP31-2
1 North Waukegan Road
North Chicago, IL 60064
Safety Hotline:
+1 847-938-8737
Email:
GPRD_SafetyManagement_Immunology @abbvie.com


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
95
For any subject safety concerns, please contact the physician listed below:
Primary Therapeutic Area Medical Director:
1 North Waukegan Road
North Chicago, IL 60064
United States
Telephone Contact Information:
Office:
Mobile
Email:
In emergency situations involving study subjects when the primary AbbVie TA MD is not 
available by phone, please contact the 24-hour AbbVie Medical Escalation Hotline where 
your call will be re-directed to a designated backup AbbVie TA MD:
Phone:  +1 (973) 784-6402
AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions 
(SUSAR) reporting for the investigational medicinal product (IMP) in accordance with 
global and local guidelines and Appendix A of the Investigator Brochure will serve as the 
Reference Safety Information (RSI).  The RSI in effect at the start of a DSUR reporting 
period serves as the RSI during the reporting period.  For follow up report, the RSI in 
place at the time of occurrence of the suspected Serious Adverse Reaction will be used to 
assess expectedness.  
6.1.5.1
Adverse Events Commonly Associated with CD in Study 
Population
Certain events are anticipated to occur in the study population as known consequences of 
CD (e.g., as symptoms or due to disease progression) independent of drug exposure.  
These events are listed in Table 4.  These AEs, captured on the appropriate eCRF, are 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
96
considered expected for reporting purposes for this protocol.  Although exempt from 
expedited reporting to certain Health Authorities and ECs/IRBs as individual cases, if any 
of these events meets seriousness criteria, it must be reported to AbbVie within 24 hours 
of the site being made aware of the SAE (as defined in Section 6.1.5).
Events commonly associated with CD population hence considered expected for 
reporting.
Table 4.
Common Events Associated with CD 
Fistulae
Abscesses
Stenoses/Obstruction
!
Anal fistula
!
Colovaginal fistula
!
Colovesical fistula
!
Enterocolonic fistula
!
Enterocutaneous fistula
!
Enterovaginal fistula
!
Female genital-digestive tract 
fistula
!
Ileal fistula
!
Ileorectal fistula
!
Ileovaginal fistula
!
Perineal fistula
!
Rectal fistula
!
Rectovaginal fistula
!
Anal abscess
!
Anorectal abscess
!
Rectal abscess
!
Anal stenosis
!
Ileal stenosis
!
Intestinal obstruction
!
Small intestine obstruction
Others
!
Anal fissure
!
Worsening of 
Crohn's disease
!
Intestinal perforation
6.1.6
Pregnancy
Pregnancy in a study subject must be reported to AbbVie within 24 hours of the site 
becoming aware of the pregnancy.  Subjects who become pregnant during the study must 
be discontinued from study drug (Section 5.4.1).
Information regarding a pregnancy occurrence in a study subject and the outcome of the 
pregnancy will be collected.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
97
Pregnancy in a study subject is not considered an adverse event.  The medical outcome for 
either mother or infant, meeting any serious criteria including an elective or spontaneous 
abortion is considered a serious adverse event and must be reported to AbbVie within 
24 hours of the site becoming aware of the event.
6.1.7
Cardiac Adjudication Committee
The independent external CAC will be adjudicating observed cardio- and cerebro-vascular 
events and will remain blinded to treatment allocation.  The events that are adjudicated 
and the adjudication process will be detailed in the Cardiac Adjudication Committee 
Charter.  Dedicated eCRFs will be used for events of myocardial infarction-unstable 
angina, stroke-transient ischemic attack, and death.  In addition, the site may be contacted 
for additional source documentation for relevant events.
6.1.8
Anaphylaxis Adjudication Committee
The independent external AAC will be adjudicating observed potential anaphylactic 
events and will remain blinded to treatment allocation.  The events that are adjudicated 
and the adjudication process will be detailed in the Anaphylaxis Adjudication Committee 
Charter.  A supplemental eCRF will be used to collect information pertinent to the events.  
In addition, the site may be contacted for additional source documentation for relevant 
events.
6.2
Product Complaint
6.2.1
Definition
A Product Complaint is any Complaint (see Section 6.0 for the definition) related to the 
biologic or drug component of the product.
For a product this may include, but is not limited to, damaged/broken product or 
packaging, product appearance whose color/markings do not match the labeling, labeling 
discrepancies/inadequacies in the labeling/instructions (example:  printing illegible), 
missing components/product, or packaging issues.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
98
Any information available to help in the determination of causality to the events outlined 
directly above should be captured.
6.2.2
Reporting
Product Complaints concerning the investigational product must be reported to the 
Sponsor within 24 hours of the study site's knowledge of the event via the Product 
Complaint form.  Product Complaints occurring during the study will be followed-up to a 
satisfactory conclusion.  All follow-up information is to be reported to the Sponsor (or an 
authorized representative) and documented in source as required by the Sponsor.  Product 
Complaints associated with AEs will be reported in the study summary.  All other 
complaints will be monitored on an ongoing basis.
Product Complaints may require return of the product with the alleged complaint 
condition.  In instances where a return is requested, every effort should be made by the 
Investigator to return the product within 30 days.  If returns cannot be accommodated 
within 30 days, the site will need to provide justification and an estimated date of return.
The description of the complaint is important for AbbVie in order to enable AbbVie to 
investigate and determine if any corrective actions are required.
7.0
Protocol Deviations
AbbVie does not allow intentional/prospective deviations from the protocol unless when 
necessary to eliminate an immediate hazard to study subjects.  The principal Investigator 
is responsible for complying with all protocol requirements, and applicable global and 
local laws regarding protocol deviations.  If a protocol deviation occurs (or is identified, 
including those that may be due to the COVID-19 pandemic) after a subject has been 
enrolled, the principal Investigator is responsible for notifying IEC/IRB regulatory 
authorities (as applicable), and AbbVie.
Such contact must be made as soon as possible to permit a review by AbbVie to 
determine the impact of the deviation on the subject and/or the study.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
99
8.0
Statistical Methods and Determination of Sample 
Size
8.1
Statistical and Analytical Plans
The primary objective of the statistical analyses is to evaluate the efficacy and safety of 
two risankizumab induction doses versus placebo in subjects with moderately to severely 
active CD who had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal disease).  
When all patients complete their Week 12/PD visit, the database will be locked and un-
blinded for the 12-week induction period.  The planned analysis for the 12-week induction 
period will be performed.  This is the only and final analysis for co-primary endpoints of 
the 12-week induction period.  When all the patients who enter the induction Period 2 
finish Week 24/PD visit, the database will be locked for the whole study and all the 
planned analyses for the induction Period 2 will be performed.
Complete, specific details of the statistical analyses will be described and fully 
documented in the study Statistical Analysis Plan (SAP).  The SAP will be finalized prior 
to the study database lock.
The impact of missing data due to COVID-19 will be monitored and appropriate 
modifications to the analysis of primary and key secondary endpoints for handling such 
missing data will be reflected and incorporated in the final SAP.
8.1.1
Datasets for Analysis 
8.1.1.1
Intent-to-Treat Analysis Set
The intent-to-treat (ITT) analysis set includes all randomized subjects who received at 
least one dose of study drug.  The primary population for efficacy analysis are the subjects 
in the intent-to-treat set who had baseline eligibility SES-CD of ≥ 6 (≥ 4 for isolated ileal 
disease).  The ITT subjects will be analyzed as randomized.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
100
8.1.1.2
Safety Analysis Set
The safety analysis set consists of all subjects who received at least one dose of the study 
drug.  The safety set will be analyzed as treated, according to treatment the subject 
actually received.  The safety set will be used for safety analysis.
8.1.2
Definition of Missing Data Imputation 
Missing data will be imputed using one or more of the following methods:
Non-Responder Imputation (NRI):  In NRI analyses, subjects who prematurely 
discontinue the study prior to efficacy assessment at Week 12 will be considered non-
responders with respect to the efficacy endpoint. 
Observed Cases (OC):  The OC analysis will not impute values for missing evaluations, 
and thus a subject who does not have an evaluation on a scheduled visit will be excluded 
from the OC analysis for that visit.
8.1.3
Subject Disposition 
The number and percentage of subjects who are enrolled, randomized and received at 
least one dose of study drug, and the number of subjects who prematurely discontinued 
and the reason for premature discontinuation will be summarized by treatment group.  
Premature discontinuation of study drug will be summarized for each treatment group, as 
well as for all subjects combined, with frequencies and percentages overall and by reason 
for discontinuation for all randomized subjects who received at least one dose of study 
drug.  Subjects may have multiple reasons for prematurely discontinuing study drug, but 
will be counted no more than once for the total ("Any Reason").
8.1.4
Demographics and Baseline Characteristics
Demographics (where collection is allowed) and Baseline characteristics of the study 
subjects will be summarized using descriptive statistics.  Summary statistics for 
continuous variables will include the number of observations, mean, standard deviation, 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
101
median, and range for each treatment group.  For other categorical or discrete variables, 
frequencies and percentages will be computed in each category for each treatment group, 
as well as for all subjects combined.
8.1.5
Prior and Concomitant Medications
Prior therapy and medications will include all therapies and medications administered 
prior to the date of the first dose of study drug.  Prior therapy and medication will be 
summarized for all randomized subjects.  No statistical test will be performed.
Concomitant medications will be summarized for all randomized subjects.  Concomitant 
medications will be summarized using the World Health Organization Drug Dictionary 
with frequencies and percentages for each treatment group.  No statistical test will be 
performed. 
8.1.6
Efficacy Analysis
8.1.6.1
Primary Efficacy Variables
The co-primary endpoints are the proportion of subjects who achieve clinical remission at 
Week 12 and the proportion of subjects who achieve endoscopic response at Week 12. 
The comparisons between each risankizumab dose versus placebo for the primary efficacy 
variable will be performed using the Cochran-Mantel-Haenszel (CMH) test adjusted by 
number of prior biologics failed (1, > 1) and steroid use at Baseline (yes, no).  A multiple 
testing procedure will be used to provide strong control of the type 1 error rate at 
alpha = 0.05 (2-sided) across analyses comparing each risankizumab dose level to placebo 
with respect to the co-primary endpoints, and ranked secondary endpoints.  Specifically, 
testing will utilize a sequence of hypothesis testing for the co-primary endpoints followed 
by the ranked secondary endpoints, and will begin with testing each of the co-primary 
endpoints using α of 0.025 (2-sided) for each dose compared to placebo.  If both co-
primary endpoints achieve statistical significance within a dose level, continued testing 
will follow a pre-specified weight of α allocation between the single hypothesis within the 
family, as well as between the families of hypotheses across the doses.  Details will be 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
102
provided in the Statistical Analysis Plan.  A CMH based two-sided 95% confidence 
interval for the difference between treatment groups will be calculated.
If average daily SF or average daily AP score or endoscopic data at Week 12 are missing, 
the NRI approach will be applied.  Subjects who discontinue prior to Week 12 for any 
reason will be considered as "not-achieved" for clinical remission and endoscopic 
response endpoints.  Sensitivity analyses for missing data handling using MI, PMM and 
OC will be performed for co-primary endpoints and details will be outlined in the SAP.
8.1.6.2
Secondary Efficacy Variables 
The secondary efficacy variables are divided into two groups.  The first group includes 
ranked secondary endpoints, which are ranked by clinical importance.  Statistical 
significance is assessed at the pre-specified alpha level (two-sided) in ranked endpoint 
order until the significant level exceeds the pre-specified alpha level.  No additional 
statistically significant treatment differences could be declared if the preceding ranked 
endpoint fails to achieve the pre-specified alpha level.  The second group includes all 
other additional secondary variables.  All analyses of secondary endpoints will be 
performed using the ITT analysis set. 
In general, continuous secondary efficacy variables will be analyzed using a Mixed-Effect 
Model Repeated Measure (MMRM) model including factors for treatment group, visit, 
visit by treatment interaction, and stratification variables, for the longitudinal continuous 
endpoints.  The MMRM analysis is considered primary for inferential purposes. 
Categorical secondary efficacy variables will be analyzed using the CMH test controlling 
for stratification variables.  Non-responder imputation for missing data will be used for 
categorical secondary endpoints. 
Analysis of Pattern Mixture Model (PMM) will be performed as sensitivity analyses for 
ranked secondary endpoints.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
103
8.1.7
Safety Analysis 
Safety analyses will be carried out using the safety analysis sets, which includes all 
subjects who receive at least one dose of study drug.  Incidence of AEs, including those 
related to study drug, changes in vital signs, physical examination results, and clinical 
laboratory values will be analyzed.
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
dictionary.  Treatment-emergent AEs are defined as AEs that began or worsened in 
severity after initiation of study drug and within 140 days after the last dose of the study 
drug.  An overview of treatment-emergent AEs, including AEs leading to death and AEs 
leading to premature discontinuation (see details in the SAP), AEs by MedDRA preferred 
term and system organ class, AEs by maximum relationship to study drug, and AEs by 
maximum severity will be summarized by number and percentage.  
Continuous laboratory and vital sign parameters will be summarized for each treatment 
group by visit.  Treatment group differences between each of the risankizumab dosing 
groups and the placebo group for changes from Baseline may be analyzed using a 
one-way Analysis of Variance (ANOVA).  Vital signs and laboratory data will be 
described by statistical characteristics and frequency of abnormal values.  In addition, 
shift tables and listings will be provided for abnormal values, whereby the normal range 
of the analyzing laboratory will be used.  Analysis details will be specified in the SAP.
8.1.8
Analysis of Optional Exploratory Variables
For exploratory biomarkers that are measured, including but not limited to 
pharmacogenetic, epigenetic, transcriptomic, proteomic, and metabolomic and immune 
cell surface markers or functional biomarkers, the association of biomarkers to the 
efficacy and safety endpoints may be explored for each biomarker one at a time, and also 
for combinations of biomarkers via some multivariate predictive modeling algorithms.  
Optimal multivariate combinations of biomarkers that associate with efficacy endpoints, 
subject response/non-response (with respect to appropriate clinical endpoints), and also 
with safety endpoints may be explored via a variety of statistical predictive modeling 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
104
algorithms.  Cut-points for individual biomarkers and optimal combinations of biomarkers 
that differentiate the subject response with respect to efficacy/safety endpoints may be 
explored using the in-house developed subgroup identification algorithms: Sequential 
BATTing, PRIM, AIM BATTing, and AIM Rule.  The significance of these multivariate 
combinations of biomarkers may be assessed via at least 20 iterations of 5-fold cross-
validation.21,22
8.1.9
Analysis of Pharmacokinetic and Pharmacodynamic 
Variables
Serum risankizumab concentrations will be summarized at each time point for each 
dosing regimen using descriptive statistics.  In addition, ADA incidence will be 
summarized by cohorts and study visits.  ADA titers will be tabulated for each subject at 
the respective study visits.  Data from this study may be combined with data from other 
studies for the population pharmacokinetic and exposure-response analyses and may not 
be part of the clinical study report.  Population pharmacokinetic and exposure-response 
analyses of only data from this study may not be conducted.  The following general 
methodology will be used for the population pharmacokinetic analysis.
Population pharmacokinetic analyses of risankizumab will be performed using the actual 
sampling time relative to dosing.  Pharmacokinetic models will be build using a non-
linear mixed-effects modeling approach with NONMEM software (Version 7, or a higher 
version).  The structure of the starting pharmacokinetic model will be based on the 
pharmacokinetic analysis data from previous studies.  Systemic clearance and volume of 
distribution of risankizumab will be the pharmacokinetic parameters of major interest in 
the NONMEM analyses.  If necessary, other parameters, including the parameters 
describing absorption characteristics, may be estimated if useful in the analysis.
The evaluation criteria described below will be used to examine the performance of 
different models:
1.
The objective function of the best model is significantly smaller than the alternative 
model(s).


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
105
2.
The observed and predicted concentrations from the preferred model are more 
randomly distributed across the line of unity (a straight line with zero intercept and 
a slope of one) than the alternative model(s).
3.
Visual inspection of model fit, standard errors of model parameters and change in 
inter-subject and intra-subject error.
Once an appropriate base pharmacokinetic model (including inter- and intra-subject error 
structure) is developed, empirical Bayesian estimates of individual model parameters will 
be calculated by the posterior conditional estimation technique using NONMEM.  The 
relationship between these conditional estimates CL/F or Vss/F values with only 
potentially physiologically relevant or clinically meaningful covariates (such as ADA 
classification, subject age, sex, body weight, concomitant medications, possibly baseline 
inflammatory and disease markers) may be explored using stepwise forward selection 
method, or another suitable regression/smoothing method at a significance level of 0.01.
After identification of all relevant covariates, a stepwise backward elimination of 
covariates from the full model will be employed to evaluate the significance (at P < 0.001, 
corresponding to a decrease in objective function > 10.83 for one degree of freedom) of 
each covariate in the full model.
Linear or non-linear relationships of primary pharmacokinetic parameters with various 
covariates may also be explored.
Relationships between exposure and clinical observations (primary or secondary efficacy 
or safety variables of interest) may be explored.  Additional analyses will be performed if 
useful and appropriate.
8.2
Determination of Sample Size
The co-primary endpoints are the proportion of subjects with clinical remission at 
Week 12 and the proportion of subjects who achieve endoscopic response at Week 12.  


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
106
Sample size calculation is based on the larger sample size needed to detect treatment 
difference for each of the co-primary endpoints.  Since historical data show slightly lower 
event rate and similar treatment difference versus placebo for the endoscopic response 
rate than the clinical remission rate at Week 12, clinical remission rates at Week 12 are 
used for power calculation.  A total of approximately 579 subjects will be randomized into 
2 risankizumab treatment groups and the placebo group in a 1:1:1 ratio with 193 subjects 
per treatment group).  The sample size for this study is based on the expected proportion 
of subjects who achieve clinical remission at Week 12 between risankizumab and placebo.  
Assuming the Week 12 clinical remission rate will be 23.5% for risankizumab groups and 
10% for the placebo group, a sample size of 193 subjects for each risankizumab group and 
193 subjects for the placebo group will have approximately 89% power to detect the 
treatment difference between risankizumab and placebo in clinical remission rates at 
Week 12 using a Fisher's exact test at alpha level of 0.025 (two-sided).  Assuming the 
Week 12 endoscopic response rate will be 17% for one of the risankizumab dose groups 
and 5% for the placebo group, this sample size will have 93% power to detect the 
treatment difference between the risankizumab dose groups and placebo in endoscopic 
response rates at Week 12 using a Fisher's exact test at alpha of 0.025 (two-sided).  
8.3
Randomization Methods
A total of approximately 579 subjects will be randomized into two risankizumab dose 
groups and the placebo group in a 1:1:1 ratio.  Randomization will be stratified by the 
number of prior biologics failed (1, > 1), steroid use at Baseline (yes, no), and Baseline 
SES-CD (original, alternative), where the stratum of "original" includes the patients with 
baseline SES-CD of ≥ 6 (or ≥ 4 for subjects with isolated ileal disease), and the stratum of 
"alternative" includes the patients with baseline SES-CD of ≥ 3 to < 6 for ileaocolonic or 
colonic disease or SES-CD of 3 for isolated ileal disease.  
Subjects with clinical non-response to risankizumab at Week 12 will be re-randomized in 
a 1:1:1 ratio to 1200 mg IV dose group, 360 mg SC dose group, or 180 mg SC dose 
group.  Subjects with clinical non-response to placebo at Week 12 will blindly receive 
1200 mg risankizumab IV dose.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
107
9.0
Ethics
9.1
Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB)
Good Clinical Practice (GCP) requires that the clinical protocol, any protocol 
amendments, the Investigator's Brochure, the informed consent and all other forms of 
subject information related to the study (e.g., advertisements used to recruit subjects) and 
any other necessary documents be reviewed by an IEC/IRB.  The IEC/IRB will review the 
ethical, scientific and medical appropriateness of the study before it is conducted.  
IEC/IRB approval of the protocol, informed consent and subject information and/or 
advertising, as relevant, will be obtained prior to the authorization of drug shipment to a 
study site.
Following local regulation, substantial amendments may also be reviewed and approved 
by the national competent authority.
Any amendments to the protocol will require IEC/IRB approval prior to implementation 
of any changes made to the study design.  The Investigator will be required to submit, 
maintain and archive study essential documents according to International Conference on 
Harmonization (ICH) GCP and all other applicable regulatory requirements.
Any SAEs that meet the reporting criteria, as dictated by local regulations, will be 
reported to both responsible Ethics Committees and Regulatory Agencies, as required by 
local regulations.  During the conduct of the study, the Investigator should promptly 
provide written reports (e.g., ICH Expedited Reports, and any additional reports required 
by local regulations) to the IEC/IRB of any changes that affect the conduct of the study 
and/or increase the risk to subjects.  Written documentation of the submission to the 
IEC/IRB should also be provided to AbbVie.
9.2
Ethical Conduct of the Study
The study will be conducted in accordance with the protocol, ICH guidelines, applicable 
regulations and guidelines governing clinical study conduct and the ethical principles that 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
108
have their origin in the Declaration of Helsinki.  Responsibilities of the clinical 
Investigator are specified in Appendix A.
In the event of a state of emergency due to the COVID-19 pandemic leading to difficulties 
in performing protocol-specified procedures, AbbVie will engage with study site 
personnel in efforts to ensure the safety of subjects, maintain protocol compliance, and 
minimize risks to the integrity of the study while trying to best manage subject continuity 
of care.  This may include alternative methods for assessments (e.g., phone contacts or 
virtual site visits), alternative locations for data collection (e.g., use of a local lab instead 
of a central lab). In all cases, these alternative measures must be allowed by local 
regulations and permitted by IRB/IEC.  Investigators should notify AbbVie if any urgent 
safety measures are taken to protect the subjects against any immediate hazard.
9.3
Subject Information and Consent
For adult subjects the Investigator or his/her representative will explain the nature of the 
study to the subject, and answer all questions regarding this study.  Prior to any study-
related screening procedures being performed on the subject, the informed consent 
statement will be reviewed and signed and dated by the subject, the person who 
administered the informed consent, and any other signatories according to local 
requirements.  A copy of the informed consent form will be given to the subject and the 
original will be placed in the subject's medical record.  An entry must also be made in the 
subject's dated source documents to confirm that informed consent was obtained prior to 
any study-related procedures and that the subject received a signed copy.
Information regarding incentives for subjects and information regarding provisions for 
treating and/or compensating subjects who are harmed as a consequence of participation 
in the study can be found in the informed consent form.
Samples for exploratory research/validation studies will only be collected if the subject 
has voluntarily signed and dated the separate written consent for exploratory 
research/validation studies, approved by an IRB/IEC, after the nature of the testing has 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
109
been explained and the subject has had an opportunity to ask questions.  The separate 
written consent must be signed before the exploratory research/validation studies samples 
are collected and testing is performed.  If the subject does not consent to the exploratory 
research/validation studies, it will not impact the subject's participation in the study.
For adolescent subjects the investigator or his/her representative will explain the nature of 
the study to the subject and the subject's parent/legal guardian, and answer all questions 
regarding this study.  Adolescent subjects will be included in all discussions in order to 
obtain verbal or written assent.  Prior to any study-related screening procedures being 
performed on the subject, the informed consent statement will be reviewed and signed and 
dated by the subject's parent/legal guardian, the person who administered the informed 
consent, and any other signatories according to local requirements.  Additionally, in 
keeping with each institution's IRB/IEC requirements, an informed assent form may also 
be obtained by each subject prior to any study-related procedures being performed.  If a 
subject becomes of legal age during the course of the study, that subject will need to be 
re-consented.
A copy of the informed consent form and the assent form will be given to the subject and 
the subject's parent/legal guardian and the original will be placed in the subject's medical 
record.  An entry must also be made in the subject's dated source documents to confirm 
that informed consent was obtained prior to any study-related procedures and that the 
subject received a signed copy. 
Genetic and non-genetic biomarker analysis will only be performed if the subject's 
parent/legal guardian has voluntarily signed and dated a separate genetic and non-genetic 
biomarker informed consent, approved by an IRB/IEC, after the nature of the testing has 
been explained and the subject and subject's parent/legal guardian has had an opportunity 
to ask questions.  The separate genetic and non-genetic biomarker informed consent must 
be signed before the genetic and non-genetic biomarker testing is performed.  If the 
subject's parent/legal guardian does not consent to the genetic and non-genetic biomarker 
testing, it will not impact the subject's participation in the study.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
110
In the event a subject withdraws from the main study, optional exploratory research 
samples will continue to be stored and analyzed unless the subject specifically withdraws 
consent for the optional samples.  If consent is withdrawn for the optional sampling, the 
subject must inform their study doctor, and once AbbVie is informed, the optional 
samples will be destroyed.  However, if the subject withdraws his/her consent and the 
samples have already been tested, those results will still remain as part of the overall 
research data.
10.0
Source Documents and Case Report Form 
Completion
10.1
Source Documents
Source documents are defined as original documents, data and records.  This may include 
hospital records, clinical and office charts, ECGs, laboratory data/information, subjects' 
diaries or evaluation checklists, pharmacy dispensing and other records, recorded data 
from automated instruments, microfiches, photographic negatives, microfilm or magnetic 
media, and/or x-rays.  IRT may also be the source for drug accountability.  Data collected 
during this study must be recorded on the appropriate source documents.  The Investigator 
Awareness Date (SAE eCRF) may serve as the source for this data point.  This AE data 
point required for eCRF completion can be entered directly in the eCRF.
The Investigator(s)/institution(s) will permit study-related monitoring, audits, IEC/IRB 
review, and regulatory inspection(s), providing direct access to source data documents.
During the COVID-19 pandemic, remote monitoring of data may be employed if allowed 
by the local regulatory authority, IRB/IEC, and the study site.
10.2
Case Report Forms
Electronic case report forms (eCRF) must be completed for each subject screened/enrolled 
in this study.  These forms will be used to transmit information collected during the study 
to AbbVie and regulatory authorities, as applicable.  The eCRF data for this study are 
being collected with an EDC system called Rave® provided by the technology vendor 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
111
Medidata Solutions Incorporated, NY, USA.  The EDC system and the study-specific 
eCRFs will comply with Title 21 CFR Part 11.  The documentation related to the 
validation of the EDC system is available through the vendor, Medidata, while the 
validation of the study-specific eCRFs will be conducted by AbbVie and will be 
maintained in the Trial Master File at AbbVie.
The Investigator will document subject data in his/her own subject files.  These subject 
files will serve as source data for the study.  All eCRF data required by this protocol will 
be recorded by investigative site personnel in the EDC system.  All data entered into the 
eCRF will be supported by source documentation.
The Investigator or an authorized member of the Investigator's staff will make any 
necessary corrections to the eCRF.  All change information, including the date and person 
performing the corrections, will be available via the audit trail, which is part of the EDC 
system.  For any correction, a reason for the alteration will be provided.  The eCRFs will 
be reviewed periodically for completeness, legibility, and acceptability by AbbVie 
personnel (or their representatives).  AbbVie (or their representatives) will also be allowed 
access to all source documents pertinent to the study in order to verify eCRF entries.  The 
principal Investigator will review the eCRFs for completeness and accuracy and provide 
his or her electronic signature and date to eCRFs as evidence thereof.
Medidata will provide access to the EDC system for the duration of the study through a 
password-protected method of internet access.  Such access will be removed from 
Investigator sites at the end of the site's participation in the study.  Data from the EDC 
system will be archived on appropriate data media (CD-ROM, etc.) and provided to the 
Investigator at that time as a durable record of the site's eCRF data.  It will be possible for 
the Investigator to make paper printouts from that media.
10.3
Electronic Patient Reported Outcomes (ePRO)
Patient reported data must be completed for each subject screened/enrolled in this study.  
Some of these data are being collected with an ePRO system called Trialmax, provided by 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
112
the technology vendor CRF Health of Plymouth Meeting, PA, USA.  The ePRO system is 
in compliance with Title 21 CFR Part 11.  The documentation related to the system 
validation of the ePRO system is available through the vendor, CRF Health, while the 
user acceptance testing of the study specific PRO design will be conducted and 
maintained at AbbVie.
The subject will be entering the data on an electronic device; these data will be uploaded 
to a server.  The data on the server will be considered source, and maintained and 
managed by CRF Health.
Internet access to the ePRO data will be provided by CRF Health for the duration of the 
study.  This access will be available for the duration of the study to the site Investigator, 
as well as delegated personnel.  Such access will be removed from Investigator sites 
following the receipt of the study archive.  Data from the ePRO system will be archived 
on appropriate data media (CD-ROM, etc.) and provided to the Investigator at that time as 
a durable record of the site's ePRO data.  It will be possible for the Investigator to make 
paper print-outs from that media.
The ePRO data will be collected by the following methods:
Diary Based
The ePRO data (number of liquid or very soft stools, use of medications used for 
endoscopy preparation, abdominal pain, and general well-being) will be collected 
electronically via a handheld device into which the subject will record the required pieces 
of information on a daily basis.  The electronic device will be programmed to allow data 
entry once per day.  All data entered on the device will be immediately stored to the 
device itself and manually/automatically uploaded to a central server administrated by 
CRF Health.  The investigational site staff will be able to access all uploaded subject 
entered data via a password protected website, up until the generation, receipt and 
confirmation of the study archive.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
113
Tablet Based
The PROs listed below will be collected electronically via a Tablet device into which the 
subject will directly enter the required pieces of information while at the site.  The 
electronic device will be programmed to allow data entry for only the visits specified in 
the protocol and will not allow for subjects to complete more than one of the same 
assessment at any one visit.  All data entered on the device will be immediately stored to 
the device itself and (manually/automatically) uploaded to a central server administrated 
by CRF Health.  The investigational site staff will be able to access all uploaded subject 
entered data via a password protected website, up until the generation, receipt and 
confirmation of the study archive.
●
CSS
●
PGIC
●
PGIS
●
EQ-5D-5L
●
FACIT-F
●
IBDQ
●
SF-36
●
WPAI-CD
11.0
Data Quality Assurance
To ensure data integrity and subject safety, a study monitor will, throughout the study, 
verify that all subjects signed agreement of informed consent prior to any study-specific 
procedures being conducted.  The study monitor will confirm that the Investigator is 
conducting the study in compliance with the protocol, GCP and applicable regulations, 
and verify that the information reported in the eCRF is complete, accurate, and supported 
by information in source documents.
Computer logic and manual checks will be created to identify items such as inconsistent 
study dates.  Any necessary corrections will be made to the eCRF.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
114
12.0
Use of Information
All information concerning risankizumab and AbbVie operations, such as AbbVie patent 
applications, formulas, manufacturing processes, basic scientific data, or formulation 
information, supplied by AbbVie and not previously published is considered confidential 
information.
The information developed during the conduct of this clinical study is also considered 
confidential and will be used by AbbVie in connection with the development of 
risankizumab.  This information may be disclosed as deemed necessary by AbbVie to 
other clinical Investigators, other pharmaceutical companies, to the Food and Drug 
Administration (FDA) and to other governmental agencies.  To allow for the use of the 
information derived from this clinical study and to ensure complete and thorough analysis, 
the Investigator is obligated to provide AbbVie with complete test results and all data 
developed in this study and to provide direct access to source data/documents for study-
related monitoring, audits, IEC/IRB review, and regulatory inspection.
This confidential information shall remain the sole property of AbbVie, shall not be 
disclosed to others without the written consent of AbbVie, and shall not be used except in 
the performance of this study.
If this protocol or the information gained from the conduct of this study will be made 
public (disclosed/published), AbbVie will determine the information that is not yet in the 
public domain and if the disclosure of such information may undermine AbbVie's 
interests, will remain confidential at the time of disclosure/publication.
The Investigator will maintain a confidential subject identification code list of all subjects 
enrolled in the study (by name and subject number).  This list will be maintained at the 
site and will not be retrieved by AbbVie. 
Any exploratory research/validation studies that may be done using the samples from this 
study will be experimental in nature and the results will not be suitable for clinical 
decision making or patient management, hence, neither the Investigator, the subject, nor 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
115
the subject's physician (if different from the Investigator) will be informed of individual 
subject results, should analyses be performed, nor will anyone not directly involved in this 
research.  Correspondingly, researchers will have no access to subject identifiers.  
Individual results will not be reported to anyone not directly involved in this research 
other than for regulatory purposes.  Aggregate data from exploratory research/validation 
studies from this study may be used in scientific publications or presented at medical 
conventions.  Exploratory research/validation studies data will be published or presented 
only in a way that does not identify any individual subject.
13.0
Completion of the Study
The Investigator will conduct the study in compliance with the protocol and complete the 
study within the timeframe specified in the contract between the Investigator and AbbVie.  
Continuation of this study beyond this date must be mutually agreed upon in writing by 
both the Investigator and AbbVie.  The Investigator will provide a final report to the 
IEC/IRB following conclusion of the study, and will forward a copy of this report to 
AbbVie or their representative.
The Investigator must submit, maintain, and archive any records related to the study 
according to ICH GCP and all other applicable regulatory requirements.  If the 
Investigator is not able to retain the records, he/she must notify AbbVie to arrange 
alternative archiving options.
AbbVie will select the signatory Investigator from the Investigators who participate in the 
study.  Selection criteria for this Investigator will include level of participation as well as 
significant knowledge of the clinical research, investigational drug and study protocol.  
The signatory Investigator for the study will review and sign the final study report in 
accordance with the European Agency for the Evaluation of Medicinal Products Guidance 
on Investigator's Signature for Study Reports.
The end-of-study is defined as the date of the last subject's last visit.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
116
14.0
Investigator's Agreement
1.
I have received and reviewed the Investigator's Brochure for risankizumab.
2.
I have read this protocol and agree that the study is ethical.
3.
I agree to conduct the study as outlined and in accordance with all applicable 
regulations and guidelines.
4.
I agree to maintain the confidentiality of all information received or developed in 
connection with this protocol.
5.
I agree that all electronic signatures will be considered the equivalent of a 
handwritten signature and will be legally binding.
Protocol Title: 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 
Induction Study to Assess the Efficacy and Safety of Risankizumab 
in Subjects with Moderately to Severely Active Crohn's Disease 
Who Failed Prior Biologic Treatment
Protocol Date:
28 July 2020
Signature of Principal Investigator
Date
Name of Principal Investigator (printed or typed)


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
117
15.0
Reference List
1.
Hanauer SB, Sandborn W; Practice Parameters Committee of the American 
College of Gastroenterology.  Management of Crohn's disease in adults.  Am J 
Gastroenterol.  2001;96(3):635-43.
2.
Loftus EV Jr.  Clinical epidemiology of inflammatory bowel disease:  incidence, 
prevalence, and environmental influences.  Gastroenterology.  
2004;126(6):1504-17. 
3.
Probert CS, Jayanthi V, Rampton DS, et al.  Epidemiology of inflammatory bowel 
disease in different ethnic and religious groups:  limitations and aetiological clues.  
Int J Colorectal Dis.  1996;11(1):25-8. 
4.
Molodecky NA, Soon IS, Rabi DM, et al.  Increasing incidence and prevalence of 
the inflammatory bowel diseases with time, based on systematic review.  
Gastroenterology.  2012;142(1):46-54.
5.
Baumgart DC, Sandborn WJ.  Crohn's disease.  Lancet.  2012;380(9853):1590-605.
6.
Leong RW, Lau JY, Sung JJ.  The epidemiology and phenotype of Crohn's disease 
in the Chinese population.  Inflamm Bowel Dis.  2004;10(5):646-51.
7.
Lee YM, Fock K, See SJ, et al.  Racial differences in the prevalence of ulcerative 
colitis and Crohn's disease in Singapore.  J Gastroenterol Hepatol.  
2000;15(6):622-5.
8.
Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of 
American College of Gastroenterology.  Management of Crohn's disease in adults.  
Am J Gastroenterol.  2009;104(2):465-83.
9.
Froslie KF, Jahnsen J, Moum BA, et al.  Mucosal healing in inflammatory bowel 
disease:  results from a Norwegian population-based cohort.  Gastroenterology.  
2007;133(2):412-22.
10.
Kakkar A, Wasan SK, Farraye FA.  Targeting mucosal healing in Crohn's disease.  
Gastroenterol Hepatol (NY).  2011;7(6):374-80.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
118
11.
Dignass A, Van Assche G, Lindsay JO, et al; European Crohn's and Colitis 
Organisation (ECCO).  The second European evidence-based consensus on the 
diagnosis and management of Crohn's disease:  current management.  J Crohns 
Colitis.  2010;4(1):28-62.  
12.
Colombel JF, Sandborn WJ, Rutgeerts P, et al.  Adalimumab for maintenance of 
clinical response and remission in patients with Crohn's disease:  the CHARM trial.  
Gastroenterology.  2007;132(1):52-65.
13.
Sandborn WJ, Feagan BG, Rutgeerts P, et al.  Vedolizumab as induction and 
maintenance therapy for Crohn's disease.  N Engl J Med.  2013;369(8):711-21.
14.
Targan SR, Hanauer SB, van Deventer SJ, et al.  A short-term study of chimeric 
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.  
Crohn's disease cA2 study group.  N Engl J Med.  1997;337(15):1029-35.
15.
Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group.  
Maintenance infliximab for Crohn's disease:  the ACCENT I randomised trial.  
Lancet.  2002;359(9317):1541-9.
16.
Hanauer SB, Sandborn WJ, Rutgeerts P, et al.  Human anti-tumor necrosis factor 
monoclonal antibody (adalimumab) in Crohn's disease:  the CLASSIC-I trial.  
Gastroenterology.  2006;130(2):323-33.
17.
Sandborn WJ, Feagan BG, Stoinov S, et al; PRECISE 1 Study Investigators.  
Certolizumab pegol for the treatment of Crohn's disease.  N Engl J Med.  
2007;357(3):228-38.
18.
Siakavellas SI, Bamias G.  Role of the IL-23/IL-17 axis in Crohn's disease.  Discov 
Med.  2012;14(77):253-62.
19.
Boyapati R, Satsangi J, Ho GT.  Pathogenesis of Crohn's disease.  F1000Prime 
Rep.  2015;7:44.  eCollection 2015.
20.
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE).  Available from:  http://ctep.cancer.gov/protocolDevelopment/ 
electronic_applications/ctc.htm#ctc_40.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
119
21.
McKeegan EM, Ansell PJ, Davis G, et al.  Plasma biomarker signature associated 
with improved survival in advanced non-small cell lung cancer patients on 
linifanib.  Lung Cancer.  2015;90(2):296-301.
22.
Chen G, Zhong H, Belousov A, et al.  A PRIM approach to predictive-signature 
development for patient stratification.  Stat Med.  2015;34(2):317-42.
23.
Daperno M, D'Haens G, Van Assche G, et al.  Development and validation of a 
new, simplified endoscopic activity score for Crohn's disease:  the SES-CD.  
Gastrointest Endosc.  2004;60(4):505-12.
24.
Sampson HA, Muñoz-Furlong A, Campbell RL, et al.  Second symposium on the 
definition and management of anaphylaxis:  summary report - Second National 
Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium.  J Allergy Clin Immunol.  2006;117(2):391-7.
25.
Marshall WA, Tanner JM.  Variations in pattern of pubertal changes in girls.  Arch 
Dis Child.  1969;44(235):291-303.
26.
Marshall WA, Tanner JM.  Variations in the pattern of pubertal changes in boys.  
Arch Dis Child.  1970;45(239):13-23.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
120
Appendix A.
Responsibilities of the Clinical Investigator
Clinical research studies sponsored by AbbVie are subject to the Good Clinical Practices 
(GCP) and local regulations and guidelines governing the study at the site location.  In 
signing the Investigator Agreement in Section 14.0 of this protocol, the Investigator is 
agreeing to the following:
1.
Conducting the study in accordance with the relevant, current protocol, making 
changes in a protocol only after notifying AbbVie, except when necessary to 
protect the safety, rights or welfare of subjects.
2.
Personally conducting or supervising the described investigation(s).
3.
Informing all subjects, or persons used as controls, that the drugs are being used for 
investigational purposes and complying with the requirements relating to informed 
consent and ethics committees (e.g., independent ethics committee [IEC] or 
institutional review board [IRB]) review and approval of the protocol and 
amendments.
4.
Reporting adverse experiences that occur in the course of the investigation(s) to 
AbbVie and the site director.
5.
Reading the information in the Investigator's Brochure/safety material provided, 
including the instructions for use and the potential risks and side effects of the 
investigational product(s).
6.
Informing all associates, colleagues, and employees assisting in the conduct of the 
study about their obligations in meeting the above commitments.
7.
Maintaining adequate and accurate records of the conduct of the study, making
those records available for inspection by representatives of AbbVie and/or the 
appropriate regulatory agency, and retaining all study-related documents until 
notification from AbbVie.
8.
Maintaining records demonstrating that an ethics committee/competent authority 
reviewed and approved the initial clinical investigation and all amendments.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
121
9.
Reporting promptly, all changes in the research activity and all unanticipated 
problems involving risks to human subjects or others, to the appropriate individuals 
(e.g., coordinating investigator, institution director) and/or directly to the ethics 
committees and AbbVie.
10.
Following the protocol and not make any changes in the research without ethics 
committee approval, except where necessary to eliminate apparent immediate 
hazards to human subjects.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
122
Appendix B.
List of Protocol Signatories
Name
Title
Functional Area
Clinical Development, Immunology
Clinical Development, Immunology
Statistics
Statistics
Clinical Pharmacology and Pharmacometrics
Bioanalysis
Clinical Operations


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
123
Appendix C.
Study Activities
Screening Period
(35 Days)a
12-Week Double-Blind Induction
Induction Period 2
Unschb
140-Day
Follow-Upc
Activity
Screening
Baseline
Week 4
Week 8
Week 12/PD
Week 16
Week 20
Week 24
Informed consent
X
Inclusion/Exclusion
X
Xd
Medical/Surgery History
X
Xd
Previous and Concomitant 
Medication
X
Xd
X
X
X
X
X
X
X
Physical Exame/Vital Signsf
X
X
X
X
X
X
X
X
X
Adverse Event Assessmentg
X
X
X
X
X
X
X
X
X
X
TB Screeningh
Xx
ECGi
Xx
Hepatitis B, Hepatitis C 
Screeningj and HIV Testk
Xx
C. difficile toxin
Xw
Urinalysisl,m
Xw
Xn
X
X
Pregnancy Testm,o
Xw
X
X
X
X
X
X
X
Chemistry and Hematologym
Xw
Xn
X
X
X
X
X
X
Optional Blood Sample for 
Biologic Drug Level
X
COVID-19 Assessmenty
X
hs-CRPm
X
X
X
X
X
Serum Risankizumabp
X
X
X
X
X


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
124
Screening Period
(35 Days)a
12-Week Double-Blind Induction
Induction Period 2
Unschb
140-Day
Follow-Upc
Activity
Screening
Baseline
Week 4
Week 8
Week 12/PD
Week 16
Week 20
Week 24
Serum Anti-Drug Antibody 
(ADA)p, u and Neutralizing 
Anti-Drug Antibodies (nAb)p
X
X
X
X
X
X
Fecal calprotectin (FCP)m,q
X
X
X
X
Crohn's Disease Activity Index 
(CDAI)
Xr
X
X
X
X
X
X
X
Endoscopy/SES-CDs
X
X
X
Intestinal Biopsiest
X
X
X
Dispense Subject Diaryv
X
Subject Diary Review
X
X
X
X
X
X
X
X
Subject Questionnaire:
CSS
X
X
X
X
X
X
X
X
Subject Questionnaire:
PGIC and PGIS
X (PGIS 
only)
X
X
X
X
X
X
X
Subject Questionnaires:
  EQ-5D-5L
  FACIT-F
  IBDQ
  SF-36  
  WPAI-CD
X
X
X
X
Study Drug Administrationu
X
X
X
Xu
X
X
a.
The Screening period should be a minimum of 4 days, preferably 7 days for CDAI calculation, (refer to Section 5.3.1.1).  The Baseline CDAI will be calculated using the data 
collected during the Screening period.  Baseline visit date will serve as the reference for all subsequent visits.  A ± 7 day window is permitted around all study visits.
b.
Visits to retest a lab will not be considered an Unscheduled visit.  Unscheduled visits according to this table are for purposes when the subject is coming in a visit for 
evaluation and assessment.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
125
c.
Subjects will be contacted 140 days following last dose of study drug for an assessment of any new or ongoing AEs, except those subjects who roll-over into the 
Study M16-000 study after the end of study participation.
d.
Update inclusion/exclusion, prior and concomitant therapy, and medical/surgical history information to assure subject eligibility.
e.
Physical examinations are full physical examinations at Screening and Week 12 and Week 24 if the subject receives treatment in Induction Period 2.  Physical examinations at 
all other visits (including unscheduled visits) are symptom based and should include the assessment of EIMs and a count of the number of cutaneous fistulas as part of 
calculating the CDAI.
f.
Blood pressure, pulse rate, temperature, respiratory rate and weight should be performed before blood draws are performed.  Height will be measured at Screening only (with 
shoes off and then adding 1 inch or 2.5 cm) for subjects ≥ 18 years of age.  Height will be re-measured at Week 12 and Week 24 (if applicable) for subjects < 18 years of age 
at Baseline.
g.
Collection of SAEs and protocol-related nonserious AEs begins the day the subject signs the informed consent.  
h.
Subjects with negative QuantiFERON-TB Gold test and/or PPD test within 90 days of Screening will not require a repeat test (documentation must be available).  PPD skin 
test is to be read 48 to 72 hours after placement.  In case of positive PPD/positive or repeat indeterminate IGRA testing, subjects may participate in the study if further work 
up (according to local practice/guidelines) is negative for active TB.   
i.
For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at Screening will not be required, provided source documentation is available.  Subjects can 
have a repeat ECG at any time during the study as warranted based on the opinion of the Investigator. 
j.
Subjects will be tested for the presence of the HBV and HCV at Screening.  A positive result for the hepatitis B surface antigen (HBs Ag) or hepatitis C (HCV RNA 
detectable in any subject with anti-HCV Ab) will be exclusionary.  For subjects who are negative for HBs Ag but are positive for core antibodies (HBc Ab), HBV DNA PCR 
will be performed and any result that meets or exceeds detection sensitivity will be exclusionary.  
k.
HIV testing will be performed at the central laboratory, which will report the results directly to the sites.  AbbVie will not receive results from the testing.
l.
Dipstick urinalysis will be completed by the sites at required visits.  A microscopic analysis will be performed by the central laboratory, in the event the dipstick results show 
leukocytes, nitrite, protein, ketones or blood greater than negative or glucose greater than normal.  
m.
Urinalysis, chemistry and hematology, hs-CRP, and FCP may be collected at other scheduled and unscheduled visits than indicated in the table if they are warranted by the 
Investigator.
n.
Lab assessments will only need to be repeated at Baseline if the time between Screening and Baseline is greater than 14 days, or if the subject's health status has changed to 
warrant a repeat test.  
o.
Serum pregnancy test will be performed on all WOCBP at Screening.  Urine pregnancy test will be performed locally as indicated in the table for all WOCBP.  The urine 
pregnancy test must be negative to receive study drug.  If any urine pregnancy test is positive, a serum pregnancy test will be performed by the central laboratory.  FSH will 
be performed in all female subjects < 55 years old with no menses for 12 months.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
126
p.
Serum risankizumab concentrations and ADA will be determined from samples collected just prior to dosing at every visit.  The date and time of sample collection will be 
captured on the eCRF.
q.
Stool sample will be collected at each time point indicated in the table.  For the visit when endoscopy will be conducted, stool sample should be collected prior to bowel prep 
and should be returned to the site per the instructions provided outside of this protocol.  If a sample cannot be obtained during the site visit, the site will give instructions and a 
stool sample supply kit.  
r.
Diary information collected during Screening will serve to calculate Baseline CDAI.  During Screening, subjects will be instructed on how to calculate the number of very 
soft and liquid stools, including a visual depiction.  CDAI should be completed at Baseline visit, just prior to randomization.  
s.
Endoscopy at/during the Screening period or within 45 days of the Baseline visit will be used to calculate the SES-CD score at Baseline.  Endoscopic evaluations using 
SES-CD confirmed by central reader will be done at Screening.  Endoscopies completed at Week 12 and Week 24, for those subjects who receive treatment in Induction 
Period 2, will use the local reader results for stratification for Study M16-000.
t.
Biopsies may be done when performing the endoscopy to confirm CD diagnosis (if appropriate documentation for confirmation of the diagnosis does not exist), and/or to rule 
out dysplasia and colon cancer at the Investigator's discretion.  These samples will be processed and assessed locally.  Histology report should be available in the subject's 
source records.  
u.
Administration of drug will be performed after all assessments and examinations scheduled for that day have been completed, including endoscopy.  Completion of PROs are 
permitted during administration of study drug.  At Week 12, study drug will only be administered for subjects who are to receive treatment in Induction Period 2.  Subjects 
will also be dispensed a patient information card.  In the event of a suspected systemic post-dose hypersensitivity reaction, serum risankizumab, ADA, and nAb should be 
collected once within 24 hours of the reaction.  In addition, tryptase sample should be obtained between 15 minutes to 3 hours of symptom onset, and no later than 6 hours, 
and another sample is requested a minimum of 2 weeks after the recorded event or at the next study visit.  Also, plasma histamine sample should be obtained within 5 to 15 
minutes of the onset of symptoms and no later than 1 hour.
v.
Subjects should also be dispensed the patient information card.
w.
For Rescreening, if a subject is being rescreened within 14 days (≤ 14 days have passed) from the collection date of the previous screening testing, it is not required to repeat 
Screening testing for chemistry/hematology, urinalysis, serum pregnancy, and C. difficile provided that the subject's health status has not changed to warrant a repeat test.
x.
For Rescreening, if the subject had a complete initial screening evaluation including the TB test, hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency 
virus (HIV), and electrocardiogram (ECG), these tests will not be required to be repeated for re-screening provided the conditions noted in Section 5.3.1.1 are met and no 
more than 90 days have passed since the collection date of the testing.
y.
Assessment for signs/symptoms of COVID-19 infection.  If the investigator suspects the possibility of COVID-19 based on the signs, symptoms and medical complaint (chief 
complaint, history of exposure, etc.), local laboratory testing must be completed.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
127
Appendix D.
Study Activities – Optional Exploratory Research Samples
Screening Period (35 Days)a
12-Week Double-Blind Induction
Samples Collecteda
Screening
Baseline
Week 4
Week 12/PD
Pharmacogeneticb
X
Epigeneticb,c
X
X
X
Transcriptomicb,c
X
X
X
Proteomic and targeted protein investigations (plasma)b,c
X
X
X
Proteomic and targeted protein investigations (serum)b,c
X
X
X
PBMC (US sites only)d
X
X
Stoolb
X
X
X
Intestinal biopsies (RNA)b,e
X
X
Intestinal biopsies (IHC)b,e
X
X
a.
Collections to be performed only if subject provides separate written consent to collect the exploratory research/validation studies samples; if the separate consent is not 
signed, no samples can be collected.
b.
Based on the value of different technologies, samples may also be used to assess other biomarker signatures, including but not limited to metabolomics, lipidomics, and other 
approaches.
c.
It is preferred that the subject has fasted (8 hours, except for water) prior to sample collection, however it is not required.  It must be recorded whether the subject has fasted or 
not at the time of collection.
d.
Samples will be collected from US sites only.
e.
Biopsy may be done when performing the endoscopy.  Biopsy for histologic assessment by central review will be conducted at each visit with endoscopy.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
128
Appendix E.
Sample SES-CD Scoring
SES-CD Scoring23
Rectum
Sigmoid 
and 
Left 
Colon
Transverse 
Colon
Right 
Colon
Ileum
Total
Size of Ulcers 
Enter:
0 if none
1 if aphthous ulcers (Ø 0.1 to 0.5 cm)
2 if large ulcers (Ø 0.5 to 2 cm)
3 if very large ulcers (Ø > 2 cm)
Ulcerated Surface
Enter:
0 if none
1 if < 10%
2 if 10% – 30%
3 if > 30%
Affected Surface
Enter:
0 if unaffected segments
1 if < 50%
2 if 50% – 75%
3 if > 75%
Presence of Narrowing
Enter:
0 if none
1 if single, can be passed
2 if multiple, can be passed
3 if cannot be passed
TOTAL =


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
129
Appendix F.
Crohn's Disease Activity Index (CDAI)
Factor
Subtotal
1.
Number of liquid or very soft stools
(Record the frequency per day)
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
2
2.
Abdominal pain rating:
0 = none, 1 = mild, 2 = moderate,
3 = severe
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
5
3.
General well-being:
0 = generally well, 1 = slightly
underpar, 2 = poor, 3 = very poor,
4 = terrible
__+___+___+___+___+___+___=___
Days:  1    2    3    4    5    6    7    Sum
×
7
4.
Number of 6 listed categories the 
subject now has 
Check all items that apply:
☐
Arthritis/arthralgia
☐
Iritis/uveitis
☐
Erythema nodosum/pyoderma 
gangrenosum/aphthous 
stomatitis
☐
Fissure, abscess and/or anal 
fistula (draining/non-draining)
☐
Other cutaneous fistula
(draining/non-draining) Fistula
☐
Fever over 100°F (37.8°C)
during past week
_________________________________ 
_________________________________
Record "0" if no categories checked
×
20
5.
Taking Lomotil/Imodium/ 
Loperamide/opiates for diarrhea 
0 = no, 1 = yes
________
×
30
6.
Abdominal mass
0 = none, 2 = questionable,
5 = defined
________
×
10
7.
Hematocrit:  ___.__
Male:  (47 – hematocrit) =
Female:  (42 – hematocrit) =
Subtotal
If hematocrit > normal, enter "0"
×
6
8.
Body weight:  ___.__(kg)
Standard weight:  ___.__(kg)
100 × [1 – (Body wt/Standard wt)] =
Percent below standard weight:  ______
If body wt > std. wt, enter "0"
×
1
Total
NOTE:
During Screening subjects will be instructed on how to calculate the number of very soft and liquid stools, 
including a visual depiction.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
130
Appendix G.
Standard Weights
Standard Height and Weight Tables – Use to Calculate CDAI Score
Standard Height
cm (Inches)
Standard Weight (Men)
kg (Pounds)
Standard Weight (Women) kg 
(Pounds)
121.9 (48.0)
40.8 (89.9)
123.2 (48.5)
41.3 (91.0)
124.5 (49.0)
41.8 (92.1)
125.7 (49.5)
42.3 (93.3)
127.0 (50.0)
42.8 (94.4)
128.3 (50.5)
43.4 (95.6)
129.5 (51.0)
43.9 (96.8)
130.8 (51.5)
44.4 (98.0)
132.1 (52.0)
55.5 (122.4)
45.0 (99.2)
133.4 (52.5)
55.7 (122.7)
45.5 (100.4)
134.6 (53.0)
55.8 (123.1)
46.1 (101.6)
135.9 (53.5)
56.0 (123.5)
46.6 (102.8)
137.2 (54.0)
56.2 (123.9)
47.2 (104.1)
138.4 (54.5)
56.4 (124.4)
47.8 (105.3)
139.7 (55.0)
56.7 (124.9)
48.3 (106.6)
141.0 (55.5)
56.9 (125.5)
48.9 (107.9)
142.2 (56.0)
57.2 (126.1)
49.5 (109.1)
143.5 (56.5)
57.4 (126.7)
50.1 (110.4)
144.8 (57.0)
57.7 (127.3)
50.7 (111.7)
146.1 (57.5)
58.1 (128.0)
51.3 (113.0)
147.3 (58.0)
58.4 (128.7)
52.2 (115.0)
148.6 (58.5)
58.7 (129.5)
52.6 (116.0)
149.9 (59.0)
59.1 (130.3)
53.1 (117.0)
151.1 (59.5)
59.5 (131.1)
53.6 (118.3)
152.4 (60.0)
59.9 (132.0)
54.2 (119.5)
153.7 (60.5)
60.3 (132.9)
54.8 (120.8)
154.9 (61.0)
60.7 (133.8)
55.3 (122.0)
156.2 (61.5)
61.1 (134.8)
56.0 (123.5)
157.5 (62.0)
61.7 (136.0)
56.7 (125.0)


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
131
Standard Height and Weight Tables – Use to Calculate CDAI Score
Standard Height
cm (Inches)
Standard Weight (Men)
kg (Pounds)
Standard Weight (Women) kg 
(Pounds)
158.8 (62.5)
62.1 (137.0)
57.4 (126.5)
160.0 (63.0)
62.6 (138.0)
58.0 (128.0)
161.3 (63.5)
63.0 (139.0)
58.7 (129.5)
162.6 (64.0)
63.5 (140.0)
59.4 (131.0)
163.8 (64.5)
64.1 (141.3)
60.1 (132.5)
165.1 (65.0)
64.6 (142.5)
60.8 (134.0)
166.4 (65.5)
65.2 (143.8)
61.4 (135.5)
167.6 (66.0)
65.8 (145.0)
62.1 (137.0)
168.9 (66.5)
66.4 (146.5)
62.8 (138.5)
170.2 (67.0)
67.1 (148.0)
63.5 (140.0)
171.5 (67.5)
67.8 (149.5)
64.2 (141.5)
172.7 (68.0)
68.5 (151.0)
64.9 (143.0)
174.0 (68.5)
69.2 (152.5)
65.5 (144.5)
175.3 (69.0)
69.8 (154.0)
66.2 (146.0)
176.5 (69.5)
70.5 (155.5)
66.9 (147.5)
177.8 (70.0)
71.2 (157.0)
67.6 (149.0)
179.1 (70.5)
71.9 (158.5)
68.3 (150.5)
180.3 (71.0)
72.6 (160.0)
68.9 (152.0)
181.6 (71.5)
73.4 (161.8)
69.6 (153.5)
182.9 (72.0)
74.1 (163.5)
70.3 (155.0)
184.2 (72.5)
75.0 (165.3)
71.2 (156.9
185.4 (73.0)
75.7 (167.0)
71.9 (158.5)
186.7 (73.5)
76.6 (169.0)
72.6 (160.2)
188.0 (74.0)
77.5 (171.0)
73.4 (161.8)
189.2 (74.5)
78.4 (172.8)
74.1 (163.4)
190.5 (75.0)
79.1 (174.5)
74.9 (165.1)
191.8 (75.5)
80.2 (176.8)
75.6 (166.8)
193.0 (76.0)
81.2 (179.0)
76.4 (168.4)
194.3 (76.5)
82.0 (180.8)
77.2 (170.1)
195.6 (77.0)
82.9 (182.9)
77.9 (171.8)
196.9 (77.5)
83.9 (185.0)
78.7 (173.5)


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
132
Standard Height and Weight Tables – Use to Calculate CDAI Score
Standard Height
cm (Inches)
Standard Weight (Men)
kg (Pounds)
Standard Weight (Women) kg 
(Pounds)
198.1 (78.0)
84.9 (187.2)
79.5 (175.2)
199.4 (78.5)
85.9 (189.4)
80.3 (177.0)
200.7 (79.0)
86.9 (191.6)
81.0 (178.7)
201.9 (79.5)
87.9 (193.9)
81.8 (180.5)
203.2 (80.0)
89.0 (196.2)
82.6 (182.2)
204.5 (80.5)
90.0 (198.6)
*Standard height is calculated using 
actual height obtained at screening 
(without shoes) plus one inch
205.7 (81.0)
91.1 (200.9)
*Indoor clothing weighing 5 pounds 
for men and 3 pounds for women
207.0 (81.5)
92.2 (203.3)
*Centimeters × 0.3937 = inches
208.3 (82.0)
93.3 (205.8)
*Pounds × 0.4535 = kilograms


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
133
Appendix H.
Clinical Criteria for Diagnosing Anaphylaxis
Anaphylaxis24 is highly likely when any one of the following 3 criteria are fulfilled:
1.
Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen 
lips-tongue-uvula)
AND AT LEAST ONE OF THE FOLLOWING
a.
Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, 
reduced PEF, hypoxemia)
b. Reduced BP or associated symptoms of end-organ dysfunction (e.g., hypotonia 
[collapse], syncope, incontinence)
2.
Two or more of the following that occur rapidly after exposure to a likely allergen 
for that patient (minutes to several hours):
a.
Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, 
swollen lips tongue-uvula)
b. Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, 
reduced PEF, hypoxemia)
c.
Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, 
incontinence)
d. Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting)
3.
Reduced BP after exposure to known allergen for that patient (minutes to several 
hours):
a.
Infants and children:  low systolic BP (age specific) or greater than 30% 
decrease in systolic BP*
b. Adults:  systolic BP of less than 90 mm Hg or greater than 30% decrease from 
that person's baseline


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
134
PEF:  peak expiratory flow; BP:  blood pressure
*
low systolic BP for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg + 
[2 × age]) from 1 to 10 years, and less than 90 mg Hg from 11 to 17 years.
Serious Systemic Hypersensitivity Reaction:  A hypersensitivity reaction is a clinical 
sign or symptom, or constellation of signs or symptoms, caused by an inappropriate and 
excessive immunologic reaction to study drug administration.  A systemic 
hypersensitivity reaction is a hypersensitivity reaction that does not occur at the local site 
of study drug administration (e.g., not an injection site reaction).  A serious systemic 
hypersensitivity reaction is a systemic hypersensitivity reaction that fulfills criteria for a 
serious adverse event as specified in Section 6.1.1.2.
In the event of an anaphylactic reaction, blood samples will be drawn per Appendix C
after the onset of the reaction.  This will include: histamine and tryptase.  A blood sample 
for ADA assessment will also be collected along with 1 hour blood samples for above 
assessments.  Separate instructions for the collection, handling, storage and shipping of 
these labs will be provided outside of the study protocol.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
135
Appendix I.
Tanner Stage 5 for Development
Tanner Stage 5 for Development25,26
Puberty and the Tanner Stages – developed by Professor James M Tanner
Introduction
Adolescents experience several types of maturation, including cognitive (the development 
of formal operational thought), psychosocial (the stages of adolescence), and biologic.  
The complex series of biologic transitions are known as puberty, and these changes may 
impact psychosocial factors.
The most visible changes during puberty are growth in stature and development of 
secondary sexual characteristics.
Equally profound are changes in body composition; the achievement of fertility; and 
changes in most body systems, such as the neuroendocrine axis, bone size, and 
mineralization; and the cardiovascular system.  As an example, normal cardiovascular 
changes, including greater aerobic power reserve, electrocardiographic changes, and 
blood pressure changes, occur during puberty.
The normal sequence of pubertal events and perils of puberty are reviewed here.  This is 
within the normal ranges and does not take into account Precocious Puberty or Delayed 
Puberty.
Tanner Stages
Conceptually, pubertal maturation can be described in terms of sequence, timing, and 
tempo (Puberty consists of a series of predictable events, and the sequence of changes in 
secondary sexual characteristics has been categorized by several groups.  The staging 
system utilized most frequently is that published by Marshall and Tanner and the 
sequence of changes, commonly referred to as "Tanner stages," is described below.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
136
Boys – development of external genitalia
Stage 1:  Prepubertal
Stage 2:  Enlargement of scrotum and testes; scrotum skin reddens and changes in texture
Stage 3:  Enlargement of penis (length at first); further growth of testes
Stage 4:  Increased size of penis with growth in breadth and development of glans; testes 
and scrotum larger, scrotum skin darker
Stage 5:  Adult genitalia
Girls – breast development
Stage 1:  Prepubertal
Stage 2:  Breast bud stage with elevation of breast and papilla; enlargement of areola
Stage 3:  Further enlargement of breast and areola; no separation of their contour
Stage 4:  Areola and papilla form a secondary mound above level of breast
Stage 5:  Mature stage:  projection of papilla only, related to recession of areola
Boys and girls – pubic hair
Stage 1:  Prepubertal (can see velus hair similar to abdominal wall)
Stage 2:  Sparse growth of long, slightly pigmented hair, straight or curled, at base of 
penis or along labia
Stage 3:  Darker, coarser and more curled hair, spreading sparsely over junction of pubes
Stage 4:  Hair adult in type, but covering smaller area than in adult; no spread to medial 
surface of thighs


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
137
Stage 5:  Adult in type and quantity, with horizontal distribution ("feminine")
Boys Growth
●
Stage 1:  5 – 6 cm/year
●
Stage 2:  5 – 6 cm/year
●
Stage 3:  7 – 8 cm/year
●
Stage 4:  10 cm/year
●
Stage 5:  No further height increase after 17 years
Girls Growth
●
Stage 1:  5 – 6 cm/year
●
Stage 2:  7 – 8 cm/year
●
Stage 3:  8 cm/year
●
Stage 4:  7 cm/year
●
Stage 5:  No further height after 16 years


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
138
Appendix J.
Protocol Amendment:  List of Changes
The summary of changes is listed in Section 1.1.
Specific Protocol Changes
Section 1.2  Synopsis
Subsection Diagnosis and Main Criteria for Inclusion/Exclusion:
Heading "Main Exclusion:"
Add:  new Criterion 31
31. No known active COVID-19 infection.  Subject must not have signs/symptoms associated with 
COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and may only rescreen 
after they meet the following COVID-19 viral clearance criteria:
!
Symptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours apart 
after at least 10 days have passed since recovery, defined as resolution of fever without use of 
antipyretics and improvement in respiratory symptoms (e.g., cough, shortness of breath)
!
Asymptomatic subjects: At least 2 negative viral tests in a row completed locally, ≥ 24 hours apart 
after at least 10 days have passed since prior positive result (Note: subjects who develop 
symptoms will follow guidance above for symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the above viral clearance 
criteria may be adjusted to account for epidemiological trends, updated information regarding 
infectivity and local/institutional guidelines.
Section 1.3  List of Abbreviations and Definition of Terms
Subsection Abbreviations
Add:
COVID-19
Coronavirus Disease 2019
Section 3.2  Benefits and Risks
Add:  new last paragraph
Considering the coronavirus (COVID-19) pandemic, the benefit and risk to subjects 
participating in this study have been re-evaluated.  Based on the limited information to 
date, no additional risk to study participants is anticipated with the use of risankizumab.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
139
Section 5.2.2  Exclusion Criteria
Add:  new Criterion 31
31.
No known active COVID-19 infection.  Subject must not have signs/symptoms 
associated with COVID-19 infection.
Subjects who do not meet COVID-19 eligibility criteria must be screen failed and 
may only rescreen after they meet the following COVID-19 viral clearance 
criteria: 
●
Symptomatic subjects:  At least 2 negative viral tests in a row completed 
locally, ≥ 24 hours apart after at least 10 days have passed since recovery, 
defined as resolution of fever without use of antipyretics and improvement in 
respiratory symptoms (e.g., cough, shortness of breath)
●
Asymptomatic subjects:  At least 2 negative viral tests in a row completed 
locally, ≥ 24 hours apart after at least 10 days have passed since prior positive 
result (Note:  subjects who develop symptoms will follow guidance above for 
symptomatic subjects)
Frequency or timing of COVID-19 testing and interval between testing for the 
above viral clearance criteria may be adjusted to account for epidemiological 
trends, updated information regarding infectivity and local/institutional guidelines.
Section 5.3.1.1  Study Procedures
Add:  new last paragraph
Study visits may be impacted by changes in local regulations due to the COVID-19 
pandemic.  This may include changes such as phone or virtual visits, visits at alternative 
locations, or changes in the visit frequency and timing of study procedures, among others.  
Every effort should be made to ensure the safety of subjects and site staff, while 
maintaining the integrity of the study.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
140
Section 5.3.1.1  Study Procedures
Subsection Informed Consent
Add:  new last paragraph
Due to the COVID-19 pandemic, modifications to the protocol may be necessary.  
Subjects should be informed of the changes to the conduct of the study relevant to their 
participation (e.g., cancellation of visits, change in laboratory testing site, etc.).  
Documentation of this notification or verbal consent should be maintained at the site as 
required per local regulatory requirements.  A signed and dated informed consent form 
should be obtained from the subject afterwards as soon as possible.
Section 5.3.1.1  Study Procedures
Subsection Clinical Laboratory Tests
Add:  new fifth and sixth paragraph
If travel restrictions or other changes in local regulations in light of the COVID-19 
pandemic prevent the subject from having blood drawn for laboratory testing at the study 
site, if possible, arrange for subjects to have laboratory work done at a local lab, hospital, 
or other facility.  Local lab results should be obtained along with reference ranges and 
kept within the subjects' source documentation.  Local lab results should be reviewed by 
the investigator as soon as possible.
If laboratory samples cannot be obtained, study drug administration may be continued 
provided the investigator has reviewed all prior laboratory results and confirms and 
discusses with the subject that there is no safety concern for the subject to continue use of 
the study drug in the absence of current labs.
Section 5.3.1.1  Study Procedures
Subsection HIV
Seventh sentence previously read:
AbbVie will not receive results from the testing and will not be made aware of any 
positive result.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
141
Has been changed to read:
AbbVie will not receive results from the testing.
Section 5.3.1.1  Study Procedures
Subsection Outcomes and Questionnaires
Add:  new last paragraph
Due to the COVID-19 pandemic and any local restrictions, sites may administer PRO 
instruments over the phone as needed. Sites may read the PRO questions and response 
options to the subject and record the subject's responses. Sites may send the 
questionnaires (email or hard copy) to the subjects to allow them to read/understand the 
questions and responses when the subject is providing responses over the phone. The date 
and time of PRO data collection should be recorded along with who collected the 
information.
Section 5.3.1.1  Study Procedures
Subsection Study Drug Dispensing/Administration
Add:  new last paragraph and bullet list
During the Study Drug Dosing Period, a subject with confirmed (viral test positive) or 
suspected COVID-19 infection can only be dosed with study drug if the following 
COVID-19 viral clearance criteria are met:
●
Symptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours apart 
after at least 10 days have passed since recovery, defined as resolution of fever 
without use of antipyretics and improvement in respiratory symptoms (e.g., 
cough, shortness of breath)
●
Asymptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (note:  
subjects who develop symptoms will follow guidance above for symptomatic 
subjects)


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
142
Section 5.5.2.2  Storage and Disposition of Study Drug(s)
Third paragraph, last sentence previously read:
Study drug should be quarantined and not dispensed until AbbVie or AbbVie 
Temperature Excursion Management System (ATEMS) deems the drug as acceptable.
Has been changed to read:
Sites are responsible to report temperature excursions into the AbbVie Temperature 
Excursion Management System (ATEMS).  Study drug should be quarantined and not 
dispensed until AbbVie or ATEMS deems the drug as acceptable.
Section 5.5.7  Drug Accountability
Second paragraph, first sentence previously read:
In addition, an accurate running inventory of study drug will be kept by the site (blinded 
or unblinded staff, as applicable) on a Site Drug Accountability log including date 
received, the lot number, kit number(s), date and number of vials and syringes dispensed, 
and subject number.
Has been changed to read:
In addition, IRT will be used to document investigational product accountability including 
date received, the lot number, kit number(s), date and number of vials and syringes 
dispensed, and subject number.
Section 5.5.7  Drug Accountability
Third paragraph previously read:
An overall accountability of the study drug will be performed and verified by the 
CRA/monitor (blinded or unblinded according to the monitoring plan) throughout the 
study and at the site close-out visit.


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
143
Has been changed to read:
An overall accountability of the study drug will be performed by the site and 
reconciliation will be performed by the CRA/monitor (blinded or unblinded according to 
the monitoring plan) throughout the study and at the site close-out visit.
Section 5.5.7  Drug Accountability
Fourth paragraph, third and fourth sentence previously read:
All unused supplies must be inventoried, accounted for and destroyed on site according to 
local procedures or regulation or returned to a destruction facility by the monitor/CRA 
(blinded or unblinded according to the monitoring plan).  A copy of the Drug 
Accountability Form, in accordance with instructions provided by the monitor/CRA 
(blinded or unblinded according to the monitoring plan), will be included in the return 
shipments.
Has been changed to read:
All unused supplies must be inventoried, accounted for and destroyed on site according to 
local procedures or regulation or returned to a destruction facility.  A copy of the Return 
Consignment Form from IRT, in accordance with instructions provided by the 
monitor/CRA (blinded or unblinded according to the monitoring plan), will be included in 
the return shipments.
Section 6.1.1.1  Adverse Event
Add:  new fourth, fifth, and sixth paragraph
Supplemental study case report forms should be completed in the event of COVID-19 
related missed/virtual visits, study drug interruptions or discontinuations, or adverse 
events (including capture of specific signs/symptoms of infection and testing results).
COVID-19 infections should be captured as adverse events.  If the event meets the criteria 
for a serious adverse event (SAE), then follow the SAE reporting directions per the 
protocol and above.  The following COVID-19 related supplemental eCRFs should be 
completed:


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
144
●
COVID-19 Supplemental Signs/ Symptoms 
●
COVID-19 Status Form
If a subject has a confirmed or suspected COVID-19 infection and study drug was 
interrupted, the investigator should contact the sponsor emergency medical contact listed 
above before reintroducing study drug.
Section 7.0  Protocol Deviations
First paragraph, last sentence previously read:
If a protocol deviation occurs (or is identified) after a subject has been enrolled, the 
principal Investigator is responsible for notifying IEC/IRB regulatory authorities (as 
applicable), and AbbVie.
Has been changed to read:
If a protocol deviation occurs (or is identified, including those that may be due to the 
COVID-19 pandemic) after a subject has been enrolled, the principal Investigator is 
responsible for notifying IEC/IRB regulatory authorities (as applicable), and AbbVie.
Section 8.1  Statistical and Analytical Plans
Add:  new last paragraph
The impact of missing data due to COVID-19 will be monitored and appropriate 
modifications to the analysis of primary and key secondary endpoints for handling such 
missing data will be reflected and incorporated in the final SAP.
Section 9.2  Ethical Conduct of the Study
Add:  new last paragraph
In the event of a state of emergency due to the COVID-19 pandemic leading to difficulties 
in performing protocol-specified procedures, AbbVie will engage with study site 
personnel in efforts to ensure the safety of subjects, maintain protocol compliance, and 
minimize risks to the integrity of the study while trying to best manage subject continuity 
of care.  This may include alternative methods for assessments (e.g., phone contacts or 


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
145
virtual site visits), alternative locations for data collection (e.g., use of a local lab instead 
of a central lab). In all cases, these alternative measures must be allowed by local 
regulations and permitted by IRB/IEC.  Investigators should notify AbbVie if any urgent 
safety measures are taken to protect the subjects against any immediate hazard.
Section 10.1  Source Documents
Add:  new last paragraph
During the COVID-19 pandemic, remote monitoring of data may be employed if allowed 
by the local regulatory authority, IRB/IEC, and the study site.
Appendix B.  List of Protocol Signatories
Previously read:
Name
Title
Functional Area
Clinical Development, Immunology
Clinical Development, Immunology
Statistics
Statistics
Clinical Pharmacology and Pharmacometrics
Bioanalysis
Clinical Operations
Has been changed to read:
Name
Title
Functional Area
Clinical Development, Immunology
Clinical Development, Immunology
Statistics
Statistics
Clinical Pharmacology and Pharmacometrics
Bioanalysis
Clinical Operations


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
146
Appendix C.  Study Activities
Add:  new Activity "COVID-19 Assessmentz"
Screening Period
(35 Days)a
12-Week Double-Blind Induction
Induction Period 2
Unschb
140-Day
Follow-Upc
Activity
Screening
Baseline
Week 4
Week 8
Week 12/PD
Week 16
Week 20
Week 24
COVID-19 Assessmenty
X


Risankizumab
M15-991 Protocol Amendment 7
EudraCT 2016-003190-17
147
Appendix C.  Study Activities
Table note "k.," last sentence previously read:
AbbVie will not receive results from the testing and not be made aware of any positive 
result.
Has been changed to read:
AbbVie will not receive results from the testing.
Appendix C.  Study Activities
Add:  new table note "y."
Assessment for signs/symptoms of COVID-19 infection.  If the investigator suspects the 
possibility of COVID-19 based on the signs, symptoms and medical complaint (chief 
complaint, history of exposure, etc.), local laboratory testing must be completed.